Processing 00000000.tx.1: Autoantibody Response to CD38 in Caucasian Patients With Type 1 and Type 2 Diabetes Immunological and Genetic Characterization Roberto Mallone1, Erika Ortolan2, Germano Baj2, Ada Funaro2, Sara Giunti1, Emma Lillaz1, Franca Saccucci3, Maurizio Cassader1, Paolo Cavallo-Perin1, and Fabio Malavasi2 1 Department of Internal Medicine 2 Laboratory of Immunogenetics, Department of Genetics, Biology and Biochemistry, University of Torino, Torino 3 Institute of Biology and Genetics, University of Ancona, Ancona, Italy  ABSTRACT TOP ABSTRACT INTRODUCTION RESEARCH DESIGN AND METHODS RESULTS DISCUSSION REFERENCES  Insulin secretion is one of the functions mediated by CD38, a nonlineage pleiotropic cell surface receptor. 

Phrase: "Autoantibody Response to CD38"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   833   C0235914:AUTO-ANTIBODY RESPONSE [Laboratory Procedure]
   770   C0871261:Response [Organism Attribute]
   770   C1704632:Response [Finding]
   770   C1706817:Response [Intellectual Product]
   770   C2911692:Response [Mental Process]

Phrase: "in Caucasian Patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]

Phrase: "With Type 1"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0441729:Type 1 [Classification]
   861   C0332307:Type [Qualitative Concept]
   861   C1547052:*Type [Quantitative Concept]

Phrase: "and"

Phrase: "Type 2 Diabetes"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
  1000   C0011860:Type 2 Diabetes [Disease or Syndrome]
   913   C1320657:type diabetes [Finding]
   901   C0441730:Type 2 [Classification]
   827   C0011847:Diabetes [Disease or Syndrome]
   827   C0011849:Diabetes [Disease or Syndrome]
   827   C0332307:Type [Qualitative Concept]
   827   C1547052:*Type [Quantitative Concept]

Phrase: "Immunological"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205470:Immunological [Functional Concept]

Phrase: "and"

Phrase: "Genetic Characterization Roberto Mallone1,"

Phrase: "Erika Ortolan2,"

Phrase: "Germano Baj2,"

Phrase: "Ada Funaro2,"

Phrase: "Sara Giunti1,"

Phrase: "Emma Lillaz1,"

Phrase: "Franca Saccucci3,"

Phrase: "Maurizio Cassader1,"

Phrase: "Paolo Cavallo-Perin1,"

Phrase: "and"

Phrase: "Fabio Malavasi2 1 Department of Internal Medicine 2 Laboratory of Immunogenetics,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   738   C1704729:Department [Organization]

Phrase: "Department of Genetics,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   858   C0587466:Genetics department [Health Care Related Organization]
   790   C1704729:Department [Organization]

Phrase: "Biology"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0005532:Biology [Biomedical Occupation or Discipline]
   928 E C0205460:Biologic [Qualitative Concept]
   928 E C2979985:BIOLOGIC [Biologically Active Substance,Pharmacologic Substance]

Phrase: "and"

Phrase: "Biochemistry,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0005477:Biochemistry [Occupation or Discipline]

Phrase: "University of Torino,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C0041740:University [Manufactured Object,Organization]

Phrase: "Torino 3 Institute of Biology"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0021622:institute [Organization]
   760   C1272753:Institute [Idea or Concept]

Phrase: "and"

Phrase: "Genetics,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0017398:Genetics [Biomedical Occupation or Discipline]
  1000   C0017399:genetics [Biologic Function]

Phrase: "University of Ancona,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C0041740:University [Manufactured Object,Organization]

Phrase: "Ancona,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0445432:Ancona [Intellectual Product]

Phrase: "Italy  ABSTRACT TOP ABSTRACT INTRODUCTION RESEARCH DESIGN"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   818   C0035171:Research Design [Research Activity]
   795   C0035168:research [Research Activity]
   795   C0242481:Research [Research Activity]
   795   C1707689:Design [Activity]
   795   C2983265:DESIGN [Intellectual Product]

Phrase: "AND"

Phrase: "METHODS RESULTS DISCUSSION"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0557061:Discussion [Therapeutic or Preventive Procedure]
   827   C2584313:Discussion [Social Behavior]

Phrase: "REFERENCES"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1514811:Reference [Idea or Concept]
  1000   C1706462:Reference [Conceptual Entity]

Phrase: "Insulin secretion"
Meta Candidates (Total=8; Excluded=2; Pruned=0; Remaining=6)
  1000   C1256369:insulin secretion [Cell Function]
   861   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C0036536:secretion [Biologic Function]
   861   C0036537:Secretion [Body Substance]
   861   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C1579433:Insulin [Pharmacologic Substance]
   805 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   777 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "is"

Phrase: "one of the functions"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0205447:One [Quantitative Concept]

Phrase: "mediated by CD38,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0086597:mediated [Social Behavior]
   790   C0127400:Mediated [Organic Chemical,Pharmacologic Substance]

Phrase: "a nonlineage pleiotropic cell surface receptor."
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   884   C0034800:Cell Surface Receptor [Amino Acid, Peptide, or Protein,Receptor]
   840   C0699040:Cell surface [Cell Component]
   804   C0007634:Cell [Cell]
   804   C0205148:Surface [Spatial Concept]
   804   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   804   C1269647:Cell [Cell]
   804   C1704653:Cell [Medical Device]
   804   C1948049:Cell [Spatial Concept]
Processing 00000000.tx.2: The molecule is the target of an autoimmune response, because serum autoantibodies (aAbs) to CD38 have been detected in diabetic patients. 

Phrase: "The molecule"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0567416:Molecule [Substance]
   928 E C1521991:Molecular [Qualitative Concept]

Phrase: "is"

Phrase: "the target of an autoimmune response,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   783   C3272920:Target Response [Finding]
   753   C1521840:Target [Functional Concept]
   753   C2986546:TARGET [Diagnostic Procedure]

Phrase: "because"

Phrase: "serum autoantibodies (aAbs) to CD38"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0004358:Autoantibodies [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: "have"

Phrase: "been"

Phrase: "detected in diabetic patients."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   770   C0030705:Patients [Patient or Disabled Group]
   770   C0241863:DIABETIC [Finding]
   770   C0442726:Detected [Finding]
   770   C1511790:Detected [Therapeutic or Preventive Procedure]
Processing 00000000.tx.3: In the healthy Caucasian population, the CD38 gene is bi-allelic (86% CD38*B and 14% CD38*A), whereas an Arg140Trp mutation has been identified in Japanese diabetic patients. 

Phrase: "In the healthy Caucasian population,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0032659:Population [Quantitative Concept]
   827   C1257890:Population [Population Group]

Phrase: "the CD38 gene"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1413221:CD38 gene [Gene or Genome]
   861   C0017337:Gene [Gene or Genome]

Phrase: "is"

Phrase: "bi-allelic"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   789   C0002085:Allele [Gene or Genome]

Phrase: "(86% CD38"

Phrase: "*B"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2347469:/B [Quantitative Concept]

Phrase: "and"

Phrase: "14% CD38"

Phrase: "*A"

Phrase: ")"

Phrase: ","

Phrase: "whereas"

Phrase: "an Arg140Trp mutation"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0026882:Mutation [Genetic Function]
   861   C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "has"

Phrase: "been"

Phrase: "identified in Japanese diabetic patients."
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   760   C0030705:Patients [Patient or Disabled Group]
   760   C0205396:Identified [Qualitative Concept]
   760   C0241863:DIABETIC [Finding]
   760   C1550043:Identified [Finding]
   760   C1551388:Identified [Functional Concept]
   760   C1556094:Japanese [Population Group]
Processing 00000000.tx.4: We investigated the relationship between CD38 and diabetes in Caucasian patients by characterizing anti-CD38 aAbs in terms of prevalence and function (agonistic/nonagonistic activity) and by exploring the potential influence of the CD38 genetic background. 

Phrase: "We"

Phrase: "investigated"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1292732:investigated [Functional Concept]

Phrase: "the relationship between CD38"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   770   C0439849:Relationship [Qualitative Concept]
   770   C1705630:Relationship [Idea or Concept]
   770   C1706279:Relationship [Idea or Concept]
   770   C3540605:Relationship [Intellectual Product]

Phrase: "and"

Phrase: "diabetes in Caucasian patients"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0011847:Diabetes [Disease or Syndrome]
   770   C0011849:Diabetes [Disease or Syndrome]

Phrase: "by characterizing anti-CD38 aAbs"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C0004358:Autoantibodies [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: "in terms of prevalence"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0033105:Prevalence [Quantitative Concept]
  1000   C0220900:prevalence [Quantitative Concept]

Phrase: "and"

Phrase: "function"
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
  1000   C0031843:function [Physiologic Function]
  1000   C0542341:Function [Functional Concept]
  1000   C0700205:FUNCTION [Classification]
  1000   C1705273:Function [Intellectual Product]
   928 E C0205245:Functional [Functional Concept]
   928 E C2700217:Functional [Conceptual Entity]

Phrase: "(agonistic/nonagonistic activity"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   827   C0205177:Activity [Functional Concept]
   827   C0439167:% activity [Quantitative Concept]
   827   C0441655:Activity [Activity]
   827   C1561536:*Activity [Idea or Concept]

Phrase: ")"

Phrase: "and by exploring"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C1515981:And [Idea or Concept]

Phrase: "the potential influence of the CD38 genetic background."
Processing 00000000.tx.5: A novel enzymatic immunoassay, using recombinant soluble CD38 as the target antigen, was developed for the analysis of anti-CD38 aAb titers. 

Phrase: "A novel enzymatic immunoassay,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0020980:Immunoassay [Laboratory Procedure]
   827   C0021060:immunoassay [Laboratory Procedure]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "recombinant soluble CD38 as the target antigen,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   774   C0075742:CD38 Antigen [Amino Acid, Peptide, or Protein,Enzyme,Immunologic Factor]
   774   C1413221:CD38 ANTIGEN [Gene or Genome]
   774   C2827388:CD38 Antigen [Amino Acid, Peptide, or Protein]

Phrase: "was"

Phrase: "developed for the analysis of anti-CD38 aAb titers."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   742   C0002778:Analysis [Laboratory Procedure]
   742   C0936012:Analysis [Research Activity]
   742   C1524024:analysis [Functional Concept]
   708   C0475208:Titer [Quantitative Concept]
Processing 00000000.tx.6: Sera from 19.15% of type 1 and 16.67% of type 2 diabetic patients were positive. 

Phrase: "Sera from 19.15% of type 1"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   748   C0229671:Sera [Body Substance]
   748   C1151254:SerA [Molecular Function]
   714 E C1546774:Serum [Intellectual Product]
   714 E C1550100:Serum [Body Substance]

Phrase: "and"

Phrase: "16.67% of type 2 diabetic patients"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   778   C0441730:Type 2 [Classification]
   757   C1550335:Patient type [Classification]
   748   C0030705:Patients [Patient or Disabled Group]
   748   C0241863:DIABETIC [Finding]
   748   C0332307:Type [Qualitative Concept]
   748   C1547052:*Type [Quantitative Concept]

Phrase: "were"

Phrase: "positive."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0439178:% Positive [Quantitative Concept]
  1000   C1446409:Positive [Qualitative Concept]
  1000   C1514241:Positive [Finding]
  1000   C2825490:Positive [Qualitative Concept]
Processing 00000000.tx.7: The majority of anti-CD38 aAbs (57.14%) displayed agonistic properties, i.e., they demonstrated the capability to trigger Ca2+ release in lymphocytic cell lines. 

Phrase: "The majority of anti-CD38 aAbs"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C0680220:majority [Social Behavior]

Phrase: "(57.14%"

Phrase: ")"

Phrase: "displayed"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0870432:displayed [Functional Concept]
   966 E C1705417:Display [Manufactured Object]

Phrase: "agonistic properties,"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   861   C0871161:properties [Qualitative Concept]
   861   C1292721:properties [Functional Concept]
   827 E C1882134:Property [Conceptual Entity]
   827 E C2347695:Property [Entity]

Phrase: "i.e.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0683454:I-E [Diagnostic Procedure,Intellectual Product]
   861   C0021966:I- [Inorganic Chemical]
   861   C0221138:I NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: "they"

Phrase: "demonstrated"

Phrase: "the capability to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C2698977:Capability [Qualitative Concept]

Phrase: "trigger"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0032930:Trigger [Clinical Attribute]
  1000   C1444748:Trigger [Qualitative Concept]

Phrase: "Ca2+ release in lymphocytic cell lines."
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   753   C0030685:Release [Health Care Activity]
   753   C0391871:Release [Functional Concept]
   753   C0439180:% release [Quantitative Concept]
   753   C0680255:release [Health Care Activity]
   753   C1283071:Release [Functional Concept]
   753   C1963578:Release [Therapeutic or Preventive Procedure]
Processing 00000000.tx.8: In agreement with these functional features, the presence of anti-CD38 aAbs in type 2 diabetic patients was associated with significantly higher levels of fasting plasma C-peptide and insulin, as compared with anti-CD38 counterparts. 

Phrase: "In agreement"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0680240:Agreement [Social Behavior]

Phrase: "with these functional features,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   827   C1521970:Feature [Qualitative Concept]
   827   C1706388:Feature [Conceptual Entity]
   827   C2346469:Feature [Qualitative Concept]
   827   C2348519:Feature [Qualitative Concept]

Phrase: "the presence of anti-CD38 aAbs"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C0392148:Presence [Therapeutic or Preventive Procedure]

Phrase: "in type 2 diabetic patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C0030705:Patients [Patient or Disabled Group]

Phrase: "was"

Phrase: "associated with significantly higher levels of fasting plasma C-peptide"
Meta Candidates (Total=20; Excluded=7; Pruned=0; Remaining=13)
   777   C0202100:c peptide levels [Laboratory Procedure]
   760   C0006558:C-Peptide [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   760   C0332281:Associated with [Qualitative Concept]
           Associated
   757 E C0071642:peptide C [Amino Acid, Peptide, or Protein]
   739   C0015663:Fasting [Finding]
   739   C0030956:Peptide [Amino Acid, Peptide, or Protein]
   739   C0032105:Plasma [Body Substance]
   739   C0441889:Levels [Qualitative Concept]
   739   C1550098:Plasma, NOS (not otherwise specified) [Body Substance]
   739   C1550565:fasting [Intellectual Product]
   706   C0205250:High [Qualitative Concept]
   706 E C0456079:Level [Classification]
   706 E C0456962:Fast [Qualitative Concept]
   706 E C0750490:Associate [Idea or Concept]
   706   C1299351:High [Qualitative Concept]
   706 E C1547707:Level [Geographic Area]
   706 E C1706221:Associate [Professional or Occupational Group]
   706   C2700149:HIGH [Intellectual Product]
   706 E C2946261:Level [Pharmacologic Substance]

Phrase: "and"

Phrase: "insulin,"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
  1000   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
  1000   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
  1000   C1579433:Insulin [Pharmacologic Substance]
   944 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   916 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "as"

Phrase: "compared with anti-CD38 counterparts."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C1707455:Compared [Activity]
Processing 00000000.tx.9: No diabetic subject carrying the Arg140Trp mutation and no preferential association between diabetes or aAb status and the CD38*A allele was found in the study population. 

Phrase: "No diabetic subject carrying"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   827   C0206243:Carrying [Activity]
   793 E C0699809:carry [Finding]

Phrase: "the Arg140Trp mutation"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0026882:Mutation [Genetic Function]
   861   C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "and"

Phrase: "no preferential association between diabetes"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   760   C0004083:Association [Mental Process]
   760   C0439849:Association [Qualitative Concept]
   760   C0596306:Association [Phenomenon or Process]
   760   C0699792:association [Social Behavior]

Phrase: "or"

Phrase: "aAb status"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0449438:Status [Qualitative Concept]

Phrase: "and"

Phrase: "the CD38"

Phrase: "*"

Phrase: "A allele"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0002085:Allele [Gene or Genome]

Phrase: "was"

Phrase: "found in the study population."
Meta Candidates (Total=8; Excluded=2; Pruned=0; Remaining=6)
   806   C2348561:Study Population [Population Group]
   797 E C0681876:Population Study [Research Activity]
   760   C0032659:Population [Quantitative Concept]
   760   C0150312:Found [Quantitative Concept]
   760   C0557651:Study [Manufactured Object]
   760   C1257890:Population [Population Group]
   760   C2603343:Study [Research Activity]
   726 E C0243095:Find [Finding]
Processing 00000000.tx.10: These results show the significance of anti-CD38 aAbs as a new diagnostic marker of -cell autoimmunity in diabetes. 

Phrase: "These results"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   966   C1274040:Result [Functional Concept]
   966   C1546471:Result [Idea or Concept]
   966   C2825142:Result [Finding]

Phrase: "show"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1547282:Show [Intellectual Product]

Phrase: "the significance of anti-CD38 aAbs"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0237881:Significance [Quantitative Concept]
   753   C0750502:Significance [Idea or Concept]

Phrase: "as a new diagnostic marker of -cell autoimmunity"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   799   C0004368:Autoimmunity [Pathologic Function]
   727 E C0443146:Autoimmune [Pathologic Function]

Phrase: "in diabetes."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0011847:Diabetes [Disease or Syndrome]
  1000   C0011849:Diabetes [Disease or Syndrome]
Processing 00000000.tx.11: Moreover, the prevalent agonistic activity of these aAbs suggests that they could mediate relevant effects on target cells by means of Ca2+ mobilization. 

Phrase: "Moreover,"

Phrase: "the prevalent agonistic activity of these aAbs"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   748   C0205177:Activity [Functional Concept]
   748   C0439167:% activity [Quantitative Concept]
   748   C0441655:Activity [Activity]
   748   C1561536:*Activity [Idea or Concept]

Phrase: "suggests"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1705535:Suggest [Idea or Concept]

Phrase: "that"

Phrase: "they"

Phrase: "could"

Phrase: "mediate"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0086597:Mediate [Social Behavior]

Phrase: "relevant effects on target cells"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   760   C1280500:effects [Qualitative Concept]
   726 E C2348382:Effect [Qualitative Concept]

Phrase: "by means of Ca2+ mobilization."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0185112:Mobilisation [Therapeutic or Preventive Procedure]
   861   C0300926:mobilization [Functional Concept]
Processing 00000000.tx.12: aAb, autoantibody; 

Phrase: "aAb,"

Phrase: "autoantibody"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0004358:Autoantibody [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: ";"
Processing 00000000.tx.13: BSA, bovine serum albumin; 

Phrase: "BSA,"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
  1000   C0036774:Serum Albumin, Bovine [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   901   C0036773:Serum Albumin [Amino Acid, Peptide, or Protein]
   901   C0728877:serum albumin [Laboratory or Test Result]
   827   C0001924:Albumin [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   827   C0007452:Bovine [Mammal]
   827   C0229671:Serum [Body Substance]
   827   C1140701:bovine [Mammal]
   827   C1546774:Serum [Intellectual Product]
   827   C1550100:Serum [Body Substance]

Phrase: "bovine serum albumin"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
  1000   C0036774:Serum Albumin, Bovine [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   901   C0036773:Serum Albumin [Amino Acid, Peptide, or Protein]
   901   C0728877:serum albumin [Laboratory or Test Result]
   827   C0001924:Albumin [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   827   C0007452:Bovine [Mammal]
   827   C0229671:Serum [Body Substance]
   827   C1140701:bovine [Mammal]
   827   C1546774:Serum [Intellectual Product]
   827   C1550100:Serum [Body Substance]

Phrase: ";"
Processing 00000000.tx.14: [Ca2+]i, intracellular Ca2+ level; 

Phrase: "[Ca2+"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0596235:Ca2+ [Element, Ion, or Isotope,Pharmacologic Substance]

Phrase: "]i,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0021966:I- [Inorganic Chemical]
  1000   C0221138:I NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: "intracellular Ca2+ level"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   827   C0441889:Level [Qualitative Concept]
   827   C0456079:Level [Classification]
   827   C1547707:Level [Geographic Area]
   827   C2946261:Level [Pharmacologic Substance]

Phrase: ";"
Processing 00000000.tx.15: cADPR, cyclic ADP-ribose; 

Phrase: "cADPR,"
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
  1000   C0056693:Cyclic ADP-Ribose [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   901   C0001461:ADP Ribose [Biologically Active Substance,Carbohydrate,Nucleic Acid, Nucleoside, or Nucleotide]
   827   C0035549:Ribose [Carbohydrate]
   827   C0439596:Cyclic [Temporal Concept]
   827   C0523452:ADP [Laboratory Procedure]
   827   C1511572:Cyclic [Temporal Concept]
   755 E C0031084:Cyclicities [Temporal Concept]

Phrase: "cyclic ADP-ribose"
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
  1000   C0056693:Cyclic ADP-Ribose [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   901   C0001461:ADP Ribose [Biologically Active Substance,Carbohydrate,Nucleic Acid, Nucleoside, or Nucleotide]
   827   C0035549:Ribose [Carbohydrate]
   827   C0439596:Cyclic [Temporal Concept]
   827   C0523452:ADP [Laboratory Procedure]
   827   C1511572:Cyclic [Temporal Concept]
   755 E C0031084:Cyclicities [Temporal Concept]

Phrase: ";"
Processing 00000000.tx.16: EIA, enzymatic immunoassay; 

Phrase: "EIA,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0020980:Immunoassay [Laboratory Procedure]
   861   C0021060:immunoassay [Laboratory Procedure]

Phrase: "enzymatic immunoassay"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0020980:Immunoassay [Laboratory Procedure]
   861   C0021060:immunoassay [Laboratory Procedure]

Phrase: ";"
Processing 00000000.tx.17: FCS, fetal calf serum; 

Phrase: "FCS,"
Meta Candidates (Total=8; Excluded=1; Pruned=0; Remaining=7)
   827   C0015965:Fetal [Embryonic Structure]
   827   C0229671:Serum [Body Substance]
   827   C0230445:Calf [Body Location or Region]
   827   C0521457:Fetal [Functional Concept]
   827   C1305418:Calf [Body Part, Organ, or Organ Component]
   827   C1546774:Serum [Intellectual Product]
   827   C1550100:Serum [Body Substance]
   771 E C0626053:sural [Pharmacologic Substance]

Phrase: "fetal calf serum"
Meta Candidates (Total=8; Excluded=1; Pruned=0; Remaining=7)
   827   C0015965:Fetal [Embryonic Structure]
   827   C0229671:Serum [Body Substance]
   827   C0230445:Calf [Body Location or Region]
   827   C0521457:Fetal [Functional Concept]
   827   C1305418:Calf [Body Part, Organ, or Organ Component]
   827   C1546774:Serum [Intellectual Product]
   827   C1550100:Serum [Body Substance]
   771 E C0626053:sural [Pharmacologic Substance]

Phrase: ";"
Processing 00000000.tx.18: IL, interleukin; 

Phrase: "IL,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0021764:Interleukin [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C1527200:Interleukin [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]

Phrase: "interleukin"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0021764:Interleukin [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C1527200:Interleukin [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]

Phrase: ";"
Processing 00000000.tx.19: LADA, latent autoimmune diabetes in the adult; 

Phrase: "LADA,"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   790   C0205734:Diabetes, Autoimmune [Disease or Syndrome]
   783   C0271650:Latent diabetes [Disease or Syndrome]
   753   C0011847:Diabetes [Disease or Syndrome]
   753   C0011849:Diabetes [Disease or Syndrome]
   753   C0205275:Latent [Qualitative Concept]
   753   C0443146:Autoimmune [Pathologic Function]

Phrase: "latent autoimmune diabetes in the adult"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   790   C0205734:Diabetes, Autoimmune [Disease or Syndrome]
   783   C0271650:Latent diabetes [Disease or Syndrome]
   753   C0011847:Diabetes [Disease or Syndrome]
   753   C0011849:Diabetes [Disease or Syndrome]
   753   C0205275:Latent [Qualitative Concept]
   753   C0443146:Autoimmune [Pathologic Function]

Phrase: ";"
Processing 00000000.tx.20: mAb, monoclonal antibody; 

Phrase: "mAb,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0003250:Monoclonal antibody [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0003241:Antibody [Amino Acid, Peptide, or Protein,Cell Component,Immunologic Factor]
   861   C0021027:Antibody [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   861   C0746619:monoclonal [Finding]

Phrase: "monoclonal antibody"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0003250:Monoclonal antibody [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0003241:Antibody [Amino Acid, Peptide, or Protein,Cell Component,Immunologic Factor]
   861   C0021027:Antibody [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   861   C0746619:monoclonal [Finding]

Phrase: ";"
Processing 00000000.tx.21: OD, optical density; 

Phrase: "OD,"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
  1000   C0439164:Optical density [Quantitative Concept]
  1000   C1268822:Optical density [Clinical Attribute]
   861   C0178587:density [Quantitative Concept]
   805   C0042789:Vision [Organism Function]
   805   C2707266:Vision [Clinical Attribute]
   789 E C0439794:Dense [Qualitative Concept]

Phrase: "optical density"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
  1000   C0439164:Optical density [Quantitative Concept]
  1000   C1268822:Optical density [Clinical Attribute]
   861   C0178587:density [Quantitative Concept]
   805   C0042789:Vision [Organism Function]
   805   C2707266:Vision [Clinical Attribute]
   789 E C0439794:Dense [Qualitative Concept]

Phrase: ";"
Processing 00000000.tx.22: PBMC, peripheral blood mononuclear cell; 

Phrase: "PBMC,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1321301:PBMC [Cell]

Phrase: "peripheral blood mononuclear cell"
Meta Candidates (Total=23; Excluded=9; Pruned=0; Remaining=14)
  1000   C1321301:Peripheral blood mononuclear cell [Cell]
   923   C0005773:Peripheral blood cell [Cell]
           Blood cell
   861   C0229664:peripheral blood [Body Substance]
           Blood
   861   C0806987:mononuclear cell [Cell]
   847 E C2328697:Hemal cell [Cell]
   819 E C0150936:Peripheral Blood Vessel [Body Part, Organ, or Organ Component]
   812   C0005767:Blood [Tissue]
   812   C0005768:blood [Body Substance]
   812   C0007634:Cell [Cell]
   812   C0205100:Peripheral [Spatial Concept]
   812   C1269647:Cell [Cell]
   812   C1513475:Mononuclear [Clinical Attribute]
   812   C1704653:Cell [Medical Device]
   812   C1948049:Cell [Spatial Concept]
   741 E C0333275:Bloody [Qualitative Concept]
   729 E C0005847:Blood Vessel [Body Part, Organ, or Organ Component]
   729 E C0392895:Bloods [Population Group]
   729 E C1283786:Blood vessel [Body Part, Organ, or Organ Component]
   729 E C1511228:VESSEL, BLOOD [Tissue]
   712 E C1558950:VASCULAR [Finding]
   712 E C1801960:Vascular [Qualitative Concept]

Phrase: ";"
Processing 00000000.tx.23: PBS, phosphate-buffered saline; 

Phrase: "PBS,"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   884   C0991865:Phosphate Buffer [Indicator, Reagent, or Diagnostic Aid,Pharmacologic Substance]
   827   C0006353:Buffered [Indicator, Reagent, or Diagnostic Aid,Pharmacologic Substance]
   827   C0031603:Phosphate [Inorganic Chemical,Pharmacologic Substance]
   827   C0031701:phosphate [Organophosphorus Compound]
   827   C0036082:Saline [Substance]
   827   C1601799:PHOSPHATE [Inorganic Chemical,Pharmacologic Substance]

Phrase: "phosphate-buffered saline"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   884   C0991865:Phosphate Buffer [Indicator, Reagent, or Diagnostic Aid,Pharmacologic Substance]
   827   C0006353:Buffered [Indicator, Reagent, or Diagnostic Aid,Pharmacologic Substance]
   827   C0031603:Phosphate [Inorganic Chemical,Pharmacologic Substance]
   827   C0031701:phosphate [Organophosphorus Compound]
   827   C0036082:Saline [Substance]
   827   C1601799:PHOSPHATE [Inorganic Chemical,Pharmacologic Substance]

Phrase: ";"
Processing 00000000.tx.24: PCR, polymerase chain reaction; 

Phrase: "PCR,"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
  1000   C0032520:Polymerase Chain Reaction [Laboratory Procedure,Molecular Biology Research Technique]
   827   C0337112:Chain [Manufactured Object]
   827   C0443286:Reaction [Functional Concept]
   827   C1114821:Reaction [Clinical Attribute]
   827   C1335439:Polymerase [Amino Acid, Peptide, or Protein,Enzyme]
   827   C1524075:Chain [Idea or Concept]

Phrase: "polymerase chain reaction"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
  1000   C0032520:Polymerase Chain Reaction [Laboratory Procedure,Molecular Biology Research Technique]
   827   C0337112:Chain [Manufactured Object]
   827   C0443286:Reaction [Functional Concept]
   827   C1114821:Reaction [Clinical Attribute]
   827   C1335439:Polymerase [Amino Acid, Peptide, or Protein,Enzyme]
   827   C1524075:Chain [Idea or Concept]

Phrase: ";"
Processing 00000000.tx.25: PVDF, polyvinilydene difluoride; 

Phrase: "PVDF,"

Phrase: "polyvinilydene difluoride"

Phrase: ";"
Processing 00000000.tx.26: rsCD38, recombinant soluble CD38; 

Phrase: "rsCD38,"

Phrase: "recombinant soluble CD38"

Phrase: ";"
Processing 00000000.tx.27: TBST, Tris-buffered saline with Tween; 

Phrase: "TBST,"

Phrase: "Tris-buffered saline with Tween"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   790   C0041175:Tris Buffer [Organic Chemical,Pharmacologic Substance]
           TRIS
   760   C0006353:Buffered [Indicator, Reagent, or Diagnostic Aid,Pharmacologic Substance]
   760   C0036082:Saline [Substance]
   760   C0077281:Tris [Hazardous or Poisonous Substance,Organophosphorus Compound]
   760   C0814229:TRI [Intellectual Product]

Phrase: ";"
Processing 00000000.tx.28: WHO, World Health Organization  INTRODUCTION TOP ABSTRACT INTRODUCTION RESEARCH DESIGN AND METHODS RESULTS DISCUSSION REFERENCES  Insulin secretion is a key element in the regulation of glucose homeostasis. 

Phrase: "WHO,"
Meta Candidates (Total=11; Excluded=1; Pruned=0; Remaining=10)
  1000   C0043237:World Health Organization [Health Care Related Organization]
   901   C0043236:World Health [Idea or Concept]
   901   C0920545:health organization [Health Care Related Organization]
   827   C0018684:Health [Idea or Concept]
   827   C0029237:Organisation [Physiologic Function]
   827   C0029246:Organization [Organization]
   827   C0220885:organization [Qualitative Concept]
   827   C1300196:Organization [Functional Concept]
   827   C1522486:Organization [Professional or Occupational Group]
   827   C2700280:World [Population Group]
   727 E C0031206:healthiness [Finding]

Phrase: "World Health Organization  INTRODUCTION TOP ABSTRACT INTRODUCTION RESEARCH DESIGN"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   807   C0035171:Research Design [Research Activity]
   791   C0035168:research [Research Activity]
   791   C0242481:Research [Research Activity]
   791   C1707689:Design [Activity]
   791   C2983265:DESIGN [Intellectual Product]

Phrase: "AND"

Phrase: "METHODS RESULTS DISCUSSION"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0557061:Discussion [Therapeutic or Preventive Procedure]
   827   C2584313:Discussion [Social Behavior]

Phrase: "REFERENCES"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1514811:Reference [Idea or Concept]
  1000   C1706462:Reference [Conceptual Entity]

Phrase: "Insulin secretion"
Meta Candidates (Total=8; Excluded=2; Pruned=0; Remaining=6)
  1000   C1256369:insulin secretion [Cell Function]
   861   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C0036536:secretion [Biologic Function]
   861   C0036537:Secretion [Body Substance]
   861   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C1579433:Insulin [Pharmacologic Substance]
   805 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   777 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "is"

Phrase: "a key element in the regulation of glucose homeostasis."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   742   C0013879:Element [Element, Ion, or Isotope]
   742   C1705248:Element [Conceptual Entity]
Processing 00000000.tx.29: Disruption of the secretion mechanisms is pivotal in the progressive decline of -cell function, marking the transition from impaired glucose tolerance to overt type 2 diabetes (13). 

Phrase: "Disruption of the secretion mechanisms"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0332453:Disruption [Functional Concept]

Phrase: "is"

Phrase: "pivotal in the progressive decline of -cell function,"

Phrase: "marking"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0522501:marking [Qualitative Concept]

Phrase: "the transition from impaired glucose tolerance"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0599156:Transition [Cell or Molecular Dysfunction]
   753   C2700061:Transition [Activity]

Phrase: "to overt type 2 diabetes"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   923   C0011860:Type 2 Diabetes [Disease or Syndrome]
   875   C1320657:type diabetes [Finding]
   861   C0441730:Type 2 [Classification]
   812   C0011847:Diabetes [Disease or Syndrome]
   812   C0011849:Diabetes [Disease or Syndrome]
   812   C0332307:Type [Qualitative Concept]
   812   C1547052:*Type [Quantitative Concept]

Phrase: "(13"

Phrase: ")."
Processing 00000000.tx.30: Several reports suggest that CD38 plays a role as one of the physiological mediators of insulin release (4). 

Phrase: "Several reports"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   861   C0684224:Reports [Intellectual Product]
   861   C0700287:reports [Health Care Activity]
   827 E C3273238:Report [Intellectual Product]

Phrase: "suggest"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1705535:Suggest [Idea or Concept]

Phrase: "that CD38"

Phrase: "plays"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0032214:Play [Daily or Recreational Activity]
  1000   C0600138:Plays [Finding]

Phrase: "a role as one of the physiological mediators of insulin release"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   738   C0035820:Role [Social Behavior]
   738   C1705810:Role [Conceptual Entity]

Phrase: "(4"

Phrase: ")."
Processing 00000000.tx.31: Human CD38 is an ecto-enzyme and a signal transducing cell surface receptor (57) found to be mainly expressed in hematopoietic lineages and, more recently, in other tissues (8). 

Phrase: "Human CD38"

Phrase: "is"

Phrase: "an ecto-enzyme"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   861   C0014442:Enzyme [Enzyme,Organic Chemical]
   861   C1424158:ECTO [Gene or Genome]
   861   C3273663:ECTO [Gene or Genome]
   777 E C0014445:enzymes [Functional Concept]

Phrase: "and"

Phrase: "a signal transducing cell surface receptor"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   884   C0034800:Cell Surface Receptor [Amino Acid, Peptide, or Protein,Receptor]
   853   C0037083:signal cell [Cell Function]
   840   C0699040:Cell surface [Cell Component]
   804   C0007634:Cell [Cell]
   804   C0205148:Surface [Spatial Concept]
   804   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   804   C1269647:Cell [Cell]
   804   C1704653:Cell [Medical Device]
   804   C1948049:Cell [Spatial Concept]

Phrase: "(57"

Phrase: ")"

Phrase: "found"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0150312:Found [Quantitative Concept]
   966 E C0243095:Find [Finding]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "be"

Phrase: "mainly"

Phrase: "expressed in hematopoietic lineages"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0018957:Haematopoietic [Body System]
   770   C0229601:Hematopoietic [Functional Concept]
   737   C1881379:Lineage [Conceptual Entity]

Phrase: "and"

Phrase: ","

Phrase: "more recently,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0205172:More [Functional Concept]
   861   C0332185:Recently [Temporal Concept]

Phrase: "in other tissues"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0040300:Tissues [Tissue]
   966 E C1547928:Tissue [Intellectual Product]

Phrase: "(8"

Phrase: ")."
Processing 00000000.tx.32: The enzymatic activities of CD38 lead to the production and degradation of cyclic ADP-ribose (cADPR) (9), a potent Ca2+ mobilizer (10) capable of triggering exocytosis of insulin granules in rat and mouse pancreatic islet cells (11). 

Phrase: "The enzymatic activities of CD38"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   790   C2267219:Enzymatic Activity [Molecular Function]
   760   C0441655:Activities [Activity]
   726 E C0205177:Activity [Functional Concept]
   726 E C0439167:% activity [Quantitative Concept]
   726 E C1561536:*Activity [Idea or Concept]

Phrase: "lead to the production"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   770   C0023175:???lead [Element, Ion, or Isotope,Hazardous or Poisonous Substance]
   770   C0033268:production [Occupational Activity]
   770   C1442948:lead [Inorganic Chemical,Pharmacologic Substance]
   770   C1522538:Lead [Functional Concept]
   770   C2348269:Lead [Element, Ion, or Isotope]
   770   C3275067:LEAD [Therapeutic or Preventive Procedure]

Phrase: "and"

Phrase: "degradation of cyclic ADP-ribose (cADPR)"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   797   C1158076:ADP degradation [Molecular Function]
   760   C0243125:degradation [Functional Concept]
   760   C0699900:Degradation [Organism Function]

Phrase: "(9"

Phrase: ")"

Phrase: ","

Phrase: "a potent Ca2+ mobilizer"

Phrase: "(10"

Phrase: ")"

Phrase: "capable of triggering exocytosis of insulin granules"

Phrase: "in rat"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0034693:Rat, NOS [Mammal]
  1000   C0034721:Rat [Mammal]

Phrase: "and"

Phrase: "mouse pancreatic islet cells"
Meta Candidates (Total=9; Excluded=4; Pruned=0; Remaining=5)
   906   C0734999:Pancreatic islet cell [Cell]
   906   C1522528:Mouse Islet Cell [Tissue]
   861   C0022131:Islet Cells [Body Part, Organ, or Organ Component]
   827 E C1522529:Islet Cell [Cell]
   812   C0007634:Cells [Cell]
   812   C3282337:Cells [Cell]
   779 E C1269647:Cell [Cell]
   779 E C1704653:Cell [Medical Device]
   779 E C1948049:Cell [Spatial Concept]

Phrase: "(11"

Phrase: ")."
Processing 00000000.tx.33: Indeed, glucose-induced insulin secretion is enhanced in transgenic mice that overexpress human CD38 in pancreatic -cells (12) and is attenuated in CD38-knockout mice (13). 

Phrase: "Indeed,"

Phrase: "glucose-induced insulin secretion"
Meta Candidates (Total=9; Excluded=2; Pruned=0; Remaining=7)
   875   C1719133:Glucose/Insulin [Quantitative Concept]
   861   C1256369:insulin secretion [Cell Function]
   812   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   812   C0036536:secretion [Biologic Function]
   812   C0036537:Secretion [Body Substance]
   812   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   812   C1579433:Insulin [Pharmacologic Substance]
   756 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   729 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "is"

Phrase: "enhanced in transgenic mice"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   833   C0025936:Mice, Transgenic [Mammal]
   770   C0003069:Transgenic [Animal]
   770   C0025914:Mice [Mammal]
   770   C0025929:mice [Mammal]
   770   C0026809:Mice [Mammal]
   770   C2349975:Enhanced [Activity]

Phrase: "that"

Phrase: "overexpress"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1514559:overexpress [Genetic Function]

Phrase: "human CD38 in pancreatic -cells"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   797   C0945928:Cells.CD38 [Cell]

Phrase: "(12"

Phrase: ")"

Phrase: "and"

Phrase: "is"

Phrase: "attenuated in CD38-knockout mice"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   806   C0206745:Knock-out Mice [Mammal]
   760   C0025914:Mice [Mammal]
   760   C0025929:mice [Mammal]
   760   C0026809:Mice [Mammal]
   760   C0332161:Attenuated [Qualitative Concept]
   760   C0560617:knock out [Injury or Poisoning]
   760   C0599946:Attenuated [Activity]
   760   C1522225:Knock-out [Experimental Model of Disease]

Phrase: "(13"

Phrase: ")."
Processing 00000000.tx.34: Peculiar genetic and autoimmune features involving CD38 have been associated with human diabetes. 

Phrase: "Peculiar genetic"
Meta Candidates (Total=16; Excluded=14; Pruned=0; Remaining=2)
   861   C0017296:GENETIC [Therapeutic or Preventive Procedure]
   861   C0314603:Genetic [Functional Concept]
   805 E C0005615:Birth [Organism Function]
   805 E C0035150:Reproduction [Organism Function]
   805 E C0079946:origin [Classification]
   805 E C0439659:Origin [Temporal Concept]
   805 E C1550512:origin [Intellectual Product]
   805 E C1550722:birth [Idea or Concept]
   805 E C3245487:birth [Intellectual Product]
   777 E C0454729:Natal [Geographic Area]
   777 E C0559522:Genital [Body System]
   777 E C1546649:Genital [Intellectual Product]
   777 E C1550642:Genital [Body Substance]
   768 E C0205313:Original [Idea or Concept]
   768 E C2347409:Original [Occupational Activity]
   750 E C0598240:originality [Mental Process]

Phrase: "and"

Phrase: "autoimmune features"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   827   C1521970:Feature [Qualitative Concept]
   827   C1706388:Feature [Conceptual Entity]
   827   C2346469:Feature [Qualitative Concept]
   827   C2348519:Feature [Qualitative Concept]

Phrase: "involving"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1314939:Involving [Functional Concept]

Phrase: "CD38"

Phrase: "have"

Phrase: "been"

Phrase: "associated with human diabetes."
Meta Candidates (Total=7; Excluded=2; Pruned=0; Remaining=5)
   833   C0332281:Associated with [Qualitative Concept]
           Associated
   770   C0011847:Diabetes [Disease or Syndrome]
   770   C0011849:Diabetes [Disease or Syndrome]
   770   C0086418:Human [Human]
   737 E C0750490:Associate [Idea or Concept]
   737 E C1706221:Associate [Professional or Occupational Group]
Processing 00000000.tx.35: The study of potential pathological impairment of CD38-mediated insulin secretion in this disease has gained momentum with the finding of a mutation in the CD38 gene (Arg140Trp) in 13% of Japanese type 2 diabetic patients with a family history of the disease (14). 

Phrase: "The study of potential pathological impairment of CD38-mediated insulin secretion"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   738   C0557651:Study [Manufactured Object]
   738   C2603343:Study [Research Activity]
   718   C0551718:Pathology study [Clinical Attribute]

Phrase: "in this disease"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C0012634:Disease [Disease or Syndrome]
   944 E C1836721:MALS [Finding]
   944 E C3538764:MALS [Gene or Genome]
   944 E C3540595:MAL [Gene or Genome]

Phrase: "has"

Phrase: "gained momentum with the finding of a mutation"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   744   C0563597:Momentum [Natural Phenomenon or Process]

Phrase: "in the CD38 gene"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1413221:CD38 gene [Gene or Genome]
   861   C0017337:Gene [Gene or Genome]

Phrase: "(Arg140Trp"

Phrase: ")"

Phrase: "in 13%"

Phrase: "of Japanese type 2 diabetic patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   804   C0030705:Patients [Patient or Disabled Group]

Phrase: "with a family history"
Meta Candidates (Total=13; Excluded=3; Pruned=0; Remaining=10)
  1000   C0241889:Family history [Finding]
  1000   C1705495:Family History [Idea or Concept]
   861   C0015576:Family [Family Group]
   861   C0019664:History [Occupation or Discipline]
   861   C0019665:history [Intellectual Product]
   861   C0262512:History, NOS [Organism Attribute]
   861   C0262926:History [Finding]
   861   C1704727:Family [Conceptual Entity]
   861   C1705255:History [Conceptual Entity]
   861   C2004062:History [Finding]
   789 E C0241888:Familial [Functional Concept]
   789 E C1552658:Historical [Idea or Concept]
   789 E C1552723:Historical [Idea or Concept]

Phrase: "of the disease"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C0012634:Disease [Disease or Syndrome]
   944 E C1836721:MALS [Finding]
   944 E C3538764:MALS [Gene or Genome]
   944 E C3540595:MAL [Gene or Genome]

Phrase: "(14"

Phrase: ")."
Processing 00000000.tx.36: The protein product of the mutated gene displays altered in vitro enzymatic activities, possibly leading to decreased cADPR production and impaired insulin release in vivo (14). 

Phrase: "The protein product of the mutated gene displays"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   789   C0751455:protein gene product [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   767   C0033684:gene product [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   767   C1704222:Gene Product [Amino Acid, Peptide, or Protein,Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   744   C1514468:product [Entity]
   744   C1704444:Product [Quantitative Concept]

Phrase: "altered"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0392747:Altered [Functional Concept]

Phrase: "in vitro enzymatic activities,"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   844   C2267219:Enzymatic Activity [Molecular Function]
   812   C0441655:Activities [Activity]
   779 E C0205177:Activity [Functional Concept]
   779 E C0439167:% activity [Quantitative Concept]
   779 E C1561536:*Activity [Idea or Concept]

Phrase: "possibly"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2362652:Possibly [Qualitative Concept]

Phrase: "leading to decreased cADPR production"
Meta Candidates (Total=17; Excluded=5; Pruned=0; Remaining=12)
   814   C0056693:Cyclic ADP-Ribose [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   778   C0001461:ADP Ribose [Biologically Active Substance,Carbohydrate,Nucleic Acid, Nucleoside, or Nucleotide]
   748   C0033268:production [Occupational Activity]
   748   C0035549:Ribose [Carbohydrate]
   748   C0205216:Decreased [Quantitative Concept]
   748   C0332152:Leading [Temporal Concept]
   748   C0392756:Decreased [Qualitative Concept]
   748   C0439596:Cyclic [Temporal Concept]
   748   C0442797:decreased [Qualitative Concept]
   748   C0523452:ADP [Laboratory Procedure]
   748   C1511572:Cyclic [Temporal Concept]
   748   C1522538:Leading [Functional Concept]
   714 E C0023175:???lead [Element, Ion, or Isotope,Hazardous or Poisonous Substance]
   714 E C0547047:Decrease [Quantitative Concept]
   714 E C1442948:lead [Inorganic Chemical,Pharmacologic Substance]
   714 E C2348269:Lead [Element, Ion, or Isotope]
   714 E C3275067:LEAD [Therapeutic or Preventive Procedure]

Phrase: "and"

Phrase: "impaired insulin release"
Meta Candidates (Total=11; Excluded=2; Pruned=0; Remaining=9)
   827   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   827   C0030685:Release [Health Care Activity]
   827   C0391871:Release [Functional Concept]
   827   C0439180:% release [Quantitative Concept]
   827   C0680255:release [Health Care Activity]
   827   C1283071:Release [Functional Concept]
   827   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   827   C1579433:Insulin [Pharmacologic Substance]
   827   C1963578:Release [Therapeutic or Preventive Procedure]
   771 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   743 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "in vivo"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1515655:In Vivo [Spatial Concept]
           vivo

Phrase: "(14"

Phrase: ")."
Processing 00000000.tx.37: Furthermore, autoantibodies (aAbs) to CD38 have been found in sera from Japanese type 2 diabetic patients (13.8%) (15) and Caucasian type 2 (9.7%) and type 1 (13.1%) diabetic subjects (16). 

Phrase: "Furthermore,"

Phrase: "autoantibodies"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0004358:Autoantibodies [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: "(aAbs"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0004358:Autoantibodies [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: ")"

Phrase: "to CD38"

Phrase: "have"

Phrase: "been"

Phrase: "found in sera"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
   790   C0150312:Found [Quantitative Concept]
   790   C0229671:Sera [Body Substance]
   790   C1151254:SerA [Molecular Function]
   756 E C0243095:Find [Finding]
   756 E C1546774:Serum [Intellectual Product]
   756 E C1550100:Serum [Body Substance]

Phrase: "from Japanese type 2 diabetic patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   804   C0030705:Patients [Patient or Disabled Group]

Phrase: "(13.8%"

Phrase: ")"

Phrase: "(15"

Phrase: ")"

Phrase: "and"

Phrase: "Caucasian type 2"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   901   C0441730:Type 2 [Classification]
   827   C0007457:Caucasian [Population Group]
   827   C0043157:Caucasian [Population Group]
   827   C0332307:Type [Qualitative Concept]
   827   C1547052:*Type [Quantitative Concept]

Phrase: "(9.7%"

Phrase: ")"

Phrase: "and"

Phrase: "type 1"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0441729:Type 1 [Classification]
   861   C0332307:Type [Qualitative Concept]
   861   C1547052:*Type [Quantitative Concept]

Phrase: "(13.1%"

Phrase: ")"

Phrase: "diabetic subjects"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   827   C0681850:Subject [Group]
   827   C1550501:{Subject} [Idea or Concept]
   827   C1706203:Subject [Idea or Concept]
   827   C2349001:Subject [Human]
   827   C2697811:Subject [Functional Concept]

Phrase: "(16"

Phrase: ")."
Processing 00000000.tx.38: Conflicting results have been obtained concerning the functional capacity of these aAbs to release insulin, as they show inhibitory properties on hormone exocytosis in the Japanese study (15) and stimulatory features in the Italian study (16); 

Phrase: "Conflicting results"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C1274040:Result [Functional Concept]
   827   C1546471:Result [Idea or Concept]
   827   C2825142:Result [Finding]

Phrase: "have"

Phrase: "been"

Phrase: "obtained"
Meta Candidates (Total=8; Excluded=7; Pruned=0; Remaining=1)
  1000   C1301820:Obtained [Functional Concept]
   966 E C1706701:Obtain [Activity]
   928 E C1517378:Gain [Quantitative Concept]
   907 E C0205217:Increased [Quantitative Concept]
   907 E C0439661:Acquired [Temporal Concept]
   907 E C0442805:Increase [Functional Concept]
   907 E C0442808:Increasing [Functional Concept]
   907 E C3245488:acquired [Intellectual Product]

Phrase: "concerning"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C2699424:Concern [Idea or Concept]

Phrase: "the functional capacity of these aAbs to"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   778   C0695468:functional capacity [Therapeutic or Preventive Procedure]
   778   C1998319:Functional capacity [Finding]
   748   C1516240:Capacity [Quantitative Concept]

Phrase: "release"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
  1000   C0030685:Release [Health Care Activity]
  1000   C0391871:Release [Functional Concept]
  1000   C0439180:% release [Quantitative Concept]
  1000   C0680255:release [Health Care Activity]
  1000   C1283071:Release [Functional Concept]
  1000   C1963578:Release [Therapeutic or Preventive Procedure]

Phrase: "insulin,"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
  1000   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
  1000   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
  1000   C1579433:Insulin [Pharmacologic Substance]
   944 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   916 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "as"

Phrase: "they"

Phrase: "show"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1547282:Show [Intellectual Product]

Phrase: "inhibitory properties on hormone exocytosis"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   760   C0871161:properties [Qualitative Concept]
   760   C1292721:properties [Functional Concept]
   726 E C1882134:Property [Conceptual Entity]
   726 E C2347695:Property [Entity]

Phrase: "in the Japanese study"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0557651:Study [Manufactured Object]
   861   C2603343:Study [Research Activity]

Phrase: "(15"

Phrase: ")"

Phrase: "and"

Phrase: "stimulatory features in the Italian study"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   719   C1521970:Feature [Qualitative Concept]
   719   C1706388:Feature [Conceptual Entity]
   719   C2346469:Feature [Qualitative Concept]
   719   C2348519:Feature [Qualitative Concept]

Phrase: "(16"

Phrase: ")"

Phrase: ";"
Processing 00000000.tx.39: however, this discrepancy could result from the use of rat islets in the first case and human islets in the second. 

Phrase: "however,"

Phrase: "this discrepancy"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1290905:Discrepancy [Finding]

Phrase: "could"

Phrase: "result from the use of rat islets"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   778   C1524063:Use of [Functional Concept]
   748   C0034693:Rat, NOS [Mammal]
   748   C0034721:Rat [Mammal]
   748   C0042153:use [Functional Concept]
   748   C0457083:Use [Functional Concept]
   748   C1274040:Result [Functional Concept]
   748   C1546471:Result [Idea or Concept]
   748   C1947944:Use [Intellectual Product]
   748   C2825142:Result [Finding]

Phrase: "in the first case"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0868928:Case [Functional Concept]
   861   C1706255:CASE [Medical Device]
   861   C1706256:Case [Conceptual Entity]

Phrase: "and"

Phrase: "human islets in the second."
Processing 00000000.tx.40: A genetic restriction fragmentlength polymorphism of the CD38 gene, with a common CD38*B (86%) and a less frequent CD38*A allele (14%), has been described in healthy Caucasian subjects (17). 

Phrase: "A genetic restriction fragmentlength polymorphism of the CD38 gene,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   762   C0032529:Genetic Polymorphism [Genetic Function]
           Polymorphism
   762   C0678951:gene polymorphism [Genetic Function]
   742   C1882417:Polymorphism [Qualitative Concept]

Phrase: "with a common CD38"

Phrase: "*B (86%"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C2347469:/B [Quantitative Concept]

Phrase: ")"

Phrase: "and"

Phrase: "a less frequent CD38"

Phrase: "*"

Phrase: "A allele"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0002085:Allele [Gene or Genome]

Phrase: "(14%"

Phrase: ")"

Phrase: ","

Phrase: "has"

Phrase: "been"

Phrase: "described in healthy Caucasian subjects"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   797   C1708335:HEALTHY SUBJECTS [Population Group]
   760   C0007457:Caucasian [Population Group]
   760   C0043157:Caucasian [Population Group]
   760   C1552738:described [Idea or Concept]
   726   C0681850:Subject [Group]
   726   C1550501:{Subject} [Idea or Concept]
   726   C1706203:Subject [Idea or Concept]
   726   C2349001:Subject [Human]
   726   C2697811:Subject [Functional Concept]

Phrase: "(17"

Phrase: ")."
Processing 00000000.tx.41: The relevance of this polymorphism in selected pathological conditions, i.e., whether the CD38*A allele is more common in diabetic subjects, has not yet been established. 

Phrase: "The relevance of this polymorphism"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C2347946:Relevance [Qualitative Concept]

Phrase: "in selected pathological conditions,"
Meta Candidates (Total=16; Excluded=11; Pruned=0; Remaining=5)
   827   C0030664:Pathological [Biomedical Occupation or Discipline]
   827   C1521733:Pathological [Functional Concept]
   793   C0012634:condition [Disease or Syndrome]
   793   C0348080:Condition [Qualitative Concept]
   793   C1705253:Condition [Conceptual Entity]
   771 E C0040607:Training [Educational Activity]
   771 E C0220931:Training [Educational Activity]
   771 E C0336809:Train [Manufactured Object]
   771 E C1552514:Train [Manufactured Object]
   771 E C2673163:training [Qualitative Concept]
   755 E C0205469:pathology [Functional Concept]
   755 E C0677042:pathology [Pathologic Function]
   743 E C0009647:Conditioned [Mental Process]
   743 E C1701901:Conditional [Qualitative Concept]
   743 E C1963686:Conditional [Functional Concept]
   721 E C1519605:Conditionality [Conceptual Entity]

Phrase: "i.e.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0683454:I-E [Diagnostic Procedure,Intellectual Product]
   861   C0021966:I- [Inorganic Chemical]
   861   C0221138:I NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: "whether"

Phrase: "the CD38"

Phrase: "*"

Phrase: "A allele"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0002085:Allele [Gene or Genome]

Phrase: "is"

Phrase: "more common in diabetic subjects,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C0205214:Common [Quantitative Concept]
   760   C1522138:Common [Functional Concept]
   760   C3245511:common [Intellectual Product]

Phrase: "has"

Phrase: "not yet"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1518422:Not [Functional Concept]

Phrase: "been"

Phrase: "established."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0443211:Established [Qualitative Concept]
  1000   C1272684:Established [Qualitative Concept]
Processing 00000000.tx.42: A genetic polymorphism has also been described for the CD38-related ecto-enzyme PC-1 and has been found to be associated with insulin resistance (18). 

Phrase: "A genetic polymorphism"
Meta Candidates (Total=19; Excluded=14; Pruned=0; Remaining=5)
  1000   C0032529:Genetic Polymorphism [Genetic Function]
           Polymorphism
   861   C0017296:GENETIC [Therapeutic or Preventive Procedure]
   861   C0314603:Genetic [Functional Concept]
   861   C1882417:Polymorphism [Qualitative Concept]
   805 E C0005615:Birth [Organism Function]
   805 E C0035150:Reproduction [Organism Function]
   805 E C0079946:origin [Classification]
   805 E C0439659:Origin [Temporal Concept]
   805 E C1550512:origin [Intellectual Product]
   805 E C1550722:birth [Idea or Concept]
   805 E C3245487:birth [Intellectual Product]
   777 E C0454729:Natal [Geographic Area]
   777 E C0559522:Genital [Body System]
   777 E C1546649:Genital [Intellectual Product]
   777 E C1550642:Genital [Body Substance]
   768 E C0205313:Original [Idea or Concept]
   768 E C2347409:Original [Occupational Activity]
   750 E C0598240:originality [Mental Process]

Phrase: "has"

Phrase: "also"

Phrase: "been"

Phrase: "described for the CD38-related ecto-enzyme PC-1"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   764   C1414407:PC-1 [Gene or Genome]
   764   C1418599:Pc-1 [Gene or Genome]
   742   C0014442:Enzyme [Enzyme,Organic Chemical]
   742   C0439849:Related [Qualitative Concept]
   742   C0445223:Related [Finding]
   742   C1424158:ECTO [Gene or Genome]
   742   C1552738:described [Idea or Concept]
   742   C3273663:ECTO [Gene or Genome]
   742   C3540812:PC [Gene or Genome]

Phrase: "and"

Phrase: "has"

Phrase: "been"

Phrase: "found"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0150312:Found [Quantitative Concept]
   966 E C0243095:Find [Finding]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "be"

Phrase: "associated with insulin resistance"
Meta Candidates (Total=12; Excluded=3; Pruned=0; Remaining=9)
   833   C0021655:Insulin Resistance [Pathologic Function]
   833   C0332281:Associated with [Qualitative Concept]
           Associated
   833   C2700570:INSULIN RESISTANCE [Gene or Genome]
   770   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   770   C0237834:Resistance [Mental Process]
   770   C1514892:Resistance [Physiologic Function]
   770   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   770   C1579433:Insulin [Pharmacologic Substance]
   737 E C0750490:Associate [Idea or Concept]
   737 E C1706221:Associate [Professional or Occupational Group]
   715 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]

Phrase: "(18"

Phrase: ")."
Processing 00000000.tx.43: The lower frequency of the CD38*A allele could mask its preferential association with the diabetic condition; 

Phrase: "The lower frequency of the CD38"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   753   C0376249:frequency [Quantitative Concept]
   753   C0439603:Frequency [Temporal Concept]
   753   C0871396:Frequency [Quantitative Concept]
   753   C1561548:Frequency [Qualitative Concept]
   753   C1705502:Frequency [Quantitative Concept]

Phrase: "*"

Phrase: "A allele"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0002085:Allele [Gene or Genome]

Phrase: "could"

Phrase: "mask"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0024861:Mask [Medical Device]
  1000   C1538279:MASK [Gene or Genome]
  1000   C1845191:MASK [Gene or Genome]

Phrase: "its preferential association with the diabetic condition"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   748   C0004083:Association [Mental Process]
   748   C0439849:Association [Qualitative Concept]
   748   C0596306:Association [Phenomenon or Process]
   748   C0699792:association [Social Behavior]

Phrase: ";"
Processing 00000000.tx.44: moreover, the Arg140Trp mutation has not yet been explored in Caucasian patients. 

Phrase: "moreover,"

Phrase: "the Arg140Trp mutation"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0026882:Mutation [Genetic Function]
   861   C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "has"

Phrase: "not yet"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1518422:Not [Functional Concept]

Phrase: "been"

Phrase: "explored in Caucasian patients."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0007457:Caucasian [Population Group]
   770   C0030705:Patients [Patient or Disabled Group]
   770   C0043157:Caucasian [Population Group]
Processing 00000000.tx.45: The aim of the present study was as follows: 1) to define the prevalence of anti-CD38 aAbs in Caucasian diabetic subjects, using an immunoenzymatic assay suitable for large-scale screening; 

Phrase: "The aim of the present study"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   753   C1947946:Aim [Idea or Concept]
   753   C2948600:Aim [Pharmacologic Substance]
   753   C3540471:AIM [Gene or Genome]
   753   C3540472:AIM [Functional Concept]

Phrase: "was"

Phrase: "as"

Phrase: "follows"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0332283:follow [Temporal Concept]
  1000   C1719822:Follow [Intellectual Product]

Phrase: ":"

Phrase: "1"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C2827734:1+ [Quantitative Concept]
  1000   C2981698:1+ [Classification]

Phrase: ")"

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "define"

Phrase: "the prevalence of anti-CD38 aAbs"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0033105:Prevalence [Quantitative Concept]
   753   C0220900:prevalence [Quantitative Concept]

Phrase: "in Caucasian diabetic subjects,"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   793   C0681850:Subject [Group]
   793   C1550501:{Subject} [Idea or Concept]
   793   C1706203:Subject [Idea or Concept]
   793   C2349001:Subject [Human]
   793   C2697811:Subject [Functional Concept]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "an immunoenzymatic assay"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0086231:Immunoenzymatic assay, NOS [Laboratory Procedure]
   861   C0005507:Assay [Laboratory Procedure]
   861   C0243073:assay [Qualitative Concept]
   861   C1510438:Assay [Laboratory Procedure]

Phrase: "suitable for large-scale screening"

Phrase: ";"
Processing 00000000.tx.46: 2) to explore the functional activities of the anti-CD38 aAbs identified and their association with differential diabetic characteristics; 

Phrase: "2"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0740116:+2 [Quantitative Concept]
  1000   C2827735:2+ [Quantitative Concept]
  1000   C2981700:2+ [Classification]

Phrase: ")"

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "explore"

Phrase: "the functional activities of the anti-CD38 aAbs"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   770   C0695584:functional activities [Therapeutic or Preventive Procedure]
   744   C0441655:Activities [Activity]
   711 E C0205177:Activity [Functional Concept]
   711 E C0439167:% activity [Quantitative Concept]
   711 E C1561536:*Activity [Idea or Concept]

Phrase: "identified"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205396:Identified [Qualitative Concept]
  1000   C1550043:Identified [Finding]
  1000   C1551388:Identified [Functional Concept]

Phrase: "and"

Phrase: "their association with differential diabetic characteristics"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   753   C0004083:Association [Mental Process]
   753   C0439849:Association [Qualitative Concept]
   753   C0596306:Association [Phenomenon or Process]
   753   C0699792:association [Social Behavior]

Phrase: ";"
Processing 00000000.tx.47: and 3) to define the relative significance of the CD38 genetic background. 

Phrase: "and"

Phrase: "3"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0439086:<3 [Quantitative Concept]
  1000   C2827736:3+ [Quantitative Concept]
  1000   C2981702:3+ [Classification]

Phrase: ")"

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "define"

Phrase: "the relative significance of the CD38 genetic background."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   744   C0237881:Significance [Quantitative Concept]
   744   C0750502:Significance [Idea or Concept]
Processing 00000000.tx.48: The results obtained indicate that the anti-CD38 autoimmune response is widely represented not only in type 1 but also in type 2 diabetic patients and mainly involves agonistic antibodies, whereas the genetic parameters examined do not appear to be relevant in this context.  

Phrase: "The results"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   966   C1274040:Result [Functional Concept]
   966   C1546471:Result [Idea or Concept]
   966   C2825142:Result [Finding]

Phrase: "obtained"
Meta Candidates (Total=8; Excluded=7; Pruned=0; Remaining=1)
  1000   C1301820:Obtained [Functional Concept]
   966 E C1706701:Obtain [Activity]
   928 E C1517378:Gain [Quantitative Concept]
   907 E C0205217:Increased [Quantitative Concept]
   907 E C0439661:Acquired [Temporal Concept]
   907 E C0442805:Increase [Functional Concept]
   907 E C0442808:Increasing [Functional Concept]
   907 E C3245488:acquired [Intellectual Product]

Phrase: "indicate"

Phrase: "that"

Phrase: "the anti-CD38 autoimmune response"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   861   C0004366:Autoimmune Response [Pathologic Function]
   812   C0443146:Autoimmune [Pathologic Function]
   812   C0871261:Response [Organism Attribute]
   812   C1704632:Response [Finding]
   812   C1706817:Response [Intellectual Product]
   812   C2911692:Response [Mental Process]

Phrase: "is"

Phrase: "widely"

Phrase: "represented"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1882932:Represent [Activity]

Phrase: "not only in type 1"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   806   C0441729:Type 1 [Classification]
   760   C0205171:Only [Quantitative Concept]
   760   C0332307:Type [Qualitative Concept]
   760   C1518422:Not [Functional Concept]
   760   C1547052:*Type [Quantitative Concept]
   760   C1720467:Only [Intellectual Product]

Phrase: "but"

Phrase: "also in type 2 diabetic patients"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   790   C0441730:Type 2 [Classification]
   767   C1550335:Patient type [Classification]
   753   C0030705:Patients [Patient or Disabled Group]
   753   C0241863:DIABETIC [Finding]
   753   C0332307:Type [Qualitative Concept]
   753   C1547052:*Type [Quantitative Concept]

Phrase: "and"

Phrase: "mainly"

Phrase: "involves"

Phrase: "agonistic antibodies,"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0003241:Antibodies [Amino Acid, Peptide, or Protein,Cell Component,Immunologic Factor]
   827 E C0021027:Antibody [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]

Phrase: "whereas"

Phrase: "the genetic parameters"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
   861   C0449381:Parameters [Finding]
   827 E C0549193:Parameter [Spatial Concept]
   827 E C1704769:Parameter [Conceptual Entity]
   827 E C2350001:Parameter [Quantitative Concept]

Phrase: "examined"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0332128:Examined [Finding]

Phrase: "do"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "appear"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0700364:APPEAR [Qualitative Concept]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "be"

Phrase: "relevant in this context."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C2347946:Relevant [Qualitative Concept]
Processing 00000000.tx.49: RESEARCH DESIGN AND METHODS TOP ABSTRACT INTRODUCTION RESEARCH DESIGN AND METHODS RESULTS DISCUSSION REFERENCES  Selection of patients. 

Phrase: "RESEARCH DESIGN"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0035171:Research Design [Research Activity]
   861   C0035168:research [Research Activity]
   861   C0242481:Research [Research Activity]
   861   C1707689:Design [Activity]
   861   C2983265:DESIGN [Intellectual Product]

Phrase: "AND"

Phrase: "METHODS TOP ABSTRACT INTRODUCTION RESEARCH DESIGN"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   876   C0086912:methods research [Research Activity]
   827   C0035171:Research Design [Research Activity]
   799   C0035168:research [Research Activity]
   799   C0242481:Research [Research Activity]
   799   C1707689:Design [Activity]
   799   C2983265:DESIGN [Intellectual Product]

Phrase: "AND"

Phrase: "METHODS RESULTS DISCUSSION"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0557061:Discussion [Therapeutic or Preventive Procedure]
   827   C2584313:Discussion [Social Behavior]

Phrase: "REFERENCES"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1514811:Reference [Idea or Concept]
  1000   C1706462:Reference [Conceptual Entity]

Phrase: "Selection of patients."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   841   C0242802:Patient Selection [Research Activity]
   790   C0036576:selection [Genetic Function]
Processing 00000000.tx.50: A total of 208 diabetic patients (94 type 1 and 114 type 2) were randomly selected among the outpatients attending the Diabetology Clinic at the San Giovanni Battista Hospital in Torino, Italy. 

Phrase: "A total of 208 diabetic patients"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0439175:% total [Quantitative Concept]
   753   C0439810:Total [Qualitative Concept]

Phrase: "(94 type 1"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   901   C0441729:Type 1 [Classification]
   827   C0332307:Type [Qualitative Concept]
   827   C1547052:*Type [Quantitative Concept]

Phrase: "and"

Phrase: "114 type 2"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   901   C0441730:Type 2 [Classification]
   827   C0332307:Type [Qualitative Concept]
   827   C1547052:*Type [Quantitative Concept]

Phrase: ")"

Phrase: "were"

Phrase: "randomly"

Phrase: "selected among the outpatients"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   770   C0029921:Outpatients [Patient or Disabled Group]
   737 E C1548439:Outpatient [Idea or Concept]
   737 E C1549405:Outpatient [Classification]
   737   C1707391:Select [Activity]

Phrase: "attending"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1547429:Attending [Professional or Occupational Group]
  1000   C1999232:attending [Functional Concept]

Phrase: "the Diabetology Clinic at the San Giovanni Battista Hospital"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   762   C0587906:Hospital clinic [Health Care Related Organization,Manufactured Object]
   742   C0002424:Clinic [Health Care Related Organization,Manufactured Object]
   742   C0442592:Clinic [Health Care Related Organization,Manufactured Object]

Phrase: "in Torino,"

Phrase: "Italy."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0022277:Italy [Geographic Area]
Processing 00000000.tx.51: Diagnosis of either type 1 or type 2 diabetes was made according to the American Diabetes Association and World Health Organization (WHO) criteria (19,20). 

Phrase: "Diagnosis of either type 1"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   797   C1550351:Diagnosis Type [Classification]
   760   C0011900:Diagnosis [Finding]
   760   C1704338:diagnosis [Qualitative Concept]
   760   C1704656:DIAGNOSIS [Research Activity]

Phrase: "or"

Phrase: "type 2 diabetes"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
  1000   C0011860:Type 2 Diabetes [Disease or Syndrome]
   913   C1320657:type diabetes [Finding]
   901   C0441730:Type 2 [Classification]
   827   C0011847:Diabetes [Disease or Syndrome]
   827   C0011849:Diabetes [Disease or Syndrome]
   827   C0332307:Type [Qualitative Concept]
   827   C1547052:*Type [Quantitative Concept]

Phrase: "was"

Phrase: "made according to the American Diabetes Association"
Meta Candidates (Total=10; Excluded=0; Pruned=0; Remaining=10)
   814   C1705019:American Diabetes Association [Professional Society]
   748   C0004083:Association [Mental Process]
   748   C0011847:Diabetes [Disease or Syndrome]
   748   C0011849:Diabetes [Disease or Syndrome]
   748   C0439849:Association [Qualitative Concept]
   748   C0596070:American [Population Group]
   748   C0596306:Association [Phenomenon or Process]
   748   C0680240:according [Social Behavior]
   748   C0699792:association [Social Behavior]
   714   C1881534:Make [Functional Concept]

Phrase: "and"

Phrase: "World Health Organization (WHO) criteria"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   812   C0243161:criteria [Intellectual Product]
   756   C0043237:World Health Organization [Health Care Related Organization]

Phrase: "(19,"

Phrase: "20"

Phrase: ")."
Processing 00000000.tx.52: Healthy control subjects with no family history of diabetes, normal fasting plasma glucose levels, and similar sex, age, and BMI distribution were selected at the local blood bank. 

Phrase: "Healthy control"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
  1000   C2986479:Healthy Control [Qualitative Concept]
   861   C0243148:control [Qualitative Concept]
   861   C1550141:Control [Substance]
   861   C1882979:Control [Conceptual Entity]
   861   C2587213:Control [Functional Concept]
   861   C3274648:Control [Qualitative Concept]
   789   C0018684:Health [Idea or Concept]
   789   C0031206:healthiness [Finding]

Phrase: "subjects with no family history of diabetes,"
Meta Candidates (Total=17; Excluded=0; Pruned=0; Remaining=17)
   778   C0241889:Family history [Finding]
   778   C1705495:Family History [Idea or Concept]
   748   C0011847:Diabetes [Disease or Syndrome]
   748   C0011849:Diabetes [Disease or Syndrome]
   748   C0015576:Family [Family Group]
   748   C0019664:History [Occupation or Discipline]
   748   C0019665:history [Intellectual Product]
   748   C0262512:History, NOS [Organism Attribute]
   748   C0262926:History [Finding]
   748   C0681850:Subject [Group]
   748   C1550501:{Subject} [Idea or Concept]
   748   C1704727:Family [Conceptual Entity]
   748   C1705255:History [Conceptual Entity]
   748   C1706203:Subject [Idea or Concept]
   748   C2004062:History [Finding]
   748   C2349001:Subject [Human]
   748   C2697811:Subject [Functional Concept]

Phrase: "normal fasting plasma glucose levels,"
Meta Candidates (Total=9; Excluded=4; Pruned=0; Remaining=5)
   894   C0522082:Normal glucose level [Finding]
   851   C0455280:plasma glucose level [Laboratory or Test Result]
   840   C0428548:glucose levels [Laboratory or Test Result]
   806 E C0337438:glucose level [Laboratory Procedure]
   804   C0441889:Levels [Qualitative Concept]
   771 E C0456079:Level [Classification]
   771 E C1547707:Level [Geographic Area]
   771 E C2946261:Level [Pharmacologic Substance]
   708   C0860800:normal glucose [Finding]

Phrase: "and"

Phrase: "similar sex,"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   861   C0009253:Sex [Organism Function]
   861   C0036864:Sex [Behavior]
   861   C0079399:sex [Organism Attribute]
   861   C1314687:Sex [Finding]
   861   C1522384:sex [Organism Attribute]

Phrase: "age,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0001779:Age [Organism Attribute]

Phrase: "and"

Phrase: "BMI distribution"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0520511:distribution [Idea or Concept]
   861   C1704711:Distribution [Functional Concept]

Phrase: "were"

Phrase: "selected at the local blood bank."
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   790   C0005770:Blood Bank [Health Care Related Organization,Manufactured Object]
   790   C1547977:Blood Bank [Intellectual Product]
   753   C0005767:Blood [Tissue]
   753   C0005768:blood [Body Substance]
   753   C0205276:Local [Spatial Concept]
   753   C0229664:Blood [Body Substance]
   753   C0442598:Bank [Manufactured Object]
   753   C0872261:Bank [Manufactured Object]
   719   C1707391:Select [Activity]
Processing 00000000.tx.53: All blood samples were obtained in the morning after overnight fasting. 

Phrase: "All blood samples"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0178913:blood samples [Body Substance]
   827   C0370003:Sample [Substance]
   827   C2347026:Sample [Conceptual Entity]

Phrase: "were"

Phrase: "obtained in the morning"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   770   C0332170:Morning [Temporal Concept]
   770   C1301820:Obtained [Functional Concept]
   737 E C1706701:Obtain [Activity]

Phrase: "after overnight fasting."
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   861   C0015663:Fasting [Finding]
   861   C1550565:fasting [Intellectual Product]
   827 E C0456962:Fast [Qualitative Concept]
Processing 00000000.tx.54: Informed consent was obtained from each participant, and the study was approved by the San Giovanni Battista Hospital Review Board and Ethics Committee. 

Phrase: "Informed consent"
Meta Candidates (Total=7; Excluded=3; Pruned=0; Remaining=4)
  1000   C0021430:Informed Consent [Regulation or Law]
   861   C1511481:Consent [Functional Concept]
   861   C1522154:Informed [Qualitative Concept]
   861   C1554192:consent [Idea or Concept]
   827 E C0537670:Inform [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   827 E C0700287:inform [Health Care Activity]
   827 E C1552002:inform [Idea or Concept]

Phrase: "was"

Phrase: "obtained from each participant,"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   770   C0679646:Participant [Population Group]
   770   C1301820:Obtained [Functional Concept]
   770   C2698741:Participant [Classification]
   737 E C1706701:Obtain [Activity]

Phrase: "and"

Phrase: "the study"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0557651:Study [Manufactured Object]
  1000   C2603343:Study [Research Activity]

Phrase: "was"

Phrase: "approved by the San Giovanni Battista Hospital Review Board"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   742   C0019994:Hospital, NOS [Health Care Related Organization,Manufactured Object]
   742   C0205540:Approved [Qualitative Concept]
   742   C0282443:Review [Intellectual Product]
   742   C0972401:board [Medical Device]
   742   C1510665:Hospital [Qualitative Concept]
   742   C1552617:Review [Idea or Concept]
   742   C1826357:San [Gene or Genome]
   742   C1948070:Board [Organization]

Phrase: "and"

Phrase: "Ethics Committee."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0085546:Ethics Committee [Professional or Occupational Group]
   861   C2699414:Committee [Group]
Processing 00000000.tx.55: Titer analysis of anti-CD38 aAbs by enzymatic immunoassay. 

Phrase: "Titer analysis of anti-CD38 aAbs"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   753   C0002778:Analysis [Laboratory Procedure]
   753   C0936012:Analysis [Research Activity]
   753   C1524024:analysis [Functional Concept]

Phrase: "by enzymatic immunoassay."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0020980:Immunoassay [Laboratory Procedure]
   861   C0021060:immunoassay [Laboratory Procedure]
Processing 00000000.tx.56: Recombinant soluble CD38 (rsCD38) (received from H.C. Lee, University of Minnesota, Minneapolis, MN) was used as the target antigen in the enzymatic immunoassay (EIA). 

Phrase: "Recombinant soluble CD38 (rsCD38)"

Phrase: "("

Phrase: "received from H.C. Lee,"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   760   C0033727:H+ [Element, Ion, or Isotope]
   760   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   760   C0441932:H+ [Classification]
   760   C0564385:/h [Quantitative Concept]
   760   C1514756:Received [Qualitative Concept]

Phrase: "University of Minnesota,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0026183:Minnesota [Geographic Area]
   827   C0041740:University [Manufactured Object,Organization]

Phrase: "Minneapolis,"

Phrase: "MN)"

Phrase: "was"

Phrase: "used as the target antigen"
Meta Candidates (Total=7; Excluded=3; Pruned=0; Remaining=4)
   760   C0003320:Antigen [Immunologic Factor]
   760   C1273517:used [Finding]
   760   C1521840:Target [Functional Concept]
   760   C2986546:TARGET [Diagnostic Procedure]
   726 E C0042153:use [Functional Concept]
   726 E C0457083:Use [Functional Concept]
   726 E C1947944:Use [Intellectual Product]

Phrase: "in the enzymatic immunoassay (EIA)."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0020980:Immunoassay [Laboratory Procedure]
   861   C0021060:immunoassay [Laboratory Procedure]
Processing 00000000.tx.57: This protein was obtained from Pichia pastoris yeast cells and represents the unglycosylated extracellular domain of CD38 (21). 

Phrase: "This protein"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "was"

Phrase: "obtained from Pichia pastoris yeast cells"
Meta Candidates (Total=13; Excluded=4; Pruned=0; Remaining=9)
   790   C2700289:Yeast Cells [Laboratory Procedure]
   753   C0007634:Cells [Cell]
   753   C0031874:Pichia [Fungus]
   753   C0036025:yeast [Fungus]
   753   C0043392:Yeast [Food]
   753   C0043393:Yeast [Fungus]
   753   C0717551:YEAST [Immunologic Factor,Pharmacologic Substance]
   753   C1301820:Obtained [Functional Concept]
   753   C3282337:Cells [Cell]
   719 E C1269647:Cell [Cell]
   719 E C1704653:Cell [Medical Device]
   719 E C1706701:Obtain [Activity]
   719 E C1948049:Cell [Spatial Concept]

Phrase: "and"

Phrase: "represents"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1882932:Represent [Activity]

Phrase: "the unglycosylated extracellular domain of CD38"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   790   C1517050:Extracellular Domain [Spatial Concept]
   753   C0521119:Extracellular [Cell Component]
   753   C1880389:Domain [Functional Concept]
   753   C1883221:Domain [Conceptual Entity]
   753   C3541951:Domain [Intellectual Product]

Phrase: "(21"

Phrase: ")."
Processing 00000000.tx.58: EIA plates were incubated overnight at 4C with rsCD38 previously dialyzed against phosphate-buffered saline (PBS). 

Phrase: "EIA plates"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   827   C1139930:plates [Medical Device]
   793 E C0005971:Plate [Medical Device]
   793 E C3537155:Plate [Manufactured Object]

Phrase: "were"

Phrase: "incubated"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1439852:Incubated [Laboratory Procedure]

Phrase: "overnight at 4C"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0439583:Overnight [Temporal Concept]
   790   C0450376:4c [Intellectual Product]

Phrase: "with rsCD38 previously"

Phrase: "dialyzed against phosphate-buffered saline (PBS)."
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   797   C0991865:buffered phosphate [Indicator, Reagent, or Diagnostic Aid,Pharmacologic Substance]
   760   C0006353:Buffered [Indicator, Reagent, or Diagnostic Aid,Pharmacologic Substance]
   760   C0031603:Phosphate [Inorganic Chemical,Pharmacologic Substance]
   760   C0031701:phosphate [Organophosphorus Compound]
   760   C0036082:Saline [Substance]
   760   C1601799:PHOSPHATE [Inorganic Chemical,Pharmacologic Substance]
Processing 00000000.tx.59: After three washings in PBS, wells were saturated with 5% nonfat dry milk in PBS and washed again in PTN (0.05% Tween 20 and 0.05% sodium azide in PBS). 

Phrase: "After three washings"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0441648:Washing [Activity]

Phrase: "in PBS,"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   884   C0991865:Phosphate Buffer [Indicator, Reagent, or Diagnostic Aid,Pharmacologic Substance]
   827   C0006353:Buffered [Indicator, Reagent, or Diagnostic Aid,Pharmacologic Substance]
   827   C0031603:Phosphate [Inorganic Chemical,Pharmacologic Substance]
   827   C0031701:phosphate [Organophosphorus Compound]
   827   C0036082:Saline [Substance]
   827   C1601799:PHOSPHATE [Inorganic Chemical,Pharmacologic Substance]

Phrase: "wells"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   966   C0205170:Well [Qualitative Concept]
   966   C3146287:Well [Manufactured Object]

Phrase: "were"

Phrase: "saturated with 5% nonfat dry milk"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   753   C0011682:Dry [Natural Phenomenon or Process]
   753   C0026131:Milk [Body Substance]
   753   C0205222:Dry [Qualitative Concept]
   753   C0349374:Milk [Food]
   753   C0444318:Milk [Substance]
   753   C0522534:Saturated [Phenomenon or Process]
   753   C1512080:Dry [Qualitative Concept]
   753   C1705188:SATURATED [Quantitative Concept]
   753   C2825079:Milk [Food]

Phrase: "in PBS"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   884   C0991865:Phosphate Buffer [Indicator, Reagent, or Diagnostic Aid,Pharmacologic Substance]
   827   C0006353:Buffered [Indicator, Reagent, or Diagnostic Aid,Pharmacologic Substance]
   827   C0031603:Phosphate [Inorganic Chemical,Pharmacologic Substance]
   827   C0031701:phosphate [Organophosphorus Compound]
   827   C0036082:Saline [Substance]
   827   C1601799:PHOSPHATE [Inorganic Chemical,Pharmacologic Substance]

Phrase: "and"

Phrase: "washed"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1548982:Washed [Idea or Concept]
   966 E C0441648:Wash [Activity]

Phrase: "again in PTN (0.05% Tween 20"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   778   C0041415:Tween 20 [Organic Chemical,Pharmacologic Substance]
   751 E C0032600:Polysorbate 20 [Organic Chemical,Pharmacologic Substance]
   748   C0041420:tween [Organic Chemical,Pharmacologic Substance]
   748   C0084084:PTN [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   748   C1335278:PTN [Gene or Genome]

Phrase: "and"

Phrase: "0.05% sodium azide in PBS"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0074721:Sodium Azide [Hazardous or Poisonous Substance,Inorganic Chemical,Indicator, Reagent, or Diagnostic Aid]
   744   C0004492:azide [Chemical Viewed Structurally]

Phrase: ")."
Processing 00000000.tx.60: Sera of patients diluted 1:640 in PTN were added and incubated for 2 h at 37C. 

Phrase: "Sera of patients"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   790   C0229671:Sera [Body Substance]
   790   C1151254:SerA [Molecular Function]
   756 E C1546774:Serum [Intellectual Product]
   756 E C1550100:Serum [Body Substance]

Phrase: "diluted"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   966   C1720119:Dilute [Functional Concept]
   966   C1948037:Dilute [Functional Concept]

Phrase: "1"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C2827734:1+ [Quantitative Concept]
  1000   C2981698:1+ [Classification]

Phrase: ":"

Phrase: "640 in PTN"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0084084:PTN [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   790   C1335278:PTN [Gene or Genome]

Phrase: "were"

Phrase: "added"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1524062:Added [Functional Concept]
   966 E C1883712:Add [Functional Concept]

Phrase: "and"

Phrase: "incubated for 2 h"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   819   C0011744:h 2 [Element, Ion, or Isotope]
   770   C0033727:H+ [Element, Ion, or Isotope]
   770   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   770   C0441932:H+ [Classification]
   770   C0564385:/h [Quantitative Concept]
   770   C1439852:Incubated [Laboratory Procedure]

Phrase: "at 37C."
Processing 00000000.tx.61: Plates were subsequently washed with PTN, and an alkaline phosphatase-conjugated anti-human IgG monoclonal antibody (mAb) (Cappel; Organon Teknika, Durham, NC) was added for 2 h at 37C. 

Phrase: "Plates"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C1139930:plates [Medical Device]
   966 E C0005971:Plate [Medical Device]
   966 E C3537155:Plate [Manufactured Object]

Phrase: "were"

Phrase: "subsequently"

Phrase: "washed with PTN,"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   790   C0084084:PTN [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   790   C1335278:PTN [Gene or Genome]
   790   C1548982:Washed [Idea or Concept]
   756 E C0441648:Wash [Activity]

Phrase: "and"

Phrase: "an alkaline phosphatase-conjugated anti-human IgG monoclonal antibody (mAb)"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   850   C0003242:anti antibody [Amino Acid, Peptide, or Protein,Immunologic Factor]
   822   C2754943:IgG antibody [Cell Component]
   812   C0003250:Monoclonal antibody [Amino Acid, Peptide, or Protein,Immunologic Factor]
   812   C0946139:IgG.monoclonal [Amino Acid, Peptide, or Protein,Immunologic Factor]
   793   C0003241:Antibody [Amino Acid, Peptide, or Protein,Cell Component,Immunologic Factor]
   793   C0021027:Antibody [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   793   C0746619:monoclonal [Finding]

Phrase: "(Cappel"

Phrase: "; Organon Teknika,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0331880:Organon [Health Care Related Organization]

Phrase: "Durham,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0454851:Durham [Geographic Area]

Phrase: "NC)"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0027964:NC [Geographic Area]
  1000   C0028407:NC [Geographic Area]
  1000   C0067895:NC [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "was"

Phrase: "added for 2 h"
Meta Candidates (Total=8; Excluded=1; Pruned=0; Remaining=7)
   819   C0011744:h 2 [Element, Ion, or Isotope]
   802   C0947272:Add 2 [Quantitative Concept]
   770   C0033727:H+ [Element, Ion, or Isotope]
   770   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   770   C0441932:H+ [Classification]
   770   C0564385:/h [Quantitative Concept]
   770   C1524062:Added [Functional Concept]
   737 E C1883712:Add [Functional Concept]

Phrase: "at 37C."
Processing 00000000.tx.62: After washing in PTN, paranitrophenylphosphate chromogen (1 mg/ml in 10% diethanolamine, 0.5% mmol/l MgCl2, and 0.1 mmol/l sodium azide, pH 9.8) was added, and absorbance was read at 405 nm after 45 min. 

Phrase: "After washing"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0441648:Washing [Activity]

Phrase: "in PTN,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0084084:PTN [Amino Acid, Peptide, or Protein,Biologically Active Substance]
  1000   C1335278:PTN [Gene or Genome]

Phrase: "paranitrophenylphosphate chromogen"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0052799:Chromogen [Indicator, Reagent, or Diagnostic Aid,Organic Chemical]

Phrase: "(1 mg/ml in 10% diethanolamine,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0439294:mg ml [Quantitative Concept]
   753   C0439526:/mL [Quantitative Concept]

Phrase: "0.5% mmol/l MgCl2,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   804   C0024472:MgCl2 [Inorganic Chemical,Pharmacologic Substance]

Phrase: "and"

Phrase: "0.1 mmol/l sodium azide,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0074721:Sodium Azide [Hazardous or Poisonous Substance,Inorganic Chemical,Indicator, Reagent, or Diagnostic Aid]
   799   C0004492:azide [Chemical Viewed Structurally]

Phrase: "pH 9.8"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   827   C0020283:[pH] [Quantitative Concept]
   827   C0450407:ph+ [Finding]
   827   C0450408:ph++ [Finding]
   827   C0450409:ph+++ [Finding]

Phrase: ")"

Phrase: "was"

Phrase: "added"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1524062:Added [Functional Concept]
   966 E C1883712:Add [Functional Concept]

Phrase: ","

Phrase: "and"

Phrase: "absorbance"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1268822:Absorbance [Clinical Attribute]
  1000   C2825050:Absorbance [Phenomenon or Process]

Phrase: "was"

Phrase: "read at 405 nm"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0034754:Read [Daily or Recreational Activity]
   770   C0312860:NM [Cell Function]
   770   C1705179:read [Finding]

Phrase: "after 45 min."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0702093:/min [Temporal Concept]
Processing 00000000.tx.63: The IB4 murine anti-human CD38 mAb (IgG2a) (22) was used as positive control. 

Phrase: "The IB4 murine anti-human CD38 mAb"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   879   C2346801:Anti-CD38 Monoclonal Antibody [Pharmacologic Substance]
   861   C0003242:anti antibody [Amino Acid, Peptide, or Protein,Immunologic Factor]
   818   C0003250:Monoclonal antibody [Amino Acid, Peptide, or Protein,Immunologic Factor]
   795   C0003241:Antibody [Amino Acid, Peptide, or Protein,Cell Component,Immunologic Factor]
   795   C0021027:Antibody [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   795   C0746619:monoclonal [Finding]

Phrase: "(IgG2a"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0020857:IgG2A [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: ")"

Phrase: "(22"

Phrase: ")"

Phrase: "was"

Phrase: "used as positive control."
Meta Candidates (Total=14; Excluded=3; Pruned=0; Remaining=11)
   833   C1883676:Positive Control [Conceptual Entity]
   770   C0243148:control [Qualitative Concept]
   770   C0439178:% Positive [Quantitative Concept]
   770   C1273517:used [Finding]
   770   C1446409:Positive [Qualitative Concept]
   770   C1514241:Positive [Finding]
   770   C1550141:Control [Substance]
   770   C1882979:Control [Conceptual Entity]
   770   C2587213:Control [Functional Concept]
   770   C2825490:Positive [Qualitative Concept]
   770   C3274648:Control [Qualitative Concept]
   737 E C0042153:use [Functional Concept]
   737 E C0457083:Use [Functional Concept]
   737 E C1947944:Use [Intellectual Product]
Processing 00000000.tx.64: Each sample was assayed in triplicate in at least two different experiments; 

Phrase: "Each sample"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0370003:Sample [Substance]
  1000   C2347026:Sample [Conceptual Entity]

Phrase: "was"

Phrase: "assayed in triplicate"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   790   C0205174:Triplicate [Quantitative Concept]
   756   C0005507:Assay [Laboratory Procedure]
   756   C0243073:assay [Qualitative Concept]
   756   C1510438:Assay [Laboratory Procedure]

Phrase: "in"

Phrase: "at least two different experiments"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   812   C0681814:Experiments [Research Activity]
   779 E C1706386:Experiment [Conceptual Entity]
   729 E C1517586:Experimental [Qualitative Concept]

Phrase: ";"
Processing 00000000.tx.65: therefore, the mean of six measurements was used for all subsequent calculations. 

Phrase: "therefore,"

Phrase: "the mean of six measurements"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C0444504:Mean [Quantitative Concept]
   760   C2347634:Mean [Quantitative Concept]
   760   C2348143:Mean [Quantitative Concept]

Phrase: "was"

Phrase: "used for all subsequent calculations."
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
   760   C0332282:Subsequent [Temporal Concept]
   760   C1273517:used [Finding]
   726 E C0042153:use [Functional Concept]
   726 E C0457083:Use [Functional Concept]
   726   C1441506:Calculation [Activity]
   726 E C1947944:Use [Intellectual Product]
Processing 00000000.tx.66: A standard curve was determined including a highly reactive serum in each experiment; 

Phrase: "A standard curve"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0205134:Curve [Spatial Concept]

Phrase: "was"

Phrase: "determined"

Phrase: "including"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0332257:Including [Functional Concept]
   966 E C1552866:include [Idea or Concept]
   966 E C2700399:Include [Activity]

Phrase: "a highly reactive serum in each experiment"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   748   C0229671:Serum [Body Substance]
   748   C1546774:Serum [Intellectual Product]
   748   C1550100:Serum [Body Substance]

Phrase: ";"
Processing 00000000.tx.67: the optical density (OD) obtained with this serum at a 1:640 dilution was conventionally defined as equal to 10,000 AU/ml (arbitrary units), and the reactivity of the other samples was calculated in proportion (23) with the following formula: where the negative control was obtained by incubation of the immobilized rsCD38 with secondary mAb alone. 

Phrase: "the optical density (OD)"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
  1000   C0439164:Optical density [Quantitative Concept]
  1000   C1268822:Optical density [Clinical Attribute]
   861   C0178587:density [Quantitative Concept]
   805   C0042789:Vision [Organism Function]
   805   C2707266:Vision [Clinical Attribute]
   789 E C0439794:Dense [Qualitative Concept]

Phrase: "obtained with this serum"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   770   C0229671:Serum [Body Substance]
   770   C1301820:Obtained [Functional Concept]
   770   C1546774:Serum [Intellectual Product]
   770   C1550100:Serum [Body Substance]
   737 E C1706701:Obtain [Activity]

Phrase: "at a 1"

Phrase: ":"

Phrase: "640 dilution"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0079240:Dilution [Laboratory Procedure]
   861   C1948037:Dilution [Functional Concept]

Phrase: "was"

Phrase: "conventionally"

Phrase: "defined as equal"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   790   C0205163:Equal [Qualitative Concept]
   790   C1549782:Equal [Idea or Concept]
   790   C1704788:Defined [Conceptual Entity]
   790   C3539106:Defined [Intellectual Product]

Phrase: "to 10,000 AU/ml (arbitrary units"
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
   799   C0439148:Units [Quantitative Concept]
   799   C1264693:*Arbitrary [Quantitative Concept]
   799   C1519795:Units [Quantitative Concept]
   793   C0439183:Arbitrary unit [Quantitative Concept]
   766 E C1704753:Unit [Manufactured Object]
   766 E C1880519:Unit [Quantitative Concept]

Phrase: ")"

Phrase: ","

Phrase: "and"

Phrase: "the reactivity of the"

Phrase: "other samples"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   966   C0370003:Sample [Substance]
   966   C2347026:Sample [Conceptual Entity]

Phrase: "was"

Phrase: "calculated in proportion"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   790   C0444686:Calculated [Functional Concept]
   790   C1441506:Calculated [Activity]
   790   C1443182:Calculated [Laboratory Procedure]
   790   C1709707:Proportion [Quantitative Concept]
   718 E C0205351:Proportional [Qualitative Concept]

Phrase: "(23"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0450348:23 [Quantitative Concept]

Phrase: ")"

Phrase: "with the following formula"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0489829:Formula [Intellectual Product]
   861   C1705501:Formula [Intellectual Product]

Phrase: ":"

Phrase: "where"

Phrase: "the negative control"
Meta Candidates (Total=11; Excluded=0; Pruned=0; Remaining=11)
  1000   C1639518:% negative control [Quantitative Concept]
  1000   C1947986:Negative Control [Conceptual Entity]
   861   C0205160:Negative [Qualitative Concept]
   861   C0243148:control [Qualitative Concept]
   861   C1513916:Negative [Finding]
   861   C1550141:Control [Substance]
   861   C1882979:Control [Conceptual Entity]
   861   C2587213:Control [Functional Concept]
   861   C2825415:Negative [Conceptual Entity]
   861   C2825491:Negative [Qualitative Concept]
   861   C3274648:Control [Qualitative Concept]

Phrase: "was"

Phrase: "obtained by incubation of the immobilized rsCD38"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   742   C1301820:Obtained [Functional Concept]
   742   C1514798:recombinant [Organism]
   742   C1749467:soluble [Cell Component]
   742   C1948047:Soluble [Qualitative Concept]
   708 E C1706701:Obtain [Activity]

Phrase: "with secondary mAb"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   901   C0003250:Monoclonal antibody [Amino Acid, Peptide, or Protein,Immunologic Factor]
   827   C0003241:Antibody [Amino Acid, Peptide, or Protein,Cell Component,Immunologic Factor]
   827   C0021027:Antibody [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   827   C0746619:monoclonal [Finding]

Phrase: "alone."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205171:Alone [Quantitative Concept]
  1000   C0439044:alone [Finding]
  1000   C0679994:alone [Group Attribute]
Processing 00000000.tx.68: The upper limit of the normal range was defined as the mean + 3 SD of the values obtained from the sera of healthy control subjects. 

Phrase: "The upper limit of the normal range"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   840   C1519815:Upper Limit of Normal [Quantitative Concept]
   774   C0442816:normal limit [Quantitative Concept]
   774   C1265570:normal limit [Finding]
   748   C0439801:limit [Functional Concept]
   748   C1282910:Upper [Spatial Concept]
   748   C1549649:Limit [Idea or Concept]
   748   C2349209:Limit [Conceptual Entity]

Phrase: "was"

Phrase: "defined as the mean + 3 SD of the values"
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
   742   C0042295:Values [Qualitative Concept]
   742   C0444504:Mean [Quantitative Concept]
   742   C1704788:Defined [Conceptual Entity]
   742   C2347634:Mean [Quantitative Concept]
   742   C2348143:Mean [Quantitative Concept]
   742   C3539106:Defined [Intellectual Product]
   708 E C1522609:Value [Quantitative Concept]

Phrase: "obtained from the sera of healthy control subjects."
Meta Candidates (Total=18; Excluded=3; Pruned=0; Remaining=15)
   770   C2986479:Healthy Control [Qualitative Concept]
   767   C1708335:HEALTHY SUBJECTS [Population Group]
   744   C0229671:Sera [Body Substance]
   744   C0243148:control [Qualitative Concept]
   744   C1151254:SerA [Molecular Function]
   744   C1301820:Obtained [Functional Concept]
   744   C1550141:Control [Substance]
   744   C1882979:Control [Conceptual Entity]
   744   C2587213:Control [Functional Concept]
   744   C3274648:Control [Qualitative Concept]
   711   C0681850:Subject [Group]
   711 E C1546774:Serum [Intellectual Product]
   711 E C1550100:Serum [Body Substance]
   711   C1550501:{Subject} [Idea or Concept]
   711   C1706203:Subject [Idea or Concept]
   711 E C1706701:Obtain [Activity]
   711   C2349001:Subject [Human]
   711   C2697811:Subject [Functional Concept]
Processing 00000000.tx.69: Sera with anti-CD38 response >10,000 AU/ml were diluted up to 1:2,000 to determine exact reactivity levels. 

Phrase: "Sera with anti-CD38 response"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   760   C0229671:Sera [Body Substance]
   760   C1151254:SerA [Molecular Function]
   726 E C1546774:Serum [Intellectual Product]
   726 E C1550100:Serum [Body Substance]

Phrase: ">10,000 AU/ml"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C2348421:AU/mL [Quantitative Concept]
   812   C0439526:/mL [Quantitative Concept]

Phrase: "were"

Phrase: "diluted up to 1"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   737   C1720119:Dilute [Functional Concept]
   737   C1948037:Dilute [Functional Concept]

Phrase: ":"

Phrase: "2,000 to"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0740116:+2 [Quantitative Concept]
   827   C2827735:2+ [Quantitative Concept]
   827   C2981700:2+ [Classification]

Phrase: "determine"

Phrase: "exact reactivity levels."
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
   827   C0441889:Levels [Qualitative Concept]
   793 E C0456079:Level [Classification]
   793 E C1547707:Level [Geographic Area]
   793 E C2946261:Level [Pharmacologic Substance]
Processing 00000000.tx.70: For determination of intra-assay variability, a pool of sera with reactivity near the cutoff values (6,0007,000 AU/ml) was tested 20 times in a single experiment. 

Phrase: "For determination"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1148554:determination [Laboratory Procedure]

Phrase: "of intra-assay variability,"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   827   C2827666:Variability [Conceptual Entity]
   755 E C0439828:Variable [Qualitative Concept]

Phrase: "a pool of sera"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0337051:Pool [Geographic Area]
   770   C1509144:pool [Clinical Attribute]
   770   C2349200:Pool [Functional Concept]

Phrase: "with reactivity"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   928   C0205332:Reactive [Qualitative Concept]

Phrase: "near the cutoff values"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   861   C0042295:Values [Qualitative Concept]
   861   C1442160:Cutoff [Functional Concept]
   827 E C1522609:Value [Quantitative Concept]

Phrase: "(6,"

Phrase: "0007,"

Phrase: "000 AU/ml)"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   901   C2348421:AU/mL [Quantitative Concept]
   827   C0439526:/mL [Quantitative Concept]

Phrase: "was"

Phrase: "tested"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0392366:tested [Intellectual Product]
   966 E C0022885:Test [Laboratory Procedure]
   966 E C0039593:Test [Functional Concept]

Phrase: "20 times in a single experiment."
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   753   C0040223:times [Temporal Concept]
   753   C1632851:Times [Quantitative Concept]
   719 E C3541383:Time [Temporal Concept]
Processing 00000000.tx.71: For interassay variability, the same pool was tested on seven different occasions. 

Phrase: "For interassay variability,"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C2827666:Variability [Conceptual Entity]
   789 E C0439828:Variable [Qualitative Concept]

Phrase: "the same pool"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0337051:Pool [Geographic Area]
   861   C1509144:pool [Clinical Attribute]
   861   C2349200:Pool [Functional Concept]

Phrase: "was"

Phrase: "tested on seven different occasions."
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
   760   C0205453:Seven [Quantitative Concept]
   760   C0392366:tested [Intellectual Product]
   760   C1705242:Different [Qualitative Concept]
   726 E C0022885:Test [Laboratory Procedure]
   726 E C0039593:Test [Functional Concept]
Processing 00000000.tx.72: Specificity analysis of anti-CD38 aAbs by preadsorption and Western blot. 

Phrase: "Specificity analysis of anti-CD38 aAbs"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   753   C0002778:Analysis [Laboratory Procedure]
   753   C0936012:Analysis [Research Activity]
   753   C1524024:analysis [Functional Concept]

Phrase: "by preadsorption"

Phrase: "and"

Phrase: "Western blot."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0005863:Western Blot [Laboratory Procedure,Molecular Biology Research Technique]
  1000   C0949466:Western Blot [Laboratory Procedure]
   861   C1705493:Western [Spatial Concept]
Processing 00000000.tx.73: Preadsorption experiments were performed by preincubating highly reactive sera (8,000 AU/ml) overnight with saturating concentrations of rsCD38 (1 in 10 l of each serum), an equal amount of an irrelevant protein (HIV gp120; Chiron, Emeryville, CA), or PBS alone before EIA testing. 

Phrase: "Preadsorption experiments"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   861   C0681814:Experiments [Research Activity]
   827 E C1706386:Experiment [Conceptual Entity]
   777 E C1517586:Experimental [Qualitative Concept]

Phrase: "were"

Phrase: "performed by preincubating highly reactive sera"
Meta Candidates (Total=9; Excluded=3; Pruned=0; Remaining=6)
   790   C1550369:Performed By [Qualitative Concept]
   753   C0205250:Highly [Qualitative Concept]
   753   C0205332:Reactive [Qualitative Concept]
   753   C0229671:Sera [Body Substance]
   753   C0884358:Performed [Functional Concept]
   753   C1151254:SerA [Molecular Function]
   719 E C1546774:Serum [Intellectual Product]
   719 E C1550100:Serum [Body Substance]
   719 E C2947996:Perform [Pharmacologic Substance]

Phrase: "(8,000 AU/ml) overnight with saturating concentrations"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
   770   C2348421:AU/mL [Quantitative Concept]
   744   C0086045:Concentrations [Mental Process]
   744   C0439526:/mL [Quantitative Concept]
   744   C0439583:Overnight [Temporal Concept]
   744   C0522534:saturating [Phenomenon or Process]
   711 E C1446561:Concentration [Quantitative Concept]

Phrase: "of rsCD38"

Phrase: "(1 in 10 l of each serum"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   748   C0229671:Serum [Body Substance]
   748   C1546774:Serum [Intellectual Product]
   748   C1550100:Serum [Body Substance]
   748   C2827734:1+ [Quantitative Concept]
   748   C2981698:1+ [Classification]

Phrase: ")"

Phrase: ","

Phrase: "an equal amount of an irrelevant protein"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C1265611:Amount [Quantitative Concept]

Phrase: "(HIV gp120"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0019691:HIV gp120 [Amino Acid, Peptide, or Protein,Biologically Active Substance]
           gp120

Phrase: "; Chiron,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1504071:Chiron [Eukaryote]

Phrase: "Emeryville,"

Phrase: "CA),"

Phrase: "or"

Phrase: "PBS"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   884   C0991865:Phosphate Buffer [Indicator, Reagent, or Diagnostic Aid,Pharmacologic Substance]
   827   C0006353:Buffered [Indicator, Reagent, or Diagnostic Aid,Pharmacologic Substance]
   827   C0031603:Phosphate [Inorganic Chemical,Pharmacologic Substance]
   827   C0031701:phosphate [Organophosphorus Compound]
   827   C0036082:Saline [Substance]
   827   C1601799:PHOSPHATE [Inorganic Chemical,Pharmacologic Substance]

Phrase: "alone before EIA testing."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C0205171:Alone [Quantitative Concept]
   760   C0439044:alone [Finding]
   760   C0679994:alone [Group Attribute]
Processing 00000000.tx.74: For Western blot analysis, rsCD38 was run on 10% SDS-PAGE minigels, loading 2 g of protein in each lane. 

Phrase: "For Western blot analysis,"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
  1000   C0949466:Western blot analysis [Laboratory Procedure]
           Western Blot
   901   C0005863:Western Blot [Laboratory Procedure,Molecular Biology Research Technique]
   827   C0002778:Analysis [Laboratory Procedure]
   827   C0936012:Analysis [Research Activity]
   827   C1524024:analysis [Functional Concept]
   827   C1705493:Western [Spatial Concept]

Phrase: "rsCD38"

Phrase: "was"

Phrase: "run on 10% SDS-PAGE minigels,"

Phrase: "loading"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C1708715:Loading [Activity]
   966 E C1550025:Load [Idea or Concept]
   966 E C1704782:Load [Manufactured Object]

Phrase: "2 g of protein"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   819   C0060916:protein g [Amino Acid, Peptide, or Protein]
   819   C0086376:G-Protein [Amino Acid, Peptide, or Protein,Enzyme]
   770   C0439267:g% [Quantitative Concept]

Phrase: "in each lane."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1708639:Lane [Spatial Concept]
Processing 00000000.tx.75: Migrated proteins were then transferred to polyvinilydene difluoride (PVDF) membrane with a semi-dry transfer apparatus (Hoefer Pharmacia Biotech, San Francisco, CA) in Tris-glycine buffer containing 20% methanol and 0.035% SDS at 0.8 mA/cm2. 

Phrase: "Migrated proteins"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0033684:Proteins [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "were"

Phrase: "then"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883708:Then [Temporal Concept]

Phrase: "transferred to polyvinilydene difluoride (PVDF) membrane"
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
   760   C0025255:Membrane [Tissue]
   760   C0348011:transferred [Functional Concept]
   760   C0596901:Membrane [Cell Component]
   760   C1706182:Membrane [Manufactured Object]
   726 E C0040671:Transfer [Mental Process]
   726 E C1705822:Transfer [Activity]

Phrase: "with a semi-dry transfer apparatus"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   812   C0243111:apparatus [Manufactured Object]
   812   C1947951:Apparatus [Anatomical Structure]

Phrase: "(Hoefer Pharmacia Biotech,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0331955:Pharmacia [Health Care Related Organization]

Phrase: "San Francisco,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0036152:San Francisco [Geographic Area]
   861   C1826357:San [Gene or Genome]

Phrase: "CA) in Tris-glycine buffer"

Phrase: "containing"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0332256:Containing [Functional Concept]
  1000   C2700400:Containing [Activity]

Phrase: "20% methanol"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0001963:Methanol [Hazardous or Poisonous Substance,Organic Chemical,Pharmacologic Substance]

Phrase: "and"

Phrase: "0.035% SDS at 0.8 mA/cm2."
Processing 00000000.tx.76: Filters were saturated with 5% nonfat dry milk and 1% bovine serum albumin (BSA) in Tris-buffered saline with Tween (TBST)-20 (10 mmol/l Tris [pH 7.4], 100 mmol/l NaCl, and 0.1% Tween-20) and incubated with sera of patients diluted 1:1,000 in 5% milk and 1% BSA TBST. 

Phrase: "Filters"
Meta Candidates (Total=6; Excluded=5; Pruned=0; Remaining=1)
  1000   C0180860:Filters [Manufactured Object]
   966 E C0581406:Filter [Medical Device]
   966 E C1522664:Filter [Intellectual Product]
   966 E C1704449:Filter [Conceptual Entity]
   966 E C1704684:Filter [Medical Device]
   966 E C1875155:FILTER [Medical Device]

Phrase: "were"

Phrase: "saturated with 5% nonfat dry milk"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   753   C0011682:Dry [Natural Phenomenon or Process]
   753   C0026131:Milk [Body Substance]
   753   C0205222:Dry [Qualitative Concept]
   753   C0349374:Milk [Food]
   753   C0444318:Milk [Substance]
   753   C0522534:Saturated [Phenomenon or Process]
   753   C1512080:Dry [Qualitative Concept]
   753   C1705188:SATURATED [Quantitative Concept]
   753   C2825079:Milk [Food]

Phrase: "and"

Phrase: "1% bovine serum albumin (BSA) in Tris-buffered saline"
Meta Candidates (Total=10; Excluded=1; Pruned=0; Remaining=9)
   800   C0036774:Serum Albumin, Bovine [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   770   C0036773:Serum Albumin [Amino Acid, Peptide, or Protein]
   770   C0728877:serum albumin [Laboratory or Test Result]
   767 E C0523465:Albumin - serum [Laboratory Procedure]
   744   C0001924:Albumin [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   744   C0007452:Bovine [Mammal]
   744   C0229671:Serum [Body Substance]
   744   C1140701:bovine [Mammal]
   744   C1546774:Serum [Intellectual Product]
   744   C1550100:Serum [Body Substance]

Phrase: "with Tween"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0041420:tween [Organic Chemical,Pharmacologic Substance]
   944 E C0032602:Polysorbate [Biomedical or Dental Material,Organic Chemical,Pharmacologic Substance]

Phrase: "(TBST"

Phrase: ")-"

Phrase: "20"

Phrase: "(10 mmol/l Tris"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   812   C0041175:TRIS [Organic Chemical,Pharmacologic Substance]
   812   C0077281:Tris [Hazardous or Poisonous Substance,Organophosphorus Compound]
   812   C0814229:TRI [Intellectual Product]

Phrase: "[pH 7.4"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   913   C2678549:PH-4 [Gene or Genome]
   901   C1882074:pH 7 [Qualitative Concept]
   827   C0020283:[pH] [Quantitative Concept]
   827   C0450407:ph+ [Finding]
   827   C0450408:ph++ [Finding]
   827   C0450409:ph+++ [Finding]

Phrase: "],"

Phrase: "100 mmol/l NaCl,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   812   C0037494:NaCl [Biologically Active Substance,Inorganic Chemical,Pharmacologic Substance]
   812   C1959973:% NaCl [Quantitative Concept]

Phrase: "and"

Phrase: "0.1% Tween-20"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   861   C0041415:Tween 20 [Organic Chemical,Pharmacologic Substance]
   833 E C0032600:Polysorbate 20 [Organic Chemical,Pharmacologic Substance]
   812   C0041420:tween [Organic Chemical,Pharmacologic Substance]
   756 E C0032602:Polysorbate [Biomedical or Dental Material,Organic Chemical,Pharmacologic Substance]

Phrase: ")"

Phrase: "and"

Phrase: "incubated with sera of patients"
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
   760   C0030705:Patients [Patient or Disabled Group]
   760   C0229671:Sera [Body Substance]
   760   C1151254:SerA [Molecular Function]
   760   C1439852:Incubated [Laboratory Procedure]
   726 E C1546774:Serum [Intellectual Product]
   726 E C1550100:Serum [Body Substance]

Phrase: "diluted"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   966   C1720119:Dilute [Functional Concept]
   966   C1948037:Dilute [Functional Concept]

Phrase: "1"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C2827734:1+ [Quantitative Concept]
  1000   C2981698:1+ [Classification]

Phrase: ":"

Phrase: "1,000 in 5% milk"
Meta Candidates (Total=9; Excluded=2; Pruned=0; Remaining=7)
   797   C0450316:1/5 [Quantitative Concept]
   760   C0026131:Milk [Body Substance]
   760   C0349374:Milk [Food]
   760   C0444318:Milk [Substance]
   760   C2825079:Milk [Food]
   760   C2827734:1+ [Quantitative Concept]
   760   C2981698:1+ [Classification]
   704 E C0229890:Lacteal [Body Part, Organ, or Organ Component]
   704 E C1281353:Lacteal [Body Part, Organ, or Organ Component]

Phrase: "and"

Phrase: "1% BSA TBST."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   717   C0036774:Serum Albumin, Bovine [Amino Acid, Peptide, or Protein,Biologically Active Substance]
Processing 00000000.tx.77: After washing, a biotin-conjugated anti-human IgG mAb was added, followed by horseradish peroxidaseconjugated streptavidin (Amersham Italia, Milano, Italy). 

Phrase: "After washing,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0441648:Washing [Activity]

Phrase: "a biotin-conjugated anti-human IgG mAb"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   861   C0003242:anti antibody [Amino Acid, Peptide, or Protein,Immunologic Factor]
   829   C2754943:IgG antibody [Cell Component]
   818   C0003250:Monoclonal antibody [Amino Acid, Peptide, or Protein,Immunologic Factor]
   818   C0946139:IgG.monoclonal [Amino Acid, Peptide, or Protein,Immunologic Factor]
   795   C0003241:Antibody [Amino Acid, Peptide, or Protein,Cell Component,Immunologic Factor]
   795   C0021027:Antibody [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   795   C0746619:monoclonal [Finding]

Phrase: "was"

Phrase: "added"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1524062:Added [Functional Concept]
   966 E C1883712:Add [Functional Concept]

Phrase: ","

Phrase: "followed by horseradish peroxidaseconjugated streptavidin"
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
   806   C0332283:Followed by [Temporal Concept]
           followed
   760   C0075278:Streptavidin [Amino Acid, Peptide, or Protein,Biologically Active Substance,Indicator, Reagent, or Diagnostic Aid]
   760   C0330510:Horseradish [Food]
   760   C0939835:HORSERADISH [Organic Chemical,Pharmacologic Substance]
   760   C1110641:Horseradish [Plant]
   726 E C1719822:Follow [Intellectual Product]

Phrase: "(Amersham Italia,"

Phrase: "Milano,"

Phrase: "Italy"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0022277:Italy [Geographic Area]

Phrase: ")."
Processing 00000000.tx.78: The reaction was visualized using enhanced chemiluminiscence reagents (Amersham) and exposure to X-ray film. 

Phrase: "The reaction"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0443286:Reaction [Functional Concept]
  1000   C1114821:Reaction [Clinical Attribute]

Phrase: "was"

Phrase: "visualized"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0234621:Visualized [Functional Concept]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "enhanced chemiluminiscence reagents"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0034760:Reagents [Indicator, Reagent, or Diagnostic Aid]

Phrase: "(Amersham"

Phrase: ")"

Phrase: "and"

Phrase: "exposure to X-ray film."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   844   C0868115:exposure x ray [Injury or Poisoning]
   806   C0332157:Exposure to [Clinical Attribute]
           Exposure
   760   C0274281:Exposure, NOS [Injury or Poisoning]
Processing 00000000.tx.79: Functional analysis of anti-CD38 aAbs on Ca2+ release. 

Phrase: "Functional analysis of anti-CD38 aAbs"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   790   C0558024:Functional analysis [Health Care Activity]
   753   C0002778:Analysis [Laboratory Procedure]
   753   C0936012:Analysis [Research Activity]
   753   C1524024:analysis [Functional Concept]

Phrase: "on Ca2+ release."
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   861   C0030685:Release [Health Care Activity]
   861   C0391871:Release [Functional Concept]
   861   C0439180:% release [Quantitative Concept]
   861   C0680255:release [Health Care Activity]
   861   C1283071:Release [Functional Concept]
   861   C1963578:Release [Therapeutic or Preventive Procedure]
Processing 00000000.tx.80: Analysis of Ca2+ mobilization mediated by anti-CD38 aAbs was performed on the Jurkat T acute lymphoblastic leukemia cell line, cloned by limiting dilution, and positively selected with anti-mouse IgG-coated magnetic beads and the MACS system (Miltenyi Biotech, Bergisch-Gladbach, Germany) to obtain a population with a homogeneous CD3+CD38+ phenotype. 

Phrase: "Analysis of Ca2+ mobilization"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0002778:Analysis [Laboratory Procedure]
   770   C0936012:Analysis [Research Activity]
   770   C1524024:analysis [Functional Concept]

Phrase: "mediated by anti-CD38 aAbs"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C0004358:Autoantibodies [Amino Acid, Peptide, or Protein,Immunologic Factor]
   760   C0086597:mediated [Social Behavior]
   760   C0127400:Mediated [Organic Chemical,Pharmacologic Substance]

Phrase: "was"

Phrase: "performed on the Jurkat T acute lymphoblastic leukemia cell line,"
Meta Candidates (Total=27; Excluded=1; Pruned=0; Remaining=26)
   813   C1961099:Acute T-Cell Lymphoblastic Leukemia [Neoplastic Process]
           T Acute Lymphoblastic Leukemia
           T-Cell Leukemia, Acute
   782   C0023449:Acute lymphoblastic leukaemia [Neoplastic Process]
           Lymphoblastic leukaemia
   782   C1961102:Lymphoblastic Leukemia, Acute [Neoplastic Process]
           Lymphoblastic Leukemia
   782   C3542401:Acute Lymphoblastic Leukemia [Intellectual Product]
   775   C0023492:leukemia t-cell [Neoplastic Process]
   760   C0007600:Cell Line [Cell]
   760   C0023448:Lymphoblastic leukemia [Neoplastic Process]
   757   C0085669:Acute leukaemia [Neoplastic Process]
   757   C0280141:Acute Leukemia Not Otherwise Specified [Neoplastic Process]
   757   C0376448:Jurkat Cell [Cell]
   739   C0007634:Cell [Cell]
   739   C0023418:Leukaemia [Neoplastic Process]
   739   C0205132:Line [Spatial Concept]
   739   C0205178:acute [Temporal Concept]
   739   C0229613:lymphoblastic [Cell]
   739   C0884358:Performed [Functional Concept]
   739   C1269647:Cell [Cell]
   739   C1550648:Line [Substance]
   739   C1552960:Line [Quantitative Concept]
   739   C1704653:Cell [Medical Device]
   739   C1948049:Cell [Spatial Concept]
   724   C1517806:Leukemic Cell [Cell]
   706 E C2947996:Perform [Pharmacologic Substance]

Phrase: "cloned by limiting dilution,"
Meta Candidates (Total=7; Excluded=3; Pruned=0; Remaining=4)
   770   C0009013:cloned [Cell]
   770   C0079240:Dilution [Laboratory Procedure]
   770   C0439801:limiting [Functional Concept]
   770   C1948037:Dilution [Functional Concept]
   737 E C1522642:Clone [Tissue]
   737 E C1549649:Limit [Idea or Concept]
   737 E C2349209:Limit [Conceptual Entity]

Phrase: "and"

Phrase: "positively"

Phrase: "selected with anti-mouse IgG-coated magnetic beads"
Meta Candidates (Total=13; Excluded=3; Pruned=0; Remaining=10)
   770   C1328924:magnetic beads [Medical Device]
   767   C0051979:anti-IgG [Amino Acid, Peptide, or Protein,Immunologic Factor]
   744   C0024488:Magnetic [Occupation or Discipline]
   744   C0025914:Mouse [Mammal]
   744   C0025929:mouse [Mammal]
   744   C0026809:Mouse [Mammal]
   744   C0563532:magnetic [Natural Phenomenon or Process]
   744   C0991566:Beads [Biomedical or Dental Material]
   744   C1522408:Coated [Qualitative Concept]
   711 E C0453946:Coat [Manufactured Object]
   711   C1707391:Select [Activity]
   711 E C2346972:Bead [Spatial Concept]
   711 E C2987482:Coat [Body Part, Organ, or Organ Component]

Phrase: "and"

Phrase: "the MACS system"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   861   C0449913:System [Functional Concept]
   861   C1553451:System [Manufactured Object]
   861   C1704459:System [Medical Device]
   789 E C0205373:Systemic [Functional Concept]

Phrase: "(Miltenyi Biotech,"

Phrase: "Bergisch-Gladbach,"

Phrase: "Germany"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0017480:Germany [Geographic Area]

Phrase: ")"

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "obtain"
Meta Candidates (Total=8; Excluded=6; Pruned=0; Remaining=2)
  1000   C1301820:Obtain [Functional Concept]
  1000   C1706701:Obtain [Activity]
   944 E C1517378:Gain [Quantitative Concept]
   916 E C0205217:Increased [Quantitative Concept]
   916 E C0439661:Acquired [Temporal Concept]
   916 E C0442805:Increase [Functional Concept]
   916 E C0442808:Increasing [Functional Concept]
   916 E C3245488:acquired [Intellectual Product]

Phrase: "a population with a homogeneous CD3+CD38+ phenotype."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   744   C0032659:Population [Quantitative Concept]
   744   C1257890:Population [Population Group]
Processing 00000000.tx.81: Cells were cultured in RPMI-1640 medium containing penicillin, streptomycin, glutamine, and 10% fetal calf serum (FCS), subsequently referred to as complete medium. 

Phrase: "Cells"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
  1000   C0007634:Cells [Cell]
  1000   C3282337:Cells [Cell]
   966 E C1269647:Cell [Cell]
   966 E C1704653:Cell [Medical Device]
   966 E C1948049:Cell [Spatial Concept]

Phrase: "were"

Phrase: "cultured in RPMI-1640 medium containing penicillin,"
Meta Candidates (Total=13; Excluded=0; Pruned=0; Remaining=13)
   757   C0010454:Culture medium [Indicator, Reagent, or Diagnostic Aid]
   748   C0009458:Medium [Intellectual Product]
   748   C0030842:Penicillin [Antibiotic,Organic Chemical]
   748   C0220892:Penicillin [Antibiotic,Organic Chemical]
   748   C0332256:Containing [Functional Concept]
   748   C0439536:Medium [Quantitative Concept]
   748   C1705217:Medium [Substance]
   748   C2700400:Containing [Activity]
   748   C3244283:medium [Intellectual Product]
   714   C0010453:Culture [Idea or Concept]
   714   C0220814:culture [Functional Concept]
   714   C0430400:Culture [Laboratory Procedure]
   714   C2242979:Culture [Laboratory Procedure]

Phrase: "streptomycin,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0038425:Streptomycin [Antibiotic,Carbohydrate]

Phrase: "glutamine,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0017797:Glutamine [Amino Acid, Peptide, or Protein,Biologically Active Substance,Pharmacologic Substance]

Phrase: "and"

Phrase: "10% fetal calf serum (FCS),"
Meta Candidates (Total=8; Excluded=1; Pruned=0; Remaining=7)
   812   C0015965:Fetal [Embryonic Structure]
   812   C0229671:Serum [Body Substance]
   812   C0230445:Calf [Body Location or Region]
   812   C0521457:Fetal [Functional Concept]
   812   C1305418:Calf [Body Part, Organ, or Organ Component]
   812   C1546774:Serum [Intellectual Product]
   812   C1550100:Serum [Body Substance]
   756 E C0626053:sural [Pharmacologic Substance]

Phrase: "subsequently"

Phrase: "referred"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0205543:referred [Functional Concept]
  1000   C1691010:Referred [Functional Concept]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "as"

Phrase: "complete medium."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0009458:Medium [Intellectual Product]
   861   C0439536:Medium [Quantitative Concept]
   861   C1705217:Medium [Substance]
   861   C3244283:medium [Intellectual Product]
Processing 00000000.tx.82: Cells were loaded with Fluo 3-AM (Sigma, St. Louis, MO), a Ca2+-sensitive fluorescent dye (24,25). 

Phrase: "Cells"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
  1000   C0007634:Cells [Cell]
  1000   C3282337:Cells [Cell]
   966 E C1269647:Cell [Cell]
   966 E C1704653:Cell [Medical Device]
   966 E C1948049:Cell [Spatial Concept]

Phrase: "were"

Phrase: "loaded with Fluo 3-AM (Sigma,"
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
   790   C0060505:Fluo-3 [Organic Chemical,Pharmacologic Substance]
   753   C0385473:fluo [Organic Chemical,Pharmacologic Substance]
   753   C1708715:Loaded [Activity]
   753   C1719918:Sigma [Intellectual Product]
   719 E C1550025:Load [Idea or Concept]
   719 E C1704782:Load [Manufactured Object]

Phrase: "St. Louis,"

Phrase: "MO"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C3538743:MO [Idea or Concept]

Phrase: ")"

Phrase: ","

Phrase: "a Ca2+-sensitive fluorescent dye"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0016320:fluorescent dye [Indicator, Reagent, or Diagnostic Aid]
   812   C0013343:Dye [Indicator, Reagent, or Diagnostic Aid]

Phrase: "(24,"

Phrase: "25"

Phrase: ")."
Processing 00000000.tx.83: Briefly, cells were washed twice in Hanks balanced salt solution, pH 7.0, with 5% FCS, resuspended in the same buffer at a concentration of 2 x 106 cells/ml, and incubated for 30 min at 37C with 5 mol/l Fluo 3-AM in the presence of 0.01% Pluronic F-127 detergent (Sigma). 

Phrase: "Briefly,"

Phrase: "cells"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
  1000   C0007634:Cells [Cell]
  1000   C3282337:Cells [Cell]
   966 E C1269647:Cell [Cell]
   966 E C1704653:Cell [Medical Device]
   966 E C1948049:Cell [Spatial Concept]

Phrase: "were"

Phrase: "washed"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1548982:Washed [Idea or Concept]
   966 E C0441648:Wash [Activity]

Phrase: "twice in Hanks"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   790   C1720725:Twice [Intellectual Product]
   790   C1948050:Twice [Quantitative Concept]
   756   C1423529:HANK [Gene or Genome]

Phrase: "balanced"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0205415:Balanced [Functional Concept]
   966 E C0014653:Balance [Organism Function]
   966 E C0560184:Balance [Finding]

Phrase: "salt solution,"
Meta Candidates (Total=7; Excluded=2; Pruned=0; Remaining=5)
   861   C0036140:Salt [Chemical Viewed Structurally]
   861   C0037494:Salt [Biologically Active Substance,Inorganic Chemical,Pharmacologic Substance]
   861   C0037633:Solution [Substance]
   861   C0206136:Salt [Food,Inorganic Chemical]
   861   C0525069:Solution [Biomedical or Dental Material]
   789 E C1537053:salty [Qualitative Concept]
   761 E C0678584:saltiness [Qualitative Concept]

Phrase: "pH 7.0,"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   901   C1882074:pH 7 [Qualitative Concept]
   827   C0020283:[pH] [Quantitative Concept]
   827   C0450407:ph+ [Finding]
   827   C0450408:ph++ [Finding]
   827   C0450409:ph+++ [Finding]

Phrase: "with 5% FCS,"
Meta Candidates (Total=8; Excluded=1; Pruned=0; Remaining=7)
   812   C0015965:Fetal [Embryonic Structure]
   812   C0229671:Serum [Body Substance]
   812   C0230445:Calf [Body Location or Region]
   812   C0521457:Fetal [Functional Concept]
   812   C1305418:Calf [Body Part, Organ, or Organ Component]
   812   C1546774:Serum [Intellectual Product]
   812   C1550100:Serum [Body Substance]
   756 E C0626053:sural [Pharmacologic Substance]

Phrase: "resuspended in the same buffer"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0006353:Buffer [Indicator, Reagent, or Diagnostic Aid,Pharmacologic Substance]
   760   C0445247:Same [Qualitative Concept]

Phrase: "at a concentration"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0086045:Concentration [Mental Process]
  1000   C1446561:Concentration [Quantitative Concept]
   928 E C1880165:Concentrated [Biomedical or Dental Material]

Phrase: "of 2 x 106 cells/ml,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   840   C2699156:Cells/mL [Quantitative Concept]
   804   C0439526:/mL [Quantitative Concept]

Phrase: "and"

Phrase: "incubated for 30 min"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   833   C0456693:/30 min [Temporal Concept]
   833   C1442458:30 min [Temporal Concept]
   770   C0702093:/min [Temporal Concept]
   770   C1439852:Incubated [Laboratory Procedure]

Phrase: "at 37C"

Phrase: "with 5 mol/l Fluo 3-"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   840   C0060505:Fluo-3 [Organic Chemical,Pharmacologic Substance]
   804   C0385473:fluo [Organic Chemical,Pharmacologic Substance]

Phrase: "AM in the presence of 0.01% Pluronic F-127 detergent"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   775   C0032253:Pluronic F-127 [Organic Chemical,Pharmacologic Substance]
   738   C0011740:Detergent [Chemical Viewed Functionally]
   738   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
   738   C0032251:pluronic [Organic Chemical]
   738   C0392148:Presence [Therapeutic or Preventive Procedure]
   738   C0439133:(f) [Intellectual Product]
   738   C1553038:[f] [Quantitative Concept]

Phrase: "(Sigma"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1719918:Sigma [Intellectual Product]

Phrase: ")."
Processing 00000000.tx.84: Cells were then washed twice, resuspended at a concentration of 106 cells/ml, and used within 1 h. 

Phrase: "Cells"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
  1000   C0007634:Cells [Cell]
  1000   C3282337:Cells [Cell]
   966 E C1269647:Cell [Cell]
   966 E C1704653:Cell [Medical Device]
   966 E C1948049:Cell [Spatial Concept]

Phrase: "were"

Phrase: "then"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883708:Then [Temporal Concept]

Phrase: "washed"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1548982:Washed [Idea or Concept]
   966 E C0441648:Wash [Activity]

Phrase: "twice,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1720725:Twice [Intellectual Product]
  1000   C1948050:Twice [Quantitative Concept]

Phrase: "resuspended at a concentration of 106 cells/ml,"
Meta Candidates (Total=9; Excluded=3; Pruned=0; Remaining=6)
   770   C2699156:Cells/mL [Quantitative Concept]
   744   C0007634:Cells [Cell]
   744   C0086045:Concentration [Mental Process]
   744   C0439526:/mL [Quantitative Concept]
   744   C1446561:Concentration [Quantitative Concept]
   744   C3282337:Cells [Cell]
   711 E C1269647:Cell [Cell]
   711 E C1704653:Cell [Medical Device]
   711 E C1948049:Cell [Spatial Concept]

Phrase: "and"

Phrase: "used within 1 h."
Meta Candidates (Total=9; Excluded=3; Pruned=0; Remaining=6)
   819   C0700308:h 1 [Element, Ion, or Isotope]
   770   C0033727:H+ [Element, Ion, or Isotope]
   770   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   770   C0441932:H+ [Classification]
   770   C0564385:/h [Quantitative Concept]
   770   C1273517:used [Finding]
   737 E C0042153:use [Functional Concept]
   737 E C0457083:Use [Functional Concept]
   737 E C1947944:Use [Intellectual Product]
Processing 00000000.tx.85: After calibration of the basal levels, 50 l serum was added to a suspension of Jurkat cells (107 cells/ml in 650 l of complete medium). 

Phrase: "After calibration"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0006751:Calibration [Quantitative Concept]

Phrase: "of the basal levels,"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
   861   C0441889:Levels [Qualitative Concept]
   827 E C0456079:Level [Classification]
   827 E C1547707:Level [Geographic Area]
   827 E C2946261:Level [Pharmacologic Substance]

Phrase: "50 l serum"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0229671:Serum [Body Substance]
   827   C1546774:Serum [Intellectual Product]
   827   C1550100:Serum [Body Substance]

Phrase: "was"

Phrase: "added to a suspension of Jurkat cells"
Meta Candidates (Total=11; Excluded=4; Pruned=0; Remaining=7)
   778   C0376448:Jurkat Cells [Cell]
   748   C0007634:Cells [Cell]
   748   C0038960:Suspension [Biomedical or Dental Material]
   748   C1382107:Suspension [Substance]
   748   C1524062:Added [Functional Concept]
   748   C1705537:Suspension [Functional Concept]
   748   C3282337:Cells [Cell]
   714 E C1269647:Cell [Cell]
   714 E C1704653:Cell [Medical Device]
   714 E C1883712:Add [Functional Concept]
   714 E C1948049:Cell [Spatial Concept]

Phrase: "(107 cells/ml in 650 l of complete medium"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   764   C2699156:Cells/mL [Quantitative Concept]
   762   C1635169:mL/L [Quantitative Concept]
   742   C0439526:/mL [Quantitative Concept]

Phrase: ")."
Processing 00000000.tx.86: Effects on intracellular Ca2+ levels ([Ca2+]i) were continuously analyzed at 37C with a FACSort cytofluorimeter (Becton Dickinson, Milano, Italy) and Lysis II software. 

Phrase: "Effects on intracellular Ca2+ levels"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   760   C1280500:effects [Qualitative Concept]
   726 E C2348382:Effect [Qualitative Concept]

Phrase: "("

Phrase: "[Ca2+"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0596235:Ca2+ [Element, Ion, or Isotope,Pharmacologic Substance]

Phrase: "]i)"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0021966:I- [Inorganic Chemical]
  1000   C0221138:I NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: "were"

Phrase: "continuously"

Phrase: "analyzed at 37C"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C0936012:Analyzed [Research Activity]

Phrase: "with a FACSort cytofluorimeter"

Phrase: "(Becton Dickinson,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0331782:Becton Dickinson [Health Care Related Organization]

Phrase: "Milano,"

Phrase: "Italy"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0022277:Italy [Geographic Area]

Phrase: ")"

Phrase: "and"

Phrase: "Lysis II software."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0037585:Software [Intellectual Product,Manufactured Object]
Processing 00000000.tx.87: Cells were separated by size and side scatter to eliminate debris and dead cells. 

Phrase: "Cells"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
  1000   C0007634:Cells [Cell]
  1000   C3282337:Cells [Cell]
   966 E C1269647:Cell [Cell]
   966 E C1704653:Cell [Medical Device]
   966 E C1948049:Cell [Spatial Concept]

Phrase: "were"

Phrase: "separated by size"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   790   C0086972:Separated [Finding]
   790   C0443299:separated [Spatial Concept]
   790   C0456389:size [Spatial Concept]
   790   C0687118:Separated [Functional Concept]

Phrase: "and"

Phrase: "side scatter to"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0439742:scatter [Spatial Concept]
   827   C0441987:Side [Spatial Concept]

Phrase: "eliminate"

Phrase: "debris"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0440266:Debris [Substance]

Phrase: "and"

Phrase: "dead cells."
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   861   C0007634:Cells [Cell]
   861   C3282337:Cells [Cell]
   827 E C1269647:Cell [Cell]
   827 E C1704653:Cell [Medical Device]
   827 E C1948049:Cell [Spatial Concept]
Processing 00000000.tx.88: Controls included cells treated with the 4-bromo A23187 ionophore (Sigma) to ensure proper Fluo 3-AM loading and sera from healthy subjects and diabetic patients negative by anti-CD38 EIA. 

Phrase: "Controls"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0243148:control [Qualitative Concept]
  1000   C1550141:Control [Substance]
  1000   C1882979:Control [Conceptual Entity]
  1000   C2587213:Control [Functional Concept]
  1000   C3274648:Control [Qualitative Concept]

Phrase: "included cells"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   861   C0007634:Cells [Cell]
   861   C3282337:Cells [Cell]
   827 E C1269647:Cell [Cell]
   827 E C1704653:Cell [Medical Device]
   827 E C1948049:Cell [Spatial Concept]

Phrase: "treated with the 4-bromo A23187 ionophore"
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
   778   C0332293:Treated with [Therapeutic or Preventive Procedure]
           treated
   748   C0022022:Ionophore [Pharmacologic Substance]
   748   C0878412:A23187 [Antibiotic,Organic Chemical]
   748   C1517596:ionophore [Molecular Function]
   748   C1522326:Treated [Functional Concept]
   714 E C1292734:TREAT [Functional Concept]

Phrase: "(Sigma"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1719918:Sigma [Intellectual Product]

Phrase: ")"

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "ensure"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0218063:Ensure [Food]

Phrase: "proper Fluo 3-"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   901   C0060505:Fluo-3 [Organic Chemical,Pharmacologic Substance]
   827   C0385473:fluo [Organic Chemical,Pharmacologic Substance]

Phrase: "AM"

Phrase: "loading"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1708715:Loading [Activity]

Phrase: "and"

Phrase: "sera from healthy subjects"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   770   C0229671:Sera [Body Substance]
   770   C1151254:SerA [Molecular Function]
   737 E C1546774:Serum [Intellectual Product]
   737 E C1550100:Serum [Body Substance]

Phrase: "and"

Phrase: "diabetic patients negative by anti-CD38 EIA."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   744   C0205160:Negative [Qualitative Concept]
   744   C1513916:Negative [Finding]
   744   C2825415:Negative [Conceptual Entity]
   744   C2825491:Negative [Qualitative Concept]
Processing 00000000.tx.89: Modifications over time of [Ca2+]i were followed by continuously recording fluorescence shifts of Fluo 3-AM during a 5-min time course and graphically represented as density plots. 

Phrase: "Modifications over time of [Ca2+"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   726   C0392747:Modification [Functional Concept]
   726   C1554963:modification [Qualitative Concept]

Phrase: "]i"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0021966:I- [Inorganic Chemical]
  1000   C0221138:I NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: "were"

Phrase: "followed by continuously"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   882   C0332283:Followed by [Temporal Concept]
           followed
   756 E C1719822:Follow [Intellectual Product]

Phrase: "recording"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C0034869:Record [Intellectual Product]

Phrase: "fluorescence"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0016315:Fluorescence [Natural Phenomenon or Process]
   928 E C0303920:Fluorescent [Indicator, Reagent, or Diagnostic Aid,Organic Chemical]

Phrase: "shifts of Fluo 3-"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   833   C0060505:Fluo-3 [Organic Chemical,Pharmacologic Substance]
   770   C0333051:Shift [Functional Concept]
   770   C0385473:fluo [Organic Chemical,Pharmacologic Substance]
   770   C2347509:Shift [Phenomenon or Process]

Phrase: "AM during a 5-min time course"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   778   C0449247:Time course [Temporal Concept]
   748   C0040223:Time [Temporal Concept]
   748   C0702093:/min [Temporal Concept]
   748   C0750729:Course [Temporal Concept]
   748   C3541383:Time [Temporal Concept]

Phrase: "and"

Phrase: "graphically"

Phrase: "represented as density plots."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0178587:density [Quantitative Concept]
   737   C1882932:Represent [Activity]
Processing 00000000.tx.90: To explore potential antiagonistic properties of samples not featuring Ca2+ release (nonagonistic), competition experiments were performed by preincubating these sera with Jurkat cells, followed by the addition of suboptimal concentrations (<500 ng/ml) of the IB4 agonistic anti-CD38 mAb. 

Phrase: "To"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "explore"

Phrase: "potential antiagonistic properties of samples"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   760   C0871161:properties [Qualitative Concept]
   760   C1292721:properties [Functional Concept]
   726 E C1882134:Property [Conceptual Entity]
   726 E C2347695:Property [Entity]

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "featuring"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   966   C1521970:Feature [Qualitative Concept]
   966   C1706388:Feature [Conceptual Entity]
   966   C2346469:Feature [Qualitative Concept]
   966   C2348519:Feature [Qualitative Concept]

Phrase: "Ca2+ release"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   861   C0030685:Release [Health Care Activity]
   861   C0391871:Release [Functional Concept]
   861   C0439180:% release [Quantitative Concept]
   861   C0680255:release [Health Care Activity]
   861   C1283071:Release [Functional Concept]
   861   C1963578:Release [Therapeutic or Preventive Procedure]

Phrase: "(nonagonistic"

Phrase: ")"

Phrase: ","

Phrase: "competition experiments"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   861   C0681814:Experiments [Research Activity]
   827 E C1706386:Experiment [Conceptual Entity]
   777 E C1517586:Experimental [Qualitative Concept]

Phrase: "were"

Phrase: "performed by preincubating"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   882   C1550369:Performed By [Qualitative Concept]
   790   C0884358:Performed [Functional Concept]
   756 E C2947996:Perform [Pharmacologic Substance]

Phrase: "these sera with Jurkat cells,"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   760   C0229671:Sera [Body Substance]
   760   C1151254:SerA [Molecular Function]
   726 E C1546774:Serum [Intellectual Product]
   726 E C1550100:Serum [Body Substance]

Phrase: "followed by the addition of suboptimal concentrations"
Meta Candidates (Total=7; Excluded=2; Pruned=0; Remaining=5)
   778   C0332283:Followed by [Temporal Concept]
           followed
   748   C0086045:Concentrations [Mental Process]
   748   C1883712:Addition [Functional Concept]
   748   C2984009:Suboptimal [Qualitative Concept]
   714 E C1446561:Concentration [Quantitative Concept]
   714 E C1719822:Follow [Intellectual Product]

Phrase: "("

Phrase: "<500 ng/ml)"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   901   C0439275:ng/mL [Quantitative Concept]
   827   C0439526:/mL [Quantitative Concept]

Phrase: "of the IB4 agonistic anti-CD38 mAb."
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   901   C2346801:Anti-CD38 Monoclonal Antibody [Pharmacologic Substance]
   858   C0003242:anti antibody [Amino Acid, Peptide, or Protein,Immunologic Factor]
   827   C0003250:Monoclonal antibody [Amino Acid, Peptide, or Protein,Immunologic Factor]
   799   C0003241:Antibody [Amino Acid, Peptide, or Protein,Cell Component,Immunologic Factor]
   799   C0021027:Antibody [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   799   C0746619:monoclonal [Finding]
Processing 00000000.tx.91: CBT3G anti-CD3 mAb (IgG2a) was added as control. 

Phrase: "CBT3G anti-CD3 mAb"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   888   C0879551:Anti-CD3 Antibody [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
           Anti CD3
   875   C0003242:anti antibody [Amino Acid, Peptide, or Protein,Immunologic Factor]
   840   C0003250:Monoclonal antibody [Amino Acid, Peptide, or Protein,Immunologic Factor]
   804   C0003241:Antibody [Amino Acid, Peptide, or Protein,Cell Component,Immunologic Factor]
   804   C0021027:Antibody [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   804   C0746619:monoclonal [Finding]
   804   C3542405:CD3 [Laboratory Procedure]

Phrase: "(IgG2a"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0020857:IgG2A [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: ")"

Phrase: "was"

Phrase: "added as control."
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
   790   C0243148:control [Qualitative Concept]
   790   C1524062:Added [Functional Concept]
   790   C1550141:Control [Substance]
   790   C1882979:Control [Conceptual Entity]
   790   C2587213:Control [Functional Concept]
   790   C3274648:Control [Qualitative Concept]
   756 E C1883712:Add [Functional Concept]
Processing 00000000.tx.92: In preadsorption experiments, sera were preincubated overnight with Sepharose-conjugated protein G (vol/vol) or with saturating amounts of rsCD38 (5 g/150 l serum) and subsequently used for determination of Ca2+ currents, as previously described. 

Phrase: "In preadsorption experiments,"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   861   C0681814:Experiments [Research Activity]
   827 E C1706386:Experiment [Conceptual Entity]
   777 E C1517586:Experimental [Qualitative Concept]

Phrase: "sera"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
  1000   C0229671:Sera [Body Substance]
  1000   C1151254:SerA [Molecular Function]
   966 E C1546774:Serum [Intellectual Product]
   966 E C1550100:Serum [Body Substance]

Phrase: "were"

Phrase: "preincubated"

Phrase: "overnight with Sepharose-conjugated protein G (vol/vol)"
Meta Candidates (Total=11; Excluded=2; Pruned=0; Remaining=9)
   770   C0060916:protein g [Amino Acid, Peptide, or Protein]
   767 E C0086376:G-Protein [Amino Acid, Peptide, or Protein,Enzyme]
   744   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   744   C0036681:Sepharose [Carbohydrate]
   744   C0439267:g% [Quantitative Concept]
   744   C0439583:Overnight [Temporal Concept]
   744   C0449468:VOL [Quantitative Concept]
   744   C0522529:Conjugated [Spatial Concept]
   744   C0560268:vol% [Quantitative Concept]
   744   C1690016:% vol [Qualitative Concept]
   711 E C0301869:Conjugate [Immunologic Factor]

Phrase: "or with saturating amounts of rsCD38"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   744   C0522534:saturating [Phenomenon or Process]
   744   C1265611:amounts [Quantitative Concept]
   744   C1514798:recombinant [Organism]
   744   C1749467:soluble [Cell Component]
   744   C1948047:Soluble [Qualitative Concept]

Phrase: "(5 g/150 l serum"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   804   C0229671:Serum [Body Substance]
   804   C1546774:Serum [Intellectual Product]
   804   C1550100:Serum [Body Substance]
   708   C2348935:.5 L [Quantitative Concept]

Phrase: ")"

Phrase: "and"

Phrase: "subsequently"

Phrase: "used for determination of Ca2+ currents,"
Meta Candidates (Total=9; Excluded=4; Pruned=0; Remaining=5)
   767   C1524063:Use of [Functional Concept]
   753   C0521116:currents [Temporal Concept]
   753   C0596235:Ca2+ [Element, Ion, or Isotope,Pharmacologic Substance]
   753   C1148554:determination [Laboratory Procedure]
   753   C1273517:used [Finding]
   719 E C0042153:use [Functional Concept]
   719 E C0457083:Use [Functional Concept]
   719 E C1705970:Current [Natural Phenomenon or Process]
   719 E C1947944:Use [Intellectual Product]

Phrase: "as"

Phrase: "previously"

Phrase: "described."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1552738:described [Idea or Concept]
Processing 00000000.tx.93: Numerical presentation of data were obtained by extrapolating the Fluo 3-AM mean fluorescence intensity over the 5-min time-course from the density plots. 

Phrase: "Numerical presentation of data"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0449450:Presentation [Idea or Concept]

Phrase: "were"

Phrase: "obtained by extrapolating"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   790   C1301820:Obtained [Functional Concept]
   756 E C1706701:Obtain [Activity]
   718 E C1517378:Gain [Quantitative Concept]

Phrase: "the Fluo 3-"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0060505:Fluo-3 [Organic Chemical,Pharmacologic Substance]
   861   C0385473:fluo [Organic Chemical,Pharmacologic Substance]

Phrase: "AM"

Phrase: "mean fluorescence intensity over the 5-min time-course"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   742   C0016315:Fluorescence [Natural Phenomenon or Process]
   742   C0522510:Intensity [Qualitative Concept]

Phrase: "from the density plots."
Processing 00000000.tx.94: The cutoff was arbitrarily set at the mean + 3 SD of the values obtained from the sera of diabetic patients negative by EIA. 

Phrase: "The cutoff"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1442160:Cutoff [Functional Concept]

Phrase: "was"

Phrase: "arbitrarily"

Phrase: "set at the mean + 3 SD of the values"
Meta Candidates (Total=8; Excluded=1; Pruned=0; Remaining=7)
   742   C0036849:Set [Mental Process]
   742   C0042295:Values [Qualitative Concept]
   742   C0444504:Mean [Quantitative Concept]
   742   C1442518:Set [Functional Concept]
   742   C1705195:Set [Conceptual Entity]
   742   C2347634:Mean [Quantitative Concept]
   742   C2348143:Mean [Quantitative Concept]
   708 E C1522609:Value [Quantitative Concept]

Phrase: "obtained from the sera of diabetic patients negative"
Meta Candidates (Total=12; Excluded=3; Pruned=0; Remaining=9)
   744   C0030705:Patients [Patient or Disabled Group]
   744   C0205160:Negative [Qualitative Concept]
   744   C0229671:Sera [Body Substance]
   744   C0241863:DIABETIC [Finding]
   744   C1151254:SerA [Molecular Function]
   744   C1301820:Obtained [Functional Concept]
   744   C1513916:Negative [Finding]
   744   C2825415:Negative [Conceptual Entity]
   744   C2825491:Negative [Qualitative Concept]
   711 E C1546774:Serum [Intellectual Product]
   711 E C1550100:Serum [Body Substance]
   711 E C1706701:Obtain [Activity]

Phrase: "by EIA."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0020980:Immunoassay [Laboratory Procedure]
   861   C0021060:immunoassay [Laboratory Procedure]
Processing 00000000.tx.95: Clinical and metabolic parameters. 

Phrase: "Clinical"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205210:Clinical [Qualitative Concept]

Phrase: "and"

Phrase: "metabolic parameters."
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
   861   C0449381:Parameters [Finding]
   827 E C0549193:Parameter [Spatial Concept]
   827 E C1704769:Parameter [Conceptual Entity]
   827 E C2350001:Parameter [Quantitative Concept]
Processing 00000000.tx.96: BMI was calculated as the weight in kilograms divided by the square of the height in meters. 

Phrase: "BMI"

Phrase: "was"

Phrase: "calculated as the weight"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   770   C0005910:weight [Organism Attribute]
   770   C0043100:Weight [Quantitative Concept]
   770   C0444686:Calculated [Functional Concept]
   770   C1305866:weight [Diagnostic Procedure]
   770   C1441506:Calculated [Activity]
   770   C1443182:Calculated [Laboratory Procedure]
   770   C1705104:Weight [Idea or Concept]

Phrase: "in kilograms"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439209:kilograms [Quantitative Concept]

Phrase: "divided by the square of the height"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   748   C0205120:Square [Spatial Concept]
   748   C0332849:Divided [Functional Concept]
   748   C0489786:Height [Organism Attribute]
   748   C1552595:Square [Intellectual Product]

Phrase: "in meters."
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0441074:Meters [Medical Device]
   966 E C0475209:Meter [Quantitative Concept]
   966 E C1706378:METER [Manufactured Object]
Processing 00000000.tx.97: Blood glucose control was assessed by means of fasting plasma glucose levels (measured by the glucose oxidase technique) and glycated hemoglobin (HbA1c) (measured by high-performance liquid chromatography). 

Phrase: "Blood glucose control"
Meta Candidates (Total=18; Excluded=7; Pruned=0; Remaining=11)
   901   C0005802:Blood Glucose [Carbohydrate]
   901   C0726398:GLUCOSE CONTROL [Indicator, Reagent, or Diagnostic Aid]
   827   C0005767:Blood [Tissue]
   827   C0005768:blood [Body Substance]
   827   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]
   827   C0229664:Blood [Body Substance]
   827   C0243148:control [Qualitative Concept]
   827   C1550141:Control [Substance]
   827   C1882979:Control [Conceptual Entity]
   827   C2587213:Control [Functional Concept]
   827   C3274648:Control [Qualitative Concept]
   755 E C0333275:Bloody [Qualitative Concept]
   743 E C0005847:Blood Vessel [Body Part, Organ, or Organ Component]
   743 E C0392895:Bloods [Population Group]
   743 E C1283786:Blood vessel [Body Part, Organ, or Organ Component]
   743 E C1511228:VESSEL, BLOOD [Tissue]
   727 E C1558950:VASCULAR [Finding]
   727 E C1801960:Vascular [Qualitative Concept]

Phrase: "was"

Phrase: "assessed by means of fasting plasma glucose levels"
Meta Candidates (Total=21; Excluded=8; Pruned=0; Remaining=13)
   804   C0583513:Plasma fasting glucose level [Laboratory Procedure]
   793   C0455280:glucose levels plasma [Laboratory or Test Result]
           plasma glucose
   770   C0202042:Plasma glucose [Laboratory Procedure]
   770   C0428548:glucose levels [Laboratory or Test Result]
   744   C0015663:Fasting [Finding]
   744   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]
   744   C0032105:Plasma [Body Substance]
   744   C0441889:Levels [Qualitative Concept]
   744   C1516048:Assessed [Activity]
   744   C1550098:Plasma, NOS (not otherwise specified) [Body Substance]
   744   C1550565:fasting [Intellectual Product]
   744   C1704970:Means [Conceptual Entity]
   737 E C0337438:glucose level [Laboratory Procedure]
   711 E C0444504:Mean [Quantitative Concept]
   711 E C0456079:Level [Classification]
   711 E C0456962:Fast [Qualitative Concept]
   711 E C1547707:Level [Geographic Area]
   711 E C2347634:Mean [Quantitative Concept]
   711 E C2348143:Mean [Quantitative Concept]
   711 E C2946261:Level [Pharmacologic Substance]

Phrase: "("

Phrase: "measured by the glucose oxidase technique"
Meta Candidates (Total=8; Excluded=2; Pruned=0; Remaining=6)
   790   C0017735:GLUCOSE OXIDASE [Amino Acid, Peptide, or Protein,Enzyme]
   753   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]
   753   C0242417:Oxidase [Amino Acid, Peptide, or Protein,Enzyme]
   753   C0444706:Measured [Qualitative Concept]
   753   C0449851:Technique [Functional Concept]
   753   C3541902:MEASURED [Diagnostic Procedure]
   719 E C0079809:Measure [Quantitative Concept]
   719 E C0242485:Measure [Functional Concept]

Phrase: ")"

Phrase: "and"

Phrase: "glycated hemoglobin"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0017853:Glycated haemoglobin [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   861   C0019046:Haemoglobin [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "(HbA1c"

Phrase: ")"

Phrase: "("

Phrase: "measured by high-performance liquid chromatography"
Meta Candidates (Total=18; Excluded=2; Pruned=0; Remaining=16)
   882   C0008562:Chromatography, High Performance Liquid [Laboratory Procedure]
   882   C0687276:LIQUID CHROMATOGRAPHY, HIGH PERFORMANCE [Medical Device]
   882   C1579831:High performance liquid chromatography [Functional Concept]
   790   C0008565:Liquid Chromatography [Laboratory Procedure]
   753   C0008550:Chromatography [Laboratory Procedure]
   753   C0205250:High [Qualitative Concept]
   753   C0302908:Liquid [Substance]
   753   C0444706:Measured [Qualitative Concept]
   753   C0597198:Performance [Individual Behavior]
   753   C1299351:High [Qualitative Concept]
   753   C1304698:Liquid [Finding]
   753   C1546699:Liquid NOS [Intellectual Product]
   753   C1561501:Liquid NOS [Substance]
   753   C1882330:Performance [Activity]
   753   C2700149:HIGH [Intellectual Product]
   753   C3541902:MEASURED [Diagnostic Procedure]
   719 E C0079809:Measure [Quantitative Concept]
   719 E C0242485:Measure [Functional Concept]

Phrase: ")."
Processing 00000000.tx.98: Fasting plasma C-peptide and insulin levels were measured via radioimmunoassay (DPC, Los Angeles, CA, and Radim, Rome, Italy, respectively). 

Phrase: "Fasting plasma C-peptide"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0006558:C-Peptide [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   812   C0030956:Peptide [Amino Acid, Peptide, or Protein]

Phrase: "and"

Phrase: "insulin levels"
Meta Candidates (Total=11; Excluded=5; Pruned=0; Remaining=6)
  1000   C0202098:insulin levels [Laboratory Procedure]
  1000   C0428405:insulin levels [Laboratory or Test Result]
   861   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C0441889:Levels [Qualitative Concept]
   861   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C1579433:Insulin [Pharmacologic Substance]
   827 E C0456079:Level [Classification]
   827 E C1547707:Level [Geographic Area]
   827 E C2946261:Level [Pharmacologic Substance]
   805 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   777 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "were"

Phrase: "measured via radioimmunoassay"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
   790   C0034580:Radioimmunoassay [Laboratory Procedure]
   790   C0444706:Measured [Qualitative Concept]
   790   C3541902:MEASURED [Diagnostic Procedure]
   756 E C0079809:Measure [Quantitative Concept]
   756 E C0242485:Measure [Functional Concept]

Phrase: "(DPC,"

Phrase: "Los Angeles,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0024015:Los Angeles [Geographic Area]

Phrase: "CA,"

Phrase: "and"

Phrase: "Radim,"

Phrase: "Rome,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0035831:Rome [Geographic Area]

Phrase: "Italy,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0022277:Italy [Geographic Area]

Phrase: "respectively"

Phrase: ")."
Processing 00000000.tx.99: Insulinemia was measured only in noninsulin-treated type 2 diabetic patients to avoid interference by anti-insulin aAbs (26). 

Phrase: "Insulinemia"

Phrase: "was"

Phrase: "measured"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
  1000   C0444706:Measured [Qualitative Concept]
  1000   C3541902:MEASURED [Diagnostic Procedure]
   966 E C0079809:Measure [Quantitative Concept]
   966 E C0242485:Measure [Functional Concept]

Phrase: "only in noninsulin-treated type 2 diabetic patients to"
Meta Candidates (Total=11; Excluded=1; Pruned=0; Remaining=10)
   764   C0441730:Type 2 [Classification]
   745   C1550335:Patient type [Classification]
   742   C0030705:Patients [Patient or Disabled Group]
   742   C0205171:Only [Quantitative Concept]
   742   C0241863:DIABETIC [Finding]
   742   C0332293:treated [Therapeutic or Preventive Procedure]
   742   C0332307:Type [Qualitative Concept]
   742   C1522326:Treated [Functional Concept]
   742   C1547052:*Type [Quantitative Concept]
   742   C1720467:Only [Intellectual Product]
   708 E C1292734:TREAT [Functional Concept]

Phrase: "avoid"

Phrase: "interference by anti-insulin aAbs"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0521102:Interference [Qualitative Concept]

Phrase: "(26"

Phrase: ")."
Processing 00000000.tx.100: To obtain a parameter of the severity of the disease in type 2 diabetes, patients were assigned to only one of three therapy categories according to their current regimens (diet alone, oral hypoglycemic agents, or insulin), in a progressive manner paralleling the usual course of disease. 

Phrase: "To"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "obtain"
Meta Candidates (Total=8; Excluded=6; Pruned=0; Remaining=2)
  1000   C1301820:Obtain [Functional Concept]
  1000   C1706701:Obtain [Activity]
   944 E C1517378:Gain [Quantitative Concept]
   916 E C0205217:Increased [Quantitative Concept]
   916 E C0439661:Acquired [Temporal Concept]
   916 E C0442805:Increase [Functional Concept]
   916 E C0442808:Increasing [Functional Concept]
   916 E C3245488:acquired [Intellectual Product]

Phrase: "a parameter of the severity of the disease"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   744   C0549193:Parameter [Spatial Concept]
   744   C1704769:Parameter [Conceptual Entity]
   744   C2350001:Parameter [Quantitative Concept]

Phrase: "in type 2 diabetes,"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
  1000   C0011860:Type 2 Diabetes [Disease or Syndrome]
   913   C1320657:type diabetes [Finding]
   901   C0441730:Type 2 [Classification]
   827   C0011847:Diabetes [Disease or Syndrome]
   827   C0011849:Diabetes [Disease or Syndrome]
   827   C0332307:Type [Qualitative Concept]
   827   C1547052:*Type [Quantitative Concept]

Phrase: "patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "were"

Phrase: "assigned"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1516050:Assigned [Functional Concept]
  1000   C1552601:assigned [Intellectual Product]

Phrase: "to only one of three therapy categories"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C0205447:One [Quantitative Concept]

Phrase: "according to their current regimens"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C2945654:regimens [Intellectual Product]
   827 E C0040808:Regimen [Therapeutic or Preventive Procedure]

Phrase: "(diet alone, oral hypoglycemic agents,"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   884   C0359086:HYPOGLYCEMIC AGENTS, ORAL [Pharmacologic Substance]
           Oral hypoglycaemic
   840   C0020616:Hypoglycemic Agents [Pharmacologic Substance]
           Hypoglycaemic
   804   C0442027:Oral [Spatial Concept]
   771   C0450442:Agent [Chemical Viewed Functionally]
   771   C1254351:Agent [Pharmacologic Substance]
   771   C1521826:Agent [Intellectual Product]

Phrase: "or"

Phrase: "insulin"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
  1000   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
  1000   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
  1000   C1579433:Insulin [Pharmacologic Substance]
   944 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   916 E C3537244:Insulins [Pharmacologic Substance]

Phrase: ")"

Phrase: ","

Phrase: "in a progressive manner paralleling"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   793   C2348042:Parallel [Qualitative Concept]
   793   C2826345:PARALLEL [Research Activity]

Phrase: "the usual course of disease."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   797   C0242656:disease course [Pathologic Function]
   760   C0750729:Course [Temporal Concept]
Processing 00000000.tx.101: Patients were considered as having hypertension either if they were on current therapy with antihypertensive agents or if they were presenting with blood pressure values >140/90 mmHg, according to the WHO guidelines (27). 

Phrase: "Patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "were"

Phrase: "considered"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0750591:considered [Idea or Concept]

Phrase: "as"

Phrase: "having"

Phrase: "hypertension either"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0020538:Hypertension [Disease or Syndrome]
   861   C1963138:Hypertension [Finding]

Phrase: "if"

Phrase: "they"

Phrase: "were on current therapy"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   833   C2827774:Current Therapy [Therapeutic or Preventive Procedure]
   770   C0039798:therapy [Functional Concept]
   770   C0087111:Therapy [Therapeutic or Preventive Procedure]
   770   C0521116:Current [Temporal Concept]
   770   C1363945:Therapy [Finding]
   770   C1705970:Current [Natural Phenomenon or Process]

Phrase: "with antihypertensive agents"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0003364:Anti-Hypertensive Agents [Pharmacologic Substance]
   827   C0450442:Agent [Chemical Viewed Functionally]
   827   C1254351:Agent [Pharmacologic Substance]
   827   C1521826:Agent [Intellectual Product]

Phrase: "or"

Phrase: "if"

Phrase: "they"

Phrase: "were"

Phrase: "presenting with blood pressure values"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   760   C0449450:Presenting [Idea or Concept]
   726 E C0150312:Present [Quantitative Concept]

Phrase: ">140/90 mmHg,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0439475:mmHg [Quantitative Concept]

Phrase: "according to the WHO guidelines"
Meta Candidates (Total=14; Excluded=1; Pruned=0; Remaining=13)
   923   C0043237:World Health Organization [Health Care Related Organization]
   861   C0043236:World Health [Idea or Concept]
   861   C0920545:health organization [Health Care Related Organization]
   812   C0018684:Health [Idea or Concept]
   812   C0029237:Organisation [Physiologic Function]
   812   C0029246:Organization [Organization]
   812   C0162791:Guidelines [Intellectual Product]
   812   C0220845:guidelines [Intellectual Product]
   812   C0220885:organization [Qualitative Concept]
   812   C0282423:guidelines [Intellectual Product]
   812   C1300196:Organization [Functional Concept]
   812   C1522486:Organization [Professional or Occupational Group]
   812   C2700280:World [Population Group]
   712 E C0031206:healthiness [Finding]

Phrase: "(27"

Phrase: ")."
Processing 00000000.tx.102: Analysis of the Arg140Trp mutation by polymerase chain reaction. 

Phrase: "Analysis of the Arg140Trp mutation"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   797   C0796357:mutation analysis [Laboratory Procedure]
   760   C0002778:Analysis [Laboratory Procedure]
   760   C0936012:Analysis [Research Activity]
   760   C1524024:analysis [Functional Concept]

Phrase: "by polymerase chain reaction."
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
  1000   C0032520:Polymerase Chain Reaction [Laboratory Procedure,Molecular Biology Research Technique]
   827   C0337112:Chain [Manufactured Object]
   827   C0443286:Reaction [Functional Concept]
   827   C1114821:Reaction [Clinical Attribute]
   827   C1335439:Polymerase [Amino Acid, Peptide, or Protein,Enzyme]
   827   C1524075:Chain [Idea or Concept]
Processing 00000000.tx.103: A total of 84 type 2 diabetic subjects were screened for the Arg140Trp mutation; 

Phrase: "A total of 84 type 2 diabetic subjects"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   744   C0439175:% total [Quantitative Concept]
   744   C0439810:Total [Qualitative Concept]

Phrase: "were"

Phrase: "screened for the Arg140Trp mutation"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   760   C0026882:Mutation [Genetic Function]
   760   C1705285:Mutation [Cell or Molecular Dysfunction]
   726   C0220908:screen [Health Care Activity]
   726   C1305399:screen [Functional Concept]
   726   C1705053:Screen [Medical Device]

Phrase: ";"
Processing 00000000.tx.104: 41 subjects (48.8%) had first-degree and five subjects (6%) had second-degree relatives affected with the disease, and 25 healthy individuals were included as control subjects. 

Phrase: "41 subjects"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   827   C0681850:Subject [Group]
   827   C1550501:{Subject} [Idea or Concept]
   827   C1706203:Subject [Idea or Concept]
   827   C2349001:Subject [Human]
   827   C2697811:Subject [Functional Concept]

Phrase: "(48.8%"

Phrase: ")"

Phrase: "had"

Phrase: "first-degree"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
  1000   C0444502:First degree [Qualitative Concept]
   861   C0205435:First [Quantitative Concept]
   861   C0441889:Degree [Qualitative Concept]
   861   C0449286:Degree [Quantitative Concept]
   861   C0542560:Degree [Intellectual Product]
   861   C1279901:First [Qualitative Concept]
   861   C1561545:degree [Quantitative Concept]
   861   C2348088:Degree [Quantitative Concept]

Phrase: "and"

Phrase: "five subjects"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   827   C0681850:Subject [Group]
   827   C1550501:{Subject} [Idea or Concept]
   827   C1706203:Subject [Idea or Concept]
   827   C2349001:Subject [Human]
   827   C2697811:Subject [Functional Concept]

Phrase: "(6%"

Phrase: ")"

Phrase: "had"

Phrase: "second-degree relatives"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
   983   C1519210:Second Degree Relative [Family Group]
   827   C0080103:Relatives [Family Group]
   793 E C0205345:Relative [Qualitative Concept]
   793 E C1547039:*Relative [Quantitative Concept]
   734   C0443298:Second degree [Qualitative Concept]

Phrase: "affected with the disease,"
Meta Candidates (Total=7; Excluded=4; Pruned=0; Remaining=3)
   770   C0012634:Disease [Disease or Syndrome]
   770   C0392760:Affected [Functional Concept]
   770   C1314939:Affected [Functional Concept]
   737 E C0001721:Affect [Mental Process]
   715 E C1836721:MALS [Finding]
   715 E C3538764:MALS [Gene or Genome]
   715 E C3540595:MAL [Gene or Genome]

Phrase: "and"

Phrase: "25 healthy individuals"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   793   C0027361:Individual [Population Group]
   793   C0237401:Individual [Human]

Phrase: "were"

Phrase: "included as control subjects."
Meta Candidates (Total=14; Excluded=2; Pruned=0; Remaining=12)
   770   C0243148:control [Qualitative Concept]
   770   C0332257:included [Functional Concept]
   770   C1550141:Control [Substance]
   770   C1882979:Control [Conceptual Entity]
   770   C2587213:Control [Functional Concept]
   770   C3274648:Control [Qualitative Concept]
   770   C3538986:INCLUDED [Gene or Genome]
   737   C0681850:Subject [Group]
   737   C1550501:{Subject} [Idea or Concept]
   737 E C1552866:include [Idea or Concept]
   737   C1706203:Subject [Idea or Concept]
   737   C2349001:Subject [Human]
   737   C2697811:Subject [Functional Concept]
   737 E C2700399:Include [Activity]
Processing 00000000.tx.105: Genomic DNA was prepared from peripheral blood mononuclear cells according to the method of Laird et al. 

Phrase: "Genomic DNA"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C3272453:Genomic DNA [Nucleic Acid, Nucleoside, or Nucleotide]
   861   C0012854:DNA [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   861   C0017428:Genomic [Gene or Genome]
   861   C0887950:genomic [Biomedical Occupation or Discipline]

Phrase: "was"

Phrase: "prepared from peripheral blood mononuclear cells"
Meta Candidates (Total=19; Excluded=5; Pruned=0; Remaining=14)
   882   C1321301:Peripheral Blood Mononuclear Cells [Cell]
   804   C0005773:Peripheral blood cell [Cell]
           Blood Cells
   803   C2347293:Mononuclear Blood Cell [Cell]
   790   C0229664:peripheral blood [Body Substance]
           Blood
   790   C0806987:Mononuclear cells [Cell]
   753   C0005767:Blood [Tissue]
   753   C0005768:blood [Body Substance]
   753   C0007634:Cells [Cell]
   753   C0205100:Peripheral [Spatial Concept]
   753   C1513475:Mononuclear [Clinical Attribute]
   753   C3282337:Cells [Cell]
   748 E C0150936:Peripheral Blood Vessel [Body Part, Organ, or Organ Component]
   739 E C2328697:Hemal cell [Cell]
   719 E C1269647:Cell [Cell]
   719   C1521827:Prepare [Functional Concept]
   719 E C1704653:Cell [Medical Device]
   719 E C1948049:Cell [Spatial Concept]

Phrase: "according to the method"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0025663:Method [Intellectual Product]
  1000   C0449851:Method [Functional Concept]
  1000   C0871511:METHOD [Intellectual Product]

Phrase: "of Laird et al."
Processing 00000000.tx.106: (28), and 50 ng was used per polymerase chain reaction (PCR). 

Phrase: "(28"

Phrase: ")"

Phrase: ","

Phrase: "and"

Phrase: "50 ng"

Phrase: "was"

Phrase: "used per polymerase chain reaction (PCR)."
Meta Candidates (Total=10; Excluded=3; Pruned=0; Remaining=7)
   862   C0032520:Polymerase Chain Reaction [Laboratory Procedure,Molecular Biology Research Technique]
   760   C0337112:Chain [Manufactured Object]
   760   C0443286:Reaction [Functional Concept]
   760   C1114821:Reaction [Clinical Attribute]
   760   C1273517:used [Finding]
   760   C1335439:Polymerase [Amino Acid, Peptide, or Protein,Enzyme]
   760   C1524075:Chain [Idea or Concept]
   726 E C0042153:use [Functional Concept]
   726 E C0457083:Use [Functional Concept]
   726 E C1947944:Use [Intellectual Product]
Processing 00000000.tx.107: As the Arg140Trp variant is located in CD38 exon three (14), this was amplified using primers specific for intron two (5'-GACATGCTAAATTGATCTCAG-3') and intron three (5'-CAGCAGAAGTCACTCTGTTC-3'). 

Phrase: "As the Arg140Trp variant"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0205419:Variant [Qualitative Concept]

Phrase: "is"

Phrase: "located in CD38 exon three"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0015295:Exon [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   760   C0205449:Three [Quantitative Concept]

Phrase: "(14"

Phrase: ")"

Phrase: ","

Phrase: "this"

Phrase: "was"

Phrase: "amplified"

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "primers"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C0206415:Primer [Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "specific for intron two"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0205369:Specific [Qualitative Concept]
   770   C1552740:specific [Intellectual Product]

Phrase: "(5'-GACATGCTAAATTGATCTCAG-3'"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0439084:>5 [Quantitative Concept]
   827   C0728893:+5 [Quantitative Concept]

Phrase: ")"

Phrase: "and"

Phrase: "intron three"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0021920:Intron [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   861   C0205449:Three [Quantitative Concept]

Phrase: "(5'-CAGCAGAAGTCACTCTGTTC-3'"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0439084:>5 [Quantitative Concept]
   827   C0728893:+5 [Quantitative Concept]

Phrase: ")."
Processing 00000000.tx.108: Cycling parameters were as follows: initial denaturation at 95C for 5 min, followed by 30 cycles at 94C for 1 min, 48C for 1 min, and 72C for 1 min, with a final extension step at 72C for 7 min. 

Phrase: "Cycling parameters"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
   861   C0449381:Parameters [Finding]
   827 E C0549193:Parameter [Spatial Concept]
   827 E C1704769:Parameter [Conceptual Entity]
   827 E C2350001:Parameter [Quantitative Concept]

Phrase: "were"

Phrase: "as"

Phrase: "follows"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0332283:follow [Temporal Concept]
  1000   C1719822:Follow [Intellectual Product]

Phrase: ":"

Phrase: "initial denaturation at 95C"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0301642:Denaturation [Molecular Function]

Phrase: "for 5 min,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0702093:/min [Temporal Concept]

Phrase: "followed by 30 cycles"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   833   C0332283:Followed by [Temporal Concept]
           followed
   737   C1511572:Cycle [Temporal Concept]
   737 E C1719822:Follow [Intellectual Product]

Phrase: "at 94C"

Phrase: "for 1 min,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0702093:/min [Temporal Concept]

Phrase: "48C for 1 min,"

Phrase: "and"

Phrase: "72C for 1 min,"

Phrase: "with a final extension step"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   827   C1261552:Step [Conceptual Entity]
   827   C1704379:Step [Functional Concept]
   827   C1705117:Step [Quantitative Concept]
   827   C2825408:Step [Manufactured Object]

Phrase: "at 72C"

Phrase: "for 7 min."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0702093:/min [Temporal Concept]
Processing 00000000.tx.109: After ethanol precipitation, the amplified DNA was digested overnight with the restriction enzyme AciI (New England Biolabs, Beverly, MA) according to the manufacturers instructions. 

Phrase: "After ethanol precipitation,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0032931:Precipitation [Natural Phenomenon or Process]
   861   C0032932:Precipitation [Molecular Function]
   861   C1642401:% precipitation [Quantitative Concept]
   861   C2584299:Precipitation [Natural Phenomenon or Process]

Phrase: "the amplified DNA"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0012854:DNA [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "was"

Phrase: "digested"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0868946:digested [Physiologic Function]

Phrase: "overnight with the restriction enzyme AciI"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   790   C0012906:Restriction Enzyme [Amino Acid, Peptide, or Protein,Enzyme]
   753   C0014442:Enzyme [Enzyme,Organic Chemical]
   753   C0439583:Overnight [Temporal Concept]
   753   C0443288:Restriction [Functional Concept]

Phrase: "(New England Biolabs,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   734   C0027965:New England [Geographic Area]

Phrase: "Beverly,"

Phrase: "MA) according to the manufacturers instructions."
Processing 00000000.tx.110: The enzymes 4-bp recognition sequence (GCGG) includes the Arg140 codon (CGG) but does not cut the Trp variant (GTGG). 

Phrase: "The enzymes 4-bp recognition sequence"
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
   804   C0004793:Sequence [Nucleotide Sequence]
   804   C0162326:Sequence [Nucleotide Sequence]
   804   C0162327:Sequence [Nucleotide Sequence]
   804   C1519249:Sequence [Functional Concept]
   733 E C1548958:Sequential [Idea or Concept]
   733 E C1705294:Sequential [Qualitative Concept]

Phrase: "(GCGG"

Phrase: ")"

Phrase: "includes"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0332257:Includes [Functional Concept]
  1000   C1552866:include [Idea or Concept]
  1000   C2700399:Include [Activity]

Phrase: "the Arg140 codon"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0009221:Codon [Nucleotide Sequence]
   861   C1095825:Codon [Plant]

Phrase: "(CGG"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1864172:CGG [Disease or Syndrome]

Phrase: ")"

Phrase: "but"

Phrase: "does"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "cut"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0000925:Cut [Injury or Poisoning]
  1000   C1883724:CUT [Phenomenon or Process]

Phrase: "the Trp variant"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0205419:Variant [Qualitative Concept]

Phrase: "(GTGG"

Phrase: ")."
Processing 00000000.tx.111: Digests were separated by electrophoresis on a 2% agarose gel to distinguish the uncut 248-bp band from the 146- and 102-bp digested fragments. 

Phrase: "Digests"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0868946:Digests [Physiologic Function]

Phrase: "were"

Phrase: "separated by electrophoresis"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   790   C0013855:Electrophoresis [Laboratory Procedure]
   790   C0086972:Separated [Finding]
   790   C0443299:separated [Spatial Concept]
   790   C0687118:Separated [Functional Concept]

Phrase: "on a 2% agarose gel to"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C1706746:Agarose Gel [Research Device]
   812   C0017243:Gel [Biomedical or Dental Material]
   812   C1382104:Gel [Substance]

Phrase: "distinguish"

Phrase: "the uncut 248-bp band from the 146-"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   744   C0175723:Band [Medical Device]
   744   C0439645:Band [Spatial Concept]
   744   C1521913:band [Cell Component]

Phrase: "and"

Phrase: "102-bp digested fragments."
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   812   C0332255:fragments [Functional Concept]
   812   C0486805:Fragments [Body Substance]
   779 E C1708096:Fragment [Qualitative Concept]
Processing 00000000.tx.112: CD38 genotyping by Southern blot and PCR. 

Phrase: "CD38 genotyping by Southern blot"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C1285573:Genotyping [Laboratory Procedure]

Phrase: "and"

Phrase: "PCR."
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
  1000   C0032520:Polymerase Chain Reaction [Laboratory Procedure,Molecular Biology Research Technique]
   827   C0337112:Chain [Manufactured Object]
   827   C0443286:Reaction [Functional Concept]
   827   C1114821:Reaction [Clinical Attribute]
   827   C1335439:Polymerase [Amino Acid, Peptide, or Protein,Enzyme]
   827   C1524075:Chain [Idea or Concept]
Processing 00000000.tx.113: Initially, 10 g aliquots of genomic DNA, prepared as previously described, were digested overnight with 30 U of the PvuII endonuclease (Oncor Appligene, Rome, Italy). 

Phrase: "Initially,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205265:Initially [Temporal Concept]

Phrase: "10 g aliquots of genomic DNA,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   719   C1510844:Aliquot [Quantitative Concept]

Phrase: "prepared"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1521827:Prepare [Functional Concept]

Phrase: "as"

Phrase: "previously"

Phrase: "described"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1552738:described [Idea or Concept]

Phrase: ","

Phrase: "were"

Phrase: "digested"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0868946:digested [Physiologic Function]

Phrase: "overnight with 30 U of the PvuII endonuclease"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   744   C0014230:endonuclease [Amino Acid, Peptide, or Protein,Enzyme]
   744   C0439583:Overnight [Temporal Concept]

Phrase: "(Oncor Appligene,"

Phrase: "Rome,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0035831:Rome [Geographic Area]

Phrase: "Italy"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0022277:Italy [Geographic Area]

Phrase: ")."
Processing 00000000.tx.114: Digests were separated by electrophoresis on 0.7% agarose gels and transferred to Nylon Hybond-N membranes. 

Phrase: "Digests"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0868946:Digests [Physiologic Function]

Phrase: "were"

Phrase: "separated by electrophoresis"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   790   C0013855:Electrophoresis [Laboratory Procedure]
   790   C0086972:Separated [Finding]
   790   C0443299:separated [Spatial Concept]
   790   C0687118:Separated [Functional Concept]

Phrase: "on 0.7% agarose gels"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   844   C1706746:Agarose Gel [Research Device]
   812   C0017243:Gels [Biomedical or Dental Material]
   779 E C1382104:Gel [Substance]

Phrase: "and"

Phrase: "transferred to Nylon Hybond-N membranes."
Meta Candidates (Total=8; Excluded=4; Pruned=0; Remaining=4)
   753   C0025255:Membranes [Tissue]
   753   C0028736:Nylon [Biomedical or Dental Material,Organic Chemical]
   753   C0348011:transferred [Functional Concept]
   753   C0740034:Nylon [Biomedical or Dental Material]
   719 E C0040671:Transfer [Mental Process]
   719 E C0596901:Membrane [Cell Component]
   719 E C1705822:Transfer [Activity]
   719 E C1706182:Membrane [Manufactured Object]
Processing 00000000.tx.115: The hybridization probe was a 308-bp HindIII-AccI CD38 cDNA fragment that detects a 12-kb PvuII fragment (CD38*A) or a 9-kb PvuII fragment (CD38*B), as previously reported (17). 

Phrase: "The hybridization probe"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0182400:Probe [Medical Device]
   861   C1704681:Probe [Gene or Genome]
   861   C2347609:Probe [Chemical Viewed Functionally]
   861   C3536729:Probe [Manufactured Object]

Phrase: "was"

Phrase: "a 308-bp HindIII-AccI CD38 cDNA"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   799   C0006556:cDNA [Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "fragment"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0332255:fragment [Functional Concept]
  1000   C1708096:Fragment [Qualitative Concept]

Phrase: "that"

Phrase: "detects"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0442726:detect [Finding]

Phrase: "a 12-kb PvuII fragment"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   812   C0332255:fragment [Functional Concept]
   812   C1708096:Fragment [Qualitative Concept]

Phrase: "(CD38"

Phrase: "*A)"

Phrase: "or"

Phrase: "a 9-kb PvuII fragment"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   812   C0332255:fragment [Functional Concept]
   812   C1708096:Fragment [Qualitative Concept]

Phrase: "(CD38"

Phrase: "*B"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2347469:/B [Quantitative Concept]

Phrase: ")"

Phrase: ","

Phrase: "as"

Phrase: "previously"

Phrase: "reported"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C0684224:Reported [Intellectual Product]
  1000   C0700287:Reported [Health Care Activity]
  1000   C3496591:Reported [Clinical Attribute]
   966 E C3273238:Report [Intellectual Product]

Phrase: "(17"

Phrase: ")."
Processing 00000000.tx.116: A PCR-based screening method was subsequently devised to amplify the GC-rich genomic region containing the polymorphic PvuII site (17). 

Phrase: "A PCR-based screening method"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   827   C0422392:Screening Method [Intellectual Product]
   799   C0025663:Method [Intellectual Product]
   799   C0449851:Method [Functional Concept]
   799   C0871511:METHOD [Intellectual Product]

Phrase: "was"

Phrase: "subsequently"

Phrase: "devised"

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "amplify"

Phrase: "the GC-rich genomic region"
Meta Candidates (Total=7; Excluded=2; Pruned=0; Remaining=5)
   923   C0017215:GC Rich Region [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   812   C0017428:Genomic [Gene or Genome]
   812   C0017446:Region [Geographic Area]
   812   C0205147:Region [Spatial Concept]
   812   C0887950:genomic [Biomedical Occupation or Discipline]
   741 E C0205276:Regional [Spatial Concept]
   741 E C1947913:Regional [Spatial Concept]

Phrase: "containing"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0332256:Containing [Functional Concept]
  1000   C2700400:Containing [Activity]

Phrase: "the polymorphic PvuII site"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0205145:Site [Spatial Concept]
   827   C1515974:Site [Body Location or Region]
   827   C2825164:Site [Spatial Concept]

Phrase: "(17"

Phrase: ")."
Processing 00000000.tx.117: The PCR (100 l volume) consisted of 120 ng genomic DNA, 10x reaction buffer, 2.5 mmol/l each dNTP, 5 mol/l forward primer (5'-CCGTCCTGGCGCGATGCGTCAAG-3'), 5 mol/l reverse primer (5'-CCGTCCCTGAAGCGGTGAAGCGG-3'), and one unit Deep Vent polymerase (New England Biolabs). 

Phrase: "The PCR"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
  1000   C0032520:Polymerase Chain Reaction [Laboratory Procedure,Molecular Biology Research Technique]
   827   C0337112:Chain [Manufactured Object]
   827   C0443286:Reaction [Functional Concept]
   827   C1114821:Reaction [Clinical Attribute]
   827   C1335439:Polymerase [Amino Acid, Peptide, or Protein,Enzyme]
   827   C1524075:Chain [Idea or Concept]

Phrase: "(100 l volume"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   827   C0449468:*Volume [Quantitative Concept]
   827   C1690016:% volume [Qualitative Concept]
   827   C1705102:Volume [Intellectual Product]
   827   C2700258:Volume [Laboratory Procedure]

Phrase: ")"

Phrase: "consisted of 120 ng genomic DNA,"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   790   C3272453:Genomic DNA [Nucleic Acid, Nucleoside, or Nucleotide]
   753   C0012854:DNA [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   753   C0017428:Genomic [Gene or Genome]
   753   C0887950:genomic [Biomedical Occupation or Discipline]
   719   C0332529:CONSIST [Qualitative Concept]

Phrase: "10x reaction buffer,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0006353:Buffer [Indicator, Reagent, or Diagnostic Aid,Pharmacologic Substance]

Phrase: "2.5 mmol/l"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1532563:mmol/L [Quantitative Concept]

Phrase: "each dNTP,"

Phrase: "5 mol/l forward primer"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   840   C1953382:Forward primer [Cell]
   804   C0206415:Primer [Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "(5'-CCGTCCTGGCGCGATGCGTCAAG-3'"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0439084:>5 [Quantitative Concept]
   827   C0728893:+5 [Quantitative Concept]

Phrase: ")"

Phrase: ","

Phrase: "5 mol/l reverse primer"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   840   C1953384:Reverse primer [Amino Acid, Peptide, or Protein]
   804   C0206415:Primer [Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "(5'-CCGTCCCTGAAGCGGTGAAGCGG-3'"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0439084:>5 [Quantitative Concept]
   827   C0728893:+5 [Quantitative Concept]

Phrase: ")"

Phrase: ","

Phrase: "and"

Phrase: "one unit Deep Vent polymerase"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   804   C1335439:Polymerase [Amino Acid, Peptide, or Protein,Enzyme]

Phrase: "(New England Biolabs"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   734   C0027965:New England [Geographic Area]

Phrase: ")."
Processing 00000000.tx.118: Cycling conditions were as follows: initial denaturation at 98C for 8 min, followed by 33 cycles at 98C for 1 min, 68C for 1 min, and extension at 80C for 1 min. 

Phrase: "Cycling conditions"
Meta Candidates (Total=7; Excluded=4; Pruned=0; Remaining=3)
   827   C0012634:condition [Disease or Syndrome]
   827   C0348080:Condition [Qualitative Concept]
   827   C1705253:Condition [Conceptual Entity]
   777 E C0009647:Conditioned [Mental Process]
   777 E C1701901:Conditional [Qualitative Concept]
   777 E C1963686:Conditional [Functional Concept]
   755 E C1519605:Conditionality [Conceptual Entity]

Phrase: "were"

Phrase: "as"

Phrase: "follows"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0332283:follow [Temporal Concept]
  1000   C1719822:Follow [Intellectual Product]

Phrase: ":"

Phrase: "initial denaturation at 98C"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0301642:Denaturation [Molecular Function]

Phrase: "for 8 min,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0702093:/min [Temporal Concept]

Phrase: "followed by 33 cycles"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   833   C0332283:Followed by [Temporal Concept]
           followed
   737   C1511572:Cycle [Temporal Concept]
   737 E C1719822:Follow [Intellectual Product]

Phrase: "at 98C"

Phrase: "for 1 min,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0702093:/min [Temporal Concept]

Phrase: "68C for 1 min,"

Phrase: "and"

Phrase: "extension at 80C"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0231448:Extension [Functional Concept]
   790   C1880641:Extension [Conceptual Entity]

Phrase: "for 1 min."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0702093:/min [Temporal Concept]
Processing 00000000.tx.119: A 5-min final extension at 80C concluded the program. 

Phrase: "A 5-min final extension at 80C"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   748   C0231448:Extension [Functional Concept]
   748   C1880641:Extension [Conceptual Entity]

Phrase: "concluded"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C0917903:conclude [Biomedical or Dental Material,Organic Chemical]

Phrase: "the program."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C1709697:Program [Conceptual Entity]
  1000   C2728259:Program [Pharmacologic Substance]
  1000   C3484370:Program [Functional Concept]
Processing 00000000.tx.120: A 20-l aliquot was digested overnight at 37C with 10 U PvuII and analyzed by electrophoresis on a 2% gel. 

Phrase: "A 20-l aliquot"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C1510844:Aliquot [Quantitative Concept]

Phrase: "was"

Phrase: "digested"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0868946:digested [Physiologic Function]

Phrase: "overnight at 37C"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C0439583:Overnight [Temporal Concept]

Phrase: "with 10 U PvuII"

Phrase: "and"

Phrase: "analyzed by electrophoresis"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0013855:Electrophoresis [Laboratory Procedure]
   790   C0936012:Analyzed [Research Activity]

Phrase: "on a 2% gel."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0017243:Gel [Biomedical or Dental Material]
   861   C1382104:Gel [Substance]
Processing 00000000.tx.121: Statistical analysis. 

Phrase: "Statistical analysis."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0871424:statistical analysis [Research Activity]
   861   C0002778:Analysis [Laboratory Procedure]
   861   C0936012:Analysis [Research Activity]
   861   C1524024:analysis [Functional Concept]
Processing 00000000.tx.122: All values are expressed as mean  SD. 

Phrase: "All values"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0042295:Values [Qualitative Concept]
   966 E C1522609:Value [Quantitative Concept]

Phrase: "are"

Phrase: "expressed as mean  SD."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0444504:Mean [Quantitative Concept]
   770   C2347634:Mean [Quantitative Concept]
   770   C2348143:Mean [Quantitative Concept]
Processing 00000000.tx.123: Comparisons between proportions were made with the 2 test and Fishers exact test, when appropriate. 

Phrase: "Comparisons between proportions"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   756   C1707455:Comparison [Activity]

Phrase: "were"

Phrase: "made with the 2 test"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   760   C0022885:Test [Laboratory Procedure]
   760   C0039593:Test [Functional Concept]
   760   C0392366:test [Intellectual Product]
   726   C1881534:Make [Functional Concept]

Phrase: "and"

Phrase: "Fishers exact test,"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   988   C1708064:Fisher's Exact Test [Intellectual Product]
           Fisher's Test
   827   C0022885:Test [Laboratory Procedure]
   827   C0039593:Test [Functional Concept]
   827   C0392366:test [Intellectual Product]

Phrase: "when"

Phrase: "appropriate."
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1548787:Appropriate [Qualitative Concept]
   928 E C0814634:appropriateness [Qualitative Concept]
Processing 00000000.tx.124: Comparisons of the means between two groups were performed with the Students t test for normally distributed variables and the Mann-Whitney U test for nonnormal variables. 

Phrase: "Comparisons of the means"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   737   C1707455:Comparison [Activity]

Phrase: "between two groups"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   861   C0441833:Group [Idea or Concept]
   861   C0687744:group [Population Group]
   861   C1257890:Group [Population Group]
   861   C1552516:Group [Health Care Related Organization]
   861   C1552839:groups [Idea or Concept]
   861   C1705428:Group [Conceptual Entity]
   861   C1705429:Group [Population Group]

Phrase: "were"

Phrase: "performed with the Students t test"
Meta Candidates (Total=8; Excluded=3; Pruned=0; Remaining=5)
   753   C0022885:Test [Laboratory Procedure]
   753   C0038492:Students [Professional or Occupational Group]
   753   C0039593:Test [Functional Concept]
   753   C0392366:test [Intellectual Product]
   753   C0884358:Performed [Functional Concept]
   719 E C1551041:student [Idea or Concept]
   719 E C1552573:student [Intellectual Product]
   719 E C2947996:Perform [Pharmacologic Substance]

Phrase: "for normally distributed variables"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0439828:variables [Qualitative Concept]

Phrase: "and"

Phrase: "the Mann-Whitney U test for nonnormal variables."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   833   C0242927:Mann-Whitney U Test [Quantitative Concept]
   793   C1708930:Mann-Whitney Test [Intellectual Product]
   744   C0022885:Test [Laboratory Procedure]
   744   C0039593:Test [Functional Concept]
   744   C0392366:test [Intellectual Product]
Processing 00000000.tx.125: Differences were considered statistically significant for P values <0.05.  

Phrase: "Differences"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   966   C1705241:*Difference [Quantitative Concept]
   966   C1705242:Difference [Qualitative Concept]
   916 E C0443199:Differential [Qualitative Concept]

Phrase: "were"

Phrase: "considered"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0750591:considered [Idea or Concept]

Phrase: "statistically significant for P values"
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
   806   C0237881:statistically significant [Quantitative Concept]
           significant
   762   C1273936:Significance values [Qualitative Concept]
   760   C0038215:Statistically [Occupation or Discipline]
   760   C0750502:Significant [Idea or Concept]
   760   C1546944:Significant [Qualitative Concept]
   735 E C1709380:Statistical Significance [Quantitative Concept]

Phrase: "<0.05."
Processing 00000000.tx.126: RESULTS TOP ABSTRACT INTRODUCTION RESEARCH DESIGN AND METHODS RESULTS DISCUSSION REFERENCES  The baseline characteristics of the 208 diabetic patients (94 type 1 and 114 type 2) selected in this study are shown in Tables 1 and 2. 

Phrase: "RESULTS TOP ABSTRACT INTRODUCTION RESEARCH DESIGN"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   827   C0035171:Research Design [Research Activity]
   799   C0035168:research [Research Activity]
   799   C0242481:Research [Research Activity]
   799   C1707689:Design [Activity]
   799   C2983265:DESIGN [Intellectual Product]

Phrase: "AND"

Phrase: "METHODS RESULTS DISCUSSION"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0557061:Discussion [Therapeutic or Preventive Procedure]
   827   C2584313:Discussion [Social Behavior]

Phrase: "REFERENCES"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1514811:Reference [Idea or Concept]
  1000   C1706462:Reference [Conceptual Entity]

Phrase: "The baseline characteristics of the 208 diabetic patients"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   750   C0815172:patient characteristics [Clinical Attribute]
   744   C1521970:Characteristics [Qualitative Concept]

Phrase: "(94 type 1"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   901   C0441729:Type 1 [Classification]
   827   C0332307:Type [Qualitative Concept]
   827   C1547052:*Type [Quantitative Concept]

Phrase: "and"

Phrase: "114 type 2"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   901   C0441730:Type 2 [Classification]
   827   C0332307:Type [Qualitative Concept]
   827   C1547052:*Type [Quantitative Concept]

Phrase: ")"

Phrase: "selected in this study"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0557651:Study [Manufactured Object]
   770   C2603343:Study [Research Activity]
   737   C1707391:Select [Activity]

Phrase: "are"

Phrase: "shown in Tables 1"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   770   C0039224:tables [Manufactured Object]
   770   C1706074:Tables [Intellectual Product]
   737   C1547282:Show [Intellectual Product]
   737 E C1706073:Table [Medical Device]

Phrase: "and"

Phrase: "2."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0740116:+2 [Quantitative Concept]
  1000   C2827735:2+ [Quantitative Concept]
  1000   C2981700:2+ [Classification]
Processing 00000000.tx.127: No exclusion criteria were used for the selection of patients in order to obtain a heterogeneous sample representative of a broad spectrum of clinical and metabolic phenotypes. 

Phrase: "No exclusion criteria"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0680251:Exclusion Criteria [Functional Concept]
   861   C0243161:criteria [Intellectual Product]

Phrase: "were"

Phrase: "used for the selection of patients"
Meta Candidates (Total=8; Excluded=3; Pruned=0; Remaining=5)
   767   C0242802:Patient Selection [Research Activity]
   767   C1524063:Use of [Functional Concept]
   753   C0030705:Patients [Patient or Disabled Group]
   753   C0036576:selection [Genetic Function]
   753   C1273517:used [Finding]
   719 E C0042153:use [Functional Concept]
   719 E C0457083:Use [Functional Concept]
   719 E C1947944:Use [Intellectual Product]

Phrase: "in order to"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   861   C1705175:Order [Intellectual Product]
   861   C1705176:Order [Qualitative Concept]
   861   C1705177:Order [Classification]
   861   C1705178:Order [Activity]
   861   C1882348:Order [Qualitative Concept]

Phrase: "obtain"
Meta Candidates (Total=8; Excluded=6; Pruned=0; Remaining=2)
  1000   C1301820:Obtain [Functional Concept]
  1000   C1706701:Obtain [Activity]
   944 E C1517378:Gain [Quantitative Concept]
   916 E C0205217:Increased [Quantitative Concept]
   916 E C0439661:Acquired [Temporal Concept]
   916 E C0442805:Increase [Functional Concept]
   916 E C0442808:Increasing [Functional Concept]
   916 E C3245488:acquired [Intellectual Product]

Phrase: "a heterogeneous sample representative of a broad spectrum of clinical"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   739   C1882932:Representative [Activity]

Phrase: "and"

Phrase: "metabolic phenotypes."
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0031437:Phenotypes [Organism Attribute]
   827 E C1285572:Phenotype [Laboratory Procedure]
Processing 00000000.tx.128: View this table: [in this window] [in a new window]  TABLE 1 Characteristics of type 1 diabetic patients and healthy control subjects  View this table: [in this window] [in a new window]  TABLE 2 Characteristics of type 2 diabetic patients and healthy control subjects  EIA for anti-CD38 aAbs: reproducibility, specificity, and sensitivity. 

Phrase: "View"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0449911:View [Spatial Concept]

Phrase: "this table"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0039224:Table [Manufactured Object]
  1000   C1706073:Table [Medical Device]
  1000   C1706074:Table [Intellectual Product]

Phrase: ":"

Phrase: "["

Phrase: "in this window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0557702:Window [Manufactured Object]
  1000   C1272706:Window [Temporal Concept]
  1000   C1704674:Window [Manufactured Object]

Phrase: "]"

Phrase: "["

Phrase: "in a new window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0557702:Window [Manufactured Object]
   861   C1272706:Window [Temporal Concept]
   861   C1704674:Window [Manufactured Object]

Phrase: "]  TABLE 1 Characteristics of type 1 diabetic patients"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   750   C0815172:patient characteristics [Clinical Attribute]
   750   C3645613:Characteristic type [Intellectual Product]
   744   C1521970:Characteristics [Qualitative Concept]

Phrase: "and"

Phrase: "healthy control subjects"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   913   C1708335:HEALTHY SUBJECTS [Population Group]
   793   C0681850:Subject [Group]
   793   C1550501:{Subject} [Idea or Concept]
   793   C1706203:Subject [Idea or Concept]
   793   C2349001:Subject [Human]
   793   C2697811:Subject [Functional Concept]
   734   C2986479:Healthy Control [Qualitative Concept]

Phrase: "View"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0449911:View [Spatial Concept]

Phrase: "this table"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0039224:Table [Manufactured Object]
  1000   C1706073:Table [Medical Device]
  1000   C1706074:Table [Intellectual Product]

Phrase: ":"

Phrase: "["

Phrase: "in this window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0557702:Window [Manufactured Object]
  1000   C1272706:Window [Temporal Concept]
  1000   C1704674:Window [Manufactured Object]

Phrase: "]"

Phrase: "["

Phrase: "in a new window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0557702:Window [Manufactured Object]
   861   C1272706:Window [Temporal Concept]
   861   C1704674:Window [Manufactured Object]

Phrase: "]  TABLE 2 Characteristics of type 2 diabetic patients"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   750   C0815172:patient characteristics [Clinical Attribute]
   750   C3645613:Characteristic type [Intellectual Product]
   744   C1521970:Characteristics [Qualitative Concept]

Phrase: "and"

Phrase: "healthy control"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
  1000   C2986479:Healthy Control [Qualitative Concept]
   861   C0243148:control [Qualitative Concept]
   861   C1550141:Control [Substance]
   861   C1882979:Control [Conceptual Entity]
   861   C2587213:Control [Functional Concept]
   861   C3274648:Control [Qualitative Concept]
   789   C0018684:Health [Idea or Concept]
   789   C0031206:healthiness [Finding]

Phrase: "subjects"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0681850:Subject [Group]
  1000   C1550501:{Subject} [Idea or Concept]
  1000   C1706203:Subject [Idea or Concept]
  1000   C2349001:Subject [Human]
  1000   C2697811:Subject [Functional Concept]

Phrase: "EIA for anti-CD38 aAbs"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0020980:Immunoassay [Laboratory Procedure]
   753   C0021060:immunoassay [Laboratory Procedure]

Phrase: ":"

Phrase: "reproducibility,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1514863:Reproducibility [Qualitative Concept]

Phrase: "specificity,"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
  1000   C0037791:Specificity [Quantitative Concept]
  1000   C1511884:Specificity [Quantitative Concept]
   928 E C0205369:Specific [Qualitative Concept]
   928 E C1552740:specific [Intellectual Product]

Phrase: "and"

Phrase: "sensitivity."
Meta Candidates (Total=9; Excluded=2; Pruned=0; Remaining=7)
  1000   C0036667:Sensitivity [Quantitative Concept]
  1000   C0312418:Sensitivity [Mental Process]
  1000   C0427965:Sensitivity [Finding]
  1000   C1511883:Sensitivity [Quantitative Concept]
  1000   C1522640:Sensitivity [Qualitative Concept]
  1000   C2346484:SENSITIVITY [Phenomenon or Process]
  1000   C2349185:Sensitivity [Qualitative Concept]
   928 E C0332324:Sensitive [Functional Concept]
   928 E C1550474:sensitive [Idea or Concept]
Processing 00000000.tx.129: An immuno-enzymatic method using rsCD38 as the immobilized target molecule was developed to test for the presence of specific serum anti-CD38 aAbs. 

Phrase: "An immuno-enzymatic method"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0025663:Method [Intellectual Product]
   827   C0449851:Method [Functional Concept]
   827   C0871511:METHOD [Intellectual Product]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "rsCD38 as the immobilized target molecule"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   767   C0075742:CD38 molecule [Amino Acid, Peptide, or Protein,Enzyme,Immunologic Factor]
   767   C1413221:CD38 molecule [Gene or Genome]

Phrase: "was"

Phrase: "developed"

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "test for the presence of specific serum anti-CD38 aAbs."
Meta Candidates (Total=11; Excluded=0; Pruned=0; Remaining=11)
   757   C1272321:autoantibodies test [Laboratory Procedure]
   739   C0004358:Autoantibodies [Amino Acid, Peptide, or Protein,Immunologic Factor]
   739   C0022885:Test [Laboratory Procedure]
   739   C0039593:Test [Functional Concept]
   739   C0205369:Specific [Qualitative Concept]
   739   C0229671:Serum [Body Substance]
   739   C0392148:Presence [Therapeutic or Preventive Procedure]
   739   C0392366:test [Intellectual Product]
   739   C1546774:Serum [Intellectual Product]
   739   C1550100:Serum [Body Substance]
   739   C1552740:specific [Intellectual Product]
Processing 00000000.tx.130: Figure 1 shows the OD reading obtained with two representative sera from diabetic patients, one of which was highly reactive (anti-CD38+) and the other displaying very low binding (anti-CD38-). 

Phrase: "Figure 1"

Phrase: "shows"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1547282:Show [Intellectual Product]

Phrase: "the OD reading"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   827   C0034754:Reading [Daily or Recreational Activity]
   827   C1705179:Reading [Finding]
   734   C0439164:Optical density [Quantitative Concept]
   734   C1268822:Optical density [Clinical Attribute]

Phrase: "obtained with two representative sera"
Meta Candidates (Total=8; Excluded=3; Pruned=0; Remaining=5)
   760   C0205448:Two [Quantitative Concept]
   760   C0229671:Sera [Body Substance]
   760   C1151254:SerA [Molecular Function]
   760   C1301820:Obtained [Functional Concept]
   760   C1882932:Representative [Activity]
   726 E C1546774:Serum [Intellectual Product]
   726 E C1550100:Serum [Body Substance]
   726 E C1706701:Obtain [Activity]

Phrase: "from diabetic patients,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]

Phrase: "one of which"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C0205447:One [Quantitative Concept]

Phrase: "was"

Phrase: "highly reactive"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0205332:Reactive [Qualitative Concept]

Phrase: "(anti-CD38+"

Phrase: ")"

Phrase: "and"

Phrase: "the other displaying very low binding"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   812   C0243122:binding [Functional Concept]
   812   C1145667:Binding [Activity]
   812   C1167622:Binding [Molecular Function]

Phrase: "(anti-CD38-"

Phrase: ")."
Processing 00000000.tx.131: Reactivity obtained with anti-CD38+ sera was evident starting from dilutions of 1:10 and persisted up to 1:5,120, showing dose-dependent binding. 

Phrase: "Reactivity"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   928   C0205332:Reactive [Qualitative Concept]

Phrase: "obtained with anti-CD38+ sera"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
   760   C0229671:Sera [Body Substance]
   760   C1151254:SerA [Molecular Function]
   760   C1301820:Obtained [Functional Concept]
   726 E C1546774:Serum [Intellectual Product]
   726 E C1550100:Serum [Body Substance]
   726 E C1706701:Obtain [Activity]

Phrase: "was"

Phrase: "evident starting from dilutions of 1"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   719   C0439659:Start [Temporal Concept]

Phrase: ":"

Phrase: "10"

Phrase: "and"

Phrase: "persisted up to 1"

Phrase: ":"

Phrase: "5,120,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0439084:>5 [Quantitative Concept]
   861   C0728893:+5 [Quantitative Concept]

Phrase: "showing"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: "dose-dependent binding."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   827   C0243122:binding [Functional Concept]
   827   C1145667:Binding [Activity]
   827   C1167622:Binding [Molecular Function]
   734   C1512045:Dose-dependent [Quantitative Concept]
Processing 00000000.tx.132: On the contrary, anti-CD38- sera exhibited a binding to the target molecule that was weaker even at the lowest dilutions (1:10) and was almost totally lost at a dilution of 1:320. 

Phrase: "On the contrary,"

Phrase: "anti-CD38- sera"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   827   C0229671:Sera [Body Substance]
   827   C1151254:SerA [Molecular Function]
   793 E C1546774:Serum [Intellectual Product]
   793 E C1550100:Serum [Body Substance]

Phrase: "exhibited"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C0015272:Exhibit [Intellectual Product]

Phrase: "a binding to the target molecule"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   753   C0243122:binding [Functional Concept]
   753   C1145667:Binding [Activity]
   753   C1167622:Binding [Molecular Function]

Phrase: "that"

Phrase: "was"

Phrase: "weaker even at the lowest dilutions"
Meta Candidates (Total=8; Excluded=4; Pruned=0; Remaining=4)
   753   C0079240:dilutions [Laboratory Procedure]
   753   C1708760:Lowest [Qualitative Concept]
   719   C0004093:Weak [Sign or Symptom]
   719 E C0205251:low [Qualitative Concept]
   719 E C1299352:Low [Qualitative Concept]
   719 E C1550472:low [Idea or Concept]
   719   C1762617:Weak [Qualitative Concept]
   719 E C1948037:Dilution [Functional Concept]

Phrase: "(1"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C2827734:1+ [Quantitative Concept]
  1000   C2981698:1+ [Classification]

Phrase: ":"

Phrase: "10"

Phrase: ")"

Phrase: "and"

Phrase: "was"

Phrase: "almost totally"

Phrase: "lost at a dilution of 1"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   753   C0079240:Dilution [Laboratory Procedure]
   753   C0745777:Lost [Functional Concept]
   753   C1948037:Dilution [Functional Concept]

Phrase: ":"

Phrase: "320."
Processing 00000000.tx.133: Furthermore, the difference between positive and negative samples was lost only at very high dilutions (1:10,240). 

Phrase: "Furthermore,"

Phrase: "the difference between positive"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C1705241:*Difference [Quantitative Concept]
   770   C1705242:Difference [Qualitative Concept]

Phrase: "and"

Phrase: "negative samples"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   861   C0205160:Negative [Qualitative Concept]
   861   C1513916:Negative [Finding]
   861   C2825415:Negative [Conceptual Entity]
   861   C2825491:Negative [Qualitative Concept]
   827   C0370003:Sample [Substance]
   827   C2347026:Sample [Conceptual Entity]

Phrase: "was"

Phrase: "lost"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0745777:Lost [Functional Concept]

Phrase: "only at very high dilutions"
Meta Candidates (Total=9; Excluded=1; Pruned=0; Remaining=8)
   806   C0442804:Very high [Finding]
   760   C0079240:dilutions [Laboratory Procedure]
   760   C0205171:Only [Quantitative Concept]
   760   C0205250:High [Qualitative Concept]
   760   C0442824:Very [Qualitative Concept]
   760   C1299351:High [Qualitative Concept]
   760   C1720467:Only [Intellectual Product]
   760   C2700149:HIGH [Intellectual Product]
   726 E C1948037:Dilution [Functional Concept]

Phrase: "(1"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C2827734:1+ [Quantitative Concept]
  1000   C2981698:1+ [Classification]

Phrase: ":"

Phrase: "10,240"

Phrase: ")."
Processing 00000000.tx.134: Intra- and interassay variabilities were 4.30 and 11.63%, respectively. 

Phrase: "Intra-"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0347985:Intra [Temporal Concept]

Phrase: "and"

Phrase: "interassay variabilities"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   827   C2827666:Variability [Conceptual Entity]
   777 E C0439828:Variable [Qualitative Concept]

Phrase: "were"

Phrase: "4.30"

Phrase: "and"

Phrase: "11.63%,"

Phrase: "respectively."
Processing 00000000.tx.135: Similar results were obtained using plasma samples in place of sera or an anti-human polyvalent Ig in place of an anti-IgG as secondary mAb. 

Phrase: "Similar results"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C1274040:Result [Functional Concept]
   827   C1546471:Result [Idea or Concept]
   827   C2825142:Result [Finding]

Phrase: "were"

Phrase: "obtained"
Meta Candidates (Total=8; Excluded=7; Pruned=0; Remaining=1)
  1000   C1301820:Obtained [Functional Concept]
   966 E C1706701:Obtain [Activity]
   928 E C1517378:Gain [Quantitative Concept]
   907 E C0205217:Increased [Quantitative Concept]
   907 E C0439661:Acquired [Temporal Concept]
   907 E C0442805:Increase [Functional Concept]
   907 E C0442808:Increasing [Functional Concept]
   907 E C3245488:acquired [Intellectual Product]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "plasma samples in place of sera"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   773   C0444263:Plasma sample [Body Substance]
   750   C0444266:Serum sample [Body Substance]
   719   C0370003:Sample [Substance]
   719   C2347026:Sample [Conceptual Entity]

Phrase: "or"

Phrase: "an anti-human polyvalent Ig in place of an anti-IgG"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   738   C0021027:Ig [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   738   C0305052:IG [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   738   C0360506:IG [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   738   C3541296:IG [Idea or Concept]

Phrase: "as secondary mAb."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   901   C0003250:Monoclonal antibody [Amino Acid, Peptide, or Protein,Immunologic Factor]
   827   C0003241:Antibody [Amino Acid, Peptide, or Protein,Cell Component,Immunologic Factor]
   827   C0021027:Antibody [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   827   C0746619:monoclonal [Finding]
Processing 00000000.tx.136: View larger version (12K): [in this window] [in a new window]  FIG. 

Phrase: "View"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0449911:View [Spatial Concept]

Phrase: "larger version"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0333052:Version [Functional Concept]
   861   C2607870:Version [Spatial Concept]

Phrase: "(12K"

Phrase: ")"

Phrase: ":"

Phrase: "["

Phrase: "in this window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0557702:Window [Manufactured Object]
  1000   C1272706:Window [Temporal Concept]
  1000   C1704674:Window [Manufactured Object]

Phrase: "]"

Phrase: "["

Phrase: "in a new window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0557702:Window [Manufactured Object]
   861   C1272706:Window [Temporal Concept]
   861   C1704674:Window [Manufactured Object]

Phrase: "]  FIG."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0349966:Fig [Food]
  1000   C1337208:FIG [Food]
Processing 00000000.tx.137: 1. 

Phrase: "1."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C2827734:1+ [Quantitative Concept]
  1000   C2981698:1+ [Classification]
Processing 00000000.tx.138: Anti-CD38 immunoreactivity of sera from diabetic patients by EIA. 

Phrase: "Anti-CD38 immunoreactivity of sera"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0597879:immunoreactivity [Molecular Function]

Phrase: "from diabetic patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]

Phrase: "by EIA."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0020980:Immunoassay [Laboratory Procedure]
   861   C0021060:immunoassay [Laboratory Procedure]
Processing 00000000.tx.139: Sera were diluted at progressively higher dilutions and probed against immobilized rsCD38. 

Phrase: "Sera"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
  1000   C0229671:Sera [Body Substance]
  1000   C1151254:SerA [Molecular Function]
   966 E C1546774:Serum [Intellectual Product]
   966 E C1550100:Serum [Body Substance]

Phrase: "were"

Phrase: "diluted at progressively higher dilutions"
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
   760   C0079240:dilutions [Laboratory Procedure]
   726   C0205250:High [Qualitative Concept]
   726   C1299351:High [Qualitative Concept]
   726   C1720119:Dilute [Functional Concept]
   726   C1948037:Dilute [Functional Concept]
       E   Dilution
   726   C2700149:HIGH [Intellectual Product]

Phrase: "and"

Phrase: "probed against immobilized rsCD38."
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   753   C1514798:recombinant [Organism]
   753   C1749467:soluble [Cell Component]
   753   C1948047:Soluble [Qualitative Concept]
   719   C0182400:Probe [Medical Device]
   719   C1704681:Probe [Gene or Genome]
   719   C2347609:Probe [Chemical Viewed Functionally]
   719   C3536729:Probe [Manufactured Object]
Processing 00000000.tx.140: Results from two representative samples with high (anti-CD38+) and low (anti-CD38-) reactivities are shown.  

Phrase: "Results from two representative samples"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   726   C1274040:Result [Functional Concept]
   726   C1546471:Result [Idea or Concept]
   726   C2825142:Result [Finding]

Phrase: "with high"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205250:High [Qualitative Concept]
  1000   C1299351:High [Qualitative Concept]
  1000   C2700149:HIGH [Intellectual Product]

Phrase: "(anti-CD38+"

Phrase: ")"

Phrase: "and"

Phrase: "low"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205251:low [Qualitative Concept]
  1000   C1299352:Low [Qualitative Concept]
  1000   C1550472:low [Idea or Concept]

Phrase: "(anti-CD38-"

Phrase: ")"

Phrase: "reactivities"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   916   C0205332:Reactive [Qualitative Concept]

Phrase: "are"

Phrase: "shown."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]
Processing 00000000.tx.141: Preadsorption experiments were performed to confirm the specificity of the assay (Fig. 2); 

Phrase: "Preadsorption experiments"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   861   C0681814:Experiments [Research Activity]
   827 E C1706386:Experiment [Conceptual Entity]
   777 E C1517586:Experimental [Qualitative Concept]

Phrase: "were"

Phrase: "performed"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0884358:Performed [Functional Concept]
   966 E C2947996:Perform [Pharmacologic Substance]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "confirm"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0521093:confirm [Qualitative Concept]
  1000   C0750484:confirm [Idea or Concept]
  1000   C1456348:Confirm [Qualitative Concept]

Phrase: "the specificity of the assay"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0037791:Specificity [Quantitative Concept]
   760   C1511884:Specificity [Quantitative Concept]

Phrase: "(Fig. 2"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0349966:Fig [Food]
   861   C1337208:FIG [Food]

Phrase: ")"

Phrase: ";"
Processing 00000000.tx.142: highly reactive sera (anti-CD38+) preincubated with saturating amounts of rsCD38 displayed a consistent decrease (93.395.5%) in EIA binding to the same rsCD38 target molecule as compared with the basal reactivity of sera preincubated with PBS alone or with the irrelevant protein HIV gp120. 

Phrase: "highly reactive sera"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   827   C0229671:Sera [Body Substance]
   827   C1151254:SerA [Molecular Function]
   793 E C1546774:Serum [Intellectual Product]
   793 E C1550100:Serum [Body Substance]

Phrase: "(anti-CD38+"

Phrase: ")"

Phrase: "preincubated with saturating amounts of rsCD38"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   744   C0522534:saturating [Phenomenon or Process]
   744   C1265611:amounts [Quantitative Concept]
   744   C1514798:recombinant [Organism]
   744   C1749467:soluble [Cell Component]
   744   C1948047:Soluble [Qualitative Concept]

Phrase: "displayed"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0870432:displayed [Functional Concept]
   966 E C1705417:Display [Manufactured Object]

Phrase: "a consistent decrease"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0392756:Decrease [Qualitative Concept]
   861   C0547047:Decrease [Quantitative Concept]

Phrase: "(93.395.5%"

Phrase: ")"

Phrase: "in EIA binding"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0243122:binding [Functional Concept]
   827   C1145667:Binding [Activity]
   827   C1167622:Binding [Molecular Function]

Phrase: "to the same rsCD38 target molecule"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   839   C0075742:CD38 molecule [Amino Acid, Peptide, or Protein,Enzyme,Immunologic Factor]
   839   C1413221:CD38 molecule [Gene or Genome]
   799   C0567416:Molecule [Substance]
   727 E C1521991:Molecular [Qualitative Concept]

Phrase: "as"

Phrase: "compared with the basal reactivity of sera"
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
   748   C0205112:Basal [Spatial Concept]
   748   C0229671:Sera [Body Substance]
   748   C1151254:SerA [Molecular Function]
   748   C1707455:Compared [Activity]
   714 E C1546774:Serum [Intellectual Product]
   714 E C1550100:Serum [Body Substance]

Phrase: "preincubated with PBS"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   797   C0991865:buffered phosphate [Indicator, Reagent, or Diagnostic Aid,Pharmacologic Substance]
   760   C0006353:Buffered [Indicator, Reagent, or Diagnostic Aid,Pharmacologic Substance]
   760   C0031603:Phosphate [Inorganic Chemical,Pharmacologic Substance]
   760   C0031701:phosphate [Organophosphorus Compound]
   760   C0036082:Saline [Substance]
   760   C1601799:PHOSPHATE [Inorganic Chemical,Pharmacologic Substance]

Phrase: "alone"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205171:Alone [Quantitative Concept]
  1000   C0439044:alone [Finding]
  1000   C0679994:alone [Group Attribute]

Phrase: "or with the irrelevant protein HIV gp120."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   778   C0019691:HIV gp120 [Amino Acid, Peptide, or Protein,Biologically Active Substance]
           gp120
   748   C0019682:HIV [Virus]
   748   C0019699:HIV+ [Finding]
   748   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
Processing 00000000.tx.143: Moreover, when the immunoenzymatic assay was performed using wells coated with gp120, no reactivity was detected with any of the sera tested (data not shown). 

Phrase: "Moreover,"

Phrase: "when"

Phrase: "the immunoenzymatic assay"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0086231:Immunoenzymatic assay, NOS [Laboratory Procedure]
   861   C0005507:Assay [Laboratory Procedure]
   861   C0243073:assay [Qualitative Concept]
   861   C1510438:Assay [Laboratory Procedure]

Phrase: "was"

Phrase: "performed"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0884358:Performed [Functional Concept]
   966 E C2947996:Perform [Pharmacologic Substance]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "wells"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   966   C0205170:Well [Qualitative Concept]
   966   C3146287:Well [Manufactured Object]

Phrase: "coated with gp120,"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   790   C0019691:gp120 [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   790   C1522408:Coated [Qualitative Concept]
   756 E C0453946:Coat [Manufactured Object]
   756 E C2987482:Coat [Body Part, Organ, or Organ Component]

Phrase: "no reactivity"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   928   C0205332:Reactive [Qualitative Concept]

Phrase: "was"

Phrase: "detected with any of the sera"
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
   753   C0229671:Sera [Body Substance]
   753   C0442726:Detected [Finding]
   753   C1151254:SerA [Molecular Function]
   753   C1511790:Detected [Therapeutic or Preventive Procedure]
   719 E C1546774:Serum [Intellectual Product]
   719 E C1550100:Serum [Body Substance]

Phrase: "tested"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0392366:tested [Intellectual Product]
   966 E C0022885:Test [Laboratory Procedure]
   966 E C0039593:Test [Functional Concept]

Phrase: "(data"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1511726:Data [Idea or Concept]
  1000   C3245479:data [Medical Device]

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "shown"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: ")."
Processing 00000000.tx.144: View larger version (24K): [in this window] [in a new window]  FIG. 

Phrase: "View"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0449911:View [Spatial Concept]

Phrase: "larger version"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0333052:Version [Functional Concept]
   861   C2607870:Version [Spatial Concept]

Phrase: "(24K"

Phrase: ")"

Phrase: ":"

Phrase: "["

Phrase: "in this window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0557702:Window [Manufactured Object]
  1000   C1272706:Window [Temporal Concept]
  1000   C1704674:Window [Manufactured Object]

Phrase: "]"

Phrase: "["

Phrase: "in a new window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0557702:Window [Manufactured Object]
   861   C1272706:Window [Temporal Concept]
   861   C1704674:Window [Manufactured Object]

Phrase: "]  FIG."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0349966:Fig [Food]
  1000   C1337208:FIG [Food]
Processing 00000000.tx.145: 2. 

Phrase: "2."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0740116:+2 [Quantitative Concept]
  1000   C2827735:2+ [Quantitative Concept]
  1000   C2981700:2+ [Classification]
Processing 00000000.tx.146: Effects of sera preadsorption with rsCD38 on EIA reactivity. 

Phrase: "Effects of sera preadsorption"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   770   C1280500:effects [Qualitative Concept]
   737 E C2348382:Effect [Qualitative Concept]

Phrase: "with rsCD38"

Phrase: "on EIA reactivity."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   755   C0205332:Reactive [Qualitative Concept]
Processing 00000000.tx.147: Highly reactive (anti-CD38+) sera from patients with type 1 and type 2 diabetes (DM) were preincubated with PBS alone (), with the irrelevant protein gp120 (), or with saturating amounts of rsCD38 () and subsequently tested in EIA using the same target molecule. 

Phrase: "Highly reactive"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0205332:Reactive [Qualitative Concept]

Phrase: "(anti-CD38+"

Phrase: ")"

Phrase: "sera from patients"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   790   C0229671:Sera [Body Substance]
   790   C1151254:SerA [Molecular Function]
   756 E C1546774:Serum [Intellectual Product]
   756 E C1550100:Serum [Body Substance]

Phrase: "with type 1"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0441729:Type 1 [Classification]
   861   C0332307:Type [Qualitative Concept]
   861   C1547052:*Type [Quantitative Concept]

Phrase: "and"

Phrase: "type 2 diabetes"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
  1000   C0011860:Type 2 Diabetes [Disease or Syndrome]
   913   C1320657:type diabetes [Finding]
   901   C0441730:Type 2 [Classification]
   827   C0011847:Diabetes [Disease or Syndrome]
   827   C0011849:Diabetes [Disease or Syndrome]
   827   C0332307:Type [Qualitative Concept]
   827   C1547052:*Type [Quantitative Concept]

Phrase: "(DM)"

Phrase: "were"

Phrase: "preincubated with PBS"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   797   C0991865:buffered phosphate [Indicator, Reagent, or Diagnostic Aid,Pharmacologic Substance]
   760   C0006353:Buffered [Indicator, Reagent, or Diagnostic Aid,Pharmacologic Substance]
   760   C0031603:Phosphate [Inorganic Chemical,Pharmacologic Substance]
   760   C0031701:phosphate [Organophosphorus Compound]
   760   C0036082:Saline [Substance]
   760   C1601799:PHOSPHATE [Inorganic Chemical,Pharmacologic Substance]

Phrase: "alone"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205171:Alone [Quantitative Concept]
  1000   C0439044:alone [Finding]
  1000   C0679994:alone [Group Attribute]

Phrase: "("

Phrase: ")"

Phrase: ","

Phrase: "with the irrelevant protein gp120"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0019691:gp120 [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "("

Phrase: ")"

Phrase: ","

Phrase: "or with saturating amounts of rsCD38"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   744   C0522534:saturating [Phenomenon or Process]
   744   C1265611:amounts [Quantitative Concept]
   744   C1514798:recombinant [Organism]
   744   C1749467:soluble [Cell Component]
   744   C1948047:Soluble [Qualitative Concept]

Phrase: "("

Phrase: ")"

Phrase: "and"

Phrase: "subsequently"

Phrase: "tested in EIA"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
   770   C0020980:Immunoassay [Laboratory Procedure]
   770   C0021060:immunoassay [Laboratory Procedure]
   770   C0392366:tested [Intellectual Product]
   737 E C0022885:Test [Laboratory Procedure]
   737 E C0039593:Test [Functional Concept]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "the same target molecule."
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   827   C0567416:Molecule [Substance]
   755 E C1521991:Molecular [Qualitative Concept]
Processing 00000000.tx.148: Percent binding inhibition on preadsorption is indicated above the bars. 

Phrase: "Percent binding inhibition on preadsorption"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   797   C1628982:Percent inhibition [Quantitative Concept]
           % inhibition
   760   C0021467:Inhibition [Mental Process]
   760   C0021469:Inhibition [Molecular Function]
   760   C3463820:Inhibition [Activity]

Phrase: "is"

Phrase: "indicated above the bars."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   770   C1444656:Indicated [Finding]
   770   C1707156:BARS [Gene or Genome]
   770   C3274014:BARS [Intellectual Product]
   770   C3541345:BARS [Intellectual Product]
Processing 00000000.tx.149: Differences between PBS and gp120 preincubation were not statistically significant.  

Phrase: "Differences between PBS"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   726   C1705241:*Difference [Quantitative Concept]
   726   C1705242:Difference [Qualitative Concept]

Phrase: "and"

Phrase: "gp120 preincubation"

Phrase: "were"

Phrase: "not statistically significant."
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
   913   C1273937:Not significant [Finding]
   901   C0237881:statistically significant [Quantitative Concept]
           significant
   829 E C1709380:Statistical Significance [Quantitative Concept]
   827   C0038215:Statistically [Occupation or Discipline]
   827   C0750502:Significant [Idea or Concept]
   827   C1546944:Significant [Qualitative Concept]
Processing 00000000.tx.150: Given the intrinsic lower specificity of EIA techniques as compared with the Western blot previously adopted (15,16), we also checked the anti-CD38+ samples against the same rsCD38 target protein in Western blot (Fig. 3) with the sera diluted 1:1,000, as previously described (16). 

Phrase: "Given"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C1442162:GIVEN [Conceptual Entity]
  1000   C1550718:given [Idea or Concept]
  1000   C3244317:given [Intellectual Product]
   966 E C1947971:Give [Functional Concept]

Phrase: "the intrinsic lower specificity of EIA techniques"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   744   C0037791:Specificity [Quantitative Concept]
   744   C1511884:Specificity [Quantitative Concept]

Phrase: "as"

Phrase: "compared with the Western blot previously"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   790   C0005863:Western Blot [Laboratory Procedure,Molecular Biology Research Technique]
   790   C0949466:Western Blot [Laboratory Procedure]
   753   C1705493:Western [Spatial Concept]
   753   C1707455:Compared [Activity]

Phrase: "adopted"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0425382:Adopted [Finding]

Phrase: "(15,"

Phrase: "16"

Phrase: ")"

Phrase: ","

Phrase: "we also"

Phrase: "checked"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1283174:Checked [Activity]

Phrase: "the anti-CD38+ samples against the same rsCD38 target protein"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   703   C0370003:Sample [Substance]
   703   C2347026:Sample [Conceptual Entity]

Phrase: "in Western blot"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0005863:Western Blot [Laboratory Procedure,Molecular Biology Research Technique]
  1000   C0949466:Western Blot [Laboratory Procedure]
   861   C1705493:Western [Spatial Concept]

Phrase: "(Fig. 3"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0349966:Fig [Food]
   861   C1337208:FIG [Food]

Phrase: ")"

Phrase: "with the sera"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
  1000   C0229671:Sera [Body Substance]
  1000   C1151254:SerA [Molecular Function]
   966 E C1546774:Serum [Intellectual Product]
   966 E C1550100:Serum [Body Substance]

Phrase: "diluted"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   966   C1720119:Dilute [Functional Concept]
   966   C1948037:Dilute [Functional Concept]

Phrase: "1"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C2827734:1+ [Quantitative Concept]
  1000   C2981698:1+ [Classification]

Phrase: ":"

Phrase: "1,000,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C2827734:1+ [Quantitative Concept]
   861   C2981698:1+ [Classification]

Phrase: "as"

Phrase: "previously"

Phrase: "described"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1552738:described [Idea or Concept]

Phrase: "(16"

Phrase: ")."
Processing 00000000.tx.151: The band highlighted by different anti-CD38+ samples (lanes 16) displayed a molecular weight of 30 kDa, corresponding to the rsCD38 used for EIA. 

Phrase: "The band"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0175723:Band [Medical Device]
  1000   C0439645:Band [Spatial Concept]
  1000   C1521913:band [Cell Component]

Phrase: "highlighted by different anti-CD38+ samples"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   753   C1705242:Different [Qualitative Concept]
   719   C0370003:Sample [Substance]
   719   C2347026:Sample [Conceptual Entity]

Phrase: "(lanes 16"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C1708639:Lane [Spatial Concept]

Phrase: ")"

Phrase: "displayed"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0870432:displayed [Functional Concept]
   966 E C1705417:Display [Manufactured Object]

Phrase: "a molecular weight of 30 kDa,"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   790   C0026385:Molecular Weight [Quantitative Concept]
   753   C0005910:weight [Organism Attribute]
   753   C0043100:Weight [Quantitative Concept]
   753   C1305866:weight [Diagnostic Procedure]
   753   C1521991:Molecular [Qualitative Concept]
   753   C1705104:Weight [Idea or Concept]

Phrase: "corresponding to the rsCD38"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   753   C1514798:recombinant [Organism]
   753   C1749467:soluble [Cell Component]
   753   C1948047:Soluble [Qualitative Concept]

Phrase: "used for EIA."
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
   770   C0020980:Immunoassay [Laboratory Procedure]
   770   C0021060:immunoassay [Laboratory Procedure]
   770   C1273517:used [Finding]
   737 E C0042153:use [Functional Concept]
   737 E C0457083:Use [Functional Concept]
   737 E C1947944:Use [Intellectual Product]
Processing 00000000.tx.152: On the contrary, no signal was detected by a representative anti-CD38- serum sample (lane 7). 

Phrase: "On the contrary,"

Phrase: "no signal"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1710082:Signal [Phenomenon or Process]

Phrase: "was"

Phrase: "detected by a representative anti-CD38- serum sample"
Meta Candidates (Total=10; Excluded=0; Pruned=0; Remaining=10)
   770   C0444266:Serum sample [Body Substance]
   767   C0432616:Anti A [Amino Acid, Peptide, or Protein,Immunologic Factor]
   744   C0229671:Serum [Body Substance]
   744   C0370003:Sample [Substance]
   744   C0442726:Detected [Finding]
   744   C1511790:Detected [Therapeutic or Preventive Procedure]
   744   C1546774:Serum [Intellectual Product]
   744   C1550100:Serum [Body Substance]
   744   C1882932:Representative [Activity]
   744   C2347026:Sample [Conceptual Entity]

Phrase: "(lane 7"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1708639:Lane [Spatial Concept]

Phrase: ")."
Processing 00000000.tx.153: Visualization of the molecular species corresponding to rsCD38 as the one recognized by the patients sera, together with the absence of signal obtained with the same samples on an irrelevant protein (data not shown), confirmed the specificity of the EIA procedure. 

Phrase: "Visualization of the molecular species"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0175631:Visualization [Mental Process]
   760   C2827662:Visualization [Occupation or Discipline]

Phrase: "corresponding to rsCD38"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C1514798:recombinant [Organism]
   760   C1749467:soluble [Cell Component]
   760   C1948047:Soluble [Qualitative Concept]

Phrase: "as the one"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205447:One [Quantitative Concept]

Phrase: "recognized by the patients sera,"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
   760   C0030705:Patients [Patient or Disabled Group]
   760   C0229671:Sera [Body Substance]
   760   C1151254:SerA [Molecular Function]
   726 E C1546774:Serum [Intellectual Product]
   726 E C1550100:Serum [Body Substance]

Phrase: "together with the absence"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0332197:absence [Quantitative Concept]
  1000   C1689985:Absence [Anatomical Abnormality]
   928 E C2699517:ABSENT [Finding]

Phrase: "of signal"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1710082:Signal [Phenomenon or Process]

Phrase: "obtained with the same samples"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
   781   C1277697:Sample obtained [Finding]
   760   C0445247:Same [Qualitative Concept]
   760   C1301820:Obtained [Functional Concept]
   726   C0370003:Sample [Substance]
   726 E C1706701:Obtain [Activity]
   726   C2347026:Sample [Conceptual Entity]

Phrase: "on an irrelevant protein"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "(data"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1511726:Data [Idea or Concept]
  1000   C3245479:data [Medical Device]

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "shown"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: ")"

Phrase: ","

Phrase: "confirmed"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0521093:confirmed [Qualitative Concept]
  1000   C0750484:Confirmed [Idea or Concept]
   966 E C1456348:Confirm [Qualitative Concept]

Phrase: "the specificity of the EIA procedure."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   748   C0037791:Specificity [Quantitative Concept]
   748   C1511884:Specificity [Quantitative Concept]
Processing 00000000.tx.154: Moreover, preadsorption experiments performed by preincubating the reactive sera with rsCD38 before Western blot abolished the signal (data not shown). 

Phrase: "Moreover,"

Phrase: "preadsorption experiments"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   861   C0681814:Experiments [Research Activity]
   827 E C1706386:Experiment [Conceptual Entity]
   777 E C1517586:Experimental [Qualitative Concept]

Phrase: "performed by preincubating"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   882   C1550369:Performed By [Qualitative Concept]
   790   C0884358:Performed [Functional Concept]
   756 E C2947996:Perform [Pharmacologic Substance]

Phrase: "the reactive sera with rsCD38"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   748   C0229671:Sera [Body Substance]
   748   C1151254:SerA [Molecular Function]
   714 E C1546774:Serum [Intellectual Product]
   714 E C1550100:Serum [Body Substance]

Phrase: "before Western blot"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0005863:Western Blot [Laboratory Procedure,Molecular Biology Research Technique]
  1000   C0949466:Western Blot [Laboratory Procedure]
   861   C1705493:Western [Spatial Concept]

Phrase: "abolished"

Phrase: "the signal"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1710082:Signal [Phenomenon or Process]

Phrase: "(data"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1511726:Data [Idea or Concept]
  1000   C3245479:data [Medical Device]

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "shown"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: ")."
Processing 00000000.tx.155: Given the detection limit of a 1:5,120 dilution displayed by the EIA technique compared with the 1:1,000 dilution used for Western blot both in the present work and in previous ones (15,16), the EIA proved to be more sensitive in the identification of anti-CD38+ sera. 

Phrase: "Given"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C1442162:GIVEN [Conceptual Entity]
  1000   C1550718:given [Idea or Concept]
  1000   C3244317:given [Intellectual Product]
   966 E C1947971:Give [Functional Concept]

Phrase: "the detection limit of a 1"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   820   C2718050:Limit of Detection [Quantitative Concept]
           Detection Limit
   753   C0439801:limit [Functional Concept]
   753   C1549649:Limit [Idea or Concept]
   753   C2349209:Limit [Conceptual Entity]

Phrase: ":"

Phrase: "5,120 dilution"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0079240:Dilution [Laboratory Procedure]
   827   C1948037:Dilution [Functional Concept]

Phrase: "displayed by the EIA technique"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   753   C0020980:Immunoassay [Laboratory Procedure]
   753   C0021060:immunoassay [Laboratory Procedure]
   753   C0449851:Technique [Functional Concept]
   753   C0870432:displayed [Functional Concept]
   719 E C1705417:Display [Manufactured Object]

Phrase: "compared with the 1"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C1707455:Compared [Activity]

Phrase: ":"

Phrase: "1,000 dilution"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0079240:Dilution [Laboratory Procedure]
   827   C1948037:Dilution [Functional Concept]

Phrase: "used for Western blot"
Meta Candidates (Total=7; Excluded=3; Pruned=0; Remaining=4)
   833   C0005863:Western Blot [Laboratory Procedure,Molecular Biology Research Technique]
   833   C0949466:Western Blot [Laboratory Procedure]
   770   C1273517:used [Finding]
   770   C1705493:Western [Spatial Concept]
   737 E C0042153:use [Functional Concept]
   737 E C0457083:Use [Functional Concept]
   737 E C1947944:Use [Intellectual Product]

Phrase: "both in the present work"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   760   C0043227:Work [Occupational Activity]
   760   C0150312:Present [Quantitative Concept]
   760   C0238767:Both [Spatial Concept]
   760   C0449450:Present [Idea or Concept]
   760   C1706086:Both [Qualitative Concept]

Phrase: "and in previous ones"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   770   C0205156:Previous [Temporal Concept]
   770   C1515981:And [Idea or Concept]
   770   C1552607:previous [Temporal Concept]
   737   C0205447:One [Quantitative Concept]

Phrase: "(15,"

Phrase: "16"

Phrase: ")"

Phrase: ","

Phrase: "the EIA"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0020980:Immunoassay [Laboratory Procedure]
   861   C0021060:immunoassay [Laboratory Procedure]

Phrase: "proved"

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "be"

Phrase: "more sensitive in the identification of anti-CD38+ sera."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   742   C0332324:Sensitive [Functional Concept]
   742   C1550474:sensitive [Idea or Concept]
Processing 00000000.tx.156: View larger version (49K): [in this window] [in a new window]  FIG. 

Phrase: "View"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0449911:View [Spatial Concept]

Phrase: "larger version"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0333052:Version [Functional Concept]
   861   C2607870:Version [Spatial Concept]

Phrase: "(49K"

Phrase: ")"

Phrase: ":"

Phrase: "["

Phrase: "in this window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0557702:Window [Manufactured Object]
  1000   C1272706:Window [Temporal Concept]
  1000   C1704674:Window [Manufactured Object]

Phrase: "]"

Phrase: "["

Phrase: "in a new window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0557702:Window [Manufactured Object]
   861   C1272706:Window [Temporal Concept]
   861   C1704674:Window [Manufactured Object]

Phrase: "]  FIG."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0349966:Fig [Food]
  1000   C1337208:FIG [Food]
Processing 00000000.tx.157: 3. 

Phrase: "3."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0439086:<3 [Quantitative Concept]
  1000   C2827736:3+ [Quantitative Concept]
  1000   C2981702:3+ [Classification]
Processing 00000000.tx.158: Analysis of anti-CD38 reactivity from representative diabetic (DM) positive (anti-CD38+) and negative (anti-CD38-) sera by Western blot. 

Phrase: "Analysis of anti-CD38 reactivity"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C0002778:Analysis [Laboratory Procedure]
   760   C0936012:Analysis [Research Activity]
   760   C1524024:analysis [Functional Concept]

Phrase: "from representative diabetic"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0241863:DIABETIC [Finding]

Phrase: "(DM) positive"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0439178:% Positive [Quantitative Concept]
   861   C1446409:Positive [Qualitative Concept]
   861   C1514241:Positive [Finding]
   861   C2825490:Positive [Qualitative Concept]

Phrase: "(anti-CD38+"

Phrase: ")"

Phrase: "and"

Phrase: "negative"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0205160:Negative [Qualitative Concept]
  1000   C1513916:Negative [Finding]
  1000   C2825415:Negative [Conceptual Entity]
  1000   C2825491:Negative [Qualitative Concept]

Phrase: "(anti-CD38-"

Phrase: ")"

Phrase: "sera by Western blot."
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   770   C0229671:Sera [Body Substance]
   770   C1151254:SerA [Molecular Function]
   737 E C1546774:Serum [Intellectual Product]
   737 E C1550100:Serum [Body Substance]
Processing 00000000.tx.159: The band at 30 kDa () corresponds to the molecular weight of rsCD38.  

Phrase: "The band at 30 kDa ()"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C0175723:Band [Medical Device]
   760   C0439645:Band [Spatial Concept]
   760   C1521913:band [Cell Component]

Phrase: "corresponds to the molecular weight of rsCD38."
Meta Candidates (Total=11; Excluded=0; Pruned=0; Remaining=11)
   764   C0026385:Molecular Weight [Quantitative Concept]
   742   C0005910:weight [Organism Attribute]
   742   C0043100:Weight [Quantitative Concept]
   742   C1305866:weight [Diagnostic Procedure]
   742   C1514798:recombinant [Organism]
   742   C1521991:Molecular [Qualitative Concept]
   742   C1705104:Weight [Idea or Concept]
   742   C1749467:soluble [Cell Component]
   742   C1948047:Soluble [Qualitative Concept]
   726   C0075742:CD38 molecule [Amino Acid, Peptide, or Protein,Enzyme,Immunologic Factor]
   726   C1413221:CD38 molecule [Gene or Genome]
Processing 00000000.tx.160: Anti-CD38 aAb titers by EIA. 

Phrase: "Anti-CD38 aAb titers by EIA."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   714   C0475208:Titer [Quantitative Concept]
Processing 00000000.tx.161: Between the two representative serum samples shown in Fig. 

Phrase: "Between the two representative serum samples"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   844   C0444266:Serum sample [Body Substance]
   779   C0370003:Sample [Substance]
   779   C2347026:Sample [Conceptual Entity]

Phrase: "shown in Fig."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   790   C0349966:Fig [Food]
   790   C1337208:FIG [Food]
   756   C1547282:Show [Intellectual Product]
Processing 00000000.tx.162: 1, a whole range of intermediate reactivities was obtained with sera from other patients. 

Phrase: "1,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C2827734:1+ [Quantitative Concept]
  1000   C2981698:1+ [Classification]

Phrase: "a whole range of intermediate reactivities"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   753   C1514721:Range [Quantitative Concept]
   753   C2348147:Range [Quantitative Concept]
   753   C3542016:Range [Intellectual Product]

Phrase: "was"

Phrase: "obtained with sera"
Meta Candidates (Total=7; Excluded=4; Pruned=0; Remaining=3)
   790   C0229671:Sera [Body Substance]
   790   C1151254:SerA [Molecular Function]
   790   C1301820:Obtained [Functional Concept]
   756 E C1546774:Serum [Intellectual Product]
   756 E C1550100:Serum [Body Substance]
   756 E C1706701:Obtain [Activity]
   718 E C1517378:Gain [Quantitative Concept]

Phrase: "from other patients."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]
Processing 00000000.tx.163: Because the two curves were more widely separated using the 1:640 dilution (Fig. 1), this was chosen as the most informative for EIA testing. 

Phrase: "Because"

Phrase: "the two curves"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0205134:Curve [Spatial Concept]

Phrase: "were"

Phrase: "more widely"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0205172:More [Functional Concept]

Phrase: "separated"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0086972:Separated [Finding]
  1000   C0443299:separated [Spatial Concept]
  1000   C0687118:Separated [Functional Concept]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "the 1"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C2827734:1+ [Quantitative Concept]
  1000   C2981698:1+ [Classification]

Phrase: ":"

Phrase: "640 dilution"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0079240:Dilution [Laboratory Procedure]
   861   C1948037:Dilution [Functional Concept]

Phrase: "(Fig. 1"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0349966:Fig [Food]
   861   C1337208:FIG [Food]

Phrase: ")"

Phrase: ","

Phrase: "this"

Phrase: "was"

Phrase: "chosen as the most informative"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C1707391:Chosen [Activity]
   760   C2986490:Informative [Qualitative Concept]

Phrase: "for EIA testing."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0039593:Testing [Functional Concept]
   827   C0392366:testing [Intellectual Product]
Processing 00000000.tx.164: Moreover, to divide diabetic patients into anti-CD38+ and anti-CD38- categories, cutoff levels were arbitrarily defined as the mean + 3 SD of the measures obtained from healthy control subjects. 

Phrase: "Moreover,"

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "divide"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0332849:Divide [Functional Concept]

Phrase: "diabetic patients into anti-CD38+"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0030705:Patients [Patient or Disabled Group]

Phrase: "and"

Phrase: "anti-CD38- categories,"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   827   C0683312:Categories [Intellectual Product]
   793 E C1555713:category [Idea or Concept]

Phrase: "cutoff levels"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   861   C0441889:Levels [Qualitative Concept]
   861   C1442160:Cutoff [Functional Concept]
   827 E C0456079:Level [Classification]
   827 E C1547707:Level [Geographic Area]
   827 E C2946261:Level [Pharmacologic Substance]

Phrase: "were"

Phrase: "arbitrarily"

Phrase: "defined as the mean + 3 SD of the measures"
Meta Candidates (Total=8; Excluded=1; Pruned=0; Remaining=7)
   742   C0079809:Measures [Quantitative Concept]
   742   C0444504:Mean [Quantitative Concept]
   742   C1704788:Defined [Conceptual Entity]
   742   C1879489:Measures [Functional Concept]
   742   C2347634:Mean [Quantitative Concept]
   742   C2348143:Mean [Quantitative Concept]
   742   C3539106:Defined [Intellectual Product]
   708 E C0242485:Measure [Functional Concept]

Phrase: "obtained from healthy control subjects."
Meta Candidates (Total=14; Excluded=1; Pruned=0; Remaining=13)
   806   C2986479:Healthy Control [Qualitative Concept]
   797   C1708335:HEALTHY SUBJECTS [Population Group]
   760   C0243148:control [Qualitative Concept]
   760   C1301820:Obtained [Functional Concept]
   760   C1550141:Control [Substance]
   760   C1882979:Control [Conceptual Entity]
   760   C2587213:Control [Functional Concept]
   760   C3274648:Control [Qualitative Concept]
   726   C0681850:Subject [Group]
   726   C1550501:{Subject} [Idea or Concept]
   726   C1706203:Subject [Idea or Concept]
   726 E C1706701:Obtain [Activity]
   726   C2349001:Subject [Human]
   726   C2697811:Subject [Functional Concept]
Processing 00000000.tx.165: Thus, the values obtained were 6,015 AU/ml with the control subjects matched for type 1 and 7,021 AU/ml with the control subjects matched for type 2 diabetic subjects. 

Phrase: "Thus,"

Phrase: "the values"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0042295:Values [Qualitative Concept]
   966 E C1522609:Value [Quantitative Concept]

Phrase: "obtained"
Meta Candidates (Total=8; Excluded=7; Pruned=0; Remaining=1)
  1000   C1301820:Obtained [Functional Concept]
   966 E C1706701:Obtain [Activity]
   928 E C1517378:Gain [Quantitative Concept]
   907 E C0205217:Increased [Quantitative Concept]
   907 E C0439661:Acquired [Temporal Concept]
   907 E C0442805:Increase [Functional Concept]
   907 E C0442808:Increasing [Functional Concept]
   907 E C3245488:acquired [Intellectual Product]

Phrase: "were"

Phrase: "6,015 AU/ml with the control subjects"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C2348421:AU/mL [Quantitative Concept]
   744   C0439526:/mL [Quantitative Concept]

Phrase: "matched for type 1"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   833   C0441729:Type 1 [Classification]
   770   C0150103:matched [Research Activity]
   770   C0332307:Type [Qualitative Concept]
   770   C1547052:*Type [Quantitative Concept]
   770   C1708943:Matched [Qualitative Concept]

Phrase: "and"

Phrase: "7,021 AU/ml with the control subjects"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C2348421:AU/mL [Quantitative Concept]
   767   C0128666:ML 7 [Organic Chemical]
   744   C0439526:/mL [Quantitative Concept]

Phrase: "matched for type 2 diabetic subjects."
Meta Candidates (Total=11; Excluded=0; Pruned=0; Remaining=11)
   790   C0441730:Type 2 [Classification]
   753   C0150103:matched [Research Activity]
   753   C0241863:DIABETIC [Finding]
   753   C0332307:Type [Qualitative Concept]
   753   C1547052:*Type [Quantitative Concept]
   753   C1708943:Matched [Qualitative Concept]
   719   C0681850:Subject [Group]
   719   C1550501:{Subject} [Idea or Concept]
   719   C1706203:Subject [Idea or Concept]
   719   C2349001:Subject [Human]
   719   C2697811:Subject [Functional Concept]
Processing 00000000.tx.166: Anti-CD38 aAb titers obtained for type 1 diabetic patients are shown in Fig. 

Phrase: "Anti-CD38 aAb titers"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   779   C0475208:Titer [Quantitative Concept]

Phrase: "obtained for type 1 diabetic patients"
Meta Candidates (Total=8; Excluded=1; Pruned=0; Remaining=7)
   790   C0441729:Type 1 [Classification]
   767   C1550335:Patient type [Classification]
   753   C0030705:Patients [Patient or Disabled Group]
   753   C0241863:DIABETIC [Finding]
   753   C0332307:Type [Qualitative Concept]
   753   C1301820:Obtained [Functional Concept]
   753   C1547052:*Type [Quantitative Concept]
   719 E C1706701:Obtain [Activity]

Phrase: "are"

Phrase: "shown in Fig."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   790   C0349966:Fig [Food]
   790   C1337208:FIG [Food]
   756   C1547282:Show [Intellectual Product]
Processing 00000000.tx.167: 4. 

Phrase: "4."
Processing 00000000.tx.168: Reactivities are expressed as arbitrary units per milliliter, using the highly positive serum shown in Fig. 

Phrase: "Reactivities"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   916   C0205332:Reactive [Qualitative Concept]

Phrase: "are"

Phrase: "expressed as arbitrary units"
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
   799   C0439183:Arbitrary unit [Quantitative Concept]
   770   C0439148:Units [Quantitative Concept]
   770   C1264693:*Arbitrary [Quantitative Concept]
   770   C1519795:Units [Quantitative Concept]
   737 E C1704753:Unit [Manufactured Object]
   737 E C1880519:Unit [Quantitative Concept]

Phrase: "per milliliter,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439242:milliliter [Quantitative Concept]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "the highly positive serum"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0229671:Serum [Body Substance]
   827   C1546774:Serum [Intellectual Product]
   827   C1550100:Serum [Body Substance]

Phrase: "shown in Fig."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   790   C0349966:Fig [Food]
   790   C1337208:FIG [Food]
   756   C1547282:Show [Intellectual Product]
Processing 00000000.tx.169: 1 as the reference standard. 

Phrase: "1 as the reference standard."
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   760   C1442989:Standard [Qualitative Concept]
   760   C1514811:Reference [Idea or Concept]
   760   C1706462:Reference [Conceptual Entity]
   760   C2827734:1+ [Quantitative Concept]
   760   C2828392:Standard [Intellectual Product]
   760   C2981698:1+ [Classification]
Processing 00000000.tx.170: The distribution shows a continuous pattern spanning through all values; 

Phrase: "The distribution"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0520511:distribution [Idea or Concept]
  1000   C1704711:Distribution [Functional Concept]

Phrase: "shows"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1547282:Show [Intellectual Product]

Phrase: "a continuous pattern spanning through all values"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   714   C1711300:Span [Conceptual Entity]
   714   C2700613:Span [Quantitative Concept]

Phrase: ";"
Processing 00000000.tx.171: the majority of individuals (both diabetic and healthy) showed reactivities <1,250 AU/ml. 

Phrase: "the majority of individuals"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0680220:majority [Social Behavior]

Phrase: "("

Phrase: "both diabetic"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0241863:DIABETIC [Finding]

Phrase: "and"

Phrase: "healthy"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   928   C0018684:Health [Idea or Concept]
   928   C0031206:healthiness [Finding]

Phrase: ")"

Phrase: "showed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: "reactivities"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   916   C0205332:Reactive [Qualitative Concept]

Phrase: "<1,250 AU/ml."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C2348421:AU/mL [Quantitative Concept]
   812   C0439526:/mL [Quantitative Concept]
Processing 00000000.tx.172: Among the 94 type 1 diabetic subjects studied, 18 (19.15%) were above the cutoff value selected. 

Phrase: "Among the 94 type 1 diabetic subjects"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   771   C0681850:Subject [Group]
   771   C1550501:{Subject} [Idea or Concept]
   771   C1706203:Subject [Idea or Concept]
   771   C2349001:Subject [Human]
   771   C2697811:Subject [Functional Concept]

Phrase: "studied"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   966   C0557651:Study [Manufactured Object]
   966   C2603343:Study [Research Activity]

Phrase: ","

Phrase: "18"

Phrase: "(19.15%"

Phrase: ")"

Phrase: "were above the cutoff value"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C1442160:Cutoff [Functional Concept]
   760   C1522609:Value [Quantitative Concept]

Phrase: "selected."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1707391:Select [Activity]
Processing 00000000.tx.173: On the contrary, only 2 of the 96 control subjects (2.08%) were characterized as anti-CD38+ (P = 0.0001); 

Phrase: "On the contrary,"

Phrase: "only 2 of the 96 control subjects"
Meta Candidates (Total=12; Excluded=0; Pruned=0; Remaining=12)
   748   C0205171:Only [Quantitative Concept]
   748   C0243148:control [Qualitative Concept]
   748   C1550141:Control [Substance]
   748   C1720467:Only [Intellectual Product]
   748   C1882979:Control [Conceptual Entity]
   748   C2587213:Control [Functional Concept]
   748   C3274648:Control [Qualitative Concept]
   714   C0681850:Subject [Group]
   714   C1550501:{Subject} [Idea or Concept]
   714   C1706203:Subject [Idea or Concept]
   714   C2349001:Subject [Human]
   714   C2697811:Subject [Functional Concept]

Phrase: "(2.08%"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0740116:+2 [Quantitative Concept]
   861   C2827735:2+ [Quantitative Concept]
   861   C2981700:2+ [Classification]

Phrase: ")"

Phrase: "were"

Phrase: "characterized as anti-CD38+"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C1880022:Characterized [Activity]

Phrase: "(P = 0.0001"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   827   C2603361:P' [Clinical Attribute]

Phrase: ")"

Phrase: ";"
Processing 00000000.tx.174: moreover, the reactivity ranked in the bottom half of the positive range. 

Phrase: "moreover,"

Phrase: "the reactivity"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   928   C0205332:Reactive [Qualitative Concept]

Phrase: "ranked in the bottom half of the positive range."
Meta Candidates (Total=11; Excluded=0; Pruned=0; Remaining=11)
   742   C0439178:% Positive [Quantitative Concept]
   742   C0699794:ranked [Intellectual Product]
   742   C1446409:Positive [Qualitative Concept]
   742   C1511276:Bottom [Spatial Concept]
   742   C1514241:Positive [Finding]
   742   C1514721:Range [Quantitative Concept]
   742   C1552825:bottom [Idea or Concept]
   742   C2348147:Range [Quantitative Concept]
   742   C2825407:Half [Quantitative Concept]
   742   C2825490:Positive [Qualitative Concept]
   742   C3542016:Range [Intellectual Product]
Processing 00000000.tx.175: A similar distribution was observed for type 2 diabetic patients (Fig. 5); 

Phrase: "A similar distribution"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0520511:distribution [Idea or Concept]
   861   C1704711:Distribution [Functional Concept]

Phrase: "was"

Phrase: "observed for type 2 diabetic patients"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   790   C0441730:Type 2 [Classification]
   767   C1550335:Patient type [Classification]
   753   C0030705:Patients [Patient or Disabled Group]
   753   C0241863:DIABETIC [Finding]
   753   C0332307:Type [Qualitative Concept]
   753   C1441672:Observed [Functional Concept]
   753   C1547052:*Type [Quantitative Concept]

Phrase: "(Fig. 5"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0349966:Fig [Food]
   861   C1337208:FIG [Food]

Phrase: ")"

Phrase: ";"
Processing 00000000.tx.176: although the cutoff value obtained with the matched control subjects was higher, a similar number of positive subjects was selected (19 of 114 subjects, 16.67%; P = 0.64 for the comparison with anti-CD38+ type 1 diabetic subjects). 

Phrase: "although"

Phrase: "the cutoff value"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1442160:Cutoff [Functional Concept]
   861   C1522609:Value [Quantitative Concept]

Phrase: "obtained with the matched control subjects"
Meta Candidates (Total=14; Excluded=1; Pruned=0; Remaining=13)
   753   C0150103:matched [Research Activity]
   753   C0243148:control [Qualitative Concept]
   753   C1301820:Obtained [Functional Concept]
   753   C1550141:Control [Substance]
   753   C1708943:Matched [Qualitative Concept]
   753   C1882979:Control [Conceptual Entity]
   753   C2587213:Control [Functional Concept]
   753   C3274648:Control [Qualitative Concept]
   719   C0681850:Subject [Group]
   719   C1550501:{Subject} [Idea or Concept]
   719   C1706203:Subject [Idea or Concept]
   719 E C1706701:Obtain [Activity]
   719   C2349001:Subject [Human]
   719   C2697811:Subject [Functional Concept]

Phrase: "was"

Phrase: "higher,"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   966   C0205250:High [Qualitative Concept]
   966   C1299351:High [Qualitative Concept]
   966   C2700149:HIGH [Intellectual Product]
   916 E C0489786:Height [Organism Attribute]

Phrase: "a similar number of positive subjects"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0237753:*Number [Quantitative Concept]
   753   C0449788:Number [Quantitative Concept]

Phrase: "was"

Phrase: "selected"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1707391:Select [Activity]

Phrase: "(19 of 114 subjects,"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   737   C0681850:Subject [Group]
   737   C1550501:{Subject} [Idea or Concept]
   737   C1706203:Subject [Idea or Concept]
   737   C2349001:Subject [Human]
   737   C2697811:Subject [Functional Concept]

Phrase: "16.67%"

Phrase: "; P = 0.64 for the comparison"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   753   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   753   C1707455:Comparison [Activity]
   753   C2603361:P' [Clinical Attribute]

Phrase: "with anti-CD38+ type 1 diabetic subjects"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   766   C0681850:Subject [Group]
   766   C1550501:{Subject} [Idea or Concept]
   766   C1706203:Subject [Idea or Concept]
   766   C2349001:Subject [Human]
   766   C2697811:Subject [Functional Concept]

Phrase: ")."
Processing 00000000.tx.177: Only 1 of the 112 control subjects included (0.89%) was positive (P = 0.00003) at low titers. 

Phrase: "Only 1 of the 112 control subjects"
Meta Candidates (Total=12; Excluded=0; Pruned=0; Remaining=12)
   748   C0205171:Only [Quantitative Concept]
   748   C0243148:control [Qualitative Concept]
   748   C1550141:Control [Substance]
   748   C1720467:Only [Intellectual Product]
   748   C1882979:Control [Conceptual Entity]
   748   C2587213:Control [Functional Concept]
   748   C3274648:Control [Qualitative Concept]
   714   C0681850:Subject [Group]
   714   C1550501:{Subject} [Idea or Concept]
   714   C1706203:Subject [Idea or Concept]
   714   C2349001:Subject [Human]
   714   C2697811:Subject [Functional Concept]

Phrase: "included"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
  1000   C0332257:included [Functional Concept]
  1000   C3538986:INCLUDED [Gene or Genome]
   966 E C1552866:include [Idea or Concept]
   966 E C2700399:Include [Activity]

Phrase: "(0.89%"

Phrase: ")"

Phrase: "was"

Phrase: "positive"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0439178:% Positive [Quantitative Concept]
  1000   C1446409:Positive [Qualitative Concept]
  1000   C1514241:Positive [Finding]
  1000   C2825490:Positive [Qualitative Concept]

Phrase: "(P = 0.00003"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   827   C2603361:P' [Clinical Attribute]

Phrase: ")"

Phrase: "at low titers."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0475208:Titer [Quantitative Concept]
Processing 00000000.tx.178: View larger version (23K): [in this window] [in a new window]  FIG. 

Phrase: "View"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0449911:View [Spatial Concept]

Phrase: "larger version"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0333052:Version [Functional Concept]
   861   C2607870:Version [Spatial Concept]

Phrase: "(23K"

Phrase: ")"

Phrase: ":"

Phrase: "["

Phrase: "in this window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0557702:Window [Manufactured Object]
  1000   C1272706:Window [Temporal Concept]
  1000   C1704674:Window [Manufactured Object]

Phrase: "]"

Phrase: "["

Phrase: "in a new window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0557702:Window [Manufactured Object]
   861   C1272706:Window [Temporal Concept]
   861   C1704674:Window [Manufactured Object]

Phrase: "]  FIG."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0349966:Fig [Food]
  1000   C1337208:FIG [Food]
Processing 00000000.tx.179: 4. 

Phrase: "4."
Processing 00000000.tx.180: Anti-CD38 EIA reactivity in sera from type 1 diabetic (DM) patients. 

Phrase: "Anti-CD38 EIA reactivity in sera"

Phrase: "from type 1 diabetic"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   901   C0441729:Type 1 [Classification]
   827   C0241863:DIABETIC [Finding]
   827   C0332307:Type [Qualitative Concept]
   827   C1547052:*Type [Quantitative Concept]

Phrase: "(DM) patients."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]
Processing 00000000.tx.181: Values are expressed in arbitrary units per milliliter.    

Phrase: "Values"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0042295:Values [Qualitative Concept]
   966 E C1522609:Value [Quantitative Concept]

Phrase: "are"

Phrase: "expressed in arbitrary units"
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
   799   C0439183:Arbitrary unit [Quantitative Concept]
   770   C0439148:Units [Quantitative Concept]
   770   C1264693:*Arbitrary [Quantitative Concept]
   770   C1519795:Units [Quantitative Concept]
   737 E C1704753:Unit [Manufactured Object]
   737 E C1880519:Unit [Quantitative Concept]

Phrase: "per milliliter."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439242:milliliter [Quantitative Concept]
Processing 00000000.tx.182: , cutoff value (mean + 3 SD) of 6,015 AU/ml. 

Phrase: ", cutoff value"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1442160:Cutoff [Functional Concept]
   861   C1522609:Value [Quantitative Concept]

Phrase: "(mean + 3 SD) of 6,015 AU/ml."
Processing 00000000.tx.183: The percent proportion of anti-CD38+ subjects is indicated above each distribution plot. 

Phrase: "The percent proportion of anti-CD38+ subjects"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C1709707:Proportion [Quantitative Concept]

Phrase: "is"

Phrase: "indicated above each distribution plot."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C0520511:distribution [Idea or Concept]
   760   C1444656:Indicated [Finding]
   760   C1704711:Distribution [Functional Concept]
Processing 00000000.tx.184: P = 0.0001 for comparison between the percentage of anti-CD38+ diabetic individuals and control subjects.  

Phrase: "P = 0.0001 for comparison"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   760   C1707455:Comparison [Activity]
   760   C2603361:P' [Clinical Attribute]

Phrase: "between the percentage"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0439165:Percentage [Quantitative Concept]
  1000   C1549488:Percentage [Idea or Concept]
  1000   C1561533:Percentage [Idea or Concept]

Phrase: "of anti-CD38+ diabetic individuals"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   779   C0027361:Individual [Population Group]
   779   C0237401:Individual [Human]

Phrase: "and"

Phrase: "control subjects."
Meta Candidates (Total=10; Excluded=0; Pruned=0; Remaining=10)
   861   C0243148:control [Qualitative Concept]
   861   C1550141:Control [Substance]
   861   C1882979:Control [Conceptual Entity]
   861   C2587213:Control [Functional Concept]
   861   C3274648:Control [Qualitative Concept]
   827   C0681850:Subject [Group]
   827   C1550501:{Subject} [Idea or Concept]
   827   C1706203:Subject [Idea or Concept]
   827   C2349001:Subject [Human]
   827   C2697811:Subject [Functional Concept]
Processing 00000000.tx.185: View larger version (25K): [in this window] [in a new window]  FIG. 

Phrase: "View"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0449911:View [Spatial Concept]

Phrase: "larger version"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0333052:Version [Functional Concept]
   861   C2607870:Version [Spatial Concept]

Phrase: "(25K"

Phrase: ")"

Phrase: ":"

Phrase: "["

Phrase: "in this window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0557702:Window [Manufactured Object]
  1000   C1272706:Window [Temporal Concept]
  1000   C1704674:Window [Manufactured Object]

Phrase: "]"

Phrase: "["

Phrase: "in a new window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0557702:Window [Manufactured Object]
   861   C1272706:Window [Temporal Concept]
   861   C1704674:Window [Manufactured Object]

Phrase: "]  FIG."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0349966:Fig [Food]
  1000   C1337208:FIG [Food]
Processing 00000000.tx.186: 5. 

Phrase: "5."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0439084:>5 [Quantitative Concept]
  1000   C0728893:+5 [Quantitative Concept]
Processing 00000000.tx.187: Anti-CD38 EIA reactivity in sera from type 2 diabetic (DM) patients. 

Phrase: "Anti-CD38 EIA reactivity in sera"

Phrase: "from type 2 diabetic"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   901   C0441730:Type 2 [Classification]
   827   C0241863:DIABETIC [Finding]
   827   C0332307:Type [Qualitative Concept]
   827   C1547052:*Type [Quantitative Concept]

Phrase: "(DM) patients."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]
Processing 00000000.tx.188: Values are expressed in arbitrary units per milliliter.    

Phrase: "Values"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0042295:Values [Qualitative Concept]
   966 E C1522609:Value [Quantitative Concept]

Phrase: "are"

Phrase: "expressed in arbitrary units"
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
   799   C0439183:Arbitrary unit [Quantitative Concept]
   770   C0439148:Units [Quantitative Concept]
   770   C1264693:*Arbitrary [Quantitative Concept]
   770   C1519795:Units [Quantitative Concept]
   737 E C1704753:Unit [Manufactured Object]
   737 E C1880519:Unit [Quantitative Concept]

Phrase: "per milliliter."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439242:milliliter [Quantitative Concept]
Processing 00000000.tx.189: , cutoff value (mean + 3 SD) of 7,021 AU/ml. 

Phrase: ", cutoff value"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1442160:Cutoff [Functional Concept]
   861   C1522609:Value [Quantitative Concept]

Phrase: "(mean + 3 SD) of 7,021 AU/ml."
Processing 00000000.tx.190: The percent proportion of anti-CD38+ subjects is indicated above each distribution plot. 

Phrase: "The percent proportion of anti-CD38+ subjects"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C1709707:Proportion [Quantitative Concept]

Phrase: "is"

Phrase: "indicated above each distribution plot."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C0520511:distribution [Idea or Concept]
   760   C1444656:Indicated [Finding]
   760   C1704711:Distribution [Functional Concept]
Processing 00000000.tx.191: P = 0.00003 for comparison between the percentage of anti-CD38+ diabetic individuals and control subjects.  

Phrase: "P = 0.00003 for comparison"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   760   C1707455:Comparison [Activity]
   760   C2603361:P' [Clinical Attribute]

Phrase: "between the percentage"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0439165:Percentage [Quantitative Concept]
  1000   C1549488:Percentage [Idea or Concept]
  1000   C1561533:Percentage [Idea or Concept]

Phrase: "of anti-CD38+ diabetic individuals"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   779   C0027361:Individual [Population Group]
   779   C0237401:Individual [Human]

Phrase: "and"

Phrase: "control subjects."
Meta Candidates (Total=10; Excluded=0; Pruned=0; Remaining=10)
   861   C0243148:control [Qualitative Concept]
   861   C1550141:Control [Substance]
   861   C1882979:Control [Conceptual Entity]
   861   C2587213:Control [Functional Concept]
   861   C3274648:Control [Qualitative Concept]
   827   C0681850:Subject [Group]
   827   C1550501:{Subject} [Idea or Concept]
   827   C1706203:Subject [Idea or Concept]
   827   C2349001:Subject [Human]
   827   C2697811:Subject [Functional Concept]
Processing 00000000.tx.192: The anti-CD38 reactivity of some patients was also tested using serum samples obtained on two separate occasions, highlighting the persistence of similar titers, at least for the time intervals of 12 months analyzed (data not shown). 

Phrase: "The anti-CD38 reactivity of some patients"

Phrase: "was"

Phrase: "also"

Phrase: "tested"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0392366:tested [Intellectual Product]
   966 E C0022885:Test [Laboratory Procedure]
   966 E C0039593:Test [Functional Concept]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "serum samples"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   983   C0444266:Serum sample [Body Substance]
   827   C0370003:Sample [Substance]
   827   C2347026:Sample [Conceptual Entity]

Phrase: "obtained on two separate occasions,"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   760   C0205448:Two [Quantitative Concept]
   760   C0443299:Separate [Spatial Concept]
   760   C1301820:Obtained [Functional Concept]
   726 E C1706701:Obtain [Activity]

Phrase: "highlighting"

Phrase: "the persistence of similar titers,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0546816:Persistence [Mental Process]

Phrase: "at least"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   966   C0439092:less [Intellectual Product]
   966   C0547044:Less [Qualitative Concept]

Phrase: "for the time intervals"
Meta Candidates (Total=9; Excluded=5; Pruned=0; Remaining=4)
   966   C0872291:Time Interval [Temporal Concept]
   861   C0040223:Time [Temporal Concept]
   861   C1272706:intervals [Temporal Concept]
   861   C3541383:Time [Temporal Concept]
   827 E C1552654:Interval [Idea or Concept]
   827 E C1552713:Interval [Intellectual Product]
   805 E C0442043:Temporal [Spatial Concept]
   805 E C2362314:Temporal [Temporal Concept]
   777 E C1632851:Times [Quantitative Concept]

Phrase: "of 12 months"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0439231:months [Temporal Concept]
   827 E C0439507:/month [Temporal Concept]

Phrase: "analyzed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0936012:Analyzed [Research Activity]

Phrase: "(data"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1511726:Data [Idea or Concept]
  1000   C3245479:data [Medical Device]

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "shown"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: ")."
Processing 00000000.tx.193: Functional properties of anti-CD38 aAbs on Ca2+ release. 

Phrase: "Functional properties of anti-CD38 aAbs"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   753   C0871161:properties [Qualitative Concept]
   753   C1292721:properties [Functional Concept]
   719 E C1882134:Property [Conceptual Entity]
   719 E C2347695:Property [Entity]

Phrase: "on Ca2+ release."
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   861   C0030685:Release [Health Care Activity]
   861   C0391871:Release [Functional Concept]
   861   C0439180:% release [Quantitative Concept]
   861   C0680255:release [Health Care Activity]
   861   C1283071:Release [Functional Concept]
   861   C1963578:Release [Therapeutic or Preventive Procedure]
Processing 00000000.tx.194: Next, the functional activity of anti-CD38 aAbs was evaluated. 

Phrase: "Next,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205117:next [Spatial Concept]
  1000   C0332282:Next [Temporal Concept]
  1000   C1883708:Next [Temporal Concept]

Phrase: "the functional activity of anti-CD38 aAbs"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   748   C0205177:Activity [Functional Concept]
   748   C0439167:% activity [Quantitative Concept]
   748   C0441655:Activity [Activity]
   748   C1561536:*Activity [Idea or Concept]

Phrase: "was"

Phrase: "evaluated."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0220825:Evaluated [Functional Concept]
Processing 00000000.tx.195: Anti-CD38 mAbs are generally identified as either agonistic or nonagonistic, depending on their binding to different portions of the CD38 protein (29) and the triggering of different signals. 

Phrase: "Anti-CD38 mAbs"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   793   C0003250:MAb [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: "are"

Phrase: "generally"

Phrase: "identified as either agonistic"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0205396:Identified [Qualitative Concept]
   770   C1550043:Identified [Finding]
   770   C1551388:Identified [Functional Concept]

Phrase: "or"

Phrase: "nonagonistic,"

Phrase: "depending on their binding"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   770   C0243122:binding [Functional Concept]
   770   C1145667:Binding [Activity]
   770   C1167622:Binding [Molecular Function]
   737   C0725813:depend [Medical Device]

Phrase: "to different portions"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0449719:Portion [Spatial Concept]

Phrase: "of the CD38 protein"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "(29"

Phrase: ")"

Phrase: "and"

Phrase: "the triggering of different signals."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   726   C0032930:Trigger [Clinical Attribute]
   726   C1444748:Trigger [Qualitative Concept]
Processing 00000000.tx.196: Therefore, the effect of anti-CD38 aAbs on Ca2+ release was analyzed in the human Jurkat T-cell line to characterize these serum immunoglobulins in a similar way. 

Phrase: "Therefore,"

Phrase: "the effect of anti-CD38 aAbs"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C1280500:Effect [Qualitative Concept]
   753   C2348382:Effect [Qualitative Concept]

Phrase: "on Ca2+ release"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   861   C0030685:Release [Health Care Activity]
   861   C0391871:Release [Functional Concept]
   861   C0439180:% release [Quantitative Concept]
   861   C0680255:release [Health Care Activity]
   861   C1283071:Release [Functional Concept]
   861   C1963578:Release [Therapeutic or Preventive Procedure]

Phrase: "was"

Phrase: "analyzed in the human Jurkat T-cell line to"
Meta Candidates (Total=14; Excluded=0; Pruned=0; Remaining=14)
   784   C0682523:Human Cell Line [Cell]
   764   C0007600:Cell Line [Cell]
   764   C0039194:T-cell [Cell]
   762   C0376448:Jurkat Cell [Cell]
   762   C0427861:cell human [Laboratory or Test Result]
   742   C0007634:Cell [Cell]
   742   C0086418:Human [Human]
   742   C0205132:Line [Spatial Concept]
   742   C0936012:Analyzed [Research Activity]
   742   C1269647:Cell [Cell]
   742   C1550648:Line [Substance]
   742   C1552960:Line [Quantitative Concept]
   742   C1704653:Cell [Medical Device]
   742   C1948049:Cell [Spatial Concept]

Phrase: "characterize"

Phrase: "these serum immunoglobulins in a similar way."
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
   793   C0858451:serum immunoglobulin a [Laboratory Procedure]
           immunoglobulins serum
   757   C0020835:Immunoglobulin A [Amino Acid, Peptide, or Protein,Immunologic Factor]
   757   C2825347:Immunoglobulin A [Immunologic Factor,Pharmacologic Substance]
   748   C0021027:Immunoglobulins [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   748   C0202081:Immunoglobulins NOS [Laboratory Procedure]
   714 E C1621846:immunoglobulin [Molecular Function]
Processing 00000000.tx.197: Different patterns of Ca2+ triggering by representative sera from patients are presented in Fig. 

Phrase: "Different patterns of Ca2+ triggering"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0449774:Patterns [Spatial Concept]

Phrase: "by representative sera"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   861   C0229671:Sera [Body Substance]
   861   C1151254:SerA [Molecular Function]
   827 E C1546774:Serum [Intellectual Product]
   827 E C1550100:Serum [Body Substance]

Phrase: "from patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "are"

Phrase: "presented in Fig."
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   790   C0349966:Fig [Food]
   790   C0449450:Presented [Idea or Concept]
   790   C1337208:FIG [Food]
   756 E C0150312:Present [Quantitative Concept]
Processing 00000000.tx.198: 6. 

Phrase: "6."
Processing 00000000.tx.199: Fig. 

Phrase: "Fig."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0349966:Fig [Food]
  1000   C1337208:FIG [Food]
Processing 00000000.tx.200: 6A shows an anti-CD38+ serum displaying agonistic activity, documented by a consistent shift in the [Ca2+]i. 

Phrase: "6A"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1553638:6a [Medical Device]

Phrase: "shows"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1547282:Show [Intellectual Product]

Phrase: "an anti-CD38+ serum"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0229671:Serum [Body Substance]
   827   C1546774:Serum [Intellectual Product]
   827   C1550100:Serum [Body Substance]

Phrase: "displaying"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0870432:displaying [Functional Concept]
   966 E C1705417:Display [Manufactured Object]

Phrase: "agonistic activity,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0205177:Activity [Functional Concept]
   861   C0439167:% activity [Quantitative Concept]
   861   C0441655:Activity [Activity]
   861   C1561536:*Activity [Idea or Concept]

Phrase: "documented by a consistent shift"
Meta Candidates (Total=7; Excluded=2; Pruned=0; Remaining=5)
   760   C0332290:Consistent [Idea or Concept]
   760   C0333051:Shift [Functional Concept]
   760   C1301725:Documented [Health Care Activity]
   760   C1609436:documented [Idea or Concept]
   760   C2347509:Shift [Phenomenon or Process]
   726 E C1301746:document [Intellectual Product]
   726 E C1547673:Document [Intellectual Product]

Phrase: "in the [Ca2+"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0596235:Ca2+ [Element, Ion, or Isotope,Pharmacologic Substance]

Phrase: "]i."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0021966:I- [Inorganic Chemical]
  1000   C0221138:I NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
Processing 00000000.tx.201: Other anti-CD38+ sera did not have any effect on Ca2+ signaling (Fig. 6B) and thus were identified as nonagonistic. 

Phrase: "Other anti-CD38+ sera"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   827   C0229671:Sera [Body Substance]
   827   C1151254:SerA [Molecular Function]
   793 E C1546774:Serum [Intellectual Product]
   793 E C1550100:Serum [Body Substance]

Phrase: "did"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "have"

Phrase: "any effect on Ca2+ signaling"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C1280500:Effect [Qualitative Concept]
   760   C2348382:Effect [Qualitative Concept]

Phrase: "(Fig. 6B"

Phrase: ")"

Phrase: "and"

Phrase: "thus"

Phrase: "were"

Phrase: "identified as nonagonistic."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   790   C0205396:Identified [Qualitative Concept]
   790   C1550043:Identified [Finding]
   790   C1551388:Identified [Functional Concept]
Processing 00000000.tx.202: The Ca2+ mobilization pattern highlighted by nonagonistic anti-CD38+ sera (Fig. 6B) was similar to that evidenced by anti-CD38- sera (Fig. 6C). 

Phrase: "The Ca2+ mobilization pattern"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0449774:Pattern [Spatial Concept]

Phrase: "highlighted by nonagonistic anti-CD38+ sera"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   753   C0229671:Sera [Body Substance]
   753   C1151254:SerA [Molecular Function]
   719 E C1546774:Serum [Intellectual Product]
   719 E C1550100:Serum [Body Substance]

Phrase: "(Fig. 6B"

Phrase: ")"

Phrase: "was"

Phrase: "similar to that"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C2348205:Similar [Qualitative Concept]

Phrase: "evidenced by anti-CD38- sera"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
   760   C0229671:Sera [Body Substance]
   760   C1151254:SerA [Molecular Function]
   726   C0332120:Evidence [Functional Concept]
   726 E C1546774:Serum [Intellectual Product]
   726 E C1550100:Serum [Body Substance]

Phrase: "(Fig. 6C"

Phrase: ")."
Processing 00000000.tx.203: Competition experiments between sera, such as the one presented in Fig. 

Phrase: "Competition experiments between sera,"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   770   C0681814:Experiments [Research Activity]
   737 E C1706386:Experiment [Conceptual Entity]

Phrase: "such as the one"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205447:One [Quantitative Concept]

Phrase: "presented in Fig."
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   790   C0349966:Fig [Food]
   790   C0449450:Presented [Idea or Concept]
   790   C1337208:FIG [Food]
   756 E C0150312:Present [Quantitative Concept]
Processing 00000000.tx.204: 6B, and the agonistic anti-CD38 mAb IB4 were performed to exclude the possibility that the lack of signaling was because of misidentification of the sera as anti-CD38+ by EIA. 

Phrase: "6B,"

Phrase: "and"

Phrase: "the agonistic anti-CD38 mAb IB4"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   734   C2346801:Anti-CD38 Monoclonal Antibody [Pharmacologic Substance]

Phrase: "were"

Phrase: "performed"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0884358:Performed [Functional Concept]
   966 E C2947996:Perform [Pharmacologic Substance]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "exclude"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0332196:Exclude [Functional Concept]
  1000   C2828389:Exclude [Activity]

Phrase: "the possibility"

Phrase: "that"

Phrase: "the lack of signaling"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0332268:lack [Qualitative Concept]

Phrase: "was because of misidentification of the sera"
Meta Candidates (Total=7; Excluded=2; Pruned=0; Remaining=5)
   748   C0043194:WAS [Disease or Syndrome]
   748   C0229671:Sera [Body Substance]
   748   C0258432:WAS [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   748   C1151254:SerA [Molecular Function]
   748   C1421478:WAS [Gene or Genome]
   714 E C1546774:Serum [Intellectual Product]
   714 E C1550100:Serum [Body Substance]

Phrase: "as anti-CD38+"

Phrase: "by EIA."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0020980:Immunoassay [Laboratory Procedure]
   861   C0021060:immunoassay [Laboratory Procedure]
Processing 00000000.tx.205: Whereas binding of the IB4 mAb alone was followed by massive Ca2+ mobilization (Fig. 6D), preincubation of target cells with the latter sera determined a significant decrease in the stimulatory efficiency of IB4 (Fig. 6E). 

Phrase: "Whereas"

Phrase: "binding of the IB4 mAb"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   790   C0003250:Monoclonal antibody [Amino Acid, Peptide, or Protein,Immunologic Factor]
   753   C0003241:Antibody [Amino Acid, Peptide, or Protein,Cell Component,Immunologic Factor]
   753   C0021027:Antibody [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   753   C0243122:binding [Functional Concept]
   753   C0746619:monoclonal [Finding]
   753   C1145667:Binding [Activity]
   753   C1167622:Binding [Molecular Function]

Phrase: "alone"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205171:Alone [Quantitative Concept]
  1000   C0439044:alone [Finding]
  1000   C0679994:alone [Group Attribute]

Phrase: "was"

Phrase: "followed by massive Ca2+ mobilization"
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
   806   C0332283:Followed by [Temporal Concept]
           followed
   760   C0185112:Mobilisation [Therapeutic or Preventive Procedure]
   760   C0300926:mobilization [Functional Concept]
   760   C0522501:Massive [Qualitative Concept]
   760   C0596235:Ca2+ [Element, Ion, or Isotope,Pharmacologic Substance]
   726 E C1719822:Follow [Intellectual Product]

Phrase: "(Fig. 6D"

Phrase: ")"

Phrase: ","

Phrase: "preincubation of target cells"

Phrase: "with the latter sera"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   861   C0229671:Sera [Body Substance]
   861   C1151254:SerA [Molecular Function]
   827 E C1546774:Serum [Intellectual Product]
   827 E C1550100:Serum [Body Substance]

Phrase: "determined"

Phrase: "a significant decrease in the stimulatory efficiency of IB4"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   742   C0392756:Decrease [Qualitative Concept]
   742   C0547047:Decrease [Quantitative Concept]

Phrase: "(Fig. 6E"

Phrase: ")."
Processing 00000000.tx.206: In contrast, control anti-CD38- sera did not interfere with the IB4-triggering effect (Fig. 6F). 

Phrase: "In contrast,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1979874:Contrast [Qualitative Concept]

Phrase: "control"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0243148:control [Qualitative Concept]
  1000   C1550141:Control [Substance]
  1000   C1882979:Control [Conceptual Entity]
  1000   C2587213:Control [Functional Concept]
  1000   C3274648:Control [Qualitative Concept]

Phrase: "anti-CD38- sera"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   827   C0229671:Sera [Body Substance]
   827   C1151254:SerA [Molecular Function]
   793 E C1546774:Serum [Intellectual Product]
   793 E C1550100:Serum [Body Substance]

Phrase: "did"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "interfere with the IB4-"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0521102:Interfere [Qualitative Concept]

Phrase: "triggering"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   966   C0032930:Trigger [Clinical Attribute]
   966   C1444748:Trigger [Qualitative Concept]

Phrase: "effect"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1280500:Effect [Qualitative Concept]
  1000   C2348382:Effect [Qualitative Concept]

Phrase: "(Fig. 6F"

Phrase: ")."
Processing 00000000.tx.207: These results indicate that nonagonistic anti-CD38+ sera are not able to induce Ca2+ release as expected, but can inhibit the same effect mediated by the agonistic mAb IB4 through epitopic competition, thus indirectly confirming the specificity of such sera as that identified by EIA. 

Phrase: "These results"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   966   C1274040:Result [Functional Concept]
   966   C1546471:Result [Idea or Concept]
   966   C2825142:Result [Finding]

Phrase: "indicate"

Phrase: "that nonagonistic anti-CD38+ sera"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   812   C0229671:Sera [Body Substance]
   812   C1151254:SerA [Molecular Function]
   779 E C1546774:Serum [Intellectual Product]
   779 E C1550100:Serum [Body Substance]

Phrase: "are"

Phrase: "not able to"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0085732:Able [Organism Attribute]
   827   C1299581:Able [Finding]
   827   C1518422:Not [Functional Concept]

Phrase: "induce"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205263:Induce [Functional Concept]

Phrase: "Ca2+ release"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   861   C0030685:Release [Health Care Activity]
   861   C0391871:Release [Functional Concept]
   861   C0439180:% release [Quantitative Concept]
   861   C0680255:release [Health Care Activity]
   861   C1283071:Release [Functional Concept]
   861   C1963578:Release [Therapeutic or Preventive Procedure]

Phrase: "as"

Phrase: "expected"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1517001:Expected [Idea or Concept]

Phrase: ","

Phrase: "but"

Phrase: "can"

Phrase: "inhibit"
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
   944   C0018790:arrested [Disease or Syndrome]
   944   C0237477:Arrest [Temporal Concept]
   944   C0392351:arrest [Governmental or Regulatory Activity]
   944   C0521111:Retarded [Qualitative Concept]
   916 E C0311403:Inhibited [Qualitative Concept]
   916 E C3463820:Inhibiting [Activity]

Phrase: "the same effect"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1280500:Effect [Qualitative Concept]
   861   C2348382:Effect [Qualitative Concept]

Phrase: "mediated by the agonistic mAb IB4"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   778   C0003250:Monoclonal antibody [Amino Acid, Peptide, or Protein,Immunologic Factor]
   748   C0003241:Antibody [Amino Acid, Peptide, or Protein,Cell Component,Immunologic Factor]
   748   C0021027:Antibody [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   748   C0086597:mediated [Social Behavior]
   748   C0127400:Mediated [Organic Chemical,Pharmacologic Substance]
   748   C0746619:monoclonal [Finding]

Phrase: "through epitopic competition,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0679932:competition [Social Behavior]

Phrase: "thus indirectly"

Phrase: "confirming"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0521093:confirming [Qualitative Concept]
  1000   C0750484:confirming [Idea or Concept]
   966 E C1456348:Confirm [Qualitative Concept]

Phrase: "the specificity of such sera"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0037791:Specificity [Quantitative Concept]
   760   C1511884:Specificity [Quantitative Concept]

Phrase: "as that"

Phrase: "identified by EIA."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   770   C0020980:Immunoassay [Laboratory Procedure]
   770   C0021060:immunoassay [Laboratory Procedure]
   770   C0205396:Identified [Qualitative Concept]
   770   C1550043:Identified [Finding]
   770   C1551388:Identified [Functional Concept]
Processing 00000000.tx.208: View larger version (59K): [in this window] [in a new window]  FIG. 

Phrase: "View"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0449911:View [Spatial Concept]

Phrase: "larger version"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0333052:Version [Functional Concept]
   861   C2607870:Version [Spatial Concept]

Phrase: "(59K"

Phrase: ")"

Phrase: ":"

Phrase: "["

Phrase: "in this window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0557702:Window [Manufactured Object]
  1000   C1272706:Window [Temporal Concept]
  1000   C1704674:Window [Manufactured Object]

Phrase: "]"

Phrase: "["

Phrase: "in a new window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0557702:Window [Manufactured Object]
   861   C1272706:Window [Temporal Concept]
   861   C1704674:Window [Manufactured Object]

Phrase: "]  FIG."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0349966:Fig [Food]
  1000   C1337208:FIG [Food]
Processing 00000000.tx.209: 6. 

Phrase: "6."
Processing 00000000.tx.210: Agonistic activity of anti-CD38+ sera on Ca2+ release in Jurkat cells. 

Phrase: "Agonistic activity of anti-CD38+ sera"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   753   C0205177:Activity [Functional Concept]
   753   C0439167:% activity [Quantitative Concept]
   753   C0441655:Activity [Activity]
   753   C1561536:*Activity [Idea or Concept]

Phrase: "on Ca2+ release"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   861   C0030685:Release [Health Care Activity]
   861   C0391871:Release [Functional Concept]
   861   C0439180:% release [Quantitative Concept]
   861   C0680255:release [Health Care Activity]
   861   C1283071:Release [Functional Concept]
   861   C1963578:Release [Therapeutic or Preventive Procedure]

Phrase: "in Jurkat cells."
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
  1000   C0376448:Jurkat Cells [Cell]
   861   C0007634:Cells [Cell]
   861   C3282337:Cells [Cell]
   827 E C1269647:Cell [Cell]
   827 E C1704653:Cell [Medical Device]
   827 E C1948049:Cell [Spatial Concept]
Processing 00000000.tx.211: A: Agonistic anti-CD38+ serum. 

Phrase: "A"

Phrase: ":"

Phrase: "Agonistic anti-CD38+ serum."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   812   C0229671:Serum [Body Substance]
   812   C1546774:Serum [Intellectual Product]
   812   C1550100:Serum [Body Substance]
Processing 00000000.tx.212: B: Nonagonistic anti-CD38+ serum. 

Phrase: "B"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2347469:/B [Quantitative Concept]

Phrase: ":"

Phrase: "Nonagonistic anti-CD38+ serum."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   812   C0229671:Serum [Body Substance]
   812   C1546774:Serum [Intellectual Product]
   812   C1550100:Serum [Body Substance]
Processing 00000000.tx.213: C: Anti-CD38- serum. 

Phrase: "C"

Phrase: ":"

Phrase: "Anti-CD38- serum."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0229671:Serum [Body Substance]
   827   C1546774:Serum [Intellectual Product]
   827   C1550100:Serum [Body Substance]
Processing 00000000.tx.214: D: Agonistic anti-CD38 mAb IB4 alone. 

Phrase: "D"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0073187:D NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: ":"

Phrase: "Agonistic anti-CD38 mAb IB4"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   734   C2346801:Anti-CD38 Monoclonal Antibody [Pharmacologic Substance]

Phrase: "alone."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205171:Alone [Quantitative Concept]
  1000   C0439044:alone [Finding]
  1000   C0679994:alone [Group Attribute]
Processing 00000000.tx.215: E: Nonagonistic anti-CD38+ serum followed by IB4 mAb. 

Phrase: "E"

Phrase: ":"

Phrase: "Nonagonistic anti-CD38+ serum"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   812   C0229671:Serum [Body Substance]
   812   C1546774:Serum [Intellectual Product]
   812   C1550100:Serum [Body Substance]

Phrase: "followed by IB4 mAb."
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
   806   C0003250:Monoclonal antibody [Amino Acid, Peptide, or Protein,Immunologic Factor]
   806   C0332283:Followed by [Temporal Concept]
           followed
   760   C0003241:Antibody [Amino Acid, Peptide, or Protein,Cell Component,Immunologic Factor]
   760   C0021027:Antibody [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   760   C0746619:monoclonal [Finding]
   726 E C1719822:Follow [Intellectual Product]
Processing 00000000.tx.216: F: Anti-CD38- serum followed by IB4 mAb. 

Phrase: "F"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
  1000   C0439133:(f) [Intellectual Product]
  1000   C1553038:[f] [Quantitative Concept]

Phrase: ":"

Phrase: "Anti-CD38- serum"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0229671:Serum [Body Substance]
   827   C1546774:Serum [Intellectual Product]
   827   C1550100:Serum [Body Substance]

Phrase: "followed by IB4 mAb."
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
   806   C0003250:Monoclonal antibody [Amino Acid, Peptide, or Protein,Immunologic Factor]
   806   C0332283:Followed by [Temporal Concept]
           followed
   760   C0003241:Antibody [Amino Acid, Peptide, or Protein,Cell Component,Immunologic Factor]
   760   C0021027:Antibody [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   760   C0746619:monoclonal [Finding]
   726 E C1719822:Follow [Intellectual Product]
Processing 00000000.tx.217: G: Agonistic anti-CD38+ serum after preincubation with protein Gsepharose. 

Phrase: "G"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439267:g% [Quantitative Concept]

Phrase: ":"

Phrase: "Agonistic anti-CD38+ serum after preincubation"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   753   C0229671:Serum [Body Substance]
   753   C1546774:Serum [Intellectual Product]
   753   C1550100:Serum [Body Substance]

Phrase: "with protein Gsepharose."
Processing 00000000.tx.218: H: Agonistic anti-CD38+ serum preadsorbed with rsCD38. 

Phrase: "H"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0033727:H+ [Element, Ion, or Isotope]
  1000   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441932:H+ [Classification]
  1000   C0564385:/h [Quantitative Concept]

Phrase: ":"

Phrase: "Agonistic anti-CD38+ serum"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   812   C0229671:Serum [Body Substance]
   812   C1546774:Serum [Intellectual Product]
   812   C1550100:Serum [Body Substance]

Phrase: "preadsorbed with rsCD38."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C1514798:recombinant [Organism]
   760   C1749467:soluble [Cell Component]
   760   C1948047:Soluble [Qualitative Concept]
Processing 00000000.tx.219: Data are presented as density plots (the color code ranges from red and yellow to blue, green, and orange for progressively higher cell densities) of the shift in the Fluo 3-AM fluorescence (y-axis) over a 5-min time-course (x-axis). 

Phrase: "Data"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1511726:Data [Idea or Concept]
  1000   C3245479:data [Medical Device]

Phrase: "are"

Phrase: "presented as density plots"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   770   C0178587:density [Quantitative Concept]
   770   C0449450:Presented [Idea or Concept]
   737 E C0150312:Present [Quantitative Concept]

Phrase: "("

Phrase: "the color code ranges from red"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   753   C1514721:*Ranges [Quantitative Concept]
   719 E C2348147:Range [Quantitative Concept]
   719 E C3542016:Range [Intellectual Product]

Phrase: "and"

Phrase: "yellow to blue,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C0221205:Yellow [Qualitative Concept]

Phrase: "green,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0332583:Green [Qualitative Concept]

Phrase: "and"

Phrase: "orange for progressively higher cell densities"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   753   C0440277:Orange [Food]
   753   C0475654:orange [Food]
   753   C1313858:Orange [Qualitative Concept]

Phrase: ")"

Phrase: "of the shift"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0333051:Shift [Functional Concept]
  1000   C2347509:Shift [Phenomenon or Process]

Phrase: "in the Fluo 3-"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0060505:Fluo-3 [Organic Chemical,Pharmacologic Substance]
   861   C0385473:fluo [Organic Chemical,Pharmacologic Substance]

Phrase: "AM"

Phrase: "fluorescence"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0016315:Fluorescence [Natural Phenomenon or Process]
   928 E C0303920:Fluorescent [Indicator, Reagent, or Diagnostic Aid,Organic Chemical]

Phrase: "(y-axis"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0004457:Axis [Body Part, Organ, or Organ Component]
   861   C0999597:Axis [Mammal]
   861   C1522496:Axis [Spatial Concept]

Phrase: ")"

Phrase: "over a 5-min time-course"
Meta Candidates (Total=7; Excluded=3; Pruned=0; Remaining=4)
   861   C0449247:Time course [Temporal Concept]
   812   C0040223:Time [Temporal Concept]
   812   C0750729:Course [Temporal Concept]
   812   C3541383:Time [Temporal Concept]
   756 E C0442043:Temporal [Spatial Concept]
   756 E C2362314:Temporal [Temporal Concept]
   729 E C1632851:Times [Quantitative Concept]

Phrase: "(x-axis"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0004457:Axis [Body Part, Organ, or Organ Component]
   861   C0999597:Axis [Mammal]
   861   C1522496:Axis [Spatial Concept]

Phrase: ")."
Processing 00000000.tx.220: Results refer to a representative experiment performed in triplicate.  

Phrase: "Results"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   966   C1274040:Result [Functional Concept]
   966   C1546471:Result [Idea or Concept]
   966   C2825142:Result [Finding]

Phrase: "refer to a representative experiment"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   760   C0205543:refer [Functional Concept]
   760   C0681814:Experiment [Research Activity]
   760   C1706386:Experiment [Conceptual Entity]
   760   C1882932:Representative [Activity]

Phrase: "performed in triplicate."
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   790   C0205174:Triplicate [Quantitative Concept]
   790   C0884358:Performed [Functional Concept]
   756 E C2947996:Perform [Pharmacologic Substance]
Processing 00000000.tx.221: Further experiments were performed to confirm the specificity of the Ca2+-mobilizing effect as due to anti-CD38 aAbs. 

Phrase: "Further experiments"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   861   C0681814:Experiments [Research Activity]
   827 E C1706386:Experiment [Conceptual Entity]
   777 E C1517586:Experimental [Qualitative Concept]

Phrase: "were"

Phrase: "performed"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0884358:Performed [Functional Concept]
   966 E C2947996:Perform [Pharmacologic Substance]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "confirm"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0521093:confirm [Qualitative Concept]
  1000   C0750484:confirm [Idea or Concept]
  1000   C1456348:Confirm [Qualitative Concept]

Phrase: "the specificity of the Ca2+-mobilizing effect"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   748   C0037791:Specificity [Quantitative Concept]
   748   C1511884:Specificity [Quantitative Concept]

Phrase: "as due to anti-CD38 aAbs."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   790   C0678226:Due to [Functional Concept]
           due
   753   C0004358:Autoantibodies [Amino Acid, Peptide, or Protein,Immunologic Factor]
   753   C3146286:Due [Idea or Concept]
Processing 00000000.tx.222: Removal of the Ig fraction from anti-CD38+ sera by means of sepharoseprotein G pretreatment lead to a consistent decrease in Ca2+ mobilization (Fig. 6G), thus demonstrating the involvement of antibodies in the observed effect. 

Phrase: "Removal of the Ig fraction"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0015252:Removal [Therapeutic or Preventive Procedure]
   760   C0728940:Removal [Therapeutic or Preventive Procedure]

Phrase: "from anti-CD38+ sera"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   827   C0229671:Sera [Body Substance]
   827   C1151254:SerA [Molecular Function]
   793 E C1546774:Serum [Intellectual Product]
   793 E C1550100:Serum [Body Substance]

Phrase: "by means of sepharoseprotein G pretreatment"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   827   C1550147:Pretreatment [Substance]
   827   C2709094:pre treatment [Temporal Concept]
   827   C3539075:Pretreatment [Temporal Concept]
   827   C3539076:Pretreatment [Activity]

Phrase: "lead to a consistent decrease"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   760   C0023175:???lead [Element, Ion, or Isotope,Hazardous or Poisonous Substance]
   760   C0332290:Consistent [Idea or Concept]
   760   C0392756:Decrease [Qualitative Concept]
   760   C0547047:Decrease [Quantitative Concept]
   760   C1442948:lead [Inorganic Chemical,Pharmacologic Substance]
   760   C1522538:Lead [Functional Concept]
   760   C2348269:Lead [Element, Ion, or Isotope]
   760   C3275067:LEAD [Therapeutic or Preventive Procedure]

Phrase: "in Ca2+ mobilization"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0185112:Mobilisation [Therapeutic or Preventive Procedure]
   861   C0300926:mobilization [Functional Concept]

Phrase: "(Fig. 6G"

Phrase: ")"

Phrase: ","

Phrase: "thus"

Phrase: "demonstrating"

Phrase: "the involvement of antibodies"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C1314939:Involvement [Functional Concept]

Phrase: "in the observed effect."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1280500:Effect [Qualitative Concept]
   861   C2348382:Effect [Qualitative Concept]
Processing 00000000.tx.223: Furthermore, these antibodies are specific for CD38, because anti-CD38+ sera preincubated with saturating amounts of rsCD38 triggered minimal Ca2+ currents (Fig. 6H). 

Phrase: "Furthermore,"

Phrase: "these antibodies"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0003241:Antibodies [Amino Acid, Peptide, or Protein,Cell Component,Immunologic Factor]
   966 E C0021027:Antibody [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]

Phrase: "are"

Phrase: "specific for CD38,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0205369:Specific [Qualitative Concept]
   790   C1552740:specific [Intellectual Product]

Phrase: "because"

Phrase: "anti-CD38+ sera"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   827   C0229671:Sera [Body Substance]
   827   C1151254:SerA [Molecular Function]
   793 E C1546774:Serum [Intellectual Product]
   793 E C1550100:Serum [Body Substance]

Phrase: "preincubated with saturating amounts of rsCD38"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   744   C0522534:saturating [Phenomenon or Process]
   744   C1265611:amounts [Quantitative Concept]
   744   C1514798:recombinant [Organism]
   744   C1749467:soluble [Cell Component]
   744   C1948047:Soluble [Qualitative Concept]

Phrase: "triggered"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   966   C0032930:Trigger [Clinical Attribute]
   966   C1444748:Trigger [Qualitative Concept]

Phrase: "minimal Ca2+ currents"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   827   C0521116:currents [Temporal Concept]
   793 E C1705970:Current [Natural Phenomenon or Process]

Phrase: "(Fig. 6H"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1292428:6H [Temporal Concept]

Phrase: ")."
Processing 00000000.tx.224: On the contrary, preincubation of anti-CD38+ sera with either PBS or gp120 did not have any influence on the agonistic activity (data not shown). 

Phrase: "On the contrary,"

Phrase: "preincubation of anti-CD38+ sera"

Phrase: "with either PBS"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   844   C0991865:Phosphate Buffer [Indicator, Reagent, or Diagnostic Aid,Pharmacologic Substance]
   812   C0006353:Buffered [Indicator, Reagent, or Diagnostic Aid,Pharmacologic Substance]
   812   C0031603:Phosphate [Inorganic Chemical,Pharmacologic Substance]
   812   C0031701:phosphate [Organophosphorus Compound]
   812   C0036082:Saline [Substance]
   812   C1601799:PHOSPHATE [Inorganic Chemical,Pharmacologic Substance]

Phrase: "or"

Phrase: "gp120"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0019691:gp120 [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "did"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "have"

Phrase: "any influence on the agonistic activity"

Phrase: "(data"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1511726:Data [Idea or Concept]
  1000   C3245479:data [Medical Device]

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "shown"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: ")."
Processing 00000000.tx.225: The relative prevalence of agonistic versus nonagonistic anti-CD38 aAbs was next evaluated by extrapolating the Fluo 3-AM mean fluorescence intensity from kinetics profiles, such as the ones depicted in Fig. 

Phrase: "The relative prevalence of agonistic"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0033105:Prevalence [Quantitative Concept]
   760   C0220900:prevalence [Quantitative Concept]

Phrase: "versus"

Phrase: "nonagonistic anti-CD38 aAbs"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C0004358:Autoantibodies [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: "was"

Phrase: "next"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205117:next [Spatial Concept]
  1000   C0332282:Next [Temporal Concept]
  1000   C1883708:Next [Temporal Concept]

Phrase: "evaluated by extrapolating"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C0220825:Evaluated [Functional Concept]

Phrase: "the Fluo 3-"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0060505:Fluo-3 [Organic Chemical,Pharmacologic Substance]
   861   C0385473:fluo [Organic Chemical,Pharmacologic Substance]

Phrase: "AM"

Phrase: "mean fluorescence intensity from kinetics profiles,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0016315:Fluorescence [Natural Phenomenon or Process]
   753   C0522510:Intensity [Qualitative Concept]

Phrase: "such as the ones"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C0205447:One [Quantitative Concept]

Phrase: "depicted in Fig."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0349966:Fig [Food]
   790   C1337208:FIG [Food]
Processing 00000000.tx.226: 6. 

Phrase: "6."
Processing 00000000.tx.227: The arbitrary cutoff, defined as the mean + 3 SD of the Fluo 3 mean fluorescence intensity values obtained from anti-CD38- diabetic sera, was 11.87. 

Phrase: "The arbitrary cutoff,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1442160:Cutoff [Functional Concept]

Phrase: "defined as the mean + 3 SD"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   753   C0444504:Mean [Quantitative Concept]
   753   C1704788:Defined [Conceptual Entity]
   753   C2347634:Mean [Quantitative Concept]
   753   C2348143:Mean [Quantitative Concept]
   753   C3539106:Defined [Intellectual Product]

Phrase: "of the Fluo 3 mean fluorescence intensity values"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   799   C0042295:Values [Qualitative Concept]
   766 E C1522609:Value [Quantitative Concept]

Phrase: "obtained from anti-CD38- diabetic sera,"
Meta Candidates (Total=7; Excluded=3; Pruned=0; Remaining=4)
   753   C0229671:Sera [Body Substance]
   753   C0241863:DIABETIC [Finding]
   753   C1151254:SerA [Molecular Function]
   753   C1301820:Obtained [Functional Concept]
   719 E C1546774:Serum [Intellectual Product]
   719 E C1550100:Serum [Body Substance]
   719 E C1706701:Obtain [Activity]

Phrase: "was"

Phrase: "11.87."
Processing 00000000.tx.228: As shown in Fig. 

Phrase: "As"

Phrase: "shown in Fig."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   790   C0349966:Fig [Food]
   790   C1337208:FIG [Food]
   756   C1547282:Show [Intellectual Product]
Processing 00000000.tx.229: 7, 16 of the 28 sera considered (57.14%) displayed agonistic properties, whereas only 1 of the 21 anti-CD38- sera (4.76%) was capable of triggering modest Ca2+ mobilization (P = 0.0001). 

Phrase: "7,"

Phrase: "16 of the 28 sera"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   760   C0229671:Sera [Body Substance]
   760   C1151254:SerA [Molecular Function]
   726 E C1546774:Serum [Intellectual Product]
   726 E C1550100:Serum [Body Substance]

Phrase: "considered"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0750591:considered [Idea or Concept]

Phrase: "(57.14%"

Phrase: ")"

Phrase: "displayed"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0870432:displayed [Functional Concept]
   966 E C1705417:Display [Manufactured Object]

Phrase: "agonistic properties,"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   861   C0871161:properties [Qualitative Concept]
   861   C1292721:properties [Functional Concept]
   827 E C1882134:Property [Conceptual Entity]
   827 E C2347695:Property [Entity]

Phrase: "whereas"

Phrase: "only 1 of the 21 anti-CD38- sera"
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
   744   C0205171:Only [Quantitative Concept]
   744   C0229671:Sera [Body Substance]
   744   C1151254:SerA [Molecular Function]
   744   C1720467:Only [Intellectual Product]
   711 E C1546774:Serum [Intellectual Product]
   711 E C1550100:Serum [Body Substance]

Phrase: "(4.76%"

Phrase: ")"

Phrase: "was"

Phrase: "capable of triggering modest Ca2+ mobilization"

Phrase: "(P = 0.0001"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   827   C2603361:P' [Clinical Attribute]

Phrase: ")."
Processing 00000000.tx.230: View larger version (19K): [in this window] [in a new window]  FIG. 

Phrase: "View"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0449911:View [Spatial Concept]

Phrase: "larger version"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0333052:Version [Functional Concept]
   861   C2607870:Version [Spatial Concept]

Phrase: "(19K"

Phrase: ")"

Phrase: ":"

Phrase: "["

Phrase: "in this window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0557702:Window [Manufactured Object]
  1000   C1272706:Window [Temporal Concept]
  1000   C1704674:Window [Manufactured Object]

Phrase: "]"

Phrase: "["

Phrase: "in a new window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0557702:Window [Manufactured Object]
   861   C1272706:Window [Temporal Concept]
   861   C1704674:Window [Manufactured Object]

Phrase: "]  FIG."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0349966:Fig [Food]
  1000   C1337208:FIG [Food]
Processing 00000000.tx.231: 7. 

Phrase: "7."
Processing 00000000.tx.232: Prevalence of agonistic activity among anti-CD38+ sera. 

Phrase: "Prevalence of agonistic activity"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0033105:Prevalence [Quantitative Concept]
   770   C0220900:prevalence [Quantitative Concept]

Phrase: "among anti-CD38+ sera."
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   827   C0229671:Sera [Body Substance]
   827   C1151254:SerA [Molecular Function]
   793 E C1546774:Serum [Intellectual Product]
   793 E C1550100:Serum [Body Substance]
Processing 00000000.tx.233: Values are expressed as the Fluo 3-AM mean fluorescence intensity, as extrapolated from the kinetics profiles of Ca2+ release; 

Phrase: "Values"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0042295:Values [Qualitative Concept]
   966 E C1522609:Value [Quantitative Concept]

Phrase: "are"

Phrase: "expressed as the Fluo 3-"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   806   C0060505:Fluo-3 [Organic Chemical,Pharmacologic Substance]
   760   C0385473:fluo [Organic Chemical,Pharmacologic Substance]

Phrase: "AM"

Phrase: "mean fluorescence intensity,"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   827   C0016315:Fluorescence [Natural Phenomenon or Process]
   827   C0522510:Intensity [Qualitative Concept]
   755 E C0303920:Fluorescent [Indicator, Reagent, or Diagnostic Aid,Organic Chemical]

Phrase: "as"

Phrase: "extrapolated from the kinetics profiles of Ca2+ release"
Meta Candidates (Total=12; Excluded=0; Pruned=0; Remaining=12)
   744   C0022702:Kinetics [Natural Phenomenon or Process]
   744   C0030685:Release [Health Care Activity]
   744   C0220865:kinetics [Functional Concept]
   744   C0391871:Release [Functional Concept]
   744   C0439180:% release [Quantitative Concept]
   744   C0596235:Ca2+ [Element, Ion, or Isotope,Pharmacologic Substance]
   744   C0680255:release [Health Care Activity]
   744   C1283071:Release [Functional Concept]
   744   C1963578:Release [Therapeutic or Preventive Procedure]
   744   C2825046:Kinetics [Occupation or Discipline]
   711   C1979963:Profile [Laboratory Procedure]
   711   C2003903:Profile [Functional Concept]

Phrase: ";"
Processing 00000000.tx.234: the dotted line indicates the cutoff value (mean + 3 SD) of 11.87. 

Phrase: "the dotted line"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205132:Line [Spatial Concept]
   861   C1550648:Line [Substance]
   861   C1552960:Line [Quantitative Concept]

Phrase: "indicates"

Phrase: "the cutoff value"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1442160:Cutoff [Functional Concept]
   861   C1522609:Value [Quantitative Concept]

Phrase: "(mean + 3 SD) of 11.87."
Processing 00000000.tx.235: The percent proportion of anti-CD38+ and control (anti-CD38-) sera displaying agonistic properties is indicated above each distribution plot. 

Phrase: "The percent proportion of anti-CD38+"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C1709707:Proportion [Quantitative Concept]

Phrase: "and"

Phrase: "control"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0243148:control [Qualitative Concept]
  1000   C1550141:Control [Substance]
  1000   C1882979:Control [Conceptual Entity]
  1000   C2587213:Control [Functional Concept]
  1000   C3274648:Control [Qualitative Concept]

Phrase: "(anti-CD38-"

Phrase: ")"

Phrase: "sera"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
  1000   C0229671:Sera [Body Substance]
  1000   C1151254:SerA [Molecular Function]
   966 E C1546774:Serum [Intellectual Product]
   966 E C1550100:Serum [Body Substance]

Phrase: "displaying"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0870432:displaying [Functional Concept]
   966 E C1705417:Display [Manufactured Object]

Phrase: "agonistic properties"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   861   C0871161:properties [Qualitative Concept]
   861   C1292721:properties [Functional Concept]
   827 E C1882134:Property [Conceptual Entity]
   827 E C2347695:Property [Entity]

Phrase: "is"

Phrase: "indicated above each distribution plot."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C0520511:distribution [Idea or Concept]
   760   C1444656:Indicated [Finding]
   760   C1704711:Distribution [Functional Concept]
Processing 00000000.tx.236: P = 0.0001 for comparison between the two groups.  

Phrase: "P = 0.0001 for comparison"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   760   C1707455:Comparison [Activity]
   760   C2603361:P' [Clinical Attribute]

Phrase: "between the two groups."
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   861   C0441833:Group [Idea or Concept]
   861   C0687744:group [Population Group]
   861   C1257890:Group [Population Group]
   861   C1552516:Group [Health Care Related Organization]
   861   C1552839:groups [Idea or Concept]
   861   C1705428:Group [Conceptual Entity]
   861   C1705429:Group [Population Group]
Processing 00000000.tx.237: Correlation of anti-CD38 aAb status with clinical and metabolic parameters. 

Phrase: "Correlation of anti-CD38 aAb status"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C1707520:Correlation [Qualitative Concept]

Phrase: "with clinical"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205210:Clinical [Qualitative Concept]

Phrase: "and"

Phrase: "metabolic parameters."
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
   861   C0449381:Parameters [Finding]
   827 E C0549193:Parameter [Spatial Concept]
   827 E C1704769:Parameter [Conceptual Entity]
   827 E C2350001:Parameter [Quantitative Concept]
Processing 00000000.tx.238: Anti-CD38+ and anti-CD38- diabetic subjects were compared for relevant clinical and metabolic characteristics. 

Phrase: "Anti-CD38+"

Phrase: "and"

Phrase: "anti-CD38- diabetic subjects"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   779   C0681850:Subject [Group]
   779   C1550501:{Subject} [Idea or Concept]
   779   C1706203:Subject [Idea or Concept]
   779   C2349001:Subject [Human]
   779   C2697811:Subject [Functional Concept]

Phrase: "were"

Phrase: "compared for relevant clinical"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0205210:Clinical [Qualitative Concept]
   770   C1707455:Compared [Activity]
   770   C2347946:Relevant [Qualitative Concept]

Phrase: "and"

Phrase: "metabolic characteristics."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1521970:Characteristics [Qualitative Concept]
Processing 00000000.tx.239: Among type 1 diabetic subjects, no significant association of anti-CD38 aAbs was found with any of the parameters considered (Table 3). 

Phrase: "Among type 1 diabetic subjects,"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   779   C0681850:Subject [Group]
   779   C1550501:{Subject} [Idea or Concept]
   779   C1706203:Subject [Idea or Concept]
   779   C2349001:Subject [Human]
   779   C2697811:Subject [Functional Concept]

Phrase: "no significant association of anti-CD38 aAbs"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   748   C0004083:Association [Mental Process]
   748   C0439849:Association [Qualitative Concept]
   748   C0596306:Association [Phenomenon or Process]
   748   C0699792:association [Social Behavior]

Phrase: "was"

Phrase: "found with any of the parameters"
Meta Candidates (Total=6; Excluded=4; Pruned=0; Remaining=2)
   753   C0150312:Found [Quantitative Concept]
   753   C0449381:Parameters [Finding]
   719 E C0243095:Find [Finding]
   719 E C0549193:Parameter [Spatial Concept]
   719 E C1704769:Parameter [Conceptual Entity]
   719 E C2350001:Parameter [Quantitative Concept]

Phrase: "considered"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0750591:considered [Idea or Concept]

Phrase: "(Table 3"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0039224:Table [Manufactured Object]
   861   C1706073:Table [Medical Device]
   861   C1706074:Table [Intellectual Product]

Phrase: ")."
Processing 00000000.tx.240: On the contrary, anti-CD38+ type 2 diabetic subjects displayed significantly higher fasting plasma C-peptide and insulin levels (Table 4), in line with the agonistic properties reported here and with the previously described insulin-secreting capacity of anti-CD38 aAbs (16). 

Phrase: "On the contrary,"

Phrase: "anti-CD38+ type 2 diabetic subjects"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   766   C0681850:Subject [Group]
   766   C1550501:{Subject} [Idea or Concept]
   766   C1706203:Subject [Idea or Concept]
   766   C2349001:Subject [Human]
   766   C2697811:Subject [Functional Concept]

Phrase: "displayed"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0870432:displayed [Functional Concept]
   966 E C1705417:Display [Manufactured Object]

Phrase: "significantly higher fasting plasma C-peptide"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0006558:C-Peptide [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   799   C0030956:Peptide [Amino Acid, Peptide, or Protein]

Phrase: "and"

Phrase: "insulin levels"
Meta Candidates (Total=11; Excluded=5; Pruned=0; Remaining=6)
  1000   C0202098:insulin levels [Laboratory Procedure]
  1000   C0428405:insulin levels [Laboratory or Test Result]
   861   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C0441889:Levels [Qualitative Concept]
   861   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C1579433:Insulin [Pharmacologic Substance]
   827 E C0456079:Level [Classification]
   827 E C1547707:Level [Geographic Area]
   827 E C2946261:Level [Pharmacologic Substance]
   805 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   777 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "(Table 4"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0039224:Table [Manufactured Object]
   861   C1706073:Table [Medical Device]
   861   C1706074:Table [Intellectual Product]

Phrase: ")"

Phrase: ","

Phrase: "in line with the agonistic properties"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   861   C0871161:properties [Qualitative Concept]
   861   C1292721:properties [Functional Concept]
   827 E C1882134:Property [Conceptual Entity]
   827 E C2347695:Property [Entity]

Phrase: "reported"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C0684224:Reported [Intellectual Product]
  1000   C0700287:Reported [Health Care Activity]
  1000   C3496591:Reported [Clinical Attribute]
   966 E C3273238:Report [Intellectual Product]

Phrase: "here"

Phrase: "and with the previously described insulin-secreting capacity of anti-CD38 aAbs"
Meta Candidates (Total=10; Excluded=0; Pruned=0; Remaining=10)
   755   C1275890:Anti-insulin autoantibody [Amino Acid, Peptide, or Protein,Immunologic Factor]
           autoantibodies insulin
   736   C0004358:Autoantibodies [Amino Acid, Peptide, or Protein,Immunologic Factor]
   736   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   736   C1327616:Secreting [Cell Function]
   736   C1515981:And [Idea or Concept]
   736   C1516240:Capacity [Quantitative Concept]
   736   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   736   C1552738:described [Idea or Concept]
   736   C1579433:Insulin [Pharmacologic Substance]

Phrase: "(16"

Phrase: ")."
Processing 00000000.tx.241: Higher BMI values and a lower frequency of insulin treatment was also noted among anti-CD38+ type 2 diabetic subjects, although statistical significance was not reached. 

Phrase: "Higher BMI values"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   827   C0042295:Values [Qualitative Concept]
   793 E C1522609:Value [Quantitative Concept]

Phrase: "and"

Phrase: "a lower frequency of insulin treatment"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   753   C0376249:frequency [Quantitative Concept]
   753   C0439603:Frequency [Temporal Concept]
   753   C0871396:Frequency [Quantitative Concept]
   753   C1561548:Frequency [Qualitative Concept]
   753   C1705502:Frequency [Quantitative Concept]

Phrase: "was"

Phrase: "also"

Phrase: "noted among anti-CD38+ type 2 diabetic subjects,"
Meta Candidates (Total=12; Excluded=0; Pruned=0; Remaining=12)
   770   C0441730:Type 2 [Classification]
   744   C0241863:DIABETIC [Finding]
   744   C0332307:Type [Qualitative Concept]
   744   C1547052:*Type [Quantitative Concept]
   711   C0681850:Subject [Group]
   711   C1316572:Note [Clinical Attribute]
   711   C1317574:Note [Intellectual Product]
   711   C1369612:Note [Clinical Attribute]
   711   C1550501:{Subject} [Idea or Concept]
   711   C1706203:Subject [Idea or Concept]
   711   C2349001:Subject [Human]
   711   C2697811:Subject [Functional Concept]

Phrase: "although"

Phrase: "statistical significance"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
  1000   C0237881:Statistical Significance [Quantitative Concept]
           Significance
  1000   C1709380:Statistical Significance [Quantitative Concept]
   861   C0038215:Statistical [Occupation or Discipline]
   861   C0750502:Significance [Idea or Concept]
   789 E C1546944:Significant [Qualitative Concept]

Phrase: "was"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "reached."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C2584321:Reach [Organism Function]
Processing 00000000.tx.242: View this table: [in this window] [in a new window]  TABLE 3 Comparison between clinical and metabolic characteristics of type 1 diabetic patients positive (anti-CD38+) and negative (anti-CD38-) for anti-CD38 autoantibodies  View this table: [in this window] [in a new window]  TABLE 4 Comparison between clinical and metabolic characteristics of type 2 diabetic patients positive (anti-CD38+) and negative (anti-CD38-) for anti-CD38 autoantibodies  CD38 genetic background. 

Phrase: "View"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0449911:View [Spatial Concept]

Phrase: "this table"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0039224:Table [Manufactured Object]
  1000   C1706073:Table [Medical Device]
  1000   C1706074:Table [Intellectual Product]

Phrase: ":"

Phrase: "["

Phrase: "in this window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0557702:Window [Manufactured Object]
  1000   C1272706:Window [Temporal Concept]
  1000   C1704674:Window [Manufactured Object]

Phrase: "]"

Phrase: "["

Phrase: "in a new window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0557702:Window [Manufactured Object]
   861   C1272706:Window [Temporal Concept]
   861   C1704674:Window [Manufactured Object]

Phrase: "]  TABLE 3 Comparison between clinical"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C1707455:Comparison [Activity]

Phrase: "and"

Phrase: "metabolic characteristics of type 1 diabetic patients positive"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   750   C0815172:patient characteristics [Clinical Attribute]
   750   C3645613:Characteristic type [Intellectual Product]
   744   C1521970:Characteristics [Qualitative Concept]

Phrase: "(anti-CD38+"

Phrase: ")"

Phrase: "and"

Phrase: "negative"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0205160:Negative [Qualitative Concept]
  1000   C1513916:Negative [Finding]
  1000   C2825415:Negative [Conceptual Entity]
  1000   C2825491:Negative [Qualitative Concept]

Phrase: "(anti-CD38-"

Phrase: ")"

Phrase: "for anti-CD38 autoantibodies"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0004358:Autoantibodies [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: "View"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0449911:View [Spatial Concept]

Phrase: "this table"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0039224:Table [Manufactured Object]
  1000   C1706073:Table [Medical Device]
  1000   C1706074:Table [Intellectual Product]

Phrase: ":"

Phrase: "["

Phrase: "in this window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0557702:Window [Manufactured Object]
  1000   C1272706:Window [Temporal Concept]
  1000   C1704674:Window [Manufactured Object]

Phrase: "]"

Phrase: "["

Phrase: "in a new window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0557702:Window [Manufactured Object]
   861   C1272706:Window [Temporal Concept]
   861   C1704674:Window [Manufactured Object]

Phrase: "]  TABLE 4 Comparison between clinical"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C1707455:Comparison [Activity]

Phrase: "and"

Phrase: "metabolic characteristics of type 2 diabetic patients positive"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   750   C0815172:patient characteristics [Clinical Attribute]
   750   C3645613:Characteristic type [Intellectual Product]
   744   C1521970:Characteristics [Qualitative Concept]

Phrase: "(anti-CD38+"

Phrase: ")"

Phrase: "and"

Phrase: "negative"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0205160:Negative [Qualitative Concept]
  1000   C1513916:Negative [Finding]
  1000   C2825415:Negative [Conceptual Entity]
  1000   C2825491:Negative [Qualitative Concept]

Phrase: "(anti-CD38-"

Phrase: ")"

Phrase: "for anti-CD38 autoantibodies  CD38 genetic background."
Meta Candidates (Total=16; Excluded=13; Pruned=0; Remaining=3)
   799   C0017296:GENETIC [Therapeutic or Preventive Procedure]
   799   C0314603:Genetic [Functional Concept]
   799   C1706907:Background [Conceptual Entity]
   743 E C0005615:Birth [Organism Function]
   743 E C0035150:Reproduction [Organism Function]
   743 E C0079946:origin [Classification]
   743 E C0439659:Origin [Temporal Concept]
   743 E C1550512:origin [Intellectual Product]
   743 E C1550722:birth [Idea or Concept]
   743 E C3245487:birth [Intellectual Product]
   716 E C0454729:Natal [Geographic Area]
   716 E C0559522:Genital [Body System]
   716 E C1546649:Genital [Intellectual Product]
   716 E C1550642:Genital [Body Substance]
   706 E C0205313:Original [Idea or Concept]
   706 E C2347409:Original [Occupational Activity]
Processing 00000000.tx.243: As CD38 displays genetic heterogeneity in terms of both pathological mutations and normal allelic variants, the potential influence of this genetic milieu in the Caucasian diabetic population was explored. 

Phrase: "As CD38"

Phrase: "displays"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0870432:displays [Functional Concept]
  1000   C1705417:Display [Manufactured Object]

Phrase: "genetic heterogeneity in terms of both pathological mutations"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   770   C0242960:Genetic Heterogeneity [Organism Attribute]
   767   C0026882:genetic mutations [Genetic Function]
   744   C0017296:GENETIC [Therapeutic or Preventive Procedure]
   744   C0019409:Heterogeneity [Qualitative Concept]
   744   C0314603:Genetic [Functional Concept]
   722   C0233324:Births.term [Organism Function]
   722   C0551758:Births.term [Clinical Attribute]

Phrase: "and"

Phrase: "normal allelic variants,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0205419:variants [Qualitative Concept]

Phrase: "the potential influence of this genetic milieu"

Phrase: "in the Caucasian diabetic population"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0032659:Population [Quantitative Concept]
   827   C1257890:Population [Population Group]

Phrase: "was"

Phrase: "explored."
Processing 00000000.tx.244: The presence of the Arg140Trp mutation described in Japanese type 2 diabetic individuals (14) was first evaluated using a PCR assay. 

Phrase: "The presence of the Arg140Trp mutation"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C0392148:Presence [Therapeutic or Preventive Procedure]

Phrase: "described in Japanese type 2 diabetic individuals"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   778   C0441730:Type 2 [Classification]
   748   C0241863:DIABETIC [Finding]
   748   C0332307:Type [Qualitative Concept]
   748   C1547052:*Type [Quantitative Concept]
   748   C1552738:described [Idea or Concept]
   748   C1556094:Japanese [Population Group]
   714   C0027361:Individual [Population Group]
   714   C0237401:Individual [Human]

Phrase: "(14"

Phrase: ")"

Phrase: "was"

Phrase: "first"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0205435:First [Quantitative Concept]
  1000   C1279901:First [Qualitative Concept]

Phrase: "evaluated"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0220825:Evaluated [Functional Concept]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "a PCR assay."
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   923   C0032520:Polymerase Chain Reaction [Laboratory Procedure,Molecular Biology Research Technique]
   812   C0005507:Assay [Laboratory Procedure]
   812   C0243073:assay [Qualitative Concept]
   812   C0337112:Chain [Manufactured Object]
   812   C0443286:Reaction [Functional Concept]
   812   C1114821:Reaction [Clinical Attribute]
   812   C1335439:Polymerase [Amino Acid, Peptide, or Protein,Enzyme]
   812   C1510438:Assay [Laboratory Procedure]
   812   C1524075:Chain [Idea or Concept]
Processing 00000000.tx.245: Among the 84 Caucasian type 2 diabetic patients screened (46 of whom had first- or second-degree relatives affected), no individual carrying such a mutation was found. 

Phrase: "Among the 84 Caucasian type 2 diabetic patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   799   C0030705:Patients [Patient or Disabled Group]

Phrase: "screened"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   966   C0220908:screen [Health Care Activity]
   966   C1305399:screen [Functional Concept]
   966   C1705053:Screen [Medical Device]

Phrase: "(46 of whom"

Phrase: "had"

Phrase: "first-"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0205435:First [Quantitative Concept]
  1000   C1279901:First [Qualitative Concept]

Phrase: "or"

Phrase: "second-degree relatives"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
   983   C1519210:Second Degree Relative [Family Group]
   827   C0080103:Relatives [Family Group]
   793 E C0205345:Relative [Qualitative Concept]
   793 E C1547039:*Relative [Quantitative Concept]
   734   C0443298:Second degree [Qualitative Concept]

Phrase: "affected"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0392760:Affected [Functional Concept]
  1000   C1314939:Affected [Functional Concept]
   966 E C0001721:Affect [Mental Process]

Phrase: ")"

Phrase: ","

Phrase: "no individual carrying"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0206243:Carrying [Activity]
   827 E C0699809:carry [Finding]

Phrase: "such a mutation"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0026882:Mutation [Genetic Function]
  1000   C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "was"

Phrase: "found."
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0150312:Found [Quantitative Concept]
   966 E C0243095:Find [Finding]
Processing 00000000.tx.246: The only subject positive for the mutation was found among the 25 healthy control subjects; 

Phrase: "The only"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0205171:Only [Quantitative Concept]
  1000   C1720467:Only [Intellectual Product]

Phrase: "subject"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0681850:Subject [Group]
  1000   C1550501:{Subject} [Idea or Concept]
  1000   C1706203:Subject [Idea or Concept]
  1000   C2349001:Subject [Human]
  1000   C2697811:Subject [Functional Concept]

Phrase: "positive for the mutation"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   770   C0439178:% Positive [Quantitative Concept]
   770   C1446409:Positive [Qualitative Concept]
   770   C1514241:Positive [Finding]
   770   C2825490:Positive [Qualitative Concept]

Phrase: "was"

Phrase: "found among the 25 healthy control subjects"
Meta Candidates (Total=14; Excluded=1; Pruned=0; Remaining=13)
   778   C2986479:Healthy Control [Qualitative Concept]
   774   C1708335:HEALTHY SUBJECTS [Population Group]
   748   C0150312:Found [Quantitative Concept]
   748   C0243148:control [Qualitative Concept]
   748   C1550141:Control [Substance]
   748   C1882979:Control [Conceptual Entity]
   748   C2587213:Control [Functional Concept]
   748   C3274648:Control [Qualitative Concept]
   714 E C0243095:Find [Finding]
   714   C0681850:Subject [Group]
   714   C1550501:{Subject} [Idea or Concept]
   714   C1706203:Subject [Idea or Concept]
   714   C2349001:Subject [Human]
   714   C2697811:Subject [Functional Concept]

Phrase: ";"
Processing 00000000.tx.247: this subject repeatedly had normal fasting plasma glucose levels and no family history of diabetes. 

Phrase: "this subject repeatedly"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   861   C0681850:Subject [Group]
   861   C1550501:{Subject} [Idea or Concept]
   861   C1706203:Subject [Idea or Concept]
   861   C2349001:Subject [Human]
   861   C2697811:Subject [Functional Concept]

Phrase: "had"

Phrase: "normal fasting plasma glucose levels"
Meta Candidates (Total=9; Excluded=4; Pruned=0; Remaining=5)
   894   C0522082:Normal glucose level [Finding]
   851   C0455280:plasma glucose level [Laboratory or Test Result]
   840   C0428548:glucose levels [Laboratory or Test Result]
   806 E C0337438:glucose level [Laboratory Procedure]
   804   C0441889:Levels [Qualitative Concept]
   771 E C0456079:Level [Classification]
   771 E C1547707:Level [Geographic Area]
   771 E C2946261:Level [Pharmacologic Substance]
   708   C0860800:normal glucose [Finding]

Phrase: "and"

Phrase: "no family history of diabetes."
Meta Candidates (Total=16; Excluded=0; Pruned=0; Remaining=16)
  1000   C0455678:No family history of diabetes [Finding]
           No family history diabetes
   926   C0332123:No family history of [Finding]
           No family history
   844   C0332122:No history of [Qualitative Concept]
   806   C0241889:Family history [Finding]
   806   C0557086:No family [Finding]
   806   C1705495:Family History [Idea or Concept]
   760   C0015576:Family [Family Group]
   760   C0019664:History [Occupation or Discipline]
   760   C0019665:history [Intellectual Product]
   760   C0262512:History, NOS [Organism Attribute]
   760   C0262926:History [Finding]
   760   C1704727:Family [Conceptual Entity]
   760   C1705255:History [Conceptual Entity]
   760   C2004062:History [Finding]
Processing 00000000.tx.248: Presence of the Arg140Trp mutation in a heterozygous state was also confirmed by genomic DNA sequence analysis (data not shown). 

Phrase: "Presence of the Arg140Trp mutation"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0392148:Presence [Therapeutic or Preventive Procedure]

Phrase: "in a heterozygous state"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C1301808:State [Geographic Area]
   861   C1442792:State [Functional Concept]
   861   C3148680:State [Geographic Area]

Phrase: "was"

Phrase: "also"

Phrase: "confirmed by genomic DNA sequence analysis"
Meta Candidates (Total=19; Excluded=1; Pruned=0; Remaining=18)
   833   C0162802:Sequence Analysis, DNA [Laboratory Procedure,Molecular Biology Research Technique]
   790   C0162326:DNA Sequence [Nucleotide Sequence]
           Sequence
   790   C0162801:Sequence Analysis [Laboratory Procedure,Molecular Biology Research Technique]
   790   C0521093:Confirmed by [Qualitative Concept]
           confirmed
   790   C3272453:Genomic DNA [Nucleic Acid, Nucleoside, or Nucleotide]
   783   C0200898:DNA analysis [Laboratory Procedure]
   753   C0002778:Analysis [Laboratory Procedure]
   753   C0004793:Sequence [Nucleotide Sequence]
   753   C0012854:DNA [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   753   C0017428:Genomic [Gene or Genome]
   753   C0162327:Sequence [Nucleotide Sequence]
   753   C0750484:Confirmed [Idea or Concept]
   753   C0887950:genomic [Biomedical Occupation or Discipline]
   753   C0936012:Analysis [Research Activity]
   753   C1519249:Sequence [Functional Concept]
   753   C1524024:analysis [Functional Concept]
   719 E C1456348:Confirm [Qualitative Concept]

Phrase: "(data"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1511726:Data [Idea or Concept]
  1000   C3245479:data [Medical Device]

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "shown"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: ")."
Processing 00000000.tx.249: Because a CD38 genetic polymorphism was recently described in the healthy Caucasian population (17), we set out to determine whether any particular CD38 allele was preferentially associated with the diabetic condition. 

Phrase: "Because"

Phrase: "a CD38 genetic polymorphism"
Meta Candidates (Total=19; Excluded=14; Pruned=0; Remaining=5)
   901   C0032529:Genetic Polymorphism [Genetic Function]
           Polymorphism
   827   C0017296:GENETIC [Therapeutic or Preventive Procedure]
   827   C0314603:Genetic [Functional Concept]
   827   C1882417:Polymorphism [Qualitative Concept]
   771 E C0005615:Birth [Organism Function]
   771 E C0035150:Reproduction [Organism Function]
   771 E C0079946:origin [Classification]
   771 E C0439659:Origin [Temporal Concept]
   771 E C1550512:origin [Intellectual Product]
   771 E C1550722:birth [Idea or Concept]
   771 E C3245487:birth [Intellectual Product]
   743 E C0454729:Natal [Geographic Area]
   743 E C0559522:Genital [Body System]
   743 E C1546649:Genital [Intellectual Product]
   743 E C1550642:Genital [Body Substance]
   734 E C0205313:Original [Idea or Concept]
   734 E C2347409:Original [Occupational Activity]
   716 E C0598240:originality [Mental Process]

Phrase: "was"

Phrase: "recently"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0332185:Recently [Temporal Concept]

Phrase: "described in the healthy Caucasian population"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   753   C0007457:Caucasian [Population Group]
   753   C0032659:Population [Quantitative Concept]
   753   C0043157:Caucasian [Population Group]
   753   C1257890:Population [Population Group]
   753   C1552738:described [Idea or Concept]
   748   C3242284:population health [Health Care Activity]

Phrase: "(17"

Phrase: ")"

Phrase: ","

Phrase: "we"

Phrase: "set"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0036849:Set [Mental Process]
  1000   C1442518:Set [Functional Concept]
  1000   C1705195:Set [Conceptual Entity]

Phrase: "out to"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0439787:Out [Spatial Concept]
   861   C0849355:Out [Qualitative Concept]

Phrase: "determine"

Phrase: "whether"

Phrase: "any particular CD38 allele"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0002085:Allele [Gene or Genome]

Phrase: "was"

Phrase: "preferentially"

Phrase: "associated with the diabetic condition."
Meta Candidates (Total=8; Excluded=2; Pruned=0; Remaining=6)
   806   C0332281:Associated with [Qualitative Concept]
           Associated
   760   C0012634:condition [Disease or Syndrome]
   760   C0241863:DIABETIC [Finding]
   760   C0348080:Condition [Qualitative Concept]
   760   C1705253:Condition [Conceptual Entity]
   726 E C0750490:Associate [Idea or Concept]
   726 E C1706221:Associate [Professional or Occupational Group]
Processing 00000000.tx.250: The sample of type 2 diabetic patients analyzed was larger than that of type 1 diabetic subjects, given the heavier influence of genetic factors on the former group (2). 

Phrase: "The sample of type 2 diabetic patients"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   774   C2347029:Sample Type [Qualitative Concept]
   748   C0370003:Sample [Substance]
   748   C2347026:Sample [Conceptual Entity]

Phrase: "analyzed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0936012:Analyzed [Research Activity]

Phrase: "was"

Phrase: "larger than that of type 1 diabetic subjects,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   744   C0443228:larger [Quantitative Concept]
   744   C0549177:Larger [Quantitative Concept]
   744   C1704243:Larger [Quantitative Concept]

Phrase: "given"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C1442162:GIVEN [Conceptual Entity]
  1000   C1550718:given [Idea or Concept]
  1000   C3244317:given [Intellectual Product]
   966 E C1947971:Give [Functional Concept]

Phrase: "the heavier influence of genetic factors"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   783   C0814287:factors influence [Clinical Attribute]

Phrase: "on the former group"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   861   C0441833:Group [Idea or Concept]
   861   C0687744:group [Population Group]
   861   C1257890:Group [Population Group]
   861   C1552516:Group [Health Care Related Organization]
   861   C1705428:Group [Conceptual Entity]
   861   C1705429:Group [Population Group]

Phrase: "(2"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0740116:+2 [Quantitative Concept]
  1000   C2827735:2+ [Quantitative Concept]
  1000   C2981700:2+ [Classification]

Phrase: ")."
Processing 00000000.tx.251: Results are summarized in Table 5 and 6; 

Phrase: "Results"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   966   C1274040:Result [Functional Concept]
   966   C1546471:Result [Idea or Concept]
   966   C2825142:Result [Finding]

Phrase: "are"

Phrase: "summarized in Table 5"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0039224:Table [Manufactured Object]
   770   C1706073:Table [Medical Device]
   770   C1706074:Table [Intellectual Product]

Phrase: "and"

Phrase: "6"

Phrase: ";"
Processing 00000000.tx.252: neither the distribution of the less frequent CD38*A allele nor that of the CD38*A/*A genotype differed significantly among type 1 diabetic patients, type 2 diabetic patients, and healthy control subjects. 

Phrase: "neither"

Phrase: "the distribution of the less frequent CD38"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   748   C0520511:distribution [Idea or Concept]
   748   C1704711:Distribution [Functional Concept]
   738   C0237580:Frequency Distribution [Quantitative Concept]

Phrase: "*"

Phrase: "A allele"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0002085:Allele [Gene or Genome]

Phrase: "nor"

Phrase: "that of the CD38"

Phrase: "*A/*"

Phrase: "A genotype"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0017431:Genotype [Organism Attribute]

Phrase: "differed"

Phrase: "significantly among type 1 diabetic patients,"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   790   C0441729:Type 1 [Classification]
   767   C1550335:Patient type [Classification]
   753   C0030705:Patients [Patient or Disabled Group]
   753   C0241863:DIABETIC [Finding]
   753   C0332307:Type [Qualitative Concept]
   753   C1547052:*Type [Quantitative Concept]

Phrase: "type 2 diabetic patients,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C0030705:Patients [Patient or Disabled Group]

Phrase: "and"

Phrase: "healthy control subjects."
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   913   C1708335:HEALTHY SUBJECTS [Population Group]
   793   C0681850:Subject [Group]
   793   C1550501:{Subject} [Idea or Concept]
   793   C1706203:Subject [Idea or Concept]
   793   C2349001:Subject [Human]
   793   C2697811:Subject [Functional Concept]
   734   C2986479:Healthy Control [Qualitative Concept]
Processing 00000000.tx.253: No correlation was observed between any CD38 allele and aAb status (data not shown). 

Phrase: "No correlation"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1707520:Correlation [Qualitative Concept]

Phrase: "was"

Phrase: "observed between any CD38 allele"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0002085:Allele [Gene or Genome]
   760   C1441672:Observed [Functional Concept]

Phrase: "and"

Phrase: "aAb status"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0449438:Status [Qualitative Concept]

Phrase: "(data"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1511726:Data [Idea or Concept]
  1000   C3245479:data [Medical Device]

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "shown"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: ")."
Processing 00000000.tx.254: Furthermore, CD38*A homo- or heterozygotes did not display a stronger family history of diabetes. 

Phrase: "Furthermore,"

Phrase: "CD38"

Phrase: "*"

Phrase: "A homo-"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1300203:Homo [Mammal]
  1000   C3245470:HOMO [Finding]

Phrase: "or"

Phrase: "heterozygotes"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0019425:Heterozygotes [Organism Attribute]

Phrase: "did"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "display"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1705417:Display [Manufactured Object]

Phrase: "a stronger family history of diabetes."
Meta Candidates (Total=10; Excluded=0; Pruned=0; Remaining=10)
   790   C0241889:Family history [Finding]
   790   C1705495:Family History [Idea or Concept]
   753   C0015576:Family [Family Group]
   753   C0019664:History [Occupation or Discipline]
   753   C0019665:history [Intellectual Product]
   753   C0262512:History, NOS [Organism Attribute]
   753   C0262926:History [Finding]
   753   C1704727:Family [Conceptual Entity]
   753   C1705255:History [Conceptual Entity]
   753   C2004062:History [Finding]
Processing 00000000.tx.255: View this table: [in this window] [in a new window]  TABLE 5 CD38 allelic and genotype frequencies in type 1 diabetic patients compared with healthy control subjects   DISCUSSION TOP ABSTRACT INTRODUCTION RESEARCH DESIGN AND METHODS RESULTS DISCUSSION REFERENCES  Interactions between genes and environment are critical in the susceptibility to several human diseases; 

Phrase: "View"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0449911:View [Spatial Concept]

Phrase: "this table"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0039224:Table [Manufactured Object]
  1000   C1706073:Table [Medical Device]
  1000   C1706074:Table [Intellectual Product]

Phrase: ":"

Phrase: "["

Phrase: "in this window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0557702:Window [Manufactured Object]
  1000   C1272706:Window [Temporal Concept]
  1000   C1704674:Window [Manufactured Object]

Phrase: "]"

Phrase: "["

Phrase: "in a new window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0557702:Window [Manufactured Object]
   861   C1272706:Window [Temporal Concept]
   861   C1704674:Window [Manufactured Object]

Phrase: "]  TABLE 5 CD38"

Phrase: "allelic"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   928   C0002085:Allele [Gene or Genome]

Phrase: "and"

Phrase: "genotype frequencies in type 1 diabetic patients"
Meta Candidates (Total=5; Excluded=4; Pruned=0; Remaining=1)
   748   C0439603:Frequencies [Temporal Concept]
   714 E C0376249:frequency [Quantitative Concept]
   714 E C0871396:Frequency [Quantitative Concept]
   714 E C1561548:Frequency [Qualitative Concept]
   714 E C1705502:Frequency [Quantitative Concept]

Phrase: "compared with healthy control"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   833   C2986479:Healthy Control [Qualitative Concept]
   770   C0243148:control [Qualitative Concept]
   770   C1550141:Control [Substance]
   770   C1707455:Compared [Activity]
   770   C1882979:Control [Conceptual Entity]
   770   C2587213:Control [Functional Concept]
   770   C3274648:Control [Qualitative Concept]

Phrase: "subjects"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0681850:Subject [Group]
  1000   C1550501:{Subject} [Idea or Concept]
  1000   C1706203:Subject [Idea or Concept]
  1000   C2349001:Subject [Human]
  1000   C2697811:Subject [Functional Concept]

Phrase: "DISCUSSION TOP ABSTRACT INTRODUCTION RESEARCH DESIGN"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   827   C0035171:Research Design [Research Activity]
   799   C0035168:research [Research Activity]
   799   C0242481:Research [Research Activity]
   799   C1707689:Design [Activity]
   799   C2983265:DESIGN [Intellectual Product]

Phrase: "AND"

Phrase: "METHODS RESULTS DISCUSSION"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0557061:Discussion [Therapeutic or Preventive Procedure]
   827   C2584313:Discussion [Social Behavior]

Phrase: "REFERENCES"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1514811:Reference [Idea or Concept]
  1000   C1706462:Reference [Conceptual Entity]

Phrase: "Interactions between genes"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   824   C0596610:gene interaction [Genetic Function]
   756   C1704675:Interaction [Functional Concept]

Phrase: "and"

Phrase: "environment"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0014406:Environment [Spatial Concept]

Phrase: "are"

Phrase: "critical in the susceptibility"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C1511545:Critical [Qualitative Concept]

Phrase: "to several human diseases"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
   827   C0012634:Diseases [Disease or Syndrome]
   755 E C1836721:MALS [Finding]
   755 E C3538764:MALS [Gene or Genome]
   755 E C3540595:MAL [Gene or Genome]

Phrase: ";"
Processing 00000000.tx.256: among these, diabetes is certainly one in which the "genetic versus acquired" debate proves to be extremely complex. 

Phrase: "among these,"

Phrase: "diabetes"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0011847:Diabetes [Disease or Syndrome]
  1000   C0011849:Diabetes [Disease or Syndrome]

Phrase: "is"

Phrase: "certainly one in which"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0205447:One [Quantitative Concept]

Phrase: "the ""genetic"
Meta Candidates (Total=16; Excluded=14; Pruned=0; Remaining=2)
  1000   C0017296:GENETIC [Therapeutic or Preventive Procedure]
  1000   C0314603:Genetic [Functional Concept]
   944 E C0005615:Birth [Organism Function]
   944 E C0035150:Reproduction [Organism Function]
   944 E C0079946:origin [Classification]
   944 E C0439659:Origin [Temporal Concept]
   944 E C1550512:origin [Intellectual Product]
   944 E C1550722:birth [Idea or Concept]
   944 E C3245487:birth [Intellectual Product]
   916 E C0454729:Natal [Geographic Area]
   916 E C0559522:Genital [Body System]
   916 E C1546649:Genital [Intellectual Product]
   916 E C1550642:Genital [Body Substance]
   907 E C0205313:Original [Idea or Concept]
   907 E C2347409:Original [Occupational Activity]
   888 E C0598240:originality [Mental Process]

Phrase: "versus"

Phrase: "acquired"" debate"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0870392:debate [Activity]

Phrase: "proves"

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "be"

Phrase: "extremely complex."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0439855:Complex [Qualitative Concept]
   861   C1704241:Complex [Chemical Viewed Structurally]
Processing 00000000.tx.257: The CD38 molecule was first suspected to be a mediator of insulin secretion in 1993 (11), in virtue of its multiple enzymatic activities, which are unique in leading to synthesis and degradation of cADPR (9). 

Phrase: "The CD38 molecule"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C0075742:CD38 molecule [Amino Acid, Peptide, or Protein,Enzyme,Immunologic Factor]
  1000   C1413221:CD38 molecule [Gene or Genome]
   861   C0567416:Molecule [Substance]
   789 E C1521991:Molecular [Qualitative Concept]

Phrase: "was"

Phrase: "first"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0205435:First [Quantitative Concept]
  1000   C1279901:First [Qualitative Concept]

Phrase: "suspected"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0332147:Suspected [Qualitative Concept]
  1000   C0750491:Suspected [Idea or Concept]
   966 E C1571873:Suspect [Idea or Concept]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "be"

Phrase: "a mediator of insulin secretion"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C1363844:Mediator [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "in 1993"

Phrase: "(11"

Phrase: ")"

Phrase: ","

Phrase: "in virtue"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0042764:Virtue [Idea or Concept]
   928 E C1553497:virtual [Intellectual Product]

Phrase: "of its multiple enzymatic activities,"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   884   C2267219:Enzymatic Activity [Molecular Function]
   827   C0441655:Activities [Activity]
   793 E C0205177:Activity [Functional Concept]
   793 E C0439167:% activity [Quantitative Concept]
   793 E C1561536:*Activity [Idea or Concept]

Phrase: "which"

Phrase: "are"

Phrase: "unique in"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   833   C1710548:Unique [Qualitative Concept]

Phrase: "leading to synthesis"
Meta Candidates (Total=8; Excluded=4; Pruned=0; Remaining=4)
   790   C0220781:synthesis [Biologic Function]
   790   C0332152:Leading [Temporal Concept]
   790   C1522538:Leading [Functional Concept]
   790   C1883254:Synthesis [Activity]
   756 E C0023175:???lead [Element, Ion, or Isotope,Hazardous or Poisonous Substance]
   756 E C1442948:lead [Inorganic Chemical,Pharmacologic Substance]
   756 E C2348269:Lead [Element, Ion, or Isotope]
   756 E C3275067:LEAD [Therapeutic or Preventive Procedure]

Phrase: "and"

Phrase: "degradation of cADPR"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   797   C1158076:ADP degradation [Molecular Function]
   760   C0243125:degradation [Functional Concept]
   760   C0699900:Degradation [Organism Function]

Phrase: "(9"

Phrase: ")."
Processing 00000000.tx.258: Since then, attention has shifted from physiology to pathology, as selected populations of diabetic patients (mainly type 2 and, to a lesser extent, type 1) have proved to carry a defective CD38 gene on the one side (14) and autoreactive antibodies targeting the molecule on the other (15,16). 

Phrase: "Since then,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1711239:Since [Temporal Concept]
   861   C1883708:Then [Temporal Concept]

Phrase: "attention"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0004268:Attention [Mental Process]

Phrase: "has"

Phrase: "shifted from physiology"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
   790   C0031842:Physiology [Biomedical Occupation or Discipline]
   790   C0031843:physiology [Physiologic Function]
   790   C0333051:shifted [Functional Concept]
   756 E C2347509:Shift [Phenomenon or Process]
   718 E C0205463:Physiologic [Functional Concept]

Phrase: "to pathology,"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C0030664:Pathology [Biomedical Occupation or Discipline]
  1000   C0205469:pathology [Functional Concept]
  1000   C0677042:pathology [Pathologic Function]
   928 E C1521733:Pathologic [Functional Concept]

Phrase: "as"

Phrase: "selected populations of diabetic patients"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0032659:Population [Quantitative Concept]
   760   C1257890:Population [Population Group]

Phrase: "(mainly type 2"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   901   C0441730:Type 2 [Classification]
   827   C0332307:Type [Qualitative Concept]
   827   C1547052:*Type [Quantitative Concept]

Phrase: "and"

Phrase: ","

Phrase: "to a lesser extent,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0439792:Extent [Spatial Concept]

Phrase: "type 1"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0441729:Type 1 [Classification]
   861   C0332307:Type [Qualitative Concept]
   861   C1547052:*Type [Quantitative Concept]

Phrase: ")"

Phrase: "have"

Phrase: "proved"

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "carry"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0206243:Carry [Activity]
  1000   C0699809:carry [Finding]

Phrase: "a defective CD38 gene on the one side"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C1413221:CD38 gene [Gene or Genome]
   767   C0079429:A Gene [Gene or Genome]
   744   C0017337:Gene [Gene or Genome]

Phrase: "(14"

Phrase: ")"

Phrase: "and"

Phrase: "autoreactive antibodies"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0003241:Antibodies [Amino Acid, Peptide, or Protein,Cell Component,Immunologic Factor]
   827 E C0021027:Antibody [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]

Phrase: "targeting"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1521840:Targeting [Functional Concept]
   966 E C2986546:TARGET [Diagnostic Procedure]

Phrase: "the molecule on the"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0567416:Molecule [Substance]

Phrase: "other"

Phrase: "(15,"

Phrase: "16"

Phrase: ")."
Processing 00000000.tx.259: The aim of this study was to elucidate immunological and genetic issues concerning human CD38 in diabetes among Caucasian individuals, who until now have been evaluated only in terms of anti-CD38 autoreactivity (16). 

Phrase: "The aim of this study"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   760   C1947946:Aim [Idea or Concept]
   760   C2948600:Aim [Pharmacologic Substance]
   760   C3540471:AIM [Gene or Genome]
   760   C3540472:AIM [Functional Concept]

Phrase: "was"

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "elucidate"

Phrase: "immunological"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205470:Immunological [Functional Concept]

Phrase: "and"

Phrase: "genetic issues"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0033213:Issue [Finding]
   827   C1706387:Issue [Intellectual Product]

Phrase: "concerning"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C2699424:Concern [Idea or Concept]

Phrase: "human CD38 in diabetes"

Phrase: "among Caucasian individuals,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0027361:Individual [Population Group]
   827   C0237401:Individual [Human]

Phrase: "who"

Phrase: "until"

Phrase: "now"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1948052:Now [Temporal Concept]

Phrase: "have"

Phrase: "been"

Phrase: "evaluated"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0220825:Evaluated [Functional Concept]

Phrase: "only in terms of anti-CD38 autoreactivity"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   748   C0205171:Only [Quantitative Concept]
   748   C1720467:Only [Intellectual Product]
   714   C1515273:Term [Temporal Concept]
   714   C1705313:Term [Idea or Concept]
   714   C2826302:TERM [Intellectual Product]

Phrase: "(16"

Phrase: ")."
Processing 00000000.tx.260: A second related aim was the development of a more convenient screening test for anti-CD38 aAbs. 

Phrase: "A second related aim"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   827   C1947946:Aim [Idea or Concept]
   827   C2948600:Aim [Pharmacologic Substance]
   827   C3540471:AIM [Gene or Genome]
   827   C3540472:AIM [Functional Concept]

Phrase: "was"

Phrase: "the development of a more convenient screening test"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   744   C0243107:development [Physiologic Function]
   744   C0678723:Development [Organism Function]
   744   C1527148:Development [Functional Concept]

Phrase: "for anti-CD38 aAbs."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0004358:Autoantibodies [Amino Acid, Peptide, or Protein,Immunologic Factor]
Processing 00000000.tx.261: Using an EIA technique, 19.15% of type 1 and 16.67% of type 2 diabetic patients displayed anti-CD38 autoreactive antibodies in their sera, as opposed to a negligible proportion (0.892.08%) of healthy control subjects. 

Phrase: "Using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "an EIA technique,"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   827   C0449851:Technique [Functional Concept]
   743 E C0025664:techniques [Intellectual Product]

Phrase: "19.15% of type 1"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   806   C0441729:Type 1 [Classification]
   760   C0332307:Type [Qualitative Concept]
   760   C1547052:*Type [Quantitative Concept]

Phrase: "and"

Phrase: "16.67% of type 2 diabetic patients"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   778   C0441730:Type 2 [Classification]
   757   C1550335:Patient type [Classification]
   748   C0030705:Patients [Patient or Disabled Group]
   748   C0241863:DIABETIC [Finding]
   748   C0332307:Type [Qualitative Concept]
   748   C1547052:*Type [Quantitative Concept]

Phrase: "displayed"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0870432:displayed [Functional Concept]
   966 E C1705417:Display [Manufactured Object]

Phrase: "anti-CD38 autoreactive antibodies in their sera,"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   774   C1624602:Anti-Antibodies [Amino Acid, Peptide, or Protein,Immunologic Factor]
   757 E C0003242:anti antibody [Amino Acid, Peptide, or Protein,Immunologic Factor]
   748   C0003241:Antibodies [Amino Acid, Peptide, or Protein,Cell Component,Immunologic Factor]
   714 E C0021027:Antibody [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]

Phrase: "as"

Phrase: "opposed to a negligible proportion"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0332269:Negligible [Qualitative Concept]
   760   C1709707:Proportion [Quantitative Concept]

Phrase: "(0.892.08%"

Phrase: ")"

Phrase: "of healthy control subjects."
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   913   C1708335:HEALTHY SUBJECTS [Population Group]
   793   C0681850:Subject [Group]
   793   C1550501:{Subject} [Idea or Concept]
   793   C1706203:Subject [Idea or Concept]
   793   C2349001:Subject [Human]
   793   C2697811:Subject [Functional Concept]
   734   C2986479:Healthy Control [Qualitative Concept]
Processing 00000000.tx.262: Prevalences obtained with the EIA technique are very similar to those reported by Ikehata et al. 

Phrase: "Prevalences"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0033105:Prevalences [Quantitative Concept]
   966 E C0220900:prevalence [Quantitative Concept]

Phrase: "obtained with the EIA technique"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   753   C0020980:Immunoassay [Laboratory Procedure]
   753   C0021060:immunoassay [Laboratory Procedure]
   753   C0449851:Technique [Functional Concept]
   753   C1301820:Obtained [Functional Concept]
   719 E C1706701:Obtain [Activity]

Phrase: "are"

Phrase: "very similar to those"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C2348205:Similar [Qualitative Concept]

Phrase: "reported by Ikehata et al."
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   806   C1709908:Reported By [Group]
   760   C0684224:Reported [Intellectual Product]
   760   C0700287:Reported [Health Care Activity]
   760   C3496591:Reported [Clinical Attribute]
   726 E C3273238:Report [Intellectual Product]
Processing 00000000.tx.263: (15) in Japanese type 2 diabetic subjects (13.8%) and by Pupilli et al. 

Phrase: "(15"

Phrase: ")"

Phrase: "in Japanese type 2 diabetic subjects"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   771   C0681850:Subject [Group]
   771   C1550501:{Subject} [Idea or Concept]
   771   C1706203:Subject [Idea or Concept]
   771   C2349001:Subject [Human]
   771   C2697811:Subject [Functional Concept]

Phrase: "(13.8%"

Phrase: ")"

Phrase: "and by Pupilli et al."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C1515981:And [Idea or Concept]
Processing 00000000.tx.264: (16) in Caucasian type 2 (9.7%) and type 1 (13.1%) diabetic patients, although the higher sensitivity intrinsic to the EIA technique as compared with the Western blot gave a slightly larger proportion of anti-CD38+ samples in our study. 

Phrase: "(16"

Phrase: ")"

Phrase: "in Caucasian type 2"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   901   C0441730:Type 2 [Classification]
   827   C0007457:Caucasian [Population Group]
   827   C0043157:Caucasian [Population Group]
   827   C0332307:Type [Qualitative Concept]
   827   C1547052:*Type [Quantitative Concept]

Phrase: "(9.7%"

Phrase: ")"

Phrase: "and"

Phrase: "type 1"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0441729:Type 1 [Classification]
   861   C0332307:Type [Qualitative Concept]
   861   C1547052:*Type [Quantitative Concept]

Phrase: "(13.1%"

Phrase: ")"

Phrase: "diabetic patients,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]

Phrase: "although"

Phrase: "the higher sensitivity"
Meta Candidates (Total=10; Excluded=2; Pruned=0; Remaining=8)
   983   C1441604:High sensitivity [Laboratory Procedure]
   861   C0036667:Sensitivity [Quantitative Concept]
   861   C0312418:Sensitivity [Mental Process]
   861   C0427965:Sensitivity [Finding]
   861   C1511883:Sensitivity [Quantitative Concept]
   861   C1522640:Sensitivity [Qualitative Concept]
   861   C2346484:SENSITIVITY [Phenomenon or Process]
   861   C2349185:Sensitivity [Qualitative Concept]
   789 E C0332324:Sensitive [Functional Concept]
   789 E C1550474:sensitive [Idea or Concept]

Phrase: "intrinsic to the EIA technique"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0205102:Intrinsic [Spatial Concept]
   753   C0439674:Intrinsic [Functional Concept]

Phrase: "as"

Phrase: "compared with the Western blot"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   806   C0005863:Western Blot [Laboratory Procedure,Molecular Biology Research Technique]
   806   C0949466:Western Blot [Laboratory Procedure]
   760   C1705493:Western [Spatial Concept]
   760   C1707455:Compared [Activity]

Phrase: "gave"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1947971:Give [Functional Concept]

Phrase: "a slightly larger proportion of anti-CD38+ samples"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   744   C1709707:Proportion [Quantitative Concept]

Phrase: "in our study."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0557651:Study [Manufactured Object]
  1000   C2603343:Study [Research Activity]
Processing 00000000.tx.265: The assay also proved reliable in terms of reproducibility and specificity, as assessed by preadsorption experiments and by the conventional Western blot approach. 

Phrase: "The assay also"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0005507:Assay [Laboratory Procedure]
   861   C0243073:assay [Qualitative Concept]
   861   C1510438:Assay [Laboratory Procedure]

Phrase: "proved"

Phrase: "reliable in terms of reproducibility"

Phrase: "and"

Phrase: "specificity,"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
  1000   C0037791:Specificity [Quantitative Concept]
  1000   C1511884:Specificity [Quantitative Concept]
   928 E C0205369:Specific [Qualitative Concept]
   928 E C1552740:specific [Intellectual Product]

Phrase: "as"

Phrase: "assessed by preadsorption experiments"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   770   C0681814:Experiments [Research Activity]
   770   C1516048:Assessed [Activity]
   737 E C1706386:Experiment [Conceptual Entity]

Phrase: "and by the conventional Western blot approach."
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   778   C0005863:Western Blot [Laboratory Procedure,Molecular Biology Research Technique]
   778   C0949466:Western Blot [Laboratory Procedure]
   748   C0439858:Conventional [Qualitative Concept]
   748   C0449445:Approach [Spatial Concept]
   748   C1515981:And [Idea or Concept]
   748   C1705493:Western [Spatial Concept]
Processing 00000000.tx.266: The EIA method presents some advantages over the Western blot assaythe latter exploits immobilized rsCD38 as the target molecule, but the protein is denatured by the electrophoresis in SDS. 

Phrase: "The EIA method"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   901   C0020980:Immunoassay method [Laboratory Procedure]
   827   C0025663:Method [Intellectual Product]
   827   C0449851:Method [Functional Concept]
   827   C0871511:METHOD [Intellectual Product]

Phrase: "presents"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0150312:Present [Quantitative Concept]
  1000   C0449450:Present [Idea or Concept]

Phrase: "some advantages over the Western blot assaythe latter exploits"

Phrase: "immobilized"

Phrase: "rsCD38 as the target molecule,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   774   C0075742:CD38 molecule [Amino Acid, Peptide, or Protein,Enzyme,Immunologic Factor]
   774   C1413221:CD38 molecule [Gene or Genome]

Phrase: "but"

Phrase: "the protein"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "is"

Phrase: "denatured by the electrophoresis"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0013855:Electrophoresis [Laboratory Procedure]

Phrase: "in SDS."
Processing 00000000.tx.267: Consequently, only aAbs recognizing linear epitopes can bind, whereas this is not the case for aAbs against conformational epitopes. 

Phrase: "Consequently,"

Phrase: "only aAbs"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0004358:Autoantibodies [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: "recognizing"

Phrase: "linear epitopes"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0003316:Epitopes [Immunologic Factor]

Phrase: "can"

Phrase: "bind"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1145667:Bind [Activity]
  1000   C1167622:bind [Molecular Function]

Phrase: ","

Phrase: "whereas"

Phrase: "this"

Phrase: "is"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "the case for aAbs"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0868928:Case [Functional Concept]
   770   C1706255:CASE [Medical Device]
   770   C1706256:Case [Conceptual Entity]

Phrase: "against conformational epitopes."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0003316:Epitopes [Immunologic Factor]
Processing 00000000.tx.268: Apart from the higher sensitivity of EIA, the Western blot used in the two previous studies could therefore have led to an underestimation of the prevalence of anti-CD38 aAbs. 

Phrase: "Apart from the higher sensitivity"
Meta Candidates (Total=10; Excluded=2; Pruned=0; Remaining=8)
   983   C1441604:High sensitivity [Laboratory Procedure]
   861   C0036667:Sensitivity [Quantitative Concept]
   861   C0312418:Sensitivity [Mental Process]
   861   C0427965:Sensitivity [Finding]
   861   C1511883:Sensitivity [Quantitative Concept]
   861   C1522640:Sensitivity [Qualitative Concept]
   861   C2346484:SENSITIVITY [Phenomenon or Process]
   861   C2349185:Sensitivity [Qualitative Concept]
   789 E C0332324:Sensitive [Functional Concept]
   789 E C1550474:sensitive [Idea or Concept]

Phrase: "of EIA,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0020980:Immunoassay [Laboratory Procedure]
   861   C0021060:immunoassay [Laboratory Procedure]

Phrase: "the Western blot"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0005863:Western Blot [Laboratory Procedure,Molecular Biology Research Technique]
  1000   C0949466:Western Blot [Laboratory Procedure]
   861   C1705493:Western [Spatial Concept]

Phrase: "used in the two previous studies"
Meta Candidates (Total=11; Excluded=5; Pruned=0; Remaining=6)
   767   C0869040:Use studies [Research Activity]
   753   C0205156:Previous [Temporal Concept]
   753   C0205448:Two [Quantitative Concept]
   753   C0947630:studies [Laboratory Procedure]
   753   C1273517:used [Finding]
   753   C1552607:previous [Temporal Concept]
   719 E C0042153:use [Functional Concept]
   719 E C0457083:Use [Functional Concept]
   719 E C0557651:Study [Manufactured Object]
   719 E C1947944:Use [Intellectual Product]
   719 E C2603343:Study [Research Activity]

Phrase: "could"

Phrase: "therefore"

Phrase: "have"

Phrase: "led to an underestimation of the prevalence of anti-CD38 aAbs."
Meta Candidates (Total=9; Excluded=5; Pruned=0; Remaining=4)
   738   C0004358:Autoantibodies [Amino Acid, Peptide, or Protein,Immunologic Factor]
   738   C0033105:Prevalence [Quantitative Concept]
   738   C0220900:prevalence [Quantitative Concept]
   738   C1708698:LED [Manufactured Object]
   704 E C0023175:???lead [Element, Ion, or Isotope,Hazardous or Poisonous Substance]
   704 E C1442948:lead [Inorganic Chemical,Pharmacologic Substance]
   704 E C1522538:Lead [Functional Concept]
   704 E C2348269:Lead [Element, Ion, or Isotope]
   704 E C3275067:LEAD [Therapeutic or Preventive Procedure]
Processing 00000000.tx.269: A potential for further underestimation, unavoidable in both approaches, derives from the rsCD38 target molecules used in both the EIA (rsCD38 deprived of the putative sites of glycosylation) and the Western blot (CD38-maltose binding protein fusion protein) techniques (15,16). 

Phrase: "A potential for further underestimation,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C3245505:Potential [Qualitative Concept]

Phrase: "unavoidable in both approaches,"

Phrase: "derives from the rsCD38 target molecules"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   750   C0075742:CD38 molecule [Amino Acid, Peptide, or Protein,Enzyme,Immunologic Factor]
   750   C1413221:CD38 molecule [Gene or Genome]
   744   C0567416:molecules [Substance]
   744   C1514798:recombinant [Organism]
   744   C1521840:Target [Functional Concept]
   744   C1749467:soluble [Cell Component]
   744   C1948047:Soluble [Qualitative Concept]
   744   C2986546:TARGET [Diagnostic Procedure]
   725   C1513403:Molecular Target [Chemical Viewed Functionally,Chemical Viewed Structurally]

Phrase: "used in both"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
   790   C1273517:used [Finding]
   756 E C0042153:use [Functional Concept]
   756 E C0457083:Use [Functional Concept]
   756 E C1947944:Use [Intellectual Product]

Phrase: "the EIA"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0020980:Immunoassay [Laboratory Procedure]
   861   C0021060:immunoassay [Laboratory Procedure]

Phrase: "(rsCD38"

Phrase: "deprived of the putative sites of glycosylation"
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
   757   C2945843:Site of [Qualitative Concept]
   748   C0017982:glycosylation [Natural Phenomenon or Process]
   748   C0205145:Sites [Spatial Concept]
   748   C0376322:Glycosylation [Molecular Function]
   714 E C1515974:Site [Body Location or Region]
   714 E C2825164:Site [Spatial Concept]

Phrase: ")"

Phrase: "and"

Phrase: "the Western blot"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0005863:Western Blot [Laboratory Procedure,Molecular Biology Research Technique]
  1000   C0949466:Western Blot [Laboratory Procedure]
   861   C1705493:Western [Spatial Concept]

Phrase: "(CD38-maltose binding protein fusion protein"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0162768:Fusion protein [Amino Acid, Peptide, or Protein,Neuroreactive Substance or Biogenic Amine]
   799   C0332466:Fusion [Functional Concept]
   799   C1293131:Fusion [Therapeutic or Preventive Procedure]

Phrase: ")"

Phrase: "techniques"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0025664:techniques [Intellectual Product]
  1000   C0449851:Techniques [Functional Concept]

Phrase: "(15,"

Phrase: "16"

Phrase: ")."
Processing 00000000.tx.270: The glycosylation is important for mAb binding; 

Phrase: "The glycosylation"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0017982:glycosylation [Natural Phenomenon or Process]
  1000   C0376322:Glycosylation [Molecular Function]

Phrase: "is"

Phrase: "important for mAb binding"

Phrase: ";"
Processing 00000000.tx.271: indeed, glycosylation of both proteins is different from that of native human CD38, in which oligosaccharide residues account for 25% of the molecular weight (30). 

Phrase: "indeed,"

Phrase: "glycosylation of both proteins"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   819   C0376322:glycosylation proteins [Molecular Function]
           Glycosylation
   770   C0017982:glycosylation [Natural Phenomenon or Process]

Phrase: "is"

Phrase: "different from that of native human CD38,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C1705242:Different [Qualitative Concept]

Phrase: "in which oligosaccharide residues"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   827   C1709915:Residue [Conceptual Entity]
   827   C1882936:RESIDUE [Phenomenon or Process]
   777 E C1609982:Residual [Qualitative Concept]

Phrase: "account for 25% of the molecular weight"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   778   C0026385:Molecular Weight [Quantitative Concept]
   748   C0005910:weight [Organism Attribute]
   748   C0043100:Weight [Quantitative Concept]
   748   C1305866:weight [Diagnostic Procedure]
   748   C1521991:Molecular [Qualitative Concept]
   748   C1551359:account [Idea or Concept]
   748   C1705104:Weight [Idea or Concept]
   748   C2741673:Account # [Clinical Attribute]
   748   C2981730:Account [Classification]

Phrase: "(30"

Phrase: ")."
Processing 00000000.tx.272: Moreover, the different molecular weight of CD38 expressed in human islet cells (48 vs. the conventional 45 kDa), possibly resulting from an alternative pattern of glycosylation, may lead to a different antigenic recognition pattern of the protein expressed in this tissue (R.M. and M. Volante, unpublished observations). 

Phrase: "Moreover,"

Phrase: "the different molecular weight of CD38"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   790   C0026385:Molecular Weight [Quantitative Concept]
   753   C0005910:weight [Organism Attribute]
   753   C0043100:Weight [Quantitative Concept]
   753   C1305866:weight [Diagnostic Procedure]
   753   C1521991:Molecular [Qualitative Concept]
   753   C1705104:Weight [Idea or Concept]
   748   C0075742:CD38 molecule [Amino Acid, Peptide, or Protein,Enzyme,Immunologic Factor]
   748   C1413221:CD38 molecule [Gene or Genome]

Phrase: "expressed in human islet cells"
Meta Candidates (Total=9; Excluded=4; Pruned=0; Remaining=5)
   806   C0022131:Islet Cells [Body Part, Organ, or Organ Component]
   797   C0427861:Human cells [Laboratory or Test Result]
   773 E C1522529:Islet Cell [Cell]
   760   C0007634:Cells [Cell]
   760   C0086418:Human [Human]
   760   C3282337:Cells [Cell]
   726 E C1269647:Cell [Cell]
   726 E C1704653:Cell [Medical Device]
   726 E C1948049:Cell [Spatial Concept]

Phrase: "(48"

Phrase: "vs."

Phrase: "the conventional 45 kDa"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C1532717:kDa [Quantitative Concept]

Phrase: ")"

Phrase: ","

Phrase: "possibly"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2362652:Possibly [Qualitative Concept]

Phrase: "resulting from an alternative pattern of glycosylation,"
Meta Candidates (Total=8; Excluded=3; Pruned=0; Remaining=5)
   748   C0017982:glycosylation [Natural Phenomenon or Process]
   748   C0376322:Glycosylation [Molecular Function]
   748   C0449774:Pattern [Spatial Concept]
   748   C0678226:resulting [Functional Concept]
   748   C1523987:Alternative [Conceptual Entity]
   714 E C1274040:Result [Functional Concept]
   714 E C1546471:Result [Idea or Concept]
   714 E C2825142:Result [Finding]

Phrase: "may"

Phrase: "lead to a different antigenic recognition pattern of the protein"
Meta Candidates (Total=14; Excluded=0; Pruned=0; Remaining=14)
   757   C0038164:Protein A [Amino Acid, Peptide, or Protein,Immunologic Factor,Indicator, Reagent, or Diagnostic Aid]
   757   C1317658:Protein pattern [Clinical Attribute]
   757   C1518918:Pattern Recognition [Mental Process]
   739   C0023175:???lead [Element, Ion, or Isotope,Hazardous or Poisonous Substance]
   739   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   739   C0449774:Pattern [Spatial Concept]
   739   C0524637:Recognition [Mental Process]
   739   C1442948:lead [Inorganic Chemical,Pharmacologic Substance]
   739   C1522538:Lead [Functional Concept]
   739   C1705242:Different [Qualitative Concept]
   739   C2348269:Lead [Element, Ion, or Isotope]
   739   C3275067:LEAD [Therapeutic or Preventive Procedure]
   724   C0678894:antigen recognition [Organ or Tissue Function]
   722   C1291777:Protein antigen [Immunologic Factor]

Phrase: "expressed in this tissue"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0040300:Tissue [Tissue]
   770   C1547928:Tissue [Intellectual Product]

Phrase: "(R.M."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0694746:r m [Immunologic Factor,Pharmacologic Substance]
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "and"

Phrase: "M. Volante,"

Phrase: "unpublished observations"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
   861   C0302523:observations [Research Activity]
   861   C0700325:observations [Health Care Activity]
   861   C3244290:observations [Functional Concept]
   827 E C1964257:Observation [Diagnostic Procedure]
   777 E C1518527:OBSERVATIONAL [Research Activity]

Phrase: ")."
Processing 00000000.tx.273: Another pitfall shared by both approaches could derive from in vivo binding of aAbs to circulating soluble forms of CD38 (31,32); 

Phrase: "Another pitfall"

Phrase: "shared by both approaches"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   770   C0237876:shared [Social Behavior]
   770   C0449445:Approaches [Spatial Concept]
   770   C1292724:Approaches [Functional Concept]
   770   C1522138:Shared [Functional Concept]

Phrase: "could"

Phrase: "derive from in vivo binding of aAbs"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   778   C1515655:In Vivo [Spatial Concept]
           vivo
   748   C0004358:Autoantibodies [Amino Acid, Peptide, or Protein,Immunologic Factor]
   748   C0243122:binding [Functional Concept]
   748   C1145667:Binding [Activity]
   748   C1167622:Binding [Molecular Function]

Phrase: "to circulating soluble forms"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   827   C0348078:forms [Qualitative Concept]
   827   C0376315:Forms [Manufactured Object]
   793 E C1522492:Form [Functional Concept]

Phrase: "of CD38"

Phrase: "(31,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0450355:31 [Intellectual Product]

Phrase: "32"

Phrase: ")"

Phrase: ";"
Processing 00000000.tx.274: these molecular species could subsequently compete with the target proteins used in the assays. 

Phrase: "these molecular species"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1705920:Species [Conceptual Entity]

Phrase: "could"

Phrase: "subsequently"

Phrase: "compete with the target proteins"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   781   C1159372:protein target [Molecular Function]
   760   C0033684:Proteins [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   760   C1521840:Target [Functional Concept]
   760   C2986546:TARGET [Diagnostic Procedure]

Phrase: "used in the assays."
Meta Candidates (Total=7; Excluded=3; Pruned=0; Remaining=4)
   770   C1273517:used [Finding]
   737   C0005507:Assay [Laboratory Procedure]
   737 E C0042153:use [Functional Concept]
   737   C0243073:assay [Qualitative Concept]
   737 E C0457083:Use [Functional Concept]
   737   C1510438:Assay [Laboratory Procedure]
   737 E C1947944:Use [Intellectual Product]
Processing 00000000.tx.275: The EIA technique developed for this study might constitute a valuable routine test for the screening of anti-CD38 aAbs. 

Phrase: "The EIA technique"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   827   C0449851:Technique [Functional Concept]
   743 E C0025664:techniques [Intellectual Product]

Phrase: "developed for this study"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0557651:Study [Manufactured Object]
   770   C2603343:Study [Research Activity]

Phrase: "might"

Phrase: "constitute"

Phrase: "a valuable routine test for the screening of anti-CD38 aAbs."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   754   C0871311:screening test [Health Care Activity]
   754   C1272321:autoantibodies test [Laboratory Procedure]
   738   C0022885:Test [Laboratory Procedure]
   738   C0039593:Test [Functional Concept]
   738   C0392366:test [Intellectual Product]
Processing 00000000.tx.276: Although matching control subjects with type 2 diabetic patients was not optimal for age, this is unlikely to have determined major bias. 

Phrase: "Although"

Phrase: "matching control subjects with type 2 diabetic patients"
Meta Candidates (Total=12; Excluded=0; Pruned=0; Remaining=12)
   767   C1707504:Control Type [Research Activity]
   767   C1879930:Control Type [Intellectual Product]
   744   C0243148:control [Qualitative Concept]
   744   C1550141:Control [Substance]
   744   C1882979:Control [Conceptual Entity]
   744   C2587213:Control [Functional Concept]
   744   C3274648:Control [Qualitative Concept]
   711   C0681850:Subject [Group]
   711   C1550501:{Subject} [Idea or Concept]
   711   C1706203:Subject [Idea or Concept]
   711   C2349001:Subject [Human]
   711   C2697811:Subject [Functional Concept]

Phrase: "was"

Phrase: "not optimal for age,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C2698651:Optimal [Qualitative Concept]

Phrase: "this"

Phrase: "is"

Phrase: "unlikely to"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0750558:Unlikely [Conceptual Entity]
   861   C1710571:Unlikely [Qualitative Concept]

Phrase: "have"

Phrase: "determined major bias."
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   827   C0242568:Bias [Idea or Concept]
   827   C1504315:Bias [Bird]
   793 E C1061346:Bia [Eukaryote]
   793 E C1704746:BIA [Diagnostic Procedure]
Processing 00000000.tx.277: Prevalence of various autoreactive antibodies increases up to fourfold in healthy nonagenarians as compared with middle-aged control subjects (33). 

Phrase: "Prevalence of various autoreactive antibodies"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0033105:Prevalence [Quantitative Concept]
   760   C0220900:prevalence [Quantitative Concept]

Phrase: "increases up to fourfold"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   770   C0442805:Increase [Functional Concept]
   715 E C1517378:Gain [Quantitative Concept]

Phrase: "in healthy nonagenarians"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0028296:Nonagenarians [Age Group]

Phrase: "as"

Phrase: "compared with middle-aged control subjects"
Meta Candidates (Total=20; Excluded=1; Pruned=0; Remaining=19)
   790   C0205847:Middle Aged [Age Group]
   773 E C0026062:Middle Age [Temporal Concept]
   753   C0001779:Aged [Organism Attribute]
   753   C0001792:Aged [Population Group]
   753   C0243148:control [Qualitative Concept]
   753   C0444598:Middle [Spatial Concept]
   753   C0549183:middle [Spatial Concept]
   753   C1550141:Control [Substance]
   753   C1552826:middle [Idea or Concept]
   753   C1707455:Compared [Activity]
   753   C1882979:Control [Conceptual Entity]
   753   C1999167:aged [Population Group]
   753   C2587213:Control [Functional Concept]
   753   C3274648:Control [Qualitative Concept]
   750   C2348575:Subject Age [Organism Attribute]
   719   C0681850:Subject [Group]
   719   C1550501:{Subject} [Idea or Concept]
   719   C1706203:Subject [Idea or Concept]
   719   C2349001:Subject [Human]
   719   C2697811:Subject [Functional Concept]

Phrase: "(33"

Phrase: ")."
Processing 00000000.tx.278: Even if such an increase held true for anti-CD38 aAbs, the difference noted between diabetic patients and control subjects would have remained significant. 

Phrase: "Even"

Phrase: "if"

Phrase: "such an increase"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0442805:Increase [Functional Concept]

Phrase: "held"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
  1000   C1948036:held [Idea or Concept]
  1000   C2987518:hELD [Amino Acid, Peptide, or Protein]
   966 E C1553387:Hold [Idea or Concept]
   966 E C1948035:Hold [Activity]

Phrase: "true for anti-CD38 aAbs,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0205238:True [Qualitative Concept]

Phrase: "the difference"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C1705241:*Difference [Quantitative Concept]
  1000   C1705242:Difference [Qualitative Concept]
   928 E C0443199:Differential [Qualitative Concept]

Phrase: "noted between diabetic patients"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   786   C2360554:Patient Note [Clinical Attribute]
   770   C0030705:Patients [Patient or Disabled Group]
   770   C0241863:DIABETIC [Finding]
   737   C1316572:Note [Clinical Attribute]
   737   C1317574:Note [Intellectual Product]
   737   C1369612:Note [Clinical Attribute]

Phrase: "and"

Phrase: "control subjects"
Meta Candidates (Total=10; Excluded=0; Pruned=0; Remaining=10)
   861   C0243148:control [Qualitative Concept]
   861   C1550141:Control [Substance]
   861   C1882979:Control [Conceptual Entity]
   861   C2587213:Control [Functional Concept]
   861   C3274648:Control [Qualitative Concept]
   827   C0681850:Subject [Group]
   827   C1550501:{Subject} [Idea or Concept]
   827   C1706203:Subject [Idea or Concept]
   827   C2349001:Subject [Human]
   827   C2697811:Subject [Functional Concept]

Phrase: "would"

Phrase: "have"

Phrase: "remained"

Phrase: "significant."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0237881:significant [Quantitative Concept]
  1000   C0750502:Significant [Idea or Concept]
  1000   C1546944:Significant [Qualitative Concept]
Processing 00000000.tx.279: Moreover, preliminary results obtained in our laboratory indicate that the prevalence of anti-CD38 aAbs in nondiabetic nonagenarians is not significantly higher than that in younger individuals. 

Phrase: "Moreover,"

Phrase: "preliminary results"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C1548161:Preliminary results [Idea or Concept]
   827   C1274040:Result [Functional Concept]
   827   C1546471:Result [Idea or Concept]
   827   C2825142:Result [Finding]

Phrase: "obtained in our laboratory"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   770   C0022877:Laboratory [Manufactured Object,Organization]
   770   C1301820:Obtained [Functional Concept]
   770   C3244292:laboratory [Functional Concept]
   737 E C1706701:Obtain [Activity]

Phrase: "indicate"

Phrase: "that"

Phrase: "the prevalence of anti-CD38 aAbs"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0033105:Prevalence [Quantitative Concept]
   753   C0220900:prevalence [Quantitative Concept]

Phrase: "in nondiabetic nonagenarians"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0028296:Nonagenarians [Age Group]

Phrase: "is"

Phrase: "not significantly higher than that"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   726   C0205250:High [Qualitative Concept]
   726   C1299351:High [Qualitative Concept]
   726   C2700149:HIGH [Intellectual Product]

Phrase: "in younger individuals."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0027361:Individual [Population Group]
   827   C0237401:Individual [Human]
Processing 00000000.tx.280: The finding of such a high proportion of anti-CD38+ patients not only among type 1 but also among type 2 diabetic subjects is not surprising. 

Phrase: "The finding of such"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0037088:Finding [Sign or Symptom]
   770   C0243095:Finding [Finding]
   770   C2825141:Finding [Finding]

Phrase: "a high proportion of anti-CD38+ patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C1709707:Proportion [Quantitative Concept]

Phrase: "not only among type 1"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   806   C0441729:Type 1 [Classification]
   760   C0205171:Only [Quantitative Concept]
   760   C0332307:Type [Qualitative Concept]
   760   C1518422:Not [Functional Concept]
   760   C1547052:*Type [Quantitative Concept]
   760   C1720467:Only [Intellectual Product]

Phrase: "but"

Phrase: "also among type 2 diabetic subjects"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   790   C0441730:Type 2 [Classification]
   753   C0241863:DIABETIC [Finding]
   753   C0332307:Type [Qualitative Concept]
   753   C1547052:*Type [Quantitative Concept]
   719   C0681850:Subject [Group]
   719   C1550501:{Subject} [Idea or Concept]
   719   C1706203:Subject [Idea or Concept]
   719   C2349001:Subject [Human]
   719   C2697811:Subject [Functional Concept]

Phrase: "is"

Phrase: "not surprising."
Processing 00000000.tx.281: These patients may belong to a distinct subgroup similar to the latent autoimmune diabetes in the adult (LADA) subgroup (3436) for the autoimmune phenotype, but not for the clinical and metabolic characteristics. 

Phrase: "These patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "may"

Phrase: "belong to a distinct subgroup"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C1079230:subgroup [Virus]
   760   C1515021:Subgroup [Classification]

Phrase: "similar to the latent autoimmune diabetes in the adult (LADA) subgroup"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   739   C2348205:Similar [Qualitative Concept]

Phrase: "(3436"

Phrase: ")"

Phrase: "for the autoimmune phenotype,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0031437:Phenotype [Organism Attribute]
   861   C1285572:Phenotype [Laboratory Procedure]

Phrase: "but"

Phrase: "not for the clinical"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0205210:Clinical [Qualitative Concept]
   770   C1518422:Not [Functional Concept]

Phrase: "and"

Phrase: "metabolic characteristics."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1521970:Characteristics [Qualitative Concept]
Processing 00000000.tx.282: On the contrary, the association of anti-CD38 aAbs with higher fasting plasma C-peptide and insulin levels and higher BMI would suggest a phenotype opposite to that of LADA. 

Phrase: "On the contrary,"

Phrase: "the association of anti-CD38 aAbs"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   753   C0004083:Association [Mental Process]
   753   C0439849:Association [Qualitative Concept]
   753   C0596306:Association [Phenomenon or Process]
   753   C0699792:association [Social Behavior]

Phrase: "with higher fasting plasma C-peptide"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   840   C0006558:C-Peptide [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   804   C0030956:Peptide [Amino Acid, Peptide, or Protein]

Phrase: "and"

Phrase: "insulin levels"
Meta Candidates (Total=11; Excluded=5; Pruned=0; Remaining=6)
  1000   C0202098:insulin levels [Laboratory Procedure]
  1000   C0428405:insulin levels [Laboratory or Test Result]
   861   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C0441889:Levels [Qualitative Concept]
   861   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C1579433:Insulin [Pharmacologic Substance]
   827 E C0456079:Level [Classification]
   827 E C1547707:Level [Geographic Area]
   827 E C2946261:Level [Pharmacologic Substance]
   805 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   777 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "and"

Phrase: "higher BMI"

Phrase: "would"

Phrase: "suggest"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1705535:Suggest [Idea or Concept]

Phrase: "a phenotype opposite to that of LADA."
Meta Candidates (Total=11; Excluded=0; Pruned=0; Remaining=11)
   753   C0205734:Diabetes, Autoimmune [Disease or Syndrome]
   751   C0271650:Latent diabetes [Disease or Syndrome]
   736   C0001675:Adult [Age Group]
   736   C0011847:Diabetes [Disease or Syndrome]
   736   C0011849:Diabetes [Disease or Syndrome]
   736   C0031437:Phenotype [Organism Attribute]
   736   C0205275:Latent [Qualitative Concept]
   736   C0443146:Autoimmune [Pathologic Function]
   736   C1285572:Phenotype [Laboratory Procedure]
   736   C1521805:Opposite [Spatial Concept]
   736   C1706450:Adult [Human]
Processing 00000000.tx.283: The analysis of other conventional islet aAbs among anti-CD38+ and anti-CD38- patients will further clarify this issue. 

Phrase: "The analysis of other conventional islet aAbs"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   748   C0002778:Analysis [Laboratory Procedure]
   748   C0936012:Analysis [Research Activity]
   748   C1524024:analysis [Functional Concept]

Phrase: "among anti-CD38+"

Phrase: "and"

Phrase: "anti-CD38- patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0030705:Patients [Patient or Disabled Group]

Phrase: "will"

Phrase: "further"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1517331:Further [Spatial Concept]
   966 E C0205108:far [Spatial Concept]

Phrase: "clarify"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2986669:Clarify [Activity]

Phrase: "this issue."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0033213:Issue [Finding]
  1000   C1706387:Issue [Intellectual Product]
Processing 00000000.tx.284: Knowledge of whether these findings have a heuristic merit or a prognostic significance awaits results from ongoing evaluations of long-term complications of diabetes; 

Phrase: "Knowledge of"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   833   C0376554:Knowledge [Intellectual Product]

Phrase: "whether"

Phrase: "these findings"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
  1000   C2607943:findings [Functional Concept]
  1000   C2926606:Findings [Clinical Attribute]
  1000   C3539655:Findings [Intellectual Product]
   966 E C0037088:Finding [Sign or Symptom]
   966 E C0243095:Finding [Finding]
   966 E C2825141:Finding [Finding]

Phrase: "have"

Phrase: "a heuristic merit"

Phrase: "or"

Phrase: "a prognostic significance"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   861   C0237881:Significance [Quantitative Concept]
   861   C0750502:Significance [Idea or Concept]
   789 E C1546944:Significant [Qualitative Concept]

Phrase: "awaits"

Phrase: "results from ongoing evaluations of long-term complications of diabetes"
Meta Candidates (Total=19; Excluded=2; Pruned=0; Remaining=17)
   760   C0443252:Long-term [Temporal Concept]
   757   C0342257:Diabetes Complications [Pathologic Function]
   741   C1707704:EVALUATION RESULT [Idea or Concept]
   739   C0009566:Complications [Pathologic Function]
   739   C0011847:Diabetes [Disease or Syndrome]
   739   C0011849:Diabetes [Disease or Syndrome]
   739   C0205166:Long [Qualitative Concept]
   739   C0220825:Evaluations [Functional Concept]
   739   C0549178:ONGOING [Idea or Concept]
   739   C1171258:complications [Pathologic Function]
   739   C1274040:Result [Functional Concept]
   739   C1515273:Term [Temporal Concept]
   739   C1546471:Result [Idea or Concept]
   739   C1705313:Term [Idea or Concept]
   739   C1706317:Long [Qualitative Concept]
   739   C2825142:Result [Finding]
   739   C2826302:TERM [Intellectual Product]
   706 E C1261322:Evaluation [Health Care Activity]
   706 E C2362589:Complication [Idea or Concept]

Phrase: ";"
Processing 00000000.tx.285: further study may provide evidence in support of the use of anti-CD38 aAbs not only as a simple diagnostic marker of diabetes with autoimmune features, but also as a prognostic parameter for a particular course of the disease. 

Phrase: "further study"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0557651:Study [Manufactured Object]
   861   C2603343:Study [Research Activity]

Phrase: "may"

Phrase: "provide"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1999230:Provide [Activity]

Phrase: "evidence in support of the use of anti-CD38 aAbs"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   757   C0332120:Evidence of [Functional Concept]
           Evidence

Phrase: "not only as a simple diagnostic marker of diabetes"
Meta Candidates (Total=10; Excluded=0; Pruned=0; Remaining=10)
   764   C1511876:Diagnostic Marker [Clinical Attribute]
   742   C0005516:Marker [Clinical Attribute]
   742   C0011847:Diabetes [Disease or Syndrome]
   742   C0011849:Diabetes [Disease or Syndrome]
   742   C0011900:Diagnostic [Finding]
   742   C0205171:Only [Quantitative Concept]
   742   C0205352:Simple [Qualitative Concept]
   742   C0348026:Diagnostic [Functional Concept]
   742   C1518422:Not [Functional Concept]
   742   C1720467:Only [Intellectual Product]

Phrase: "with autoimmune features,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   827   C1521970:Feature [Qualitative Concept]
   827   C1706388:Feature [Conceptual Entity]
   827   C2346469:Feature [Qualitative Concept]
   827   C2348519:Feature [Qualitative Concept]

Phrase: "but"

Phrase: "also as a prognostic parameter"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   760   C0220901:prognostic [Intellectual Product]
   760   C0549193:Parameter [Spatial Concept]
   760   C1704769:Parameter [Conceptual Entity]
   760   C2350001:Parameter [Quantitative Concept]

Phrase: "for a particular course"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0750729:Course [Temporal Concept]

Phrase: "of the disease."
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C0012634:Disease [Disease or Syndrome]
   944 E C1836721:MALS [Finding]
   944 E C3538764:MALS [Gene or Genome]
   944 E C3540595:MAL [Gene or Genome]
Processing 00000000.tx.286: Taken together, these results also suggest that the scenario of autoimmunity in type 2 diabetes might be more heterogeneous than originally presumed. 

Phrase: "Taken"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1883727:Taken [Conceptual Entity]
   966 E C1515187:Take [Health Care Activity]

Phrase: "together,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883357:Together [Qualitative Concept]

Phrase: "these results also"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C1274040:Result [Functional Concept]
   827   C1546471:Result [Idea or Concept]
   827   C2825142:Result [Finding]

Phrase: "suggest"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1705535:Suggest [Idea or Concept]

Phrase: "that"

Phrase: "the scenario of autoimmunity"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0683579:scenario [Functional Concept]

Phrase: "in type 2 diabetes"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
  1000   C0011860:Type 2 Diabetes [Disease or Syndrome]
   913   C1320657:type diabetes [Finding]
   901   C0441730:Type 2 [Classification]
   827   C0011847:Diabetes [Disease or Syndrome]
   827   C0011849:Diabetes [Disease or Syndrome]
   827   C0332307:Type [Qualitative Concept]
   827   C1547052:*Type [Quantitative Concept]

Phrase: "might"

Phrase: "be"

Phrase: "more heterogeneous than originally"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0019409:Heterogeneous [Qualitative Concept]

Phrase: "presumed."
Processing 00000000.tx.287: Genetic analysis did not highlight any significant association between the CD38*A allele recently identified in healthy Caucasian individuals (17) and subjects with diabetes or anti-CD38 aAbs. 

Phrase: "Genetic analysis"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0679560:genetic analysis [Laboratory Procedure]
  1000   C0796344:Genetic Analysis [Laboratory Procedure]
   861   C0002778:Analysis [Laboratory Procedure]
   861   C0936012:Analysis [Research Activity]
   861   C1524024:analysis [Functional Concept]

Phrase: "did"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "highlight"

Phrase: "any significant association between the CD38"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   753   C0004083:Association [Mental Process]
   753   C0439849:Association [Qualitative Concept]
   753   C0596306:Association [Phenomenon or Process]
   753   C0699792:association [Social Behavior]

Phrase: "*"

Phrase: "A allele recently"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0002085:Allele [Gene or Genome]

Phrase: "identified in healthy Caucasian individuals"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   760   C0007457:Caucasian [Population Group]
   760   C0043157:Caucasian [Population Group]
   760   C0205396:Identified [Qualitative Concept]
   760   C1550043:Identified [Finding]
   760   C1551388:Identified [Functional Concept]
   726   C0027361:Individual [Population Group]
   726   C0237401:Individual [Human]

Phrase: "(17"

Phrase: ")"

Phrase: "and"

Phrase: "subjects with diabetes"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   790   C0011847:Diabetes [Disease or Syndrome]
   790   C0011849:Diabetes [Disease or Syndrome]
   790   C0681850:Subject [Group]
   790   C1550501:{Subject} [Idea or Concept]
   790   C1706203:Subject [Idea or Concept]
   790   C2349001:Subject [Human]
   790   C2697811:Subject [Functional Concept]

Phrase: "or"

Phrase: "anti-CD38 aAbs."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0004358:Autoantibodies [Amino Acid, Peptide, or Protein,Immunologic Factor]
Processing 00000000.tx.288: Also, the Arg140Trp mutation described in Japanese type 2 diabetic patients (14) was not detected among our screened patients, but it was identified in one healthy control subject. 

Phrase: "Also,"

Phrase: "the Arg140Trp mutation"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0026882:Mutation [Genetic Function]
   861   C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "described in Japanese type 2 diabetic patients"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   778   C0441730:Type 2 [Classification]
   757   C1550335:Patient type [Classification]
   748   C0030705:Patients [Patient or Disabled Group]
   748   C0241863:DIABETIC [Finding]
   748   C0332307:Type [Qualitative Concept]
   748   C1547052:*Type [Quantitative Concept]
   748   C1552738:described [Idea or Concept]
   748   C1556094:Japanese [Population Group]

Phrase: "(14"

Phrase: ")"

Phrase: "was"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "detected among our screened patients,"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   760   C0030705:Patients [Patient or Disabled Group]
   760   C0442726:Detected [Finding]
   760   C1511790:Detected [Therapeutic or Preventive Procedure]
   726   C0220908:screen [Health Care Activity]
   726   C1305399:screen [Functional Concept]
   726   C1705053:Screen [Medical Device]

Phrase: "but"

Phrase: "it"

Phrase: "was"

Phrase: "identified in one healthy control subject."
Meta Candidates (Total=16; Excluded=0; Pruned=0; Remaining=16)
   790   C2986479:Healthy Control [Qualitative Concept]
   783   C1708335:Healthy Subject [Population Group]
   753   C0205396:Identified [Qualitative Concept]
   753   C0205447:One [Quantitative Concept]
   753   C0243148:control [Qualitative Concept]
   753   C0681850:Subject [Group]
   753   C1550043:Identified [Finding]
   753   C1550141:Control [Substance]
   753   C1550501:{Subject} [Idea or Concept]
   753   C1551388:Identified [Functional Concept]
   753   C1706203:Subject [Idea or Concept]
   753   C1882979:Control [Conceptual Entity]
   753   C2349001:Subject [Human]
   753   C2587213:Control [Functional Concept]
   753   C2697811:Subject [Functional Concept]
   753   C3274648:Control [Qualitative Concept]
Processing 00000000.tx.289: This discrepancy can possibly be ascribed to the heterogeneity of the genetic background of diabetes in distant ethnic groups (37). 

Phrase: "This discrepancy"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1290905:Discrepancy [Finding]

Phrase: "can"

Phrase: "possibly"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2362652:Possibly [Qualitative Concept]

Phrase: "be"

Phrase: "ascribed to the heterogeneity of the genetic background of diabetes"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   757   C0242960:Genetic Heterogeneity [Organism Attribute]
   739   C0011847:Diabetes [Disease or Syndrome]
   739   C0011849:Diabetes [Disease or Syndrome]
   739   C0017296:GENETIC [Therapeutic or Preventive Procedure]
   739   C0019409:Heterogeneity [Qualitative Concept]
   739   C0314603:Genetic [Functional Concept]
   739   C1706907:Background [Conceptual Entity]

Phrase: "in distant ethnic groups"
Meta Candidates (Total=11; Excluded=1; Pruned=0; Remaining=10)
   901   C0015031:Ethnic Groups [Population Group]
           ETHNIC
   867 E C1879937:Ethnic Group [Intellectual Product]
   827   C0441833:Group [Idea or Concept]
   827   C0680174:ethnic [Finding]
   827   C0687744:group [Population Group]
   827   C1257890:Group [Population Group]
   827   C1552516:Group [Health Care Related Organization]
   827   C1552839:groups [Idea or Concept]
   827   C1705428:Group [Conceptual Entity]
   827   C1705429:Group [Population Group]

Phrase: "(37"

Phrase: ")."
Processing 00000000.tx.290: The Arg140Trp mutation is rare and probably not as critical among Caucasians. 

Phrase: "The Arg140Trp mutation"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0026882:Mutation [Genetic Function]
   861   C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "is"

Phrase: "rare"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0521114:Rare [Temporal Concept]
  1000   C0522498:Rare [Qualitative Concept]
  1000   C1514917:RARE [Gene or Genome]

Phrase: "and"

Phrase: "probably"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0750492:Probably [Idea or Concept]

Phrase: "not as critical"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C1511545:Critical [Qualitative Concept]
   790   C1518422:Not [Functional Concept]

Phrase: "among Caucasians."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0007457:Caucasians [Population Group]
  1000   C0043157:Caucasians [Population Group]
Processing 00000000.tx.291: The potential interplay between genetic and autoimmune factors could have been because of a defective antigenic recognition of alternative forms of CD38. 

Phrase: "The potential interplay between genetic"

Phrase: "and"

Phrase: "autoimmune factors"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C1521761:Factor [Functional Concept]
   827   C2827422:Factor [Conceptual Entity]

Phrase: "could"

Phrase: "have"

Phrase: "been because of a defective antigenic recognition of alternative forms of CD38."
Meta Candidates (Total=10; Excluded=1; Pruned=0; Remaining=9)
   736   C0332452:Defective [Functional Concept]
   736   C0348078:forms [Qualitative Concept]
   736   C0376315:Forms [Manufactured Object]
   736   C0524637:Recognition [Mental Process]
   736   C1523987:Alternative [Conceptual Entity]
   717   C0678894:antigen recognition [Organ or Tissue Function]
   715   C0075742:Antigens, CD38 [Amino Acid, Peptide, or Protein,Enzyme,Immunologic Factor]
   715   C1413221:CD38 ANTIGEN [Gene or Genome]
   715   C2827388:CD38 Antigen [Amino Acid, Peptide, or Protein]
   703 E C1522492:Form [Functional Concept]
Processing 00000000.tx.292: Alternatively, genetic variants could have exerted pathogenetic effects independently by altering CD38 enzymatic activities, as has been demonstrated for the Arg140Trp mutation (14). 

Phrase: "Alternatively,"

Phrase: "genetic variants"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0205419:variants [Qualitative Concept]

Phrase: "could"

Phrase: "have"

Phrase: "exerted"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0015264:Exerted [Organism Function]

Phrase: "pathogenetic effects independently by altering CD38 enzymatic activities,"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   744   C1280500:effects [Qualitative Concept]
   711 E C2348382:Effect [Qualitative Concept]

Phrase: "as"

Phrase: "has"

Phrase: "been"

Phrase: "demonstrated for the Arg140Trp mutation"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0026882:Mutation [Genetic Function]
   760   C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "(14"

Phrase: ")."
Processing 00000000.tx.293: This would have configured a pathological paradigm similar to that recently described for thrombotic thrombocytopenic purpura, in which the deficiency of the von Willebrand factorcleaving protease responsible for the disease can be due to either genetic mutations or aAbs against the protease (38). 

Phrase: "This"

Phrase: "would"

Phrase: "have"

Phrase: "configured"

Phrase: "a pathological paradigm"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0681797:paradigm [Research Activity]

Phrase: "similar to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   833   C2348205:Similar [Qualitative Concept]

Phrase: "that recently"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0332185:Recently [Temporal Concept]

Phrase: "described for thrombotic thrombocytopenic purpura,"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   862   C0034155:Purpura, Thrombotic Thrombocytopenic [Disease or Syndrome]
   806   C0034153:thrombocytopenic purpura [Pharmacologic Substance]
   806   C0857305:Thrombocytopenic purpura [Disease or Syndrome]
   760   C0034150:Purpura [Disease or Syndrome]
   760   C0087086:Thrombotic [Pathologic Function]
   760   C1552738:described [Idea or Concept]
   760   C3463943:Purpura [Eukaryote]

Phrase: "in which"

Phrase: "the deficiency of the von Willebrand factorcleaving protease"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   793   C1281611:Deficiency of protease [Disease or Syndrome]
   744   C0011155:Deficiency [Functional Concept]
   744   C0162429:Deficiency [Disease or Syndrome]
   744   C1623416:deficiency [Qualitative Concept]

Phrase: "responsible for the disease"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C1273518:Responsible [Finding]

Phrase: "can"

Phrase: "be due to either genetic mutations"
Meta Candidates (Total=9; Excluded=1; Pruned=0; Remaining=8)
   790   C0026882:genetic mutations [Genetic Function]
           Mutations
   790   C0678226:Due to [Functional Concept]
           due
   753   C0017296:GENETIC [Therapeutic or Preventive Procedure]
   753   C0314603:Genetic [Functional Concept]
   753   C2987476:Be [Conceptual Entity]
   753   C3146286:Due [Idea or Concept]
   719 E C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "or"

Phrase: "aAbs against the protease"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0004358:Autoantibodies [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: "(38"

Phrase: ")."
Processing 00000000.tx.294: However, according to the present data, the influence of the CD38 genetic background can be excluded bona fide, at least in the Caucasian population. 

Phrase: "However,"

Phrase: "according to the present data,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1511726:Data [Idea or Concept]
   861   C3245479:data [Medical Device]

Phrase: "the influence of the CD38 genetic background"

Phrase: "can"

Phrase: "be"

Phrase: "excluded"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C1554077:Excluded [Idea or Concept]
  1000   C2828389:Excluded [Activity]
   966 E C0332196:Exclude [Functional Concept]

Phrase: "bona fide,"

Phrase: "at least"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   966   C0439092:less [Intellectual Product]
   966   C0547044:Less [Qualitative Concept]

Phrase: "in the Caucasian population."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0032659:Population [Quantitative Concept]
   861   C1257890:Population [Population Group]
Processing 00000000.tx.295: A further step of this work was the study of the functional properties of anti-CD38 aAbs in terms of agonistic or nonagonistic activity. 

Phrase: "A further step of this work"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   753   C1261552:Step [Conceptual Entity]
   753   C1704379:Step [Functional Concept]
   753   C1705117:Step [Quantitative Concept]
   753   C2825408:Step [Manufactured Object]

Phrase: "was"

Phrase: "the study of the functional properties of anti-CD38 aAbs"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   739   C0557651:Study [Manufactured Object]
   739   C2603343:Study [Research Activity]

Phrase: "in terms of agonistic"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   928   C0243192:agonists [Pharmacologic Substance]
   928   C2987634:Agonist [Pharmacologic Substance]

Phrase: "or"

Phrase: "nonagonistic activity."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0205177:Activity [Functional Concept]
   861   C0439167:% activity [Quantitative Concept]
   861   C0441655:Activity [Activity]
   861   C1561536:*Activity [Idea or Concept]
Processing 00000000.tx.296: To this end, analysis of the effects triggered on Ca2+ release was chosen, as it is critical for insulin secretion and many other cellular functions (39). 

Phrase: "To this end,"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
  1000   C0444930:End [Spatial Concept]
  1000   C2746065:End [Temporal Concept]
   944 E C0205088:Terminal [Temporal Concept]
   944 E C1705314:Terminal [Manufactured Object]
   944 E C1705315:Terminal [Spatial Concept]

Phrase: "analysis of the effects"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0002778:Analysis [Laboratory Procedure]
   770   C0936012:Analysis [Research Activity]
   770   C1524024:analysis [Functional Concept]

Phrase: "triggered on Ca2+ release"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   770   C0030685:Release [Health Care Activity]
   770   C0391871:Release [Functional Concept]
   770   C0439180:% release [Quantitative Concept]
   770   C0596235:Ca2+ [Element, Ion, or Isotope,Pharmacologic Substance]
   770   C0680255:release [Health Care Activity]
   770   C1283071:Release [Functional Concept]
   770   C1963578:Release [Therapeutic or Preventive Procedure]
   737   C0032930:Trigger [Clinical Attribute]
   737   C1444748:Trigger [Qualitative Concept]

Phrase: "was"

Phrase: "chosen"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1707391:Chosen [Activity]

Phrase: ","

Phrase: "as"

Phrase: "it"

Phrase: "is"

Phrase: "critical for insulin secretion"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C1511545:Critical [Qualitative Concept]

Phrase: "and"

Phrase: "many other cellular functions"
Meta Candidates (Total=7; Excluded=5; Pruned=0; Remaining=2)
   983   C0007613:Cellular Function [Cell Function]
   861   C0542341:Functions [Functional Concept]
   827 E C0031843:function [Physiologic Function]
   827 E C0700205:FUNCTION [Classification]
   827 E C1705273:Function [Intellectual Product]
   777 E C0205245:Functional [Functional Concept]
   777 E C2700217:Functional [Conceptual Entity]

Phrase: "(39"

Phrase: ")."
Processing 00000000.tx.297: Indeed, the majority (57.14%) of anti-CD38 aAbs were characterized as agonistic. 

Phrase: "Indeed,"

Phrase: "the majority"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0680220:majority [Social Behavior]

Phrase: "(57.14%"

Phrase: ")"

Phrase: "of anti-CD38 aAbs"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0004358:Autoantibodies [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: "were"

Phrase: "characterized as agonistic."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   790   C1880022:Characterized [Activity]
   718   C0243192:agonists [Pharmacologic Substance]
   718   C2987634:Agonist [Pharmacologic Substance]
Processing 00000000.tx.298: This definition is relative, because it is the proportion of agonistic versus nonagonistic immunoglobulins of the polyclonal response toward the autoantigen that leads to the prevalence of stimulatory or blocking effects, as evidenced in the paradigmatic example of Graves disease and Hashimotos thyroiditis (40,41). 

Phrase: "This definition"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C1550452:definition [Idea or Concept]
  1000   C1704788:Definition [Conceptual Entity]
  1000   C3539107:Definition [Intellectual Product]

Phrase: "is"

Phrase: "relative,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0080103:Relative [Family Group]
  1000   C0205345:Relative [Qualitative Concept]
  1000   C1547039:*Relative [Quantitative Concept]

Phrase: "because"

Phrase: "it"

Phrase: "is"

Phrase: "the proportion of agonistic"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C1709707:Proportion [Quantitative Concept]

Phrase: "versus"

Phrase: "nonagonistic immunoglobulins of the polyclonal response"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   753   C0021027:Immunoglobulins [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   753   C0202081:Immunoglobulins NOS [Laboratory Procedure]
   719 E C1621846:immunoglobulin [Molecular Function]

Phrase: "toward the autoantigen"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0004359:Autoantigen [Immunologic Factor]

Phrase: "that"

Phrase: "leads to the prevalence of stimulatory"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   753   C0023175:???lead [Element, Ion, or Isotope,Hazardous or Poisonous Substance]
   753   C0033105:Prevalence [Quantitative Concept]
   753   C0181586:leads [Medical Device]
   753   C0220900:prevalence [Quantitative Concept]
   753   C1442948:lead [Inorganic Chemical,Pharmacologic Substance]
   753   C1522538:Lead [Functional Concept]
   753   C2348269:Lead [Element, Ion, or Isotope]
   753   C3275067:LEAD [Therapeutic or Preventive Procedure]

Phrase: "or"

Phrase: "blocking effects,"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C1280500:effects [Qualitative Concept]
   827 E C2348382:Effect [Qualitative Concept]

Phrase: "as"

Phrase: "evidenced in the paradigmatic example of Graves disease"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   770   C0018213:Grave's disease [Disease or Syndrome]
   750   C0332120:Evidence of [Functional Concept]
           Evidence
   744   C0012634:Disease [Disease or Syndrome]
   744   C1707959:Example [Conceptual Entity]

Phrase: "and"

Phrase: "Hashimotos thyroiditis"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   983   C0677607:Hashimoto Thyroiditis [Disease or Syndrome]
   861   C0040147:Thyroiditis [Disease or Syndrome]

Phrase: "(40,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439509:/40 [Temporal Concept]

Phrase: "41"

Phrase: ")."
Processing 00000000.tx.299: Nonetheless, this point is relevant because the agonistic properties of anti-CD38 aAbs could determine an increase in insulin secretion, as directly demonstrated on purified human islet cells (16). 

Phrase: "Nonetheless,"

Phrase: "this point"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1552961:Point [Quantitative Concept]
  1000   C2347617:point [Quantitative Concept]

Phrase: "is"

Phrase: "relevant"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2347946:Relevant [Qualitative Concept]

Phrase: "because"

Phrase: "the agonistic properties of anti-CD38 aAbs"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   748   C0871161:properties [Qualitative Concept]
   748   C1292721:properties [Functional Concept]
   714 E C1882134:Property [Conceptual Entity]
   714 E C2347695:Property [Entity]

Phrase: "could"

Phrase: "determine"

Phrase: "an increase in insulin secretion,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   797   C0020459:INSULIN INCREASE [Disease or Syndrome]
   760   C0442805:Increase [Functional Concept]

Phrase: "as"

Phrase: "directly"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1947931:Directly [Qualitative Concept]

Phrase: "demonstrated on purified human islet cells"
Meta Candidates (Total=10; Excluded=4; Pruned=0; Remaining=6)
   790   C0022131:Islet Cells [Body Part, Organ, or Organ Component]
   783   C0427861:Human cells [Laboratory or Test Result]
   756 E C1522529:Islet Cell [Cell]
   753   C0007634:Cells [Cell]
   753   C0086418:Human [Human]
   753   C1998793:Purified [Functional Concept]
   753   C3282337:Cells [Cell]
   719 E C1269647:Cell [Cell]
   719 E C1704653:Cell [Medical Device]
   719 E C1948049:Cell [Spatial Concept]

Phrase: "(16"

Phrase: ")."
Processing 00000000.tx.300: In line with this hypothesis, higher plasma C-peptide and insulin levels were observed in anti-CD38+ type 2 diabetic patients; 

Phrase: "In line with this hypothesis,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1512571:Hypothesis [Idea or Concept]

Phrase: "higher plasma C-peptide"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0006558:C-Peptide [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   812   C0030956:Peptide [Amino Acid, Peptide, or Protein]

Phrase: "and"

Phrase: "insulin levels"
Meta Candidates (Total=11; Excluded=5; Pruned=0; Remaining=6)
  1000   C0202098:insulin levels [Laboratory Procedure]
  1000   C0428405:insulin levels [Laboratory or Test Result]
   861   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C0441889:Levels [Qualitative Concept]
   861   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C1579433:Insulin [Pharmacologic Substance]
   827 E C0456079:Level [Classification]
   827 E C1547707:Level [Geographic Area]
   827 E C2946261:Level [Pharmacologic Substance]
   805 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   777 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "were"

Phrase: "observed in anti-CD38+ type 2 diabetic patients"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   770   C0441730:Type 2 [Classification]
   750   C1550335:Patient type [Classification]
   744   C0030705:Patients [Patient or Disabled Group]
   744   C0241863:DIABETIC [Finding]
   744   C0332307:Type [Qualitative Concept]
   744   C1441672:Observed [Functional Concept]
   744   C1547052:*Type [Quantitative Concept]

Phrase: ";"
Processing 00000000.tx.301: simultaneously, a trend toward a higher BMI and a lower frequency of insulin therapy was also noted. 

Phrase: "simultaneously,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0521115:simultaneously [Temporal Concept]

Phrase: "a trend toward a higher BMI"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C1521798:trend [Temporal Concept]

Phrase: "and"

Phrase: "a lower frequency of insulin therapy"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   753   C0376249:frequency [Quantitative Concept]
   753   C0439603:Frequency [Temporal Concept]
   753   C0871396:Frequency [Quantitative Concept]
   753   C1561548:Frequency [Qualitative Concept]
   753   C1705502:Frequency [Quantitative Concept]

Phrase: "was"

Phrase: "also"

Phrase: "noted."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   966   C1316572:Note [Clinical Attribute]
   966   C1317574:Note [Intellectual Product]
   966   C1369612:Note [Clinical Attribute]
Processing 00000000.tx.302: No significant differences in C-peptide levels were found between anti-CD38+ and anti-CD38- type 1 diabetic patients, which is likely to be because of complete -cell exhaustion. 

Phrase: "No significant differences in C-peptide levels"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   714   C1705241:*Difference [Quantitative Concept]
   714   C1705242:Difference [Qualitative Concept]

Phrase: "were"

Phrase: "found between anti-CD38+"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   770   C0150312:Found [Quantitative Concept]
   737 E C0243095:Find [Finding]

Phrase: "and"

Phrase: "anti-CD38- type 1 diabetic patients,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   799   C0030705:Patients [Patient or Disabled Group]

Phrase: "which"

Phrase: "is"

Phrase: "likely to"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0332148:Likely [Qualitative Concept]
   861   C0750492:Likely [Idea or Concept]

Phrase: "be because of complete -cell exhaustion."
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   753   C0007634:Cell [Cell]
   753   C0205197:Complete [Qualitative Concept]
   753   C0392674:Exhaustion [Sign or Symptom]
   753   C0725685:COMPLEAT [Food]
   753   C1269647:Cell [Cell]
   753   C1704653:Cell [Medical Device]
   753   C1948049:Cell [Spatial Concept]
   753   C2987476:Be [Conceptual Entity]
Processing 00000000.tx.303: Therefore, the in vivo effect of anti-CD38 aAbs could be an enhanced insulin secretion from -cells, possibly leading, in the long term, to insulin secretory failure from excess stimulation. 

Phrase: "Therefore,"

Phrase: "the in vivo effect of anti-CD38 aAbs"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   744   C1280500:Effect [Qualitative Concept]
   744   C2348382:Effect [Qualitative Concept]

Phrase: "could"

Phrase: "be"

Phrase: "an enhanced insulin secretion from -cells,"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   790   C1256369:insulin secretion [Cell Function]
   767   C0030281:Insulin Cell [Cell]
   767   C1327616:Cell secretion [Cell Function]
   753   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   753   C0036536:secretion [Biologic Function]
   753   C0036537:Secretion [Body Substance]
   753   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   753   C1579433:Insulin [Pharmacologic Substance]

Phrase: "possibly"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2362652:Possibly [Qualitative Concept]

Phrase: "leading"
Meta Candidates (Total=6; Excluded=4; Pruned=0; Remaining=2)
  1000   C0332152:Leading [Temporal Concept]
  1000   C1522538:Leading [Functional Concept]
   966 E C0023175:???lead [Element, Ion, or Isotope,Hazardous or Poisonous Substance]
   966 E C1442948:lead [Inorganic Chemical,Pharmacologic Substance]
   966 E C2348269:Lead [Element, Ion, or Isotope]
   966 E C3275067:LEAD [Therapeutic or Preventive Procedure]

Phrase: ","

Phrase: "in the long term,"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
  1000   C0443252:Long-term [Temporal Concept]
   861   C0205166:Long [Qualitative Concept]
   861   C1515273:Term [Temporal Concept]
   861   C1705313:Term [Idea or Concept]
   861   C1706317:Long [Qualitative Concept]
   861   C2826302:TERM [Intellectual Product]

Phrase: "to insulin secretory failure"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0231174:Failure [Functional Concept]
   827   C0680095:failure [Individual Behavior]

Phrase: "from excess stimulation."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1292856:Stimulation [Therapeutic or Preventive Procedure]
   861   C1948023:Stimulation [Natural Phenomenon or Process]
Processing 00000000.tx.304: Moreover, CD38 is also expressed in a number of extrapancreatic tissues at high epitopic densities. 

Phrase: "Moreover,"

Phrase: "CD38"

Phrase: "is"

Phrase: "also"

Phrase: "expressed in a number of extrapancreatic tissues"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   748   C0040300:Tissues [Tissue]
   748   C0237753:*Number [Quantitative Concept]
   748   C0449788:Number [Quantitative Concept]
   714 E C1547928:Tissue [Intellectual Product]

Phrase: "at high epitopic densities."
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   827   C0178587:densities [Quantitative Concept]
   743 E C0439794:Dense [Qualitative Concept]
Processing 00000000.tx.305: Thus, it is possible that the in vivo effects of circulating anti-CD38 aAbs may not be limited to -cells. 

Phrase: "Thus,"

Phrase: "it"

Phrase: "is"

Phrase: "possible"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0332149:Possible [Qualitative Concept]
  1000   C1705910:Possible [Qualitative Concept]
  1000   C2362652:Possible [Qualitative Concept]

Phrase: "that"

Phrase: "the in vivo effects of circulating anti-CD38 aAbs"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   742   C1280500:effects [Qualitative Concept]
   708 E C2348382:Effect [Qualitative Concept]

Phrase: "may"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "be"

Phrase: "limited"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
  1000   C0439801:Limited [Functional Concept]
  1000   C3542948:Limited [Intellectual Product]
   966 E C1549649:Limit [Idea or Concept]
   966 E C2349209:Limit [Conceptual Entity]

Phrase: "to -cells."
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   861   C0007634:Cells [Cell]
   861   C3282337:Cells [Cell]
   827 E C1269647:Cell [Cell]
   827 E C1704653:Cell [Medical Device]
   827 E C1948049:Cell [Spatial Concept]
Processing 00000000.tx.306: Among the CD38+ tissues, peripheral blood mononuclear cells (PBMCs) deserve special consideration with regard to the prevalent agonistic properties of anti-CD38 aAbs. 

Phrase: "Among the CD38+ tissues,"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0040300:Tissues [Tissue]
   827 E C1547928:Tissue [Intellectual Product]

Phrase: "peripheral blood mononuclear cells (PBMCs)"
Meta Candidates (Total=24; Excluded=12; Pruned=0; Remaining=12)
  1000   C1321301:Peripheral Blood Mononuclear Cells [Cell]
   906   C0005773:Peripheral blood cell [Cell]
           Blood Cells
   861   C0229664:peripheral blood [Body Substance]
           Blood
   861   C0806987:Mononuclear cells [Cell]
   830 E C2328697:Hemal cell [Cell]
   819 E C0150936:Peripheral Blood Vessel [Body Part, Organ, or Organ Component]
   812   C0005767:Blood [Tissue]
   812   C0005768:blood [Body Substance]
   812   C0007634:Cells [Cell]
   812   C0205100:Peripheral [Spatial Concept]
   812   C1513475:Mononuclear [Clinical Attribute]
   812   C3282337:Cells [Cell]
   779 E C1269647:Cell [Cell]
   779 E C1704653:Cell [Medical Device]
   779 E C1948049:Cell [Spatial Concept]
   741 E C0333275:Bloody [Qualitative Concept]
   729 E C0005847:Blood Vessel [Body Part, Organ, or Organ Component]
   729 E C0392895:Bloods [Population Group]
   729 E C1283786:Blood vessel [Body Part, Organ, or Organ Component]
   729 E C1511228:VESSEL, BLOOD [Tissue]
   712 E C1558950:VASCULAR [Finding]
   712 E C1801960:Vascular [Qualitative Concept]

Phrase: "deserve"

Phrase: "special consideration with regard to the prevalent agonistic properties"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   742   C0518609:consideration [Finding]

Phrase: "of anti-CD38 aAbs."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0004358:Autoantibodies [Amino Acid, Peptide, or Protein,Immunologic Factor]
Processing 00000000.tx.307: In PBMCs, binding of agonistic anti-CD38 mAbs induces release of pro-inflammatory cytokines, i.e., interleukin (IL)-1, IL-6, and tumor necrosis factor- (42), and similar effects could be triggered by anti-CD38 aAbs. 

Phrase: "In PBMCs,"
Meta Candidates (Total=24; Excluded=12; Pruned=0; Remaining=12)
  1000   C1321301:Peripheral Blood Mononuclear Cells [Cell]
   906   C0005773:Peripheral blood cell [Cell]
           Blood Cells
   861   C0229664:peripheral blood [Body Substance]
           Blood
   861   C0806987:Mononuclear cells [Cell]
   830 E C2328697:Hemal cell [Cell]
   819 E C0150936:Peripheral Blood Vessel [Body Part, Organ, or Organ Component]
   812   C0005767:Blood [Tissue]
   812   C0005768:blood [Body Substance]
   812   C0007634:Cells [Cell]
   812   C0205100:Peripheral [Spatial Concept]
   812   C1513475:Mononuclear [Clinical Attribute]
   812   C3282337:Cells [Cell]
   779 E C1269647:Cell [Cell]
   779 E C1704653:Cell [Medical Device]
   779 E C1948049:Cell [Spatial Concept]
   741 E C0333275:Bloody [Qualitative Concept]
   729 E C0005847:Blood Vessel [Body Part, Organ, or Organ Component]
   729 E C0392895:Bloods [Population Group]
   729 E C1283786:Blood vessel [Body Part, Organ, or Organ Component]
   729 E C1511228:VESSEL, BLOOD [Tissue]
   712 E C1558950:VASCULAR [Finding]
   712 E C1801960:Vascular [Qualitative Concept]

Phrase: "binding of agonistic anti-CD38 mAbs"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   753   C0243122:binding [Functional Concept]
   753   C1145667:Binding [Activity]
   753   C1167622:Binding [Molecular Function]
   719   C0003250:MAb [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: "induces"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205263:Induce [Functional Concept]

Phrase: "release of pro-inflammatory cytokines,"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   760   C0030685:Release [Health Care Activity]
   760   C0391871:Release [Functional Concept]
   760   C0439180:% release [Quantitative Concept]
   760   C0680255:release [Health Care Activity]
   760   C1283071:Release [Functional Concept]
   760   C1963578:Release [Therapeutic or Preventive Procedure]

Phrase: "i.e.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0683454:I-E [Diagnostic Procedure,Intellectual Product]
   861   C0021966:I- [Inorganic Chemical]
   861   C0221138:I NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: "interleukin (IL)-1,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0021755:Interleukin-1 [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C1522428:Interleukin 1 [Amino Acid, Peptide, or Protein,Pharmacologic Substance]
   861   C0021764:Interleukin [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C1527200:Interleukin [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]

Phrase: "IL-6,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0021760:Interleukin-6 [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C1527132:interleukin 6 [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   861   C0021764:Interleukin [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C1527200:Interleukin [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]

Phrase: "and"

Phrase: "tumor necrosis factor-"
Meta Candidates (Total=11; Excluded=0; Pruned=0; Remaining=11)
  1000   C0041368:tumor necrosis factor [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C1323304:tumor necrosis factor [Molecular Function]
  1000   C1456820:Tumour necrosis factor [Amino Acid, Peptide, or Protein,Immunologic Factor]
   901   C0333516:Tumor necrosis [Neoplastic Process]
   827   C0027540:Necrosis [Organ or Tissue Function]
   827   C0027651:Tumor [Neoplastic Process]
   827   C1334928:Necrosis [Finding]
   827   C1521761:Factor [Functional Concept]
   827   C1578706:Tumor [Intellectual Product]
   827   C2827422:Factor [Conceptual Entity]
   827   C3273930:Tumor [Finding]

Phrase: "(42"

Phrase: ")"

Phrase: ","

Phrase: "and"

Phrase: "similar effects"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C1280500:effects [Qualitative Concept]
   827 E C2348382:Effect [Qualitative Concept]

Phrase: "could"

Phrase: "be"

Phrase: "triggered by anti-CD38 aAbs."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   806   C1444748:Triggered by [Qualitative Concept]
           Trigger
   760   C0004358:Autoantibodies [Amino Acid, Peptide, or Protein,Immunologic Factor]
   726   C0032930:Trigger [Clinical Attribute]
Processing 00000000.tx.308: Cytokine release could be an important contribution to the insulitis responsible for early presentation of type 1 diabetes and would be in line with the recently proposed models of type 2 diabetes as a disease of the innate immune system (43,44). 

Phrase: "Cytokine release"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   861   C0030685:Release [Health Care Activity]
   861   C0391871:Release [Functional Concept]
   861   C0439180:% release [Quantitative Concept]
   861   C0680255:release [Health Care Activity]
   861   C1283071:Release [Functional Concept]
   861   C1963578:Release [Therapeutic or Preventive Procedure]

Phrase: "could"

Phrase: "be"

Phrase: "an important contribution to the insulitis"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C1880177:Contribution [Activity]

Phrase: "responsible for early presentation of type 1 diabetes"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   744   C1273518:Responsible [Finding]

Phrase: "and"

Phrase: "would"

Phrase: "be in line with the recently proposed models of type 2 diabetes"
Meta Candidates (Total=17; Excluded=0; Pruned=0; Remaining=17)
   770   C0011860:Type 2 Diabetes [Disease or Syndrome]
   766   C1301774:Type of line [Functional Concept]
   753   C0441730:Type 2 [Classification]
   751   C1320657:Diabetes type [Finding]
   736   C0011847:Diabetes [Disease or Syndrome]
   736   C0011849:Diabetes [Disease or Syndrome]
   736   C0205132:Line [Spatial Concept]
   736   C0332185:Recently [Temporal Concept]
   736   C0332307:Type [Qualitative Concept]
   736   C1441414:PROPOSED [Idea or Concept]
   736   C1547052:*Type [Quantitative Concept]
   736   C1550648:Line [Substance]
   736   C1552960:Line [Quantitative Concept]
   736   C1553874:Proposed [Qualitative Concept]
   736   C1578820:Proposed [Idea or Concept]
   736   C2987476:Be [Conceptual Entity]
   736   C3161035:Models [Intellectual Product]

Phrase: "as a disease"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C0012634:Disease [Disease or Syndrome]
   944 E C1836721:MALS [Finding]
   944 E C3538764:MALS [Gene or Genome]
   944 E C3540595:MAL [Gene or Genome]

Phrase: "of the innate immune system"
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
   901   C0020962:Immune system [Body System]
   901   C1291764:IMMUNE SYSTEM [Finding]
   827   C0439662:Immune [Functional Concept]
   827   C0449913:System [Functional Concept]
   827   C1553451:System [Manufactured Object]
   827   C1704459:System [Medical Device]
   755 E C0205373:Systemic [Functional Concept]

Phrase: "(43,"

Phrase: "44"

Phrase: ")."
Processing 00000000.tx.309: Apart from these speculations, anti-CD38 aAbs constitute a new marker of -cell autoimmunity in diabetes that, unlike islet cell antibodies, anti-GAD, and anti-IA-2 aAbs, is endowed with peculiar functional properties. 

Phrase: "Apart from these speculations,"

Phrase: "anti-CD38 aAbs"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0004358:Autoantibodies [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: "constitute"

Phrase: "a new marker of -cell autoimmunity in diabetes"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   744   C0004368:Autoimmunity [Pathologic Function]
   731   C0205734:Diabetes, Autoimmune [Disease or Syndrome]

Phrase: "that,"

Phrase: "unlike islet cell antibodies,"
Meta Candidates (Total=9; Excluded=1; Pruned=0; Remaining=8)
   966   C0063900:islet cell antibody [Amino Acid, Peptide, or Protein,Immunologic Factor]
   901   C0022131:Islet cell [Body Part, Organ, or Organ Component]
   901   C1522529:Islet Cell [Cell]
   827   C0003241:Antibodies [Amino Acid, Peptide, or Protein,Cell Component,Immunologic Factor]
   827   C0007634:Cell [Cell]
   827   C1269647:Cell [Cell]
   827   C1704653:Cell [Medical Device]
   827   C1948049:Cell [Spatial Concept]
   793 E C0021027:Antibody [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]

Phrase: "anti-GAD,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0270549:GAD [Mental or Behavioral Dysfunction]
   861   C1414925:GAD [Gene or Genome]

Phrase: "and"

Phrase: "anti-IA-2 aAbs,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   906   C0663193:IA-2 autoantibody [Immunologic Factor]
   812   C0004358:Autoantibodies [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: "is"

Phrase: "endowed with peculiar functional properties."
Meta Candidates (Total=7; Excluded=2; Pruned=0; Remaining=5)
   760   C0205245:Functional [Functional Concept]
   760   C0542341:Functional [Functional Concept]
   760   C0871161:properties [Qualitative Concept]
   760   C1292721:properties [Functional Concept]
   760   C2700217:Functional [Conceptual Entity]
   726 E C1882134:Property [Conceptual Entity]
   726 E C2347695:Property [Entity]
Processing 00000000.tx.310: View this table: [in this window] [in a new window]  TABLE 6 CD38 allelic and genotypic frequencies in type 2 diabetic patients compared with healthy control subjects   ACKNOWLEDGMENTS  This work was supported in part by grants from Telethon, Rome, Italy; 

Phrase: "View"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0449911:View [Spatial Concept]

Phrase: "this table"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0039224:Table [Manufactured Object]
  1000   C1706073:Table [Medical Device]
  1000   C1706074:Table [Intellectual Product]

Phrase: ":"

Phrase: "["

Phrase: "in this window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0557702:Window [Manufactured Object]
  1000   C1272706:Window [Temporal Concept]
  1000   C1704674:Window [Manufactured Object]

Phrase: "]"

Phrase: "["

Phrase: "in a new window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0557702:Window [Manufactured Object]
   861   C1272706:Window [Temporal Concept]
   861   C1704674:Window [Manufactured Object]

Phrase: "]  TABLE 6 CD38"

Phrase: "allelic"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   928   C0002085:Allele [Gene or Genome]

Phrase: "and"

Phrase: "genotypic frequencies in type 2 diabetic patients"
Meta Candidates (Total=5; Excluded=4; Pruned=0; Remaining=1)
   748   C0439603:Frequencies [Temporal Concept]
   714 E C0376249:frequency [Quantitative Concept]
   714 E C0871396:Frequency [Quantitative Concept]
   714 E C1561548:Frequency [Qualitative Concept]
   714 E C1705502:Frequency [Quantitative Concept]

Phrase: "compared with healthy control"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   833   C2986479:Healthy Control [Qualitative Concept]
   770   C0243148:control [Qualitative Concept]
   770   C1550141:Control [Substance]
   770   C1707455:Compared [Activity]
   770   C1882979:Control [Conceptual Entity]
   770   C2587213:Control [Functional Concept]
   770   C3274648:Control [Qualitative Concept]

Phrase: "subjects"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0681850:Subject [Group]
  1000   C1550501:{Subject} [Idea or Concept]
  1000   C1706203:Subject [Idea or Concept]
  1000   C2349001:Subject [Human]
  1000   C2697811:Subject [Functional Concept]

Phrase: "ACKNOWLEDGMENTS"

Phrase: "This work"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0043227:Work [Occupational Activity]

Phrase: "was"

Phrase: "supported in part"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   790   C0449719:Part [Spatial Concept]
   790   C1521721:Supported [Conceptual Entity]
   790   C1709471:Part [Quantitative Concept]
   756 E C0183683:Support [Medical Device]

Phrase: "by grants"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0018173:Grants [Quantitative Concept]
   966 E C1548284:Grant [Idea or Concept]

Phrase: "from Telethon,"

Phrase: "Rome,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0035831:Rome [Geographic Area]

Phrase: "Italy"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0022277:Italy [Geographic Area]

Phrase: ";"
Processing 00000000.tx.311: Special Project "Biotechnology" CNR/MURST, Rome, Italy; 

Phrase: "Special Project ""Biotechnology"" CNR/MURST,"

Phrase: "Rome,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0035831:Rome [Geographic Area]

Phrase: "Italy"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0022277:Italy [Geographic Area]

Phrase: ";"
Processing 00000000.tx.312: AIRC, Milan, Italy; 

Phrase: "AIRC,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1418256:AIRC [Gene or Genome]

Phrase: "Milan,"

Phrase: "Italy"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0022277:Italy [Geographic Area]

Phrase: ";"
Processing 00000000.tx.313: and Special Project "AIDS," ISS, Rome, Italy. 

Phrase: "and"

Phrase: "Special Project ""AIDS,"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
   827   C0001175:AIDS [Disease or Syndrome]
   793 E C0018896:Aid [Social Behavior]
   793 E C0449435:Aid [Manufactured Object]
   793 E C3540469:AID [Gene or Genome]

Phrase: """ ISS,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1845118:ISS [Congenital Abnormality,Disease or Syndrome]

Phrase: "Rome,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0035831:Rome [Geographic Area]

Phrase: "Italy."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0022277:Italy [Geographic Area]
Processing 00000000.tx.314: Compagnia di Sanpaolo and Cariverona Foundations provided valuable financial contributions. 

Phrase: "Compagnia di Sanpaolo"

Phrase: "and"

Phrase: "Cariverona Foundations"
Meta Candidates (Total=6; Excluded=5; Pruned=0; Remaining=1)
   861   C0016617:Foundations [Organization]
   768 E C0002055:base [Inorganic Chemical]
   768 E C0178499:Base [Chemical Viewed Functionally]
   768 E C1626935:Bases [Quantitative Concept]
   768 E C1880279:Base [Biomedical or Dental Material]
   750 E C0205112:Basal [Spatial Concept]

Phrase: "provided"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1999230:Provided [Activity]

Phrase: "valuable financial contributions."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   901   C1138437:Financial Contributions [Social Behavior]
   793   C1880177:Contribution [Activity]
Processing 00000000.tx.315: We thank Enza Ferrero, MD, for a critical reading of the manuscript and for constructive discussion. 

Phrase: "We"

Phrase: "thank"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2986676:THANK [Gene or Genome]

Phrase: "Enza Ferrero,"

Phrase: "MD,"

Phrase: "for a critical reading"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0034754:Reading [Daily or Recreational Activity]
   861   C1705179:Reading [Finding]

Phrase: "of the manuscript"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0600659:Manuscript [Intellectual Product,Manufactured Object]

Phrase: "and for constructive discussion."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0557061:Discussion [Therapeutic or Preventive Procedure]
   770   C1515981:And [Idea or Concept]
   770   C2584313:Discussion [Social Behavior]
Processing 00000000.tx.316: We also thank Dr. 

Phrase: "We also"

Phrase: "thank"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2986676:THANK [Gene or Genome]

Phrase: "Dr."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0031831:DR [Professional or Occupational Group]
  1000   C1707664:DR [Biomedical or Dental Material]
  1000   C2348314:Dr. [Conceptual Entity]
  1000   C3540849:DR [Idea or Concept]
Processing 00000000.tx.317: Gabriella Gruden and Dr. 

Phrase: "Gabriella Gruden"

Phrase: "and"

Phrase: "Dr."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0031831:DR [Professional or Occupational Group]
  1000   C1707664:DR [Biomedical or Dental Material]
  1000   C2348314:Dr. [Conceptual Entity]
  1000   C3540849:DR [Idea or Concept]
Processing 00000000.tx.318: Alda Olivero for helpful suggestions. 

Phrase: "Alda Olivero for helpful suggestions."
Processing 00000000.tx.319: R.M., S.G., and E.L. are students at the Postgraduate School of Internal Medicine, University of Torino, Torino, Italy. 

Phrase: "R."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205090:R- [Spatial Concept]
  1000   C0684010:R. [Professional or Occupational Group]
  1000   C2603358:R' [Clinical Attribute]

Phrase: "M."

Phrase: ","

Phrase: "S.G.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0439267:g% [Quantitative Concept]
   861   C2603362:S' [Clinical Attribute]

Phrase: "and"

Phrase: "E.L."

Phrase: "are"

Phrase: "students at the Postgraduate School of Internal Medicine,"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   744   C0038492:Students [Professional or Occupational Group]
   711 E C1551041:student [Idea or Concept]
   711 E C1552573:student [Intellectual Product]

Phrase: "University of Torino,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C0041740:University [Manufactured Object,Organization]

Phrase: "Torino,"

Phrase: "Italy."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0022277:Italy [Geographic Area]
Processing 00000000.tx.320: This work is dedicated to the memory of Teresa Sacco (19221994).  

Phrase: "This work"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0043227:Work [Occupational Activity]

Phrase: "is"

Phrase: "dedicated to the memory of Teresa Sacco"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   748   C0025260:Memory [Mental Process]
   748   C0700327:memory [Finding]
   748   C1706377:Memory [Manufactured Object]

Phrase: "(19221994"

Phrase: ")."
Processing 00000000.tx.321: FOOTNOTES  Address correspondence and reprint requests to Fabio Malavasi, Laboratory of Immunogenetics, Department of Genetics, Biology and Biochemistry, Via Santena 19, 10126 Torino, Italy. 

Phrase: "FOOTNOTES  Address correspondence"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0282413:Correspondence [Intellectual Product]

Phrase: "and"

Phrase: "reprint"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C3273171:Reprint [Intellectual Product]

Phrase: "requests to Fabio Malavasi,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0686900:request [Functional Concept]
   770   C1272683:Request [Functional Concept]
   770   C1522634:Request [Intellectual Product]

Phrase: "Laboratory of Immunogenetics,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0022877:Laboratory [Manufactured Object,Organization]
   790   C3244292:laboratory [Functional Concept]

Phrase: "Department of Genetics,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   858   C0587466:Genetics department [Health Care Related Organization]
   790   C1704729:Department [Organization]

Phrase: "Biology"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0005532:Biology [Biomedical Occupation or Discipline]
   928 E C0205460:Biologic [Qualitative Concept]
   928 E C2979985:BIOLOGIC [Biologically Active Substance,Pharmacologic Substance]

Phrase: "and"

Phrase: "Biochemistry,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0005477:Biochemistry [Occupation or Discipline]

Phrase: "Via Santena 19,"

Phrase: "10126 Torino,"

Phrase: "Italy."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0022277:Italy [Geographic Area]
Processing 00000000.tx.322: E-mail: fabio.malavasi{at}unito.it . G.B. is currently affiliated with the Laboratory of Gynecologic Oncology, Department of Medical Sciences, University of Eastern Piedmont "A. Avogadro," 28100 Novara, Italy. 

Phrase: "E-mail"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0013849:E-Mail [Intellectual Product]
  1000   C1705961:E-mail [Intellectual Product]
   861   C0024492:Mail [Manufactured Object]
   861   C1538057:MAIL [Gene or Genome]
   861   C1547565:Mail [Idea or Concept]

Phrase: ":"

Phrase: "fabio.malavasi{at}unito."

Phrase: "it . G.B."

Phrase: "is"

Phrase: "currently"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0521116:Currently [Temporal Concept]

Phrase: "affiliated with the Laboratory of Gynecologic Oncology,"
Meta Candidates (Total=9; Excluded=1; Pruned=0; Remaining=8)
   778   C1321164:Gynecologic Oncology [Biomedical Occupation or Discipline]
   778   C1555789:Gynecologic Oncology [Professional or Occupational Group]
   748   C0022877:Laboratory [Manufactured Object,Organization]
   748   C0205480:Gynecologic [Spatial Concept]
   748   C0278627:Oncology [Biomedical Occupation or Discipline]
   748   C1510825:Affiliated [Qualitative Concept]
   748   C1510826:Affiliated [Qualitative Concept]
   748   C3244292:laboratory [Functional Concept]
   714 E C1696107:affiliate [Idea or Concept]

Phrase: "Department of Medical Sciences,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   819   C0587450:Medical department [Health Care Related Organization]
   770   C1704729:Department [Organization]

Phrase: "University of Eastern Piedmont """
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0041740:University [Manufactured Object,Organization]

Phrase: "A. Avogadro,"

Phrase: """ 28100 Novara,"

Phrase: "Italy."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0022277:Italy [Geographic Area]
Processing 00000000.tx.323: Received for publication 7 July 2000 and accepted in revised form 19 December 2000.  

Phrase: "Received for publication 7 July 2000"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   753   C0034036:Publication [Intellectual Product,Manufactured Object]
   753   C0034037:Publication [Occupational Activity]
   753   C1514756:Received [Qualitative Concept]
   753   C1704324:Publication [Intellectual Product]

Phrase: "and"

Phrase: "accepted in revised form 19 December 2000."
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
   748   C0348078:Form [Qualitative Concept]
   748   C0376315:Form [Manufactured Object]
   748   C1272684:Accepted [Qualitative Concept]
   748   C1522492:Form [Functional Concept]
   748   C1527075:Revised [Therapeutic or Preventive Procedure]
   748   C1548435:Accepted [Idea or Concept]
   714 E C1548601:Accept [Idea or Concept]
Processing 00000000.tx.324: REFERENCES TOP ABSTRACT INTRODUCTION RESEARCH DESIGN AND METHODS RESULTS DISCUSSION REFERENCES  DeFronzo RA, Bonadonna RC, Ferrannini E: Pathogenesis of NIDDM: a balanced overview. 

Phrase: "REFERENCES"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1514811:Reference [Idea or Concept]
  1000   C1706462:Reference [Conceptual Entity]

Phrase: "TOP ABSTRACT INTRODUCTION RESEARCH DESIGN"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   840   C0035171:Research Design [Research Activity]
   804   C0035168:research [Research Activity]
   804   C0242481:Research [Research Activity]
   804   C1707689:Design [Activity]
   804   C2983265:DESIGN [Intellectual Product]

Phrase: "AND"

Phrase: "METHODS RESULTS DISCUSSION"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0557061:Discussion [Therapeutic or Preventive Procedure]
   827   C2584313:Discussion [Social Behavior]

Phrase: "REFERENCES"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1514811:Reference [Idea or Concept]
  1000   C1706462:Reference [Conceptual Entity]

Phrase: "DeFronzo RA,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C3538806:Ra [Spatial Concept]

Phrase: "Bonadonna RC,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1419366:RC [Gene or Genome]

Phrase: "Ferrannini E"

Phrase: ":"

Phrase: "Pathogenesis of NIDDM"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   753   C0543483:pathogenesis [Functional Concept]
   753   C0699748:Pathogenesis [Pathologic Function]
   716   C0011860:Diabetes Mellitus, Non-Insulin-Dependent [Disease or Syndrome]
   716   C2697407:DIABETES MELLITUS, NONINSULIN-DEPENDENT [Gene or Genome]

Phrase: ":"

Phrase: "a balanced overview."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0814812:overview [Intellectual Product]
Processing 00000000.tx.325: Diabetes Care 15:318368, 1992[Abstract] Polonsky KS, Sturis J, Bell GI: Seminars in Medicine of the Beth Israel Hospital, Boston: noninsulin-dependent diabetes mellitus, a genetically programmed failure of the beta cell to compensate for insulin resistance. 

Phrase: "Diabetes Care 15"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0011847:Diabetes [Disease or Syndrome]
   827   C0011849:Diabetes [Disease or Syndrome]
   827   C1947933:Care [Activity]

Phrase: ":"

Phrase: "318368,"

Phrase: "1992"

Phrase: "[Abstract"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0000857:Abstract [Occupational Activity]
  1000   C0600678:Abstract [Intellectual Product]
  1000   C1552863:Abstract [Idea or Concept]

Phrase: "] Polonsky KS,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C3541894:ks [Quantitative Concept]

Phrase: "Sturis J,"

Phrase: "Bell GI"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C3539617:GI [Idea or Concept]

Phrase: ":"

Phrase: "Seminars in Medicine of the Beth Israel Hospital,"

Phrase: "Boston"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0006037:Boston [Geographic Area]

Phrase: ":"

Phrase: "noninsulin-dependent diabetes mellitus,"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
  1000   C0011860:Diabetes Mellitus, Non-Insulin-Dependent [Disease or Syndrome]
           Non-Insulin Dependent Diabetes
  1000   C2697407:DIABETES MELLITUS, NONINSULIN-DEPENDENT [Gene or Genome]
   861   C0011849:Diabetes Mellitus [Disease or Syndrome]
           Diabetes
   812   C0011847:Diabetes [Disease or Syndrome]
   812   C0851827:Dependent [Qualitative Concept]
   812   C1701901:Dependent [Qualitative Concept]
   812   C3244310:dependent [Functional Concept]

Phrase: "a genetically programmed failure of the beta cell to"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   742   C0231174:Failure [Functional Concept]
   742   C0680095:failure [Individual Behavior]

Phrase: "compensate for insulin resistance."
Meta Candidates (Total=9; Excluded=1; Pruned=0; Remaining=8)
   833   C0021655:Insulin Resistance [Pathologic Function]
   833   C2700570:INSULIN RESISTANCE [Gene or Genome]
   770   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   770   C0205432:compensate [Qualitative Concept]
   770   C0237834:Resistance [Mental Process]
   770   C1514892:Resistance [Physiologic Function]
   770   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   770   C1579433:Insulin [Pharmacologic Substance]
   715 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
Processing 00000000.tx.326: N Engl J Med 334:777783, 1996[Free FullText] Ferrannini E: Insulin resistance versus insulin deficiency in noninsulin-dependent diabetes mellitus: problems and prospects. 

Phrase: "N Engl J Med 334"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   804   C0369718:N NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   804   C0441922:N+ [Intellectual Product]
   804   C1414400:ENGL [Gene or Genome]
   804   C1553036:[n] [Quantitative Concept]

Phrase: ":"

Phrase: "777783,"

Phrase: "1996"

Phrase: "[Free FullText"

Phrase: "] Ferrannini E"

Phrase: ":"

Phrase: "Insulin resistance"
Meta Candidates (Total=12; Excluded=5; Pruned=0; Remaining=7)
  1000   C0021655:Insulin Resistance [Pathologic Function]
  1000   C2700570:INSULIN RESISTANCE [Gene or Genome]
   861   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C0237834:Resistance [Mental Process]
   861   C1514892:Resistance [Physiologic Function]
   861   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C1579433:Insulin [Pharmacologic Substance]
   805 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   789 E C0332325:Resistant [Functional Concept]
   789 E C1550464:resistent [Idea or Concept]
   789 E C2827757:RESISTANT [Laboratory or Test Result]
   777 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "versus"

Phrase: "insulin deficiency in noninsulin-dependent diabetes mellitus"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   748   C0011155:Deficiency [Functional Concept]
   748   C0162429:Deficiency [Disease or Syndrome]
   748   C1623416:deficiency [Qualitative Concept]

Phrase: ":"

Phrase: "problems"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1546466:Problems [Idea or Concept]
   966 E C0033213:Problem [Finding]

Phrase: "and"

Phrase: "prospects."
Processing 00000000.tx.327: Endocr Rev 19:477490, 1998[Abstract/Free FullText] Okamoto H, Takasawa S, Nata K: The CD38-cyclic ADP-ribose signaling system in insulin secretion: molecular basis and clinical implications. 

Phrase: "Endocr Rev 19"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C2347961:Rev. [Professional or Occupational Group]

Phrase: ":"

Phrase: "477490,"

Phrase: "1998"

Phrase: "[Abstract/Free FullText"

Phrase: "] Okamoto H,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: "Takasawa S,"

Phrase: "Nata K"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: ":"

Phrase: "The CD38-cyclic ADP-ribose signaling system in insulin secretion"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   739   C0449913:System [Functional Concept]
   739   C1553451:System [Manufactured Object]
   739   C1704459:System [Medical Device]

Phrase: ":"

Phrase: "molecular basis"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C1853126:MOLECULAR BASIS [Idea or Concept]
   861   C1527178:Basis [Functional Concept]
   861   C1874451:Basis [Pharmacologic Substance]

Phrase: "and"

Phrase: "clinical implications."
Processing 00000000.tx.328: Diabetologia 40:14851491, 1997[Medline] Morra M, Zubiaur M, Terhorst C, Sancho J, Malavasi F: CD38 is functionally dependent on the TCR/CD3 complex in human T cells. 

Phrase: "Diabetologia 40"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0439509:/40 [Temporal Concept]

Phrase: ":"

Phrase: "14851491,"

Phrase: "1997"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Morra M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Zubiaur M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Terhorst C,"

Phrase: "Sancho J,"

Phrase: "Malavasi F"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
   861   C0439133:(f) [Intellectual Product]
   861   C1553038:[f] [Quantitative Concept]

Phrase: ":"

Phrase: "CD38"

Phrase: "is"

Phrase: "functionally dependent on the TCR/CD3 complex"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   748   C0851827:Dependent [Qualitative Concept]
   748   C1701901:Dependent [Qualitative Concept]
   748   C3244310:dependent [Functional Concept]

Phrase: "in human T cells."
Meta Candidates (Total=7; Excluded=3; Pruned=0; Remaining=4)
   913   C0427861:Human cells [Laboratory or Test Result]
   901   C0039194:T-Cells [Cell]
   827   C0007634:Cells [Cell]
   827   C3282337:Cells [Cell]
   793 E C1269647:Cell [Cell]
   793 E C1704653:Cell [Medical Device]
   793 E C1948049:Cell [Spatial Concept]
Processing 00000000.tx.329: FASEB J 12:581592, 1998[Abstract/Free FullText] Silvennoinen O, Nishigaki H, Kitanaka A, Kumagai M, Ito C, Malavasi F, Lin Q, Conley ME, Campana D: CD38 signal transduction in human B cell precursors. 

Phrase: "FASEB J 12"

Phrase: ":"

Phrase: "581592,"

Phrase: "1998"

Phrase: "[Abstract/Free FullText"

Phrase: "] Silvennoinen O,"

Phrase: "Nishigaki H,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: "Kitanaka A,"

Phrase: "Kumagai M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Ito C,"

Phrase: "Malavasi F,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
   861   C0439133:(f) [Intellectual Product]
   861   C1553038:[f] [Quantitative Concept]

Phrase: "Lin Q,"

Phrase: "Conley"

Phrase: "ME,"

Phrase: "Campana D"

Phrase: ":"

Phrase: "CD38 signal transduction in human B cell precursors."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   770   C0037083:Signal Transduction [Cell Function]
           signal cell
   744   C1160185:transduction [Organism Function]
   744   C1710082:Signal [Phenomenon or Process]
Processing 00000000.tx.330: Rapid induction of tyrosine phosphorylation, activation of syk tyrosine kinase, and phosphorylation of phospholipase C- and phosphatidylinositol 3-kinase. 

Phrase: "Rapid induction of tyrosine phosphorylation,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0205263:Induction [Functional Concept]
   760   C0857127:induction [Therapeutic or Preventive Procedure]

Phrase: "activation of syk tyrosine kinase,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C1879547:Activation [Activity]

Phrase: "and"

Phrase: "phosphorylation of phospholipase C-"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0031715:Phosphorylation [Molecular Function]
   770   C1158886:Phosphorylation [Molecular Function]

Phrase: "and"

Phrase: "phosphatidylinositol 3-kinase."
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0044602:Phosphatidylinositol 3-Kinase [Amino Acid, Peptide, or Protein,Enzyme]
   972 E C2936824:Phosphatidylinositol 3-Kinases [Amino Acid, Peptide, or Protein,Enzyme]
   827   C0031727:Kinase [Amino Acid, Peptide, or Protein,Enzyme]
Processing 00000000.tx.331: J Immunol 156:100107, 1996[Abstract] Zilber MT, Gregory S, Mallone R, Deaglio S, Malavasi F, Charron D, Gelin C: CD38 expressed on human monocytes: a co-accessory molecule in the superantigen-induced proliferation. 

Phrase: "J Immunol 156"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C1517844:Immunol [Organic Chemical,Pharmacologic Substance]

Phrase: ":"

Phrase: "100107,"

Phrase: "1996"

Phrase: "[Abstract"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0000857:Abstract [Occupational Activity]
  1000   C0600678:Abstract [Intellectual Product]
  1000   C1552863:Abstract [Idea or Concept]

Phrase: "] Zilber MT,"

Phrase: "Gregory S,"

Phrase: "Mallone R,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205090:R- [Spatial Concept]
   861   C0684010:R. [Professional or Occupational Group]
   861   C2603358:R' [Clinical Attribute]

Phrase: "Deaglio S,"

Phrase: "Malavasi F,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
   861   C0439133:(f) [Intellectual Product]
   861   C1553038:[f] [Quantitative Concept]

Phrase: "Charron D,"

Phrase: "Gelin C"

Phrase: ":"

Phrase: "CD38"

Phrase: "expressed on human monocytes"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0026473:Monocytes [Cell]
   770   C0086418:Human [Human]

Phrase: ":"

Phrase: "a co-accessory molecule in the superantigen-induced proliferation."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   742   C0567416:Molecule [Substance]
Processing 00000000.tx.332: Proc Natl Acad Sci U S A 97:28402845, 2000[Abstract/Free FullText] Mehta K, Malavasi F, Eds.: 

Phrase: "Proc Natl Acad Sci U S A 97"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   835   C0041703:U.S.A. [Geographic Area]
           U S
   793   C0268596:ACAD [Disease or Syndrome]
   793   C0439073:97 [Intellectual Product]
   793   C0439082:>97 [Quantitative Concept]
   793   C1418943:PROC [Gene or Genome]
   793   C2700624:ACAD [Cell Function]
   793   C3642273:SCI [Professional or Occupational Group]

Phrase: ":"

Phrase: "28402845,"

Phrase: "2000"

Phrase: "[Abstract/Free FullText"

Phrase: "] Mehta K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Malavasi F,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
   861   C0439133:(f) [Intellectual Product]
   861   C1553038:[f] [Quantitative Concept]

Phrase: "Eds."

Phrase: ":"
Processing 00000000.tx.333: Human CD38 and Related Molecules . Basel, Switzerland, Karger 2000 Howard M, Grimaldi JC, Bazan JF, Lund FE, Santos-Argumedo L, Parkhouse RM, Walseth TF, Lee HC: Formation and hydrolysis of cyclic ADP-ribose catalyzed by lymphocyte antigen CD38. 

Phrase: "Human CD38"

Phrase: "and"

Phrase: "Related Molecules . Basel,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0331779:Basel [Health Care Related Organization]

Phrase: "Switzerland,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0039021:Switzerland [Geographic Area]

Phrase: "Karger 2000 Howard M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   812   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   812   C0441923:M+ [Intellectual Product]

Phrase: "Grimaldi JC,"

Phrase: "Bazan JF,"

Phrase: "Lund FE,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C2346593:Fe+++ [Element, Ion, or Isotope]

Phrase: "Santos-Argumedo L,"

Phrase: "Parkhouse RM,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C2951520:RM [Body Location or Region]

Phrase: "Walseth TF,"

Phrase: "Lee HC"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0020268:HC [Hormone,Pharmacologic Substance,Steroid]
   861   C1413512:Hc [Gene or Genome]

Phrase: ":"

Phrase: "Formation"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0220781:formation [Biologic Function]
  1000   C0439634:formation [Spatial Concept]
  1000   C1522492:Formation [Functional Concept]

Phrase: "and"

Phrase: "hydrolysis of cyclic ADP-ribose"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0020291:Hydrolysis [Natural Phenomenon or Process]

Phrase: "catalyzed by lymphocyte antigen CD38."
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   862   C0075742:Lymphocyte antigen CD38 [Amino Acid, Peptide, or Protein,Enzyme,Immunologic Factor]
           CD38 Antigen
   806   C0023158:Lymphocyte antigen [Immunologic Factor,Organic Chemical]
   797   C1267915:CD38+ Lymphocyte [Cell]
   797   C1413221:CD38 ANTIGEN [Gene or Genome]
   797   C2827388:CD38 Antigen [Amino Acid, Peptide, or Protein]
   760   C0003320:Antigen [Immunologic Factor]
   760   C0024264:Lymphocyte [Cell]
Processing 00000000.tx.334: Science 262:10561059, 1993[Medline] Ziegler M: New functions of a long-known molecule: emerging roles of NAD in cellular signaling. 

Phrase: "Science 262"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0036397:Science [Occupation or Discipline]

Phrase: ":"

Phrase: "10561059,"

Phrase: "1993"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Ziegler M"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: ":"

Phrase: "New functions of a long-known molecule"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   748   C0542341:Functions [Functional Concept]
   721   C1148560:molecular function [Molecular Function]
   714 E C0031843:function [Physiologic Function]
   714 E C0700205:FUNCTION [Classification]
   714 E C1705273:Function [Intellectual Product]

Phrase: ":"

Phrase: "emerging roles of NAD"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   770   C0035820:Roles [Social Behavior]
   737 E C1705810:Role [Conceptual Entity]

Phrase: "in cellular signaling."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0037083:Signaling [Cell Function]
   861   C3537152:signaling [Biologic Function]
Processing 00000000.tx.335: Eur J Biochem 267:15501564, 2000[Abstract/Free FullText] Takasawa S, Nata K, Yonekura H, Okamoto H: Cyclic ADP-ribose in insulin secretion from pancreatic  cells. 

Phrase: "Eur J Biochem 267"

Phrase: ":"

Phrase: "15501564,"

Phrase: "2000"

Phrase: "[Abstract/Free FullText"

Phrase: "] Takasawa S,"

Phrase: "Nata K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Yonekura H,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: "Okamoto H"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: ":"

Phrase: "Cyclic ADP-ribose in insulin secretion"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   833   C0056693:Cyclic ADP-Ribose [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   790   C0001461:ADP Ribose [Biologically Active Substance,Carbohydrate,Nucleic Acid, Nucleoside, or Nucleotide]
   753   C0035549:Ribose [Carbohydrate]
   753   C0439596:Cyclic [Temporal Concept]
   753   C0523452:ADP [Laboratory Procedure]
   753   C1511572:Cyclic [Temporal Concept]

Phrase: "from pancreatic  cells."
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   861   C0007634:Cells [Cell]
   861   C3282337:Cells [Cell]
   827 E C1269647:Cell [Cell]
   827 E C1704653:Cell [Medical Device]
   827 E C1948049:Cell [Spatial Concept]
Processing 00000000.tx.336: Science 259:370373, 1993[Medline] Kato I, Takasawa S, Akabane A, Tanaka O, Abe H, Takamura T, Suzuki Y, Nata K, Yonekura H, Yoshimoto T, Okamoto H: Regulatory role of CD38 (ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase) in insulin secretion in pancreatic cells: enhanced insulin secretion in CD38-expressing transgenic mice. 

Phrase: "Science 259"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0036397:Science [Occupation or Discipline]

Phrase: ":"

Phrase: "370373,"

Phrase: "1993"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Kato I,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0021966:I- [Inorganic Chemical]
   861   C0221138:I NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: "Takasawa S,"

Phrase: "Akabane A,"

Phrase: "Tanaka O,"

Phrase: "Abe H,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: "Takamura T,"

Phrase: "Suzuki Y,"

Phrase: "Nata K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Yonekura H,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: "Yoshimoto T,"

Phrase: "Okamoto H"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: ":"

Phrase: "Regulatory role of CD38"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0035820:Role [Social Behavior]
   770   C1705810:Role [Conceptual Entity]

Phrase: "(ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C1413221:ADP-RIBOSYL CYCLASE/CYCLIC ADP-RIBOSE HYDROLASE [Gene or Genome]
   877   C0217585:Cyclic ADP-ribose Hydrolase [Amino Acid, Peptide, or Protein,Enzyme]
   795   C0020289:Hydrolase [Amino Acid, Peptide, or Protein,Enzyme]
   710   C0001461:ADP Ribose [Biologically Active Substance,Carbohydrate,Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: ")"

Phrase: "in insulin secretion"
Meta Candidates (Total=8; Excluded=2; Pruned=0; Remaining=6)
  1000   C1256369:insulin secretion [Cell Function]
   861   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C0036536:secretion [Biologic Function]
   861   C0036537:Secretion [Body Substance]
   861   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C1579433:Insulin [Pharmacologic Substance]
   805 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   777 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "in pancreatic cells"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   861   C0007634:Cells [Cell]
   861   C3282337:Cells [Cell]
   827 E C1269647:Cell [Cell]
   827 E C1704653:Cell [Medical Device]
   827 E C1948049:Cell [Spatial Concept]

Phrase: ":"

Phrase: "enhanced insulin secretion in CD38-"
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
   806   C1256369:insulin secretion [Cell Function]
   760   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   760   C0036536:secretion [Biologic Function]
   760   C0036537:Secretion [Body Substance]
   760   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   760   C1579433:Insulin [Pharmacologic Substance]
   704 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]

Phrase: "expressing"

Phrase: "transgenic mice."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0025936:Mice, Transgenic [Mammal]
   861   C0003069:Transgenic [Animal]
   861   C0025914:Mice [Mammal]
   861   C0025929:mice [Mammal]
   861   C0026809:Mice [Mammal]
Processing 00000000.tx.337: J Biol Chem 270:3004530050, 1995[Abstract/Free FullText] Kato I, Yamamoto Y, Fujimura M, Noguchi N, Takasawa S, Okamoto H: CD38 disruption impairs glucose-induced increases in cyclic ADP-ribose, [Ca2+]i and insulin secretion. 

Phrase: "J Biol Chem 270"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C0201682:CHEM [Laboratory Procedure]

Phrase: ":"

Phrase: "3004530050,"

Phrase: "1995"

Phrase: "[Abstract/Free FullText"

Phrase: "] Kato I,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0021966:I- [Inorganic Chemical]
   861   C0221138:I NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: "Yamamoto Y,"

Phrase: "Fujimura M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Noguchi N,"

Phrase: "Takasawa S,"

Phrase: "Okamoto H"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: ":"

Phrase: "CD38 disruption"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0332453:Disruption [Functional Concept]

Phrase: "impairs"

Phrase: "glucose-induced increases in cyclic ADP-ribose,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C0442805:increases [Functional Concept]

Phrase: "[Ca2+"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0596235:Ca2+ [Element, Ion, or Isotope,Pharmacologic Substance]

Phrase: "]i"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0021966:I- [Inorganic Chemical]
  1000   C0221138:I NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: "and"

Phrase: "insulin secretion."
Meta Candidates (Total=8; Excluded=2; Pruned=0; Remaining=6)
  1000   C1256369:insulin secretion [Cell Function]
   861   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C0036536:secretion [Biologic Function]
   861   C0036537:Secretion [Body Substance]
   861   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C1579433:Insulin [Pharmacologic Substance]
   805 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   777 E C3537244:Insulins [Pharmacologic Substance]
Processing 00000000.tx.338: J Biol Chem 274:18691872, 1999[Abstract/Free FullText] Yagui K, Shimada F, Mimura M, Hashimoto N, Suzuki Y, Tokuyama Y, Nata K, Tohgo A, Ikehata F, Takasawa S, Okamoto H, Makino H, Saito Y, Kanatsuka A: A missense mutation in the CD38 gene, a novel factor for insulin secretion: association with type II diabetes mellitus in Japanese subjects and evidence of abnormal function when expressed in vitro. 

Phrase: "J Biol Chem 274"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C0201682:CHEM [Laboratory Procedure]

Phrase: ":"

Phrase: "18691872,"

Phrase: "1999"

Phrase: "[Abstract/Free FullText"

Phrase: "] Yagui K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Shimada F,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
   861   C0439133:(f) [Intellectual Product]
   861   C1553038:[f] [Quantitative Concept]

Phrase: "Mimura M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Hashimoto N,"

Phrase: "Suzuki Y,"

Phrase: "Tokuyama Y,"

Phrase: "Nata K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Tohgo A,"

Phrase: "Ikehata F,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
   861   C0439133:(f) [Intellectual Product]
   861   C1553038:[f] [Quantitative Concept]

Phrase: "Takasawa S,"

Phrase: "Okamoto H,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: "Makino H,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: "Saito Y,"

Phrase: "Kanatsuka A"

Phrase: ":"

Phrase: "A missense mutation in the CD38 gene,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   778   C0599155:Missense Mutation [Genetic Function]
   774   C0596611:Gene Mutation [Genetic Function]
   748   C0026882:Mutation [Genetic Function]
   748   C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "a novel factor for insulin secretion"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   783   C0050325:A-factor [Biologically Active Substance,Organic Chemical]
   783   C0960756:factor A [Organic Chemical]
   753   C1521761:Factor [Functional Concept]
   753   C2827422:Factor [Conceptual Entity]

Phrase: ":"

Phrase: "association with type II diabetes mellitus"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   783   C3645563:Association type [Intellectual Product]
   753   C0004083:Association [Mental Process]
   753   C0439849:Association [Qualitative Concept]
   753   C0596306:Association [Phenomenon or Process]
   753   C0699792:association [Social Behavior]
   716   C0011860:Diabetes Mellitus, Type 2 [Disease or Syndrome]
   716   C2984301:Type II diabetes mellitus [Functional Concept]

Phrase: "in Japanese subjects"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   827   C0681850:Subject [Group]
   827   C1550501:{Subject} [Idea or Concept]
   827   C1706203:Subject [Idea or Concept]
   827   C2349001:Subject [Human]
   827   C2697811:Subject [Functional Concept]

Phrase: "and"

Phrase: "evidence of abnormal function"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   833   C0332120:Evidence of [Functional Concept]
           Evidence

Phrase: "when"

Phrase: "expressed"

Phrase: "in vitro."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0021135:In Vitro [Intellectual Product]
  1000   C1533691:in vitro [Qualitative Concept]
           vitro
  1000   C2827718:In Vitro [Functional Concept]
Processing 00000000.tx.339: Diabetologia 41:10241028, 1998[Medline] Ikehata F, Satoh J, Nata K, Tohgo A, Nakazawa T, Kato I, Kobayashi S, Akiyama T, Takasawa S, Toyota T, Okamoto H: Autoantibodies against CD38 (ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase) that impair glucose-induced insulin secretion in noninsulin-dependent diabetes patients. 

Phrase: "Diabetologia 41"

Phrase: ":"

Phrase: "10241028,"

Phrase: "1998"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Ikehata F,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
   861   C0439133:(f) [Intellectual Product]
   861   C1553038:[f] [Quantitative Concept]

Phrase: "Satoh J,"

Phrase: "Nata K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Tohgo A,"

Phrase: "Nakazawa T,"

Phrase: "Kato I,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0021966:I- [Inorganic Chemical]
   861   C0221138:I NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: "Kobayashi S,"

Phrase: "Akiyama T,"

Phrase: "Takasawa S,"

Phrase: "Toyota T,"

Phrase: "Okamoto H"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: ":"

Phrase: "Autoantibodies against CD38"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C0004358:Autoantibodies [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: "(ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C1413221:ADP-RIBOSYL CYCLASE/CYCLIC ADP-RIBOSE HYDROLASE [Gene or Genome]
   877   C0217585:Cyclic ADP-ribose Hydrolase [Amino Acid, Peptide, or Protein,Enzyme]
   795   C0020289:Hydrolase [Amino Acid, Peptide, or Protein,Enzyme]
   710   C0001461:ADP Ribose [Biologically Active Substance,Carbohydrate,Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: ")"

Phrase: "that"

Phrase: "impair"

Phrase: "glucose-induced insulin secretion in noninsulin-dependent diabetes patients."
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   784   C0011854:Insulin Dependent Diabetes [Disease or Syndrome]
   764   C1256369:insulin secretion [Cell Function]
   762   C1719133:Glucose/Insulin [Quantitative Concept]
   742   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   742   C0036536:secretion [Biologic Function]
   742   C0036537:Secretion [Body Substance]
   742   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   742   C1579433:Insulin [Pharmacologic Substance]
Processing 00000000.tx.340: J Clin Invest 102:395401, 1998[Abstract/Free FullText] Pupilli C, Giannini S, Marchetti P, Lupi R, Antonelli A, Malavasi F, Takasawa S, Okamoto H, Ferrannini E: Autoantibodies to CD38 (ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase) in Caucasian patients with diabetes: effects on insulin release from human islets. 

Phrase: "J"

Phrase: "Clin"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1315013:CLIN [Intellectual Product]

Phrase: "Invest"

Phrase: "102"

Phrase: ":"

Phrase: "395401,"

Phrase: "1998"

Phrase: "[Abstract/Free FullText"

Phrase: "] Pupilli C,"

Phrase: "Giannini S,"

Phrase: "Marchetti P,"

Phrase: "Lupi R,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205090:R- [Spatial Concept]
   861   C0684010:R. [Professional or Occupational Group]
   861   C2603358:R' [Clinical Attribute]

Phrase: "Antonelli A,"

Phrase: "Malavasi F,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
   861   C0439133:(f) [Intellectual Product]
   861   C1553038:[f] [Quantitative Concept]

Phrase: "Takasawa S,"

Phrase: "Okamoto H,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: "Ferrannini E"

Phrase: ":"

Phrase: "Autoantibodies to CD38"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C0004358:Autoantibodies [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: "(ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C1413221:ADP-RIBOSYL CYCLASE/CYCLIC ADP-RIBOSE HYDROLASE [Gene or Genome]
   877   C0217585:Cyclic ADP-ribose Hydrolase [Amino Acid, Peptide, or Protein,Enzyme]
   795   C0020289:Hydrolase [Amino Acid, Peptide, or Protein,Enzyme]
   710   C0001461:ADP Ribose [Biologically Active Substance,Carbohydrate,Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: ")"

Phrase: "in Caucasian patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]

Phrase: "with diabetes"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0011847:Diabetes [Disease or Syndrome]
  1000   C0011849:Diabetes [Disease or Syndrome]

Phrase: ":"

Phrase: "effects on insulin release"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   770   C1280500:effects [Qualitative Concept]
   737 E C2348382:Effect [Qualitative Concept]

Phrase: "from human islets."
Processing 00000000.tx.341: Diabetes 48:23092315, 1999[Abstract] Ferrero E, Saccucci F, Malavasi F: The human CD38 gene: polymorphism, CpG island, and linkage to the CD157 (BST-1) gene. 

Phrase: "Diabetes 48"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0011847:Diabetes [Disease or Syndrome]
   861   C0011849:Diabetes [Disease or Syndrome]

Phrase: ":"

Phrase: "23092315,"

Phrase: "1999"

Phrase: "[Abstract"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0000857:Abstract [Occupational Activity]
  1000   C0600678:Abstract [Intellectual Product]
  1000   C1552863:Abstract [Idea or Concept]

Phrase: "] Ferrero E,"

Phrase: "Saccucci F,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
   861   C0439133:(f) [Intellectual Product]
   861   C1553038:[f] [Quantitative Concept]

Phrase: "Malavasi F"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
   861   C0439133:(f) [Intellectual Product]
   861   C1553038:[f] [Quantitative Concept]

Phrase: ":"

Phrase: "The human CD38 gene"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   913   C0314604:Human gene [Gene or Genome]
   901   C1413221:CD38 gene [Gene or Genome]
   827   C0017337:Gene [Gene or Genome]

Phrase: ":"

Phrase: "polymorphism,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0032529:Polymorphism [Genetic Function]
  1000   C1882417:Polymorphism [Qualitative Concept]

Phrase: "CpG island,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0282523:CpG Island [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   861   C0022130:Island [Geographic Area]

Phrase: "and"

Phrase: "linkage to the CD157"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0023745:linkage [Molecular Function]

Phrase: "(BST-1"

Phrase: ")"

Phrase: "gene."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0017337:Gene [Gene or Genome]
Processing 00000000.tx.342: Immunogenetics 49:597604, 1999[Medline] Pizzuti A, Frittitta L, Argiolas A, Baratta R, Goldfine ID, Bozzali M, Ercolino T, Scarlato G, Iacoviello L, Vigneri R, Tassi V, Trischitta V: A polymorphism (K121Q) of the human glycoprotein PC-1 gene coding region is strongly associated with insulin resistance. 

Phrase: "Immunogenetics 49"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0021005:Immunogenetics [Biomedical Occupation or Discipline]

Phrase: ":"

Phrase: "597604,"

Phrase: "1999"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Pizzuti A,"

Phrase: "Frittitta L,"

Phrase: "Argiolas A,"

Phrase: "Baratta R,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205090:R- [Spatial Concept]
   861   C0684010:R. [Professional or Occupational Group]
   861   C2603358:R' [Clinical Attribute]

Phrase: "Goldfine ID,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0600091:ID [Intellectual Product]

Phrase: "Bozzali M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Ercolino T,"

Phrase: "Scarlato G,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0439267:g% [Quantitative Concept]

Phrase: "Iacoviello L,"

Phrase: "Vigneri R,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205090:R- [Spatial Concept]
   861   C0684010:R. [Professional or Occupational Group]
   861   C2603358:R' [Clinical Attribute]

Phrase: "Tassi V,"

Phrase: "Trischitta V"

Phrase: ":"

Phrase: "A polymorphism"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0032529:Polymorphism [Genetic Function]
  1000   C1882417:Polymorphism [Qualitative Concept]

Phrase: "(K121Q"

Phrase: ")"

Phrase: "of the human glycoprotein PC-1 gene coding region"
Meta Candidates (Total=10; Excluded=3; Pruned=0; Remaining=7)
   861   C0314604:Human gene [Gene or Genome]
   829   C1418288:PC gene [Gene or Genome]
   818   C0079941:Coding Region [Gene or Genome]
   795   C0009219:Coding [Occupational Activity]
   795   C0017337:Gene [Gene or Genome]
   795   C0017446:Region [Geographic Area]
   795   C0205147:Region [Spatial Concept]
   762 E C0805701:Code [Intellectual Product]
   724 E C0205276:Regional [Spatial Concept]
   724 E C1947913:Regional [Spatial Concept]

Phrase: "is"

Phrase: "strongly"

Phrase: "associated with insulin resistance."
Meta Candidates (Total=12; Excluded=3; Pruned=0; Remaining=9)
   833   C0021655:Insulin Resistance [Pathologic Function]
   833   C0332281:Associated with [Qualitative Concept]
           Associated
   833   C2700570:INSULIN RESISTANCE [Gene or Genome]
   770   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   770   C0237834:Resistance [Mental Process]
   770   C1514892:Resistance [Physiologic Function]
   770   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   770   C1579433:Insulin [Pharmacologic Substance]
   737 E C0750490:Associate [Idea or Concept]
   737 E C1706221:Associate [Professional or Occupational Group]
   715 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
Processing 00000000.tx.343: Diabetes 48:18811884, 1999[Abstract] The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. 

Phrase: "Diabetes 48"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0011847:Diabetes [Disease or Syndrome]
   861   C0011849:Diabetes [Disease or Syndrome]

Phrase: ":"

Phrase: "18811884,"

Phrase: "1999"

Phrase: "[Abstract"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0000857:Abstract [Occupational Activity]
  1000   C0600678:Abstract [Intellectual Product]
  1000   C1552863:Abstract [Idea or Concept]

Phrase: "]"

Phrase: "The Expert Committee on the Diagnosis"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C2699414:Committee [Group]

Phrase: "and"

Phrase: "Classification of Diabetes Mellitus"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0008902:Classification [Classification]
   770   C0008903:classification [Functional Concept]
   770   C0678229:classification [Occupational Activity]

Phrase: ":"

Phrase: "Report of the Expert Committee"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C0684224:Report [Intellectual Product]
   760   C0700287:Report [Health Care Activity]
   760   C3273238:Report [Intellectual Product]

Phrase: "on the Diagnosis"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0011900:Diagnosis [Finding]
  1000   C1704338:diagnosis [Qualitative Concept]
  1000   C1704656:DIAGNOSIS [Research Activity]

Phrase: "and"

Phrase: "Classification of Diabetes Mellitus."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0008902:Classification [Classification]
   770   C0008903:classification [Functional Concept]
   770   C0678229:classification [Occupational Activity]
Processing 00000000.tx.344: Diabetes Care 20:11831197, 1997[Medline] Alberti KGM, Zimmet PZ: Definition, diagnosis and classification of diabetes mellitus and its complications. 

Phrase: "Diabetes Care 20"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0011847:Diabetes [Disease or Syndrome]
   827   C0011849:Diabetes [Disease or Syndrome]
   827   C1947933:Care [Activity]

Phrase: ":"

Phrase: "11831197,"

Phrase: "1997"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Alberti KGM,"

Phrase: "Zimmet PZ"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1418952:PZ [Gene or Genome]

Phrase: ":"

Phrase: "Definition,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C1550452:definition [Idea or Concept]
  1000   C1704788:Definition [Conceptual Entity]
  1000   C3539107:Definition [Intellectual Product]

Phrase: "diagnosis"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0011900:Diagnosis [Finding]
  1000   C1704338:diagnosis [Qualitative Concept]
  1000   C1704656:DIAGNOSIS [Research Activity]

Phrase: "and"

Phrase: "classification of diabetes mellitus"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0008902:Classification [Classification]
   770   C0008903:classification [Functional Concept]
   770   C0678229:classification [Occupational Activity]

Phrase: "and"

Phrase: "its complications."
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
  1000   C0009566:Complications [Pathologic Function]
  1000   C1171258:complications [Pathologic Function]
   966 E C2362589:Complication [Idea or Concept]
   916 E C0231242:Complicated [Functional Concept]
Processing 00000000.tx.345: I. 

Phrase: "I."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0021966:I- [Inorganic Chemical]
  1000   C0221138:I NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
Processing 00000000.tx.346: Diagnosis and classification of diabetes mellitus: provisional report of a WHO consultation. 

Phrase: "Diagnosis"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0011900:Diagnosis [Finding]
  1000   C1704338:diagnosis [Qualitative Concept]
  1000   C1704656:DIAGNOSIS [Research Activity]

Phrase: "and"

Phrase: "classification of diabetes mellitus"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0008902:Classification [Classification]
   770   C0008903:classification [Functional Concept]
   770   C0678229:classification [Occupational Activity]

Phrase: ":"

Phrase: "provisional report of a WHO consultation."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   767   C1269802:Consultation report [Intellectual Product]
   744   C0684224:Report [Intellectual Product]
   744   C0700287:Report [Health Care Activity]
   744   C3273238:Report [Intellectual Product]
Processing 00000000.tx.347: Diabet Med 15:539553, 1998[Medline] Munshi CB, Fryxell KB, Lee HC, Branton WD: Large-scale production of human CD38 in yeast by fermentation. 

Phrase: "Diabet Med 15"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   901   C0378666:MED 15 [Organic Chemical,Pharmacologic Substance]

Phrase: ":"

Phrase: "539553,"

Phrase: "1998"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Munshi CB,"

Phrase: "Fryxell KB,"

Phrase: "Lee HC,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0020268:HC [Hormone,Pharmacologic Substance,Steroid]
   861   C1413512:Hc [Gene or Genome]

Phrase: "Branton WD"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0019202:WD [Disease or Syndrome]
   861   C0332135:WD [Qualitative Concept]
   861   C1862191:WD [Intellectual Product]
   861   C3538902:WD [Gene or Genome]

Phrase: ":"

Phrase: "Large-scale production of human CD38"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C0033268:production [Occupational Activity]

Phrase: "in yeast"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0036025:yeast [Fungus]
  1000   C0043392:Yeast [Food]
  1000   C0043393:Yeast [Fungus]
  1000   C0717551:YEAST [Immunologic Factor,Pharmacologic Substance]

Phrase: "by fermentation."
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0015852:Fermentation [Molecular Function]
   907 E C0014436:Zymogens [Amino Acid, Peptide, or Protein,Biologically Active Substance]
Processing 00000000.tx.348: Methods Enzymol 280:318330, 1997[Medline] Malavasi F, Caligaris-Cappio F, Dellabona P, Richiardi P, Carbonara AO: Characterization of a murine monoclonal antibody specific for human early lymphohemopoietic cells. 

Phrase: "Methods Enzymol 280"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   827   C0025663:Methods [Intellectual Product]
   827   C0025664:methods [Intellectual Product]
   827   C0449851:Methods [Functional Concept]
   793 E C0871511:METHOD [Intellectual Product]

Phrase: ":"

Phrase: "318330,"

Phrase: "1997"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Malavasi F,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
   861   C0439133:(f) [Intellectual Product]
   861   C1553038:[f] [Quantitative Concept]

Phrase: "Caligaris-Cappio F,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
   827   C0439133:(f) [Intellectual Product]
   827   C1553038:[f] [Quantitative Concept]

Phrase: "Dellabona P,"

Phrase: "Richiardi P,"

Phrase: "Carbonara AO"

Phrase: ":"

Phrase: "Characterization of a murine monoclonal antibody"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C1880022:Characterization [Activity]

Phrase: "specific for human early lymphohemopoietic cells."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0205369:Specific [Qualitative Concept]
   753   C1552740:specific [Intellectual Product]
Processing 00000000.tx.349: Hum Immunol 9:920, 1984[Medline] Riemekasten G, Marell J, Trebeljahr G, Klein R, Hausdorf G, Haupl T, Schneider-Mergener J, Burmester GR, Hiepe F: A novel epitope on the C-terminus of SmD1 is recognized by the majority of sera from patients with systemic lupus erythematosus. 

Phrase: "Hum Immunol 9"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C1517844:Immunol [Organic Chemical,Pharmacologic Substance]

Phrase: ":"

Phrase: "920,"

Phrase: "1984"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Riemekasten G,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0439267:g% [Quantitative Concept]

Phrase: "Marell J,"

Phrase: "Trebeljahr G,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0439267:g% [Quantitative Concept]

Phrase: "Klein R,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205090:R- [Spatial Concept]
   861   C0684010:R. [Professional or Occupational Group]
   861   C2603358:R' [Clinical Attribute]

Phrase: "Hausdorf G,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0439267:g% [Quantitative Concept]

Phrase: "Haupl T,"

Phrase: "Schneider-Mergener J,"

Phrase: "Burmester GR,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1552950:[gr] [Quantitative Concept]

Phrase: "Hiepe F"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
   861   C0439133:(f) [Intellectual Product]
   861   C1553038:[f] [Quantitative Concept]

Phrase: ":"

Phrase: "A novel epitope on the C-terminus of SmD1"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   742   C0003316:Epitope [Immunologic Factor]

Phrase: "is"

Phrase: "recognized by the majority of sera"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
   753   C0229671:Sera [Body Substance]
   753   C0680220:majority [Social Behavior]
   753   C1151254:SerA [Molecular Function]
   719 E C1546774:Serum [Intellectual Product]
   719 E C1550100:Serum [Body Substance]

Phrase: "from patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "with systemic lupus erythematosus."
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
  1000   C0024141:Lupus Erythematosus, Systemic [Disease or Syndrome]
  1000   C2984317:Systemic lupus erythematosus [Functional Concept]
   901   C0409974:Lupus Erythematosus [Disease or Syndrome]
           Lupus
   827   C0024131:Lupus [Disease or Syndrome]
   827   C0024138:lupus [Disease or Syndrome]
   827   C0205373:Systemic [Functional Concept]
Processing 00000000.tx.350: J Clin Invest 102:754763, 1998[Abstract/Free FullText] Baus E, Urbain J, Leo O, Andris F: Flow cytometric measurement of calcium influx in murine T cell hybrids using Fluo-3 and an organic-anion transport inhibitor. 

Phrase: "J"

Phrase: "Clin"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1315013:CLIN [Intellectual Product]

Phrase: "Invest"

Phrase: "102"

Phrase: ":"

Phrase: "754763,"

Phrase: "1998"

Phrase: "[Abstract/Free FullText"

Phrase: "] Baus E,"

Phrase: "Urbain J,"

Phrase: "Leo O,"

Phrase: "Andris F"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
   861   C0439133:(f) [Intellectual Product]
   861   C1553038:[f] [Quantitative Concept]

Phrase: ":"

Phrase: "Flow cytometric measurement of calcium influx"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   783   C0201925:Calcium measurement [Laboratory Procedure]
   753   C0242485:Measurement [Functional Concept]

Phrase: "in murine T cell hybrids"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C0020205:Hybrids [Organism]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "Fluo-3"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0060505:Fluo-3 [Organic Chemical,Pharmacologic Substance]
   861   C0385473:fluo [Organic Chemical,Pharmacologic Substance]

Phrase: "and"

Phrase: "an organic-anion transport inhibitor."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0597607:transport inhibitor [Pharmacologic Substance]
   812   C1999216:Inhibitor [Qualitative Concept]
   756   C1159606:organic anion transport [Cell Function]
Processing 00000000.tx.351: J Immunol Methods 173:4147, 1994[Medline] Vandenberghe PA, Ceuppens JL: Flow cytometric measurement of cytoplasmic free calcium in human peripheral blood T lymphocytes with fluo-3, a new fluorescent calcium indicator. 

Phrase: "J Immunol Methods 173"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   812   C0025663:Methods [Intellectual Product]
   812   C0025664:methods [Intellectual Product]
   812   C0449851:Methods [Functional Concept]
   812   C1517844:Immunol [Organic Chemical,Pharmacologic Substance]
   779 E C0871511:METHOD [Intellectual Product]

Phrase: ":"

Phrase: "4147,"

Phrase: "1994"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Vandenberghe PA,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C3541314:PA [Idea or Concept]

Phrase: "Ceuppens JL"

Phrase: ":"

Phrase: "Flow cytometric measurement of cytoplasmic free calcium"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   774   C0201925:Calcium measurement [Laboratory Procedure]
   748   C0242485:Measurement [Functional Concept]

Phrase: "in human peripheral blood T lymphocytes"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   872   C1518997:Peripheral Blood Lymphocyte [Cell]
   840   C0039194:T-Lymphocytes [Cell]
   836   C0024264:Blood lymphocyte [Cell]
           Lymphocytes

Phrase: "with fluo-3,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0060505:Fluo-3 [Organic Chemical,Pharmacologic Substance]
   861   C0385473:fluo [Organic Chemical,Pharmacologic Substance]

Phrase: "a new fluorescent calcium indicator."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0596234:calcium indicator [Indicator, Reagent, or Diagnostic Aid]
   812   C0021212:indicator [Indicator, Reagent, or Diagnostic Aid]
   812   C1235732:Indicator [Bird]
   812   C1522602:Indicator [Functional Concept]
Processing 00000000.tx.352: J Immunol Methods 127:197205, 1990[Medline] Chevenne D, Valade F, Bridel MP, Rigal O, Demelier JF, Sachs C, Porquet D: Protein A-sepharose used to measure free insulin in plasma. 

Phrase: "J Immunol Methods 127"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   812   C0025663:Methods [Intellectual Product]
   812   C0025664:methods [Intellectual Product]
   812   C0449851:Methods [Functional Concept]
   812   C1517844:Immunol [Organic Chemical,Pharmacologic Substance]
   779 E C0871511:METHOD [Intellectual Product]

Phrase: ":"

Phrase: "197205,"

Phrase: "1990"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Chevenne D,"

Phrase: "Valade F,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
   861   C0439133:(f) [Intellectual Product]
   861   C1553038:[f] [Quantitative Concept]

Phrase: "Bridel MP,"

Phrase: "Rigal O,"

Phrase: "Demelier JF,"

Phrase: "Sachs C,"

Phrase: "Porquet D"

Phrase: ":"

Phrase: "Protein A-sepharose"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0075172:protein A-sepharose [Carbohydrate]
   827   C0036681:Sepharose [Carbohydrate]
   734   C0038164:Protein A [Amino Acid, Peptide, or Protein,Immunologic Factor,Indicator, Reagent, or Diagnostic Aid]

Phrase: "used"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1273517:used [Finding]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "measure"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0079809:Measure [Quantitative Concept]
  1000   C0242485:Measure [Functional Concept]

Phrase: "free insulin in plasma."
Meta Candidates (Total=7; Excluded=2; Pruned=0; Remaining=5)
   833   C0523720:free insulin [Laboratory Procedure]
   819 E C0487017:Insulin.free [Clinical Attribute]
   819   C0857690:plasma insulin [Laboratory Procedure]
   770   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   770   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   770   C1579433:Insulin [Pharmacologic Substance]
   715 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
Processing 00000000.tx.353: Clin Chem 37:6467, 1991[Abstract/Free FullText] Guidelines Subcommittee: 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. 

Phrase: "Clin Chem 37"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0201682:CHEM [Laboratory Procedure]
   827   C1315013:CLIN [Intellectual Product]

Phrase: ":"

Phrase: "6467,"

Phrase: "1991"

Phrase: "[Abstract/Free FullText"

Phrase: "] Guidelines Subcommittee"

Phrase: ":"

Phrase: "1999 World Health Organization-International Society of Hypertension Guidelines for the Management"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   736   C0162791:Guidelines [Intellectual Product]
   736   C0220845:guidelines [Intellectual Product]
   736   C0282423:guidelines [Intellectual Product]

Phrase: "of Hypertension."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0020538:Hypertension [Disease or Syndrome]
  1000   C1963138:Hypertension [Finding]
Processing 00000000.tx.354: J Hypertens 17:151183, 1999[Medline] Laird PW, Zijderveld A, Linders K, Rudnicki MA, Jaenisch R, Berns A: Simplified mammalian DNA isolation procedure. 

Phrase: "J Hypertens 17"

Phrase: ":"

Phrase: "151183,"

Phrase: "1999"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Laird PW,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0242397:PW [Geographic Area]

Phrase: "Zijderveld A,"

Phrase: "Linders K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Rudnicki MA,"

Phrase: "Jaenisch R,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205090:R- [Spatial Concept]
   861   C0684010:R. [Professional or Occupational Group]
   861   C2603358:R' [Clinical Attribute]

Phrase: "Berns A"

Phrase: ":"

Phrase: "Simplified mammalian DNA isolation procedure."
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   840   C0204727:Isolation procedure [Therapeutic or Preventive Procedure]
   804   C0184661:Procedure [Diagnostic Procedure,Therapeutic or Preventive Procedure]
   804   C1948041:Procedure [Therapeutic or Preventive Procedure]
   804   C2700391:Procedure [Activity]
   804   C3274430:PROCEDURE [Health Care Activity]
   804   C3538935:Procedure [Idea or Concept]
   804   C3539779:Procedure [Intellectual Product]
Processing 00000000.tx.355: Nucleic Acids Res 19:4293, 1991[Medline] Hoshino S, Kukimoto I, Kontani K, Inoue S, Kanda Y, Malavasi F, Katada T: Mapping of the catalytic and epitopic sites of human CD38/NAD+ glycohydrolase to a functional domain in the carboxyl terminus. 

Phrase: "Nucleic Acids Res 19"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   861   C0028606:Nucleic Acids [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   812   C0001128:Acids [Chemical]
   812   C0007610:Nucleic [Cell Component]
   812   C2347379:RES [Finding]
   779 E C0202406:Acid [Laboratory Procedure]

Phrase: ":"

Phrase: "4293,"

Phrase: "1991"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Hoshino S,"

Phrase: "Kukimoto I,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0021966:I- [Inorganic Chemical]
   861   C0221138:I NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: "Kontani K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Inoue S,"

Phrase: "Kanda Y,"

Phrase: "Malavasi F,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
   861   C0439133:(f) [Intellectual Product]
   861   C1553038:[f] [Quantitative Concept]

Phrase: "Katada T"

Phrase: ":"

Phrase: "Mapping of the catalytic"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   770   C0007382:Catalytic [Natural Phenomenon or Process]
   770   C1283195:Mapping [Activity]
   737 E C0024779:Map [Manufactured Object]
   737 E C1706473:Map [Conceptual Entity]

Phrase: "and"

Phrase: "epitopic sites of human CD38/NAD+ glycohydrolase"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   762   C2945843:Site of [Qualitative Concept]
   748   C0205145:Sites [Spatial Concept]
   714 E C1515974:Site [Body Location or Region]
   714 E C2825164:Site [Spatial Concept]

Phrase: "to a functional domain"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C1880389:Domain [Functional Concept]
   861   C1883221:Domain [Conceptual Entity]
   861   C3541951:Domain [Intellectual Product]

Phrase: "in the carboxyl terminus."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0596260:Carboxyl [Organic Chemical]
Processing 00000000.tx.356: J Immunol 158:741747, 1997[Abstract] Alessio M, Roggero S, Funaro A, De Monte LB, Peruzzi L, Geuna M, Malavasi F: CD38 molecule: structural and biochemical analysis on human T lymphocytes, thymocytes, and plasma cells. 

Phrase: "J Immunol 158"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C1517844:Immunol [Organic Chemical,Pharmacologic Substance]

Phrase: ":"

Phrase: "741747,"

Phrase: "1997"

Phrase: "[Abstract"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0000857:Abstract [Occupational Activity]
  1000   C0600678:Abstract [Intellectual Product]
  1000   C1552863:Abstract [Idea or Concept]

Phrase: "] Alessio M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Roggero S,"

Phrase: "Funaro A,"

Phrase: "De Monte LB,"

Phrase: "Peruzzi L,"

Phrase: "Geuna M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Malavasi F"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
   861   C0439133:(f) [Intellectual Product]
   861   C1553038:[f] [Quantitative Concept]

Phrase: ":"

Phrase: "CD38 molecule"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C0075742:CD38 molecule [Amino Acid, Peptide, or Protein,Enzyme,Immunologic Factor]
  1000   C1413221:CD38 molecule [Gene or Genome]
   861   C0567416:Molecule [Substance]
   789 E C1521991:Molecular [Qualitative Concept]

Phrase: ":"

Phrase: "structural"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0678594:Structural [Spatial Concept]

Phrase: "and"

Phrase: "biochemical analysis on human T lymphocytes,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   753   C0002778:Analysis [Laboratory Procedure]
   753   C0936012:Analysis [Research Activity]
   753   C1524024:analysis [Functional Concept]

Phrase: "thymocytes,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0814999:Thymocytes [Cell]

Phrase: "and"

Phrase: "plasma cells."
Meta Candidates (Total=8; Excluded=3; Pruned=0; Remaining=5)
  1000   C0032112:Plasma Cells [Cell]
   861   C0007634:Cells [Cell]
   861   C0032105:Plasma [Body Substance]
   861   C1550098:Plasma, NOS (not otherwise specified) [Body Substance]
   861   C3282337:Cells [Cell]
   827 E C1269647:Cell [Cell]
   827 E C1704653:Cell [Medical Device]
   827 E C1948049:Cell [Spatial Concept]
Processing 00000000.tx.357: J Immunol 145:878884, 1990[Abstract/Free FullText] Funaro A, Horenstein AL, Calosso L, Morra M, Tarocco RP, Franco L, De Flora A, Malavasi F: Identification and characterization of an active soluble form of human CD38 in normal and pathological fluids. 

Phrase: "J Immunol 145"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C1517844:Immunol [Organic Chemical,Pharmacologic Substance]

Phrase: ":"

Phrase: "878884,"

Phrase: "1990"

Phrase: "[Abstract/Free FullText"

Phrase: "] Funaro A,"

Phrase: "Horenstein AL,"

Phrase: "Calosso L,"

Phrase: "Morra M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Tarocco RP,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1538326:RP [Gene or Genome]
   861   C3541325:RP [Idea or Concept]

Phrase: "Franco L,"

Phrase: "De Flora A,"

Phrase: "Malavasi F"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
   861   C0439133:(f) [Intellectual Product]
   861   C1553038:[f] [Quantitative Concept]

Phrase: ":"

Phrase: "Identification"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0020792:Identification [Mental Process]
  1000   C0205396:Identification [Qualitative Concept]

Phrase: "and"

Phrase: "characterization of an active soluble form of human CD38"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   742   C1880022:Characterization [Activity]

Phrase: "in normal"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205307:Normal [Qualitative Concept]
  1000   C0439166:% normal [Quantitative Concept]
  1000   C2347086:% Normal [Quantitative Concept]

Phrase: "and"

Phrase: "pathological fluids."
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
   861   C0005889:Fluids [Body Substance]
   861   C0302908:fluids [Substance]
   861   C1521806:Fluids [Tissue]
   827 E C0444611:Fluid [Qualitative Concept]
   827 E C1704353:Fluid [Substance]
Processing 00000000.tx.358: Int Immunol 8:16431650, 1996[Abstract] Mallone R, Ferrua S, Morra M, Zocchi E, Mehta K, Notarangelo LD, Malavasi F: Characterization of a CD38-like 78-kilodalton soluble protein released from B cell lines derived from patients with X-linked agammaglobulinemia. 

Phrase: "Int Immunol 8"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0063789:INT [Organic Chemical]
   827   C1517844:Immunol [Organic Chemical,Pharmacologic Substance]
   827   C3272375:INT [Intellectual Product]

Phrase: ":"

Phrase: "16431650,"

Phrase: "1996"

Phrase: "[Abstract"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0000857:Abstract [Occupational Activity]
  1000   C0600678:Abstract [Intellectual Product]
  1000   C1552863:Abstract [Idea or Concept]

Phrase: "] Mallone R,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205090:R- [Spatial Concept]
   861   C0684010:R. [Professional or Occupational Group]
   861   C2603358:R' [Clinical Attribute]

Phrase: "Ferrua S,"

Phrase: "Morra M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Zocchi E,"

Phrase: "Mehta K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Notarangelo LD,"

Phrase: "Malavasi F"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
   861   C0439133:(f) [Intellectual Product]
   861   C1553038:[f] [Quantitative Concept]

Phrase: ":"

Phrase: "Characterization of a CD38-"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C1880022:Characterization [Activity]

Phrase: "like 78-kilodalton soluble protein"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "released from B cell lines"
Meta Candidates (Total=15; Excluded=6; Pruned=0; Remaining=9)
   806   C0004561:B-cell [Cell]
   806   C0007600:Cell lines [Cell]
   760   C0007634:Cell [Cell]
   760   C0205132:lines [Spatial Concept]
   760   C0391871:Released [Functional Concept]
   760   C1269647:Cell [Cell]
   760   C1283071:Released [Functional Concept]
   760   C1704653:Cell [Medical Device]
   760   C1948049:Cell [Spatial Concept]
   726 E C0030685:Release [Health Care Activity]
   726 E C0439180:% release [Quantitative Concept]
   726 E C0680255:release [Health Care Activity]
   726 E C1550648:Line [Substance]
   726 E C1552960:Line [Quantitative Concept]
   726 E C1963578:Release [Therapeutic or Preventive Procedure]

Phrase: "derived from patients"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   790   C0030705:Patients [Patient or Disabled Group]
   790   C1441547:Derived [Qualitative Concept]
   790   C3245521:derived [Idea or Concept]

Phrase: "with X-linked agammaglobulinemia."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0221026:X-linked agammaglobulinaemia [Disease or Syndrome]
   901   C0241764:X-linked [Genetic Function]
   827   C0001768:Agammaglobulinaemia [Disease or Syndrome]
   793   C1517892:Link [Intellectual Product]
   793   C1704666:Link [Intellectual Product]
Processing 00000000.tx.359: J Clin Invest 101:28212830, 1998[Abstract/Free FullText] Moulias R, Proust J, Wang A, Congy F, Marescot MR, Deville Chabrolle A, Paris Hamelin A, Lesourd B: Age-related increase in autoantibodies. 

Phrase: "J"

Phrase: "Clin"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1315013:CLIN [Intellectual Product]

Phrase: "Invest"

Phrase: "101"

Phrase: ":"

Phrase: "28212830,"

Phrase: "1998"

Phrase: "[Abstract/Free FullText"

Phrase: "] Moulias R,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205090:R- [Spatial Concept]
   861   C0684010:R. [Professional or Occupational Group]
   861   C2603358:R' [Clinical Attribute]

Phrase: "Proust J,"

Phrase: "Wang"

Phrase: "A,"

Phrase: "Congy F,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
   861   C0439133:(f) [Intellectual Product]
   861   C1553038:[f] [Quantitative Concept]

Phrase: "Marescot MR,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C2347167:Mr. [Conceptual Entity]

Phrase: "Deville Chabrolle A,"

Phrase: "Paris Hamelin A,"

Phrase: "Lesourd B"

Phrase: ":"

Phrase: "Age-related increase in autoantibodies."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0442805:Increase [Functional Concept]
Processing 00000000.tx.360: Lancet 19:11281129, 1984 Groop LC, Bottazzo GF, Doniach D: Islet cell antibodies identify latent type I diabetes in patients aged 3575 years at diagnosis. 

Phrase: "Lancet 19"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0777169:Lancet [Medical Device]

Phrase: ":"

Phrase: "11281129,"

Phrase: "1984 Groop LC,"

Phrase: "Bottazzo GF,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0016703:GF [Geographic Area]
   861   C1551081:gf [Quantitative Concept]

Phrase: "Doniach D"

Phrase: ":"

Phrase: "Islet cell antibodies"
Meta Candidates (Total=9; Excluded=1; Pruned=0; Remaining=8)
   966   C0063900:islet cell antibody [Amino Acid, Peptide, or Protein,Immunologic Factor]
   901   C0022131:Islet cell [Body Part, Organ, or Organ Component]
   901   C1522529:Islet Cell [Cell]
   827   C0003241:Antibodies [Amino Acid, Peptide, or Protein,Cell Component,Immunologic Factor]
   827   C0007634:Cell [Cell]
   827   C1269647:Cell [Cell]
   827   C1704653:Cell [Medical Device]
   827   C1948049:Cell [Spatial Concept]
   793 E C0021027:Antibody [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]

Phrase: "identify"

Phrase: "latent type I diabetes in patients"
Meta Candidates (Total=11; Excluded=0; Pruned=0; Remaining=11)
   833   C0011854:Type 1 diabetes [Disease or Syndrome]
   790   C0441729:Type I [Classification]
   783   C0271650:Latent diabetes [Disease or Syndrome]
   783   C1320657:Diabetes type [Finding]
   767   C1550335:Patient type [Classification]
   753   C0011847:Diabetes [Disease or Syndrome]
   753   C0011849:Diabetes [Disease or Syndrome]
   753   C0021966:I- [Inorganic Chemical]
   753   C0221138:I NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   753   C0332307:Type [Qualitative Concept]
   753   C1547052:*Type [Quantitative Concept]

Phrase: "aged"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0001779:Aged [Organism Attribute]
  1000   C0001792:Aged [Population Group]
  1000   C1999167:aged [Population Group]

Phrase: "3575 years at diagnosis."
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   770   C0439234:years [Temporal Concept]
   737 E C0439508:/year [Temporal Concept]
Processing 00000000.tx.361: Diabetes 35:237241, 1986[Abstract] Tuomi T, Groop LC, Zimmet PZ, Rowley MJ, Knowles W, Mackay IR: Antibodies to glutamic acid decarboxylase reveal latent autoimmune diabetes mellitus in adults with a noninsulin-dependent onset of disease. 

Phrase: "Diabetes 35"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0011847:Diabetes [Disease or Syndrome]
   861   C0011849:Diabetes [Disease or Syndrome]

Phrase: ":"

Phrase: "237241,"

Phrase: "1986"

Phrase: "[Abstract"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0000857:Abstract [Occupational Activity]
  1000   C0600678:Abstract [Intellectual Product]
  1000   C1552863:Abstract [Idea or Concept]

Phrase: "] Tuomi T,"

Phrase: "Groop LC,"

Phrase: "Zimmet PZ,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1418952:PZ [Gene or Genome]

Phrase: "Rowley MJ,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0439254:MJ [Medical Device]

Phrase: "Knowles W,"

Phrase: "Mackay IR"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0022065:IR [Geographic Area]
   861   C0022071:Ir [Element, Ion, or Isotope]
   861   C0034818:IR [Amino Acid, Peptide, or Protein,Enzyme,Receptor]

Phrase: ":"

Phrase: "Antibodies to glutamic acid decarboxylase"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   883   C0443891:Glutamic Acid Decarboxylase Antibody [Amino Acid, Peptide, or Protein,Immunologic Factor]
   883   C3272934:Glutamic Acid Decarboxylase Antibody [Laboratory Procedure]
   760   C0003241:Antibodies [Amino Acid, Peptide, or Protein,Cell Component,Immunologic Factor]
   726 E C0021027:Antibody [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]

Phrase: "reveal"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0443289:reveal [Qualitative Concept]

Phrase: "latent autoimmune diabetes mellitus in adults"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   991   C1960272:Latent autoimmune diabetes mellitus in adult [Disease or Syndrome]
   820   C0259741:Diabetes mellitus, latent [Disease or Syndrome]
   790   C0011849:Diabetes Mellitus [Disease or Syndrome]

Phrase: "with a noninsulin-dependent onset"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0332162:Onset [Qualitative Concept]

Phrase: "of disease."
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C0012634:Disease [Disease or Syndrome]
   944 E C1836721:MALS [Finding]
   944 E C3538764:MALS [Gene or Genome]
   944 E C3540595:MAL [Gene or Genome]
Processing 00000000.tx.362: Diabetes 42:359362, 1993[Abstract] Tuomi T, Carlsson A, Li H, Isomaa B, Miettinen A, Nilsson A, Nissen M, Ehrnstrom BO, Forsen B, Snickars B, Lahti K, Forsblom C, Saloranta C, Taskinen MR, Groop LC: Clinical and genetic characteristics of type 2 diabetes with and without GAD antibodies. 

Phrase: "Diabetes 42"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0011847:Diabetes [Disease or Syndrome]
   861   C0011849:Diabetes [Disease or Syndrome]

Phrase: ":"

Phrase: "359362,"

Phrase: "1993"

Phrase: "[Abstract"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0000857:Abstract [Occupational Activity]
  1000   C0600678:Abstract [Intellectual Product]
  1000   C1552863:Abstract [Idea or Concept]

Phrase: "] Tuomi T,"

Phrase: "Carlsson A,"

Phrase: "Li H,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: "Isomaa B,"

Phrase: "Miettinen A,"

Phrase: "Nilsson A,"

Phrase: "Nissen M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Ehrnstrom BO,"

Phrase: "Forsen B,"

Phrase: "Snickars B,"

Phrase: "Lahti K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Forsblom C,"

Phrase: "Saloranta C,"

Phrase: "Taskinen MR,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C2347167:Mr. [Conceptual Entity]

Phrase: "Groop LC"

Phrase: ":"

Phrase: "Clinical"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205210:Clinical [Qualitative Concept]

Phrase: "and"

Phrase: "genetic characteristics of type 2 diabetes"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   767   C3645613:Characteristic type [Intellectual Product]
   753   C1521970:Characteristics [Qualitative Concept]

Phrase: "with"

Phrase: "and without GAD antibodies."
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
   816   C3272934:GAD Antibody [Laboratory Procedure]
   770   C0003241:Antibodies [Amino Acid, Peptide, or Protein,Cell Component,Immunologic Factor]
   770   C0270549:GAD [Mental or Behavioral Dysfunction]
   770   C1414925:GAD [Gene or Genome]
   770   C1515981:And [Idea or Concept]
   737 E C0021027:Antibody [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
Processing 00000000.tx.363: Diabetes 48:150157, 1999[Abstract] Fujimoto WY: Overview of noninsulin-dependent diabetes mellitus (NIDDM) in different population groups. 

Phrase: "Diabetes 48"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0011847:Diabetes [Disease or Syndrome]
   861   C0011849:Diabetes [Disease or Syndrome]

Phrase: ":"

Phrase: "150157,"

Phrase: "1999"

Phrase: "[Abstract"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0000857:Abstract [Occupational Activity]
  1000   C0600678:Abstract [Intellectual Product]
  1000   C1552863:Abstract [Idea or Concept]

Phrase: "] Fujimoto WY"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0043287:WY [Geographic Area]

Phrase: ":"

Phrase: "Overview of noninsulin-dependent diabetes mellitus (NIDDM)"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   753   C0814812:overview [Intellectual Product]
   716   C0011860:Diabetes Mellitus, Non-Insulin-Dependent [Disease or Syndrome]
   716   C2697407:DIABETES MELLITUS, NONINSULIN-DEPENDENT [Gene or Genome]

Phrase: "in different population groups."
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   901   C1257890:Population Group [Population Group]
           Group
   827   C0441833:Group [Idea or Concept]
   827   C0687744:group [Population Group]
   827   C1552516:Group [Health Care Related Organization]
   827   C1552839:groups [Idea or Concept]
   827   C1705428:Group [Conceptual Entity]
   827   C1705429:Group [Population Group]
Processing 00000000.tx.364: Diabet Med 13 (Suppl. 6):S7S10, 1996 Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B, Krause M, Scharrer I, Aumann V, Mittler U, Solenthaler M, Lammle B: von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. 

Phrase: "Diabet Med 13"

Phrase: "(Suppl. 6"

Phrase: ")"

Phrase: ":"

Phrase: "S7S10,"

Phrase: "1996 Furlan M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   827   C0441923:M+ [Intellectual Product]

Phrase: "Robles R,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205090:R- [Spatial Concept]
   861   C0684010:R. [Professional or Occupational Group]
   861   C2603358:R' [Clinical Attribute]

Phrase: "Galbusera M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Remuzzi G,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0439267:g% [Quantitative Concept]

Phrase: "Kyrle PA,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C3541314:PA [Idea or Concept]

Phrase: "Brenner B,"

Phrase: "Krause M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Scharrer I,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0021966:I- [Inorganic Chemical]
   861   C0221138:I NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: "Aumann V,"

Phrase: "Mittler U,"

Phrase: "Solenthaler M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Lammle B"

Phrase: ":"

Phrase: "von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   849   C0389918:von Willebrand factor cleaving protease [Amino Acid, Peptide, or Protein,Enzyme]
   849   C1413036:VON WILLEBRAND FACTOR-CLEAVING PROTEASE [Gene or Genome]
   790   C0042971:von Willebrand Factor [Amino Acid, Peptide, or Protein,Biologically Active Substance,Pharmacologic Substance]
   790   C1336938:VON WILLEBRAND FACTOR [Gene or Genome]
   764   C0042974:von Willebrand [Disease or Syndrome]
   742   C0030946:Protease [Amino Acid, Peptide, or Protein,Enzyme,Pharmacologic Substance]
   742   C1521761:Factor [Functional Concept]
   742   C1947941:Protease [Enzyme]
   742   C2827422:Factor [Conceptual Entity]

Phrase: "and"

Phrase: "the hemolytic-uremic syndrome."
Meta Candidates (Total=8; Excluded=3; Pruned=0; Remaining=5)
  1000   C0019061:Haemolytic uraemic syndrome [Disease or Syndrome]
   901   C0302810:UREMIC SYNDROME [Disease or Syndrome]
   827   C0039082:Syndrome [Disease or Syndrome]
   827   C0312853:Haemolytic [Qualitative Concept]
   827   C2945560:Hemolytic [Laboratory or Test Result]
   755 E C0019054:HAEMOLYSIS [Pathologic Function]
   755 E C1630417:% haemolysis [Quantitative Concept]
   755 E C2937287:Haemolysis [Cell Function]
Processing 00000000.tx.365: N Engl J Med 339:15781584, 1998[Abstract/Free FullText] Guse AH: Ca2+ signaling in T lymphocytes. 

Phrase: "N Engl J Med 339"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   804   C0369718:N NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   804   C0441922:N+ [Intellectual Product]
   804   C1414400:ENGL [Gene or Genome]
   804   C1553036:[n] [Quantitative Concept]

Phrase: ":"

Phrase: "15781584,"

Phrase: "1998"

Phrase: "[Abstract/Free FullText"

Phrase: "] Guse AH"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1836672:AH [Disease or Syndrome]

Phrase: ":"

Phrase: "Ca2+ signaling in T lymphocytes."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0037083:Signaling [Cell Function]
   760   C3537152:signaling [Biologic Function]
Processing 00000000.tx.366: Crit Rev Immunol 18:419448, 1998[Medline] Selenkow HA, Wyman P, Allweiss P: Autoimmune thyroid disease: an integrated concept of Graves and Hashimotos diseases. 

Phrase: "Crit Rev Immunol 18"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   812   C1517844:Immunol [Organic Chemical,Pharmacologic Substance]
   812   C2347961:Rev. [Professional or Occupational Group]

Phrase: ":"

Phrase: "419448,"

Phrase: "1998"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Selenkow HA,"

Phrase: "Wyman P,"

Phrase: "Allweiss P"

Phrase: ":"

Phrase: "Autoimmune thyroid disease"
Meta Candidates (Total=10; Excluded=3; Pruned=0; Remaining=7)
  1000   C0178468:Autoimmune thyroid disease [Disease or Syndrome]
  1000   C2984319:Autoimmune thyroid disease [Functional Concept]
   913   C0004364:Autoimmune Disease [Disease or Syndrome]
   901   C0040128:Thyroid disease [Disease or Syndrome]
   827   C0012634:Disease [Disease or Syndrome]
   827   C0040132:Thyroid, NOS [Body Part, Organ, or Organ Component]
   827   C0443146:Autoimmune [Pathologic Function]
   771 E C1836721:MALS [Finding]
   771 E C3538764:MALS [Gene or Genome]
   771 E C3540595:MAL [Gene or Genome]

Phrase: ":"

Phrase: "an integrated concept of Graves"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0178566:concept [Idea or Concept]

Phrase: "and"

Phrase: "Hashimotos diseases."
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   983   C0677607:Hashimotos Disease [Disease or Syndrome]
   861   C0012634:Diseases [Disease or Syndrome]
   789 E C1836721:MALS [Finding]
   789 E C3538764:MALS [Gene or Genome]
   789 E C3540595:MAL [Gene or Genome]
Processing 00000000.tx.367: Compr Ther 10:4856, 1984 Jaffiol C, Baldet L, Pages A, Clot J: Graves disease progressing to Hashimotos thyroiditis. 

Phrase: "Compr Ther 10"

Phrase: ":"

Phrase: "4856,"

Phrase: "1984 Jaffiol C,"

Phrase: "Baldet L,"

Phrase: "Pages A,"

Phrase: "Clot J"

Phrase: ":"

Phrase: "Graves disease progressing to Hashimotos thyroiditis."
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   790   C0205329:Progressing to [Functional Concept]
           progressing
   719 E C1272688:progress [Functional Concept]
   719 E C1280477:Progress [Functional Concept]
Processing 00000000.tx.368: JAMA 250:644645, 1983[Medline] Ausiello CM, la Sala A, Ramoni C, Urbani F, Funaro A, Malavasi F: Secretion of IFN-gamma, IL-6, granulocyte-macrophage colony-stimulating factor and IL-10 cytokines after activation of human purified T lymphocytes upon CD38 ligation. 

Phrase: "JAMA 250"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1422839:JAMA [Gene or Genome]

Phrase: ":"

Phrase: "644645,"

Phrase: "1983"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Ausiello CM,"

Phrase: "la Sala A,"

Phrase: "Ramoni C,"

Phrase: "Urbani F,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
   861   C0439133:(f) [Intellectual Product]
   861   C1553038:[f] [Quantitative Concept]

Phrase: "Funaro A,"

Phrase: "Malavasi F"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
   861   C0439133:(f) [Intellectual Product]
   861   C1553038:[f] [Quantitative Concept]

Phrase: ":"

Phrase: "Secretion of IFN-gamma,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   881   C3156720:IFN-gamma secretion [Cell Function]
   770   C0036536:secretion [Biologic Function]
   770   C0036537:Secretion [Body Substance]

Phrase: "IL-6,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0021760:Interleukin-6 [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C1527132:interleukin 6 [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   861   C0021764:Interleukin [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C1527200:Interleukin [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]

Phrase: "granulocyte-macrophage colony-stimulating factor"
Meta Candidates (Total=16; Excluded=0; Pruned=0; Remaining=16)
  1000   C0079460:Granulocyte-Macrophage Colony-Stimulating Factor [Amino Acid, Peptide, or Protein,Immunologic Factor]
           Colony-Stimulating Factor
  1000   C0376563:Colony-Stimulating Factor, Granulocyte-Macrophage [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
  1000   C1149401:granulocyte macrophage colony-stimulating factor [Molecular Function]
  1000   C1332791:GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR [Gene or Genome]
   937   C0079784:Macrophage Colony-Stimulating Factor [Amino Acid, Peptide, or Protein,Immunologic Factor]
   937   C1524095:macrophage colony-stimulating factor [Amino Acid, Peptide, or Protein,Pharmacologic Substance]
   933   C0079459:Granulocyte Colony-Stimulating Factor [Amino Acid, Peptide, or Protein,Immunologic Factor]
   884   C0009392:Colony-Stimulating Factor [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   804   C0018183:granulocyte [Cell]
   804   C0024432:macrophage [Cell]
   804   C0439158:colony [Quantitative Concept]
   804   C1521761:Factor [Functional Concept]
   804   C1947989:Colony [Cell]
   804   C1948023:Stimulating [Natural Phenomenon or Process]
   804   C2827422:Factor [Conceptual Entity]

Phrase: "and"

Phrase: "IL-10 cytokines after activation of human"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   757   C1511613:Cytokine Activation [Physiologic Function]
   748   C0079189:Cytokines [Amino Acid, Peptide, or Protein,Immunologic Factor]
   748   C1524094:Cytokines [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]

Phrase: "purified"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1998793:Purified [Functional Concept]
   907 E C1947930:Cleanse [Activity]

Phrase: "T lymphocytes upon CD38 ligation."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   806   C0039194:T-Lymphocytes [Cell]
   781   C1267915:CD38+ Lymphocyte [Cell]
   760   C0024264:Lymphocytes [Cell]
Processing 00000000.tx.369: Cell Immunol 173:192197, 1996[Medline] Pickup JC, Crook MA: Is type II diabetes mellitus a disease of the innate immune system? 

Phrase: "Cell Immunol 173"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   827   C0007634:Cell [Cell]
   827   C1269647:Cell [Cell]
   827   C1517844:Immunol [Organic Chemical,Pharmacologic Substance]
   827   C1704653:Cell [Medical Device]
   827   C1948049:Cell [Spatial Concept]

Phrase: ":"

Phrase: "192197,"

Phrase: "1996"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Pickup JC,"

Phrase: "Crook MA"

Phrase: ":"

Phrase: "Is"

Phrase: "type II diabetes mellitus"
Meta Candidates (Total=10; Excluded=0; Pruned=0; Remaining=10)
  1000   C0011860:Diabetes Mellitus, Type 2 [Disease or Syndrome]
           Type 2 Diabetes
  1000   C2984301:Type II diabetes mellitus [Functional Concept]
   875   C1320657:type diabetes [Finding]
   861   C0011849:Diabetes Mellitus [Disease or Syndrome]
           Diabetes
   861   C0441730:Type II [Classification]
   812   C0011847:Diabetes [Disease or Syndrome]
   812   C0332307:Type [Qualitative Concept]
   812   C1547052:*Type [Quantitative Concept]

Phrase: "a disease of the innate immune system?"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   849   C0021053:DISEASES OF THE IMMUNE SYSTEM [Disease or Syndrome]
           Disease of immune system, NOS
           Disease, Immune System
           Immune disease NOS
   748   C0012634:Disease [Disease or Syndrome]
   738   C0442893:Systemic disease [Disease or Syndrome]
Processing 00000000.tx.370: Diabetologia 41:12411248, 1998[Medline] Pietropaolo M, Barinas-Mitchell E, Pietropaolo SL, Kuller LH, Trucco M: Evidence of islet cell autoimmunity in elderly patients with type 2 diabetes. 

Phrase: "Diabetologia 41"

Phrase: ":"

Phrase: "12411248,"

Phrase: "1998"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Pietropaolo M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Barinas-Mitchell E,"

Phrase: "Pietropaolo SL,"

Phrase: "Kuller LH,"

Phrase: "Trucco M"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: ":"

Phrase: "Evidence of islet cell autoimmunity"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   806   C0332120:Evidence of [Functional Concept]
           Evidence

Phrase: "in elderly patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]

Phrase: "with type 2 diabetes."
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
  1000   C0011860:Type 2 Diabetes [Disease or Syndrome]
   913   C1320657:type diabetes [Finding]
   901   C0441730:Type 2 [Classification]
   827   C0011847:Diabetes [Disease or Syndrome]
   827   C0011849:Diabetes [Disease or Syndrome]
   827   C0332307:Type [Qualitative Concept]
   827   C1547052:*Type [Quantitative Concept]
Processing 00000000.tx.371: Diabetes 49:3238, 2000[Abstract]

Phrase: "Diabetes 49"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0011847:Diabetes [Disease or Syndrome]
   861   C0011849:Diabetes [Disease or Syndrome]

Phrase: ":"

Phrase: "3238,"

Phrase: "2000"

Phrase: "[Abstract"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0000857:Abstract [Occupational Activity]
  1000   C0600678:Abstract [Intellectual Product]
  1000   C1552863:Abstract [Idea or Concept]

Phrase: "]"

